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Abstract: Enhancing CHO cell productivity through the stable depletion of 
microRNA-23 
The Chinese hamster ovary cell (CHO) has been the “work horse” of the 
biopharmaceutical industry for the past 2 decades. Their preeminent position is due 
to their genetic tractability and capacity to produce high quality recombinant 
proteins with human-like post-translational modifications. Productivity limitations, 
however, have stimulated the application of various optimisation strategies to 
further improve therapeutic product yields. Despite the marked improvements in 
bioprocess design and media formulation, enhanced CHO cell performance is by no 
means routine. microRNAs (miRNAs) offer an attractive alternative to genetic 
engineering using a protein-coding gene due to their ability to regulate multiple 
molecular networks simultaneously in addition to reducing the cells translational 
burden. 
Our lab identified various miRNAs whose expression was closely correlated with 
CHO cell growth rate including the oncogenic miR-17~92 cluster and the ribosome-
enhancing miR-10a, as well as various growth-associated miRNAs such as miR-30e, 
miR-206, miR-451 and miR-639. Transient characterisation of a set of these 
candidates revealed several to negatively regulate growth and apoptosis such as 
miR-34a/34a* and miR-23b*; positively influence growth including miR-15a-16-1 
and miR-532-5p and potentially enhance specific productivity in the case of miR-
200a. CHO clones with enhanced growth attributes could achieve high cell densities 
early in culture prior to the induction of a temperature-shift, a process control 
strategy commonly used to enhance specific productivity but often at the cost of 
growth. 
A common trade-off for enhanced growth is often the reduction in CHO cell specific 
productivity. Stable depletion of miR-23, implicated in B-cell differentiation, using 
a miR-sponge decoy was observed to enhance recombinant protein yield by ~3-fold 
without influencing CHO-SEAP cell growth in batch culture. Interestingly, these 
high producing clones also demonstrated a ~30% increase in oxidative metabolism, 
an energy state previously associated with productivity. The mitochondrial electron 
transport system components, Complex I and II, were observed to be responsible 
for this enhanced energy provision. Proteomic analysis identified potential targets 
of miR-23 involved in the TCA cycle e.g. IDH1 and MDHA/B and related to 
mitochondrial function e.g. LETM1.  
Process adaptation to complement inherent clonal attributes can be exploited to 
enhance production yields as evident in the case of a miR-23b*-depleted clone 
achieving a 50% improved SEAP yield in a fed-batch culture with temperature shift 
(31°C). Exploiting the role of miRNAs in the regulation of bioprocess-related 
phenotypes (e.g. miR-34a and its role in antibody fucosylation) highlights the 
versatility of these small molecules for industrial application, a prospect further 
explored within this thesis. 
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ADCC   – Antibody-dependent cell cytotoxicity  
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ncRNA  – Non-coding RNA  
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Chapter 1 
 
 
 
 
 
 
Introduction 
 
 
 
 
 
 
 
This introduction has been accepted for publication as a review focusing on the 
current status of microRNAs in the field of Chinese hamster ovary cell engineering. 
The review is entitled “Bioprocess engineering: Micro-managing the CHO cell 
phenotype”, will be published in FUTURE SCIENCE – Pharmaceutical 
Bioprocessing [August 2014] and was significantly contributed to by Dr. Niall Barron 
and Dr. Colin Clarke. 
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1.1 Chinese hamster ovary (CHO) cells 
The Chinese hamster ovary (CHO) cell is the primary mammalian cell line used in the 
biopharmaceutical industry for the production of recombinant therapeutic proteins. They 
are favoured over their microbial counterparts (bacteria, yeast etc.) for their ability to 
produce high quality proteins with human like post-translational modifications, 
glycosylation, ensuring high efficacy. Since the first FDA-approved recombinant protein 
was manufactured in CHO, tissue plasminogen activator (tPA or Activase®) (Birch, 
Arathoon 1990), over 70% of all recombinants are produced in this cell, earning them the 
status of the “biological workhorse” of the biopharmaceutical industry (Jayapal et al. 
2007). Of the 58 approved biopharmaceuticals (Table 1.1) between 2006 and 2010, 32 
were manufactured in CHO with the 28 currently available antibodies constituting a large 
fraction of the market (Ho, Tong & Yang 2013).  
Optimisation of their performance has been an area of intense research over the last two 
decades in order to enhance production yields and ultimately meet the global market 
demand. Since the 1990’s, product titres have been improved ~20-fold primarily as a 
result of expression vector improvements and the ability to isolate high producing clones 
in addition to tailor-designed media formulations and the implementation of modified 
bioprocess regimes. Such improvements have boosted the industry standard to 1-5 g/L 
for monoclonal antibodies (Mabs) (Butler, Meneses-Acosta 2012, De Jesus, Wurm 2011). 
However, such achievements are by no means routine and the recent emergence of 
complex therapeutic molecules, such as fusion proteins and antibody fragments, present 
new manufacturing challenges for the CHO cell platform. 
Enhancing CHO cell performance has taken various forms including the implementation 
of bioprocess regimes such as temperature shift (Butler 2005) and chemical 
supplementation of sodium butyrate, discussed later (Hendrick et al. 2001b), to enhance 
specific productivity in addition to genetic engineering strategies to compliment these 
previous breakthroughs by overcoming side-effects associated with the bioprocess. Single 
and multi-gene engineering processes have been exploited to target CHO cell phenotypes 
critical to the bioprocess including cell cycle (Sunley, Butler 2010), apoptosis (Lee et al. 
2013), metabolism (Jeon, Yu & Lee 2011) and secretion (Rahimpour et al. 2013).  
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Table 1.1: List of FDA/EU approved biologics produced in CHO 
Selected list of FDA/EU approved biologics produced in CHO (1987-2012) 
Product Type Therapeutic use Manufacturer Year of 
approval 
(FDA/EU) 
Lucentis Anti-VEGF-A 
mAb 
Diabetic macular 
edema 
Genetech 2012 
 
Yevroy 
 
Anti-CTLA-4 mAb 
 
Melanoma 
 
Bristol-Myers-
Squibb 
 
2011 
Elonva Modified rh-FSH Controlled ovarian 
stimulation 
N.V. Organon 2010 
Opgenra rh-BMP-7 Posterolateral 
lumbar spinal 
fusion 
Howmedica 
 
2009 
 
Recothrom 
 
rh-Thrombin 
Control of minor 
bleeding during 
surgery 
Zymogenetics 
(Seattle) 
 
2008 
 
Retacrit 
 
rh-EPO 
Anemia associated 
with chronic renal 
failure 
Hospira 2007 
Vectibix Anti-EGFR mAb Metastatic 
colorectal cancer 
Amgen 2006 
 
Naglazyme 
N-
acetylgalactosamin
e-4-sulfatase 
 
Mucopoly-
saccharidosis VI 
 
Genzyme 
2005 
Luveris Luteinizing 
hormone 
Infertility Serono 2004 
Xolair Anti-IgE mAb Moderate/Severe 
Asthma 
Genetech 2003 
Humira Anti-TNFα mAb Rheumatoid 
arthritis 
Abbott 2002 
Aranesp Erythropoietin 
(engineered) 
Anemia Amgen 2001 
ReFacto Factor VIII Hemophilia A Wyeth 2000 
Herceptin Anti-HER2 mAb Metastatic breast 
cancer 
Genetech 1998 
Benefix Factor IX Hemophilia B Wyeth `1997 
Avonex Interferon-β Relapsing multiple 
sclerosis 
Biogen Idec 1996 
Cerezyme β-
glucocerebrosidase 
Gaucher’s disease Genzyme 1994 
Pulmozyme Deoxyribonuclease 
I 
Cystic fibrosis Genetech 1993 
Epogen Erythropoietin Anemia Amgen 1989 
Activase Tissue 
plasminogen 
activator 
Acute myocardial 
infarction 
Genetech 1987 
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Engineering approaches have diversified to encompass the tailored manipulation of 
antibody glycoforms for the enhancement of effector functions such as antibody-
dependent cell cytotoxicity (ADCC) (Jefferis 2009a), overviewed in greater detail in 
section 1.4. By reducing core fucosylation of the biantennary-glycan on the Fc region of 
an antibody, therapeutic potency can be heightened as described in the case of the major 
blockbuster HerceptinTM (Junttila et al. 2010). Process manipulation such as those 
described, have demonstrated improved volumetric or specific productivity (Qp) by 
sustaining a prolonged production phase, manipulating bioenergetics pathways to reduce 
toxic by-product accumulation, improving post-translational processing or indirectly 
meeting global demand by decreasing patient dosages.  
The emerging prominence of CHO has been marked by the publication of both the 
Chinese hamster (Lewis et al. 2013) and CHO (Xu et al. 2011) genomes in addition to a 
wealth of ‘omics data unravelling the molecular fingerprint of CHO cell genetics (Hackl 
et al. 2011, Becker et al. 2011) and phenotypic characterisation (Clarke et al. 2012, Clarke 
et al. 2011a). CHO-specific genomic support will focus cell line engineering, allowing 
for the derivation away from the dependency on conservation with human and mouse 
sequences. In addition, vast improvements in the development of a plethora of tools and 
techniques for the manipulation of the expression networks in order to bend the CHO cell 
to the specific requirements of product molecules. Sequence access has not only gained 
insight into the variation of bioprocess characteristics in CHO such as post-translational 
networks and apoptosis (Xu et al. 2011) but will help refine currently implemented vector 
design such as recombinase-mediated cassette exchange (Hirano et al. 2011), zinc-finger 
nucleases (Cost et al. 2010), TALENS (Joung, Sander 2013), endogenous CHO 
promoters (Pontiller et al. 2008) and CRISPR-Cas (Mali, Esvelt & Church 2013).    
With over 350 antibodies currently in the pipeline of pre-clinical trial (Reichert 2013, 
Walsh 2010) development (Reichert 2013), the emphasis on  the availability of robust 
“off-the-shelf” engineering tools encompassing the genetic diversity of parental CHO cell 
lines and product specificity remains a priority in animal cell technology. Reducing the 
translational burden (Hackl, Borth & Grillari 2012) associated with single and multi-gene 
engineering strategies is now being addressed via RNAi (Wu 2009b) with miRNAs 
offering this advantage in addition to simultaneous pathway manipulation (Jadhav et al. 
2013). 
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1.1.1 Improving CHO cell productivity  
Process limitations associated with cell line stability and transcriptional efficiency of the 
recombinant product has contributed to the low productivity profiles of recombinant CHO 
(rCHO) cultures, a constraint significantly relieved by advancements in vector constructs 
(Li et al. 2007). Random integration of the recombinant gene of interest (GOI) gives rise 
to an unpredictable expression pattern due to positional effects (Zhou et al. 2010) 
resulting in the extensive screening of large numbers of CHO clones without addressing 
stability, an attribute influenced by the type of promoter used (Brooks et al. 2004). As 
only 0.1% of the genome is considered “active” (Little 1993), the frequency of successful 
transgene insertions into a transcriptional “hot-spot” is low, further abrogating the 
isolation of high producing clones. 
The majority of production platforms utilize mutant strains of CHO cells (Table 1.2) that 
have both alleles of the dihydrofolate reductase (dhfr) gene either mutated or deleted. 
DHFR catalyses the conversion of folic acid to tetrahydrofolate and is necessary for 
biosynthetic pathways that produce glycine, purines and thymidylic acid (Cacciatore, 
Chasin & Leonard 2010). To support growth, DHFR-deficient cells would require media 
supplemented with glycine, hypoxyanthine and thymidine. Incorporation of selection 
markers on transgenes has allowed for the isolation of high producing CHO clones 
through removal of untransfected subpopulations in addition to successful transfectants 
whose endogenous expression is low. Gene amplification in dhfr-CHO and gs-CHO 
(glutamine synthase) has been applied in the industrial production of recombinant 
pharmaceuticals (Cacciatore, Chasin & Leonard 2010). By including the DHFR gene on 
a plasmid with the GOI, cells can be isolated with further stringent selection through the 
addition of methotrexate (MTX), inhibitor of DHFR, selecting high producers or gene 
amplified cells through gene duplication.  
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Table 1.2: Selected list of commercially available CHO cell lines 
Cell Line Description 
CHO-DHFR or CHO-
DUKX-B11 
Dihydrofolate reductase negative clone derived from the 
parental CHO cell line 
CHO-K1 A subclone from the parental CHO cell line 
CHO-MT+ A subclone from the parental CHO cell line 
Pro-5 Proline auxotrophs and require medium containing 40 mg/L 
of proline 
CHO-SSF A subclone of CHO-DUKX-B11 
CHO-protein free CHO cells adapted to grow in protein-free medium 
SuperCHO CHO-K1 subclone expressing insulin, transferring and IGF-
1 
ViggieCHO DUKX-B11 subclone adapted to grow in absence of 
exogenous growth factors  
   
Various selection markers are widely available (Table 1.3) in addition to the inclusion of 
reporter genes such as green-fluorescent protein (GFP) used to isolate  clones based on 
fluorescent-activated cell sorting (FACS) achieving reported specific productivities of 
38-fold increase when compared to normal selection procedures (Sleiman et al. 2008). 
FACS has also been employed under various conditions such as MTX-tagging 
(Yoshikawa et al. 2001) and secretion based on surface protein expression (DeMaria et 
al. 2008). 
Table 1.3: List of selection markers available in mammalian expression vectors 
Selectable marker Selective reagent 
Metabolic selectable marker  
Dihydrofolate reductase (DHFR) Methionine sulphoximine (MSX) 
Glutamine synthase (GS) Methotrexate (MTX) 
Antibiotic selectable marker  
Puromycin acetyltransferase Puromycin 
Blasticidin deaminase Blastcidin 
Histidinol dehydrogenase Histidinol 
Hygromycin Phosphotransferase Hygromycin 
Zeocin resistance gene Zeocin 
Bleomycin resistance gene Bleomycin 
Aminoglycoside Phosphotransferase Neomycin (G418) 
The above table was source from an excellent review on cell culture process development (Li et al. 
2010). 
 
Various recombinases such as Cre and Flp, which recognise loxP and FRT sequences, 
respectively, are applied in various fields of (Hirano et al. 2011) biotechnology (Hirano 
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et al. 2011). The availability of the CHO genomic sequence draft has allowed the 
identification and pre-tagging of transcriptional “hot-spots” using the FRT/loxP system 
in combination with a weakened promoter (Zhou et al. 2010). This process was expanded 
on to include multiple site-specific insertions (Kameyama et al. 2010) and the subsequent 
successful generation of rCHO with a high copy number of antibody genes (Kawabe et 
al. 2012). Alternative to targeting specific high transcriptionally active genomic locations, 
transposable elements have been explored for their unbiased selection in genomic 
insertion, ability to increase copy number and generate stable production cell lines (Ley 
et al. 2013). 
Promoter choice has been a double edge sword for the expression of heterologous genes 
within mammalian cell factories ensuring high transcriptional activity on one side through 
the use of viral promoters such as CMV and SV40 (Spenger et al. 2004) while 
contributing to instability due to silencing via DNA methylation, a common host response 
to foreign genetic material (Robertson, Jones 2000). The exploration of endogenous CHO 
promoters has been an area of interest as a means of navigating around this host response 
(Pontiller et al. 2008). CHEF-1 was identified to be constitutively expressed in several 
CHO cell lines (Running Deer, Allison 2004), an ideal quality for driving transgene 
expression such as house-keeping genes. However, native CHO promoters that are 
responsive to certain conditions such as temperature shift offer an attractive alternative to 
inducible systems such as the identified calcyclin promoter in CHO (Pontiller et al. 2008).   
A vast array of vector modifications can facilitate the selection of high producing CHO 
clones that circumvents the requirement of screening thousands of clones ensuring that 
the clones ultimately being selected will demonstrate a stable, constitutive and high 
producing phenotype once in the bioprocess. However, beyond this assurance, the 
heterogeneity within CHO cell clones themselves (Porter et al. 2010) allow for various 
performance phenotypes once introduced into the wide range production platforms in 
addition to the multitude of insults associated with production runs such as hypoxia, 
nutrient deprivation, shear stress and toxin build-up.   
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1.1.2 Media supplements and bioprocess regimes  
Both media composition and bioprocess design have contributed the most over the past 2 
decades to achieving gram per litre titres (De Jesus, Wurm 2011). Although capable of 
attached culture, the adaptability to suspension culture has made CHO cells a desirable 
mammalian cell type for the large-scale production of biopharmaceuticals. Fed-batch is 
the most commonly employed bioprocess used today and is generally applied to processes 
that supply material for phase 3 clinical trials and for the market (Wurm 2004). This type 
of process enhances maximal cell densities, prolongs culture viability and improves 
product yields, however, cell waste accumulation is the major limiting factor in this 
process type. Perfusion (Ryll et al. 2000) and continuous culture (Bleckwenn, Shiloach 
2004) culture types can be beneficial for producing labile recombinant products in 
addition to potential toxic proteins as culture media is constantly removed and replenished 
with cells remaining in the case of perfusion culture.   
Low temperature cultivation of recombinant CHO cells has previously been associated 
with sustained cell viability and increased productivity (Al-Fageeh et al. 2006) with the 
fundamental addition of maintaining product quality (Yoon, Song & Lee 2003). The 
reduction in growth rate associated with hypothermic growth has been linked to an 
accumulation of cells in the G1 phase of the cell cycle (Hendrick et al. 2001a), a phase 
previously characterised as highly transcriptionally active (Kumar, Gammell & Clynes 
2007). Several studies have been undertaken to explore the molecular mechanisms that 
are activated upon temperature shift in CHO cells that stimulate this prolonged production 
phase and enhanced specific productivity including miRNA profiling (Gammell et al. 
2007, Barron et al. 2011b) and temperature-sensitive regulatory genes (Kantardjieff et al. 
2010). 
Artificial induction of high CHO cell specific productivity can also be achieved with the 
addition of chemical supplements such as sodium butyrate (NaBu) in addition to other 
chemicals such DMSO (Fiore, Zanier & Degrassi 2002), pentanoic acid (Liu, Chu & 
Hwang 2001) and growth factors (Zheng et al. 2006). NaBu has been observed to arrest 
cellular proliferation through the accumulation of cells in the G1 phase (Hendrick et al. 
2001b). Residence of cells in this stage of the cell cycle is associated with a high 
transcriptional activity in addition to increased metabolism and cell size (Kumar, 
Gammell & Clynes 2007). The mechanism of action of NaBu has been suggested towards 
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its ability to act as an inhibitor of histone deacetylation improving genomic accessibility 
(Jiang, Sharfstein 2008) including its ability to suppress c-myc (Mariani et al. 2003) and 
induce p21 (Kobayashi, Tan & Fleming 2004). One metabolic state previously affiliated 
with an increase in specific productivity has been oxidative phosphorylation (Templeton 
et al. 2013) and has been observed to be induced under exposure to NaBu treatment 
(Ghorbaniaghdam, Henry & Jolicoeur 2013). A previous study has demonstrated NaBu 
to stimulate the release of calcium from the endoplasmic reticulum (ER) (Sun et al. 
2012a). The association of calcium signalling with energy metabolism through the TCA 
cycle potentially highlights the driving force of NaBu’s influence on CHO cell 
productivity.(Kaufman, Malhotra 2014) However, multiple side effects are associated 
with the addition of NaBu including growth inhibition, induction or repression of gene 
expression and the induction of apoptosis (Davie 2003).  
 
1.1.3 Waste metabolites 
All of the aforementioned process modifications including the environment of the 
bioreactor itself impose a particular set of insults which makes the culture environment 
undesirable such as oxygen deprivation (hypoxia), nutrient depletion, metabolic waste 
product build-up (lactate and ammonia) and sheer stress. These stresses ultimately reduce 
the accumulation of cell density, induce the onset of cell death ultimately reducing the 
maximum potential yield in addition to interfering with product quality.  
Dissolved oxygen (DO) has been demonstrated to effect cell metabolism and the 
glycosylation patterns of the recombinant product in addition to causing cellular damage 
through the production of reactive oxygen species (ROS) (Shigenaga, Hagen & Ames 
1994). Culture pH has also been demonstrated to elicit adverse effects on cell growth, 
metabolism, protein production and product quality (Yoon, Song & Lee 2003). This 
increase in culture pH is due to lactate production (Tsao et al. 2005), however, the 
addition of alkaline reagents such as Sodium Hydroxide (NaOH) to combat culture pH 
can be more detrimental by increasing osmolality of the culture resulting in cell death 
(Chotteau, Lindqvist 2012). Lactate is considered less of a concern compared to ammonia 
build-up (Kim do et al. 2013) due to its reversed metabolic consumption late in culture 
(Ma et al. 2009). The build-up of ammonia has been observed to affect the glycosylation 
patterns of recombinant proteins thus influencing their quality and bioactivity (Donaldson 
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et al. 1999). Reports have focused on minimising the generation of these byproducts by 
limiting the availability of the primary nutrient sources of mammalian energy 
metabolism, glucose and glutamine. Practical systems approaches have included the 
replacement of glutamine with glutamate (Hong, Cho & Yoon 2010) and glucose with 
galactose (Altamirano et al. 2004) resulting in the reduced accumulation of toxic 
byproducts and enhanced production of recombinant products with favourable 
modifications. 
The utility of temperature shift and chemical-based approaches is abrogated by the 
unfavourable side-effects induced such as apoptosis and growth arrest which ultimately 
reduce the density of producing cells. Although certain engineering options such as NaBu 
do not offer a viable application to industrial processes due to its scalability, such 
strategies do offer a means of identifying phenotype-related genetic switches potentially 
associated with desirable phenotypes such as high specific productivity (Barron et al. 
2011b, De Leon Gatti et al. 2007).  
 
1.1.4 The genomics era - Unravelling CHOs genetic knots 
Omics-based approaches, such as transcriptomics, proteomics and metabolomics, have 
been used in the development of rCHO cell lines destined for the production process, 
reviewed in (Kim, Kim & Lee 2012). Recent advancements in omics tools have allowed 
for the detection of global changes in DNA/RNA, protein and metabolites giving a better 
understanding of the mechanism associated with particular CHO phenotypes and/or 
certain metabolites that correlate adversely/beneficially with CHO cell performance. 
Omics-based analysis sets the basis for CHO cell engineering drawing on the single or 
multiple genes derived from these profiles. Recent advances in the area of omics-based 
bioengineering has presented the researcher with a wealth of insight into the mechanisms 
that drive cellular processes, reviewed in (Datta, Linhardt & Sharfstein 2013).   
Prior to the release of the CHO genomic sequence, non-CHO-derived DNA microarrays 
for mouse and rat were successfully utilised (De Leon Gatti et al. 2007, Baik et al. 2006). 
Comparative transcriptomic analysis using DNA micro-array technology has been carried 
out in rCHO cells that exhibit enhanced cell-specific productivity (q) under induced 
culture conditions such as low temperature culture (Baik et al. 2006, Yee, Gerdtzen & Hu 
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2009), high osmotic conditions (Shen et al. 2010) and Sodium Butyrate (NaBu) treatment 
(De Leon Gatti et al. 2007). Similarly, an additional study sought to predict the cell-
specific production capacity of rCHO by identifying genes expressed across a panel of 
CHO clones with varying levels of q (Clarke et al. 2011b) and growth rate (Clarke et al. 
2011a, Doolan et al. 2013).  
The global scale analysis of the post-transcriptional gene regulation (PTGR) mechanisms 
inherent in a cell system has been made possible from genomic and proteomic profiling 
(Kanitz, Gerber 2010) allowing for the identification of effector protein targets that 
functionally contribute to a specific cellular phenotype. Several proteomic studies have 
been carried within rCHO cell culture systems that have been induced either chemically 
(NaBu) or environmentally (temperature shift) to exhibit enhanced cell specific 
productivity (Kumar et al. 2008, Yee et al. 2008). In addition, shotgun proteomics was 
utilised to identify biomarkers that could be used to predict the production capacity of 
rCHO cells when comparing a high-producing cell line against a low producing (Nissom 
et al. 2006, Carlage et al. 2009b). An array of proteomic-based profiles have been carried 
out in order to characterise and identify potential engineering targets involved in 
apoptosis induction (Wei et al. 2011), hyperosmotic pressure (Lee et al. 2003) and CHO 
cells cultured in serum-free medium supplemented with hydrolysates (Kim et al. 2011). 
Several other proteomic-based tools are available for the identification of large-scale 
changes within the host cell proteome (HCP) increasing the plethora of potential targets 
for CHO cell optimization. CHO-specific sequence databases have allowed for the high 
confident identification of CHO-specific proteins (Meleady et al. 2012c) thus adding to 
the growing wealth of experimentally validated resources.    
The power of omics technology has accommodated the exploration of specific markers 
associated with CHO cell phenotypes allowing for the potential of predicting CHO cell 
performance within the bioprocess. Clonal variation is a well appreciated and problematic 
attribute in cell line development resulting in performance differences of a single clone 
across multiple bioprocesses (Porter et al. 2010). The ability of predicting a cells 
performance based on an expression pattern of a set of prerequisite candidates will 
mediate the selection of clones potentially better equipped with various attributes such as 
specific productivity (Clarke et al. 2011b) or growth (Clarke et al. 2012). Extracellular 
metabolite profiling will aid in media development and feeding strategies. Such studies 
include the characterisation of changes in metabolite accumulation over the culture 
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process (Bradley et al. 2010)(Chong et al. 2009b), profiling of both intracellular and 
extracellular metabolites in high producing versus low mAb-producing rCHO cells 
(Chong et al. 2012) and metabolite accumulation correlated with increased caspase 
activation and the onset of apoptosis (Chong et al. 2011). 
The power of omics technology is evident from the above studies and have led to the 
identification of priority targets whose genetic manipulation will further enhance the 
CHO cell phenotype, a process that can be utilised to overcome the inherent adverse side-
effects of the bioprocess. 
 
1.1.5 Cellular engineering 
An additional layer of engineering exists for the improvement of rCHO cell 
characteristics in relation to cell growth, recombinant protein production, improved 
cellular longevity and optimal nutrient utilisation and metabolism. Both gene-based, RNA 
interference (RNAi) based strategies, and a combination of both, have been successfully 
implemented in the optimisation of CHO cell activity, reviewed in (Kim, Kim & Lee 
2012) and (Wu 2009a). However, the reliance on a single component approach depends 
strongly on the identification of critical targets that have the capacity to markedly 
influence the cellular functions associated with recombinant protein expression in CHO 
cells. Engineering of particular cellular processes covering multiple avenues are 
described below. 
 
1.1.5.1 Engineering CHO cell growth 
A common feature of enhanced specific productivity (qP) conditions are perturbations 
within the cell cycle leading to a G0/G1 phase arrest, resulting in enhanced protein 
biosynthesis, mediated by physical (low temperature) and/or chemical (NaBu) 
environmental stimuli (Sunley, Butler 2010). Based on this observation, anti-cell cycle 
mediators such as p27KIP1 and p21CIP1 have been used in rCHO cell engineering to obtain 
a similar effect without altering the culture environment. Fussenegger et al. achieved a 4-
fold increase in specific productivity in a secreted alkaline phosphatase (SEAP) 
producing cell line through the transient expression of p27KIP1 and p21CIP1 under the 
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transcriptional control of a tetracycline-repressible system (Fussenegger, Mazur & Bailey 
1997). Stable overexpression of these cyclin-dependent kinase inhibitors resulted in a 
significant increase in specific productivity of 5-15 times for recombinant SEAP and 
soluble intracellular adhesion molecule (sICAM) (Mazur et al. 1998, Meents et al. 2002). 
A temperature shift-like phenotype was observed upon the transient overexpression of 
the microRNA, miR-7, in CHO cells resulting in an increase in normalised productivity 
(Barron et al. 2011b).  
Although strategies such as those described above have led to the increase in normalised 
CHO cell productivity, the inhibition of maximal CHO cell accumulation through the halt 
of cell cycle progression results in no improvement to a decline in total volumetric titre. 
Based on this consensus, the inverse relationship between growth rate and productivity 
(Wang et al. 2006) must be coupled with engineering strategies that increase maximal 
cell density before entering the “production phase”. Improvements in maximal cell 
density and growth rate have been mediated by the overexpression of pro-cell cycle genes 
such as the cyclin-dependent kinase, cyclin E, and the transcription factor E2F-1 (Jaluria 
et al. 2007, Majors et al. 2008). Another study demonstrated a 70% increase in the 
maximal cell density achieved through the overexpression of the c-myc transcription 
factor which was observed to increase the cell cycle kinetics by ushering the cells into S-
phase at an accelerated rate (Kuystermans, Al-Rubeai 2009). Target identification 
through omics-based approaches have been carried out to identify and validate several 
gene targets involved in proliferation such as Vasolin-containing protein (VCP) (Doolan 
et al. 2010) and requiem (Lim et al. 2010). 
  
1.1.5.2 Anti-apoptosis engineering 
As mentioned above, cell density is correlated with the maximum production capacity 
during the bioprocess and with this in mind cell death is considered a critical issue to be 
addressed as it effects the viable cell concentration thus impacting on product quality and 
volumetric titre (Arden, Betenbaugh 2004). During rCHO cell culture, cell death 
pathways can be triggered by a variety of stresses previously mentioned such as nutrient 
depletion, hypoxia, accumulation of toxic metabolic byproducts, increased osmolality and 
mechanical stress. The prevention of apoptosis has been recognised and established by 
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the generation of apoptosis-resistant rCHO cells as a beneficial engineering process to 
enhance CHO cell performance.  
It has already been well established that apoptosis in rCHO cells can be significantly 
abrogated by the overexpression of anti-apoptotic proteins including Bcl-2, Bcl-xL and 
Mcl-1 or the down-regulation of pro-apoptotic proteins such as Bak and Bax with the 
observed increase in protein production (Cost et al. 2010, Majors et al. 2008, Majors et 
al. 2009, Sung, Lee 2005, Chiang, Sisk 2005). 
The apoptotic signalling cascade is mediated by a series of downstream proteolytic 
enzymes composed of initiator and effector caspases that regulate the induction, 
transduction and amplification of pro-apoptotic signals. Specific inhibition of the initiator 
caspases, caspase-8/-9, through the stable expression of dominant negative (DN) mutants 
(Yun et al. 2007) and inhibition of the effector caspases, caspase-3/-7, through plasmid 
based expression of small interfering RNA (Kim, Lee 2002, Sung et al. 2007) has 
demonstrated beneficial effects on cell growth and culture longevity. A further strategy 
for suppressing caspase activity is through the overexpression of an intracellular caspase 
inhibitor, X-linked inhibitor of apoptosis (XIAP) which has previously been demonstrated 
in CHO to inhibit the activity of caspase-3, -7 and -9, offering protection against Sindbis 
virus-induced apoptosis (Sauerwald, Betenbaugh & Oyler 2002a, Sauerwald, Oyler & 
Betenbaugh 2003). Two independent studies of XIAP overexpression demonstrated the 
contrary nature of its use in apoptosis inhibition and as a viable tool in CHO cell 
engineering. The first exhibited no change in growth or productivity when CHO cells 
expressing EPO were exposed to sodium butyrate despite the simultaneous reduced 
activity of caspase-3, -7 and -9 (Kim, Kim & Lee 2009). The second conferred a 
significant growth benefit and increased viable state in CHO cells that were serum 
deprived through the reduced expression of caspase-3 (Liew et al. 2010). These mixed 
results offer XIAP overexpression as a means of eliminating serum from the CHO cell 
culture process, particularly during clonal development, while not as a combinatorial 
strategy with chemical additives.  
With the realisation that the apoptosis network is comprised of a complex network of 
genes, several studies focused on the manipulation of simultaneous avenues in a multi-
gene approach. The expression of the mitochondrial pathway associated Bcl-xL and Aven 
along with the additional expression of XIAP demonstrated additive effects in the 
22 
 
protection against cell death in mammalian cell culture (Sauerwald et al. 2006, Figueroa 
et al. 2004). Apoptosis engineering has proved to be effective; however, there are 
conflicting reports as to its influence on productivity. Some have reported negative and 
positive impacts on CHO cell productivity. Nevertheless, combining such strategies with 
chemical based methods, such as NaBu, have resulted in a significant increase in 
recombinant therapeutic protein production (Sung et al. 2007) thus supporting the need 
for the evaluation of the role of apoptosis pathway manipulation and target identification 
in CHO. 
 
1.1.5.3 Anti-autophagy engineering 
Autophagy is a variant of PCD that takes place through a caspase-independent process in 
response to both normal and stressful environmental conditions. Autophagy is a catabolic 
process that acts in a homeostatic way by actively turning over cytoplasmic organelles 
via lysosomal-mediated degradation. It has been observed that an increase in autophagy 
induction can be triggered under stressful conditions such as nutrient deprivation and 
accumulation of protein aggregates (Levine, Yuan 2005, Mizushima, Yoshimori & 
Levine 2010). It is surmised that cell death may occur in the event of a prolonged 
autophagic state as a result of excessive degradation of mitochondria or other vital cellular 
constituents (Pattingre et al. 2005). Inhibition of apoptosis does not guarantee the 
blocking of autophagy-mediated cell death. With the observation that autophagy was 
induced late into the batch culture process of rCHO upon nutrient exhaustion (Hwang, 
Lee 2008), the reverse was also noted with the reduction of apoptosis and autophagy upon 
nutrient supplementation (Han et al. 2011). There are limitations in the online monitoring 
of the induction of autophagy with the microtubule associated protein 1 light chain (LC3) 
being the only bona fide autophagy marker (Kabeya et al. 2000). Autophagy progression 
through FACS-based identification of this protein has been achieved (Eng et al. 2010) 
with the turnover of long lived proteins offering a potential alternative (Klionsky, Cuervo 
& Seglen 2007). CHO cell engineering to over-express Bcl-xL or the active form of Akt 
were observed to delay the onset of apoptosis and autophagy as a result of nutrient 
depletion (Kim et al. 2009a, Hwang, Lee 2009).    
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1.1.5.4 Metabolic engineering 
Normal cell growth and metabolic turnover of primary energy sources such as glucose 
and glutamine can result in the accumulation of byproducts including lactate and 
ammonia which have been characterised as toxic and impede cellular proliferation and 
product quantity and quality. Although feeding strategies and the availability of primary 
nutrient sources have been demonstrated to reduce the production and build-up of such 
byproducts in CHO cell culture, interference on a genetic level has proven to be a viable 
option. 
Continuously cultured rCHO cell lines have the metabolic disadvantage of completely 
oxidising glucose to CO2 and H2O (Neermann, Wagner 1996) resulting in conversion of 
glucose to pyruvate and ultimately lactate, the “Warburg effect”. Increased acidification 
due to elevated lactate levels is mediated by the interconversion of pyruvate to lactate by 
the catalytic enzyme lactate dehydrogenase (LDH). Genetic manipulation of LDH 
activity has already been demonstrated to reduce the specific production of lactate in both 
hybridoma and CHO cell lines (Chen et al. 2001, Jeong et al. 2001). siRNA-mediated 
suppression of LDH-A, the subunit predominantly associated with anaerobic metabolism 
and pyruvate reduction (Baumgart et al. 1996), yielded a 54-87% reduction in specific 
glucose consumption along with a 45-79% reduction in lactate production with no 
impairment in cellular proliferation and hTPO production (Kim, Lee 2007). An additional 
layer of glucose metabolism is the conversion of pyruvate to acetyl-CoA for further 
metabolism in the tricarboxylic acid (TCA) cycle. The enzyme, pyruvate dehydrogenase 
(PDH), is responsible for this interconversion and its activity is regulated by PDH-Kinase 
(K) and PDH-Phosphatase (P). It is for this reason that pyruvate is considered the branch 
point that determines whether the consumed carbon source is excreted as lactate or 
metabolised further in the TCA cycle. Zhou and colleagues explored the use of a dual 
siRNA-expression vector against LDH-A and PDHK as a means of further reducing 
lactate production while also maximising energy generation from the TCA cycle. CHO 
cells exhibiting limited activity of LDH-A and increased activity of PDH showed reduced 
lactate production (90%) with the addition of both increased cell specific productivity 
(75%) and volumetric productivity (68%) (Zhou et al. 2011b). Specific glucose and 
lactate production has been directly correlated with mAb production allowing the 
potential to assess and predict CHO cell productivity based on metabolic turnover. 
Additionally, a high level of mitochondrial dehydrogenase activity was observed 
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confirming that more efficient utilization of carbon sources through energy release from 
the TCA cycle impacts positively on the biosynthesis capacity of CHO (Chen et al. 2012). 
Another method explored was the controlled utilization of an alternative energy source to 
glucose, fructose. Overexpression of the fructose-specific transporter (GLUT5) allowed 
for the moderate uptake of fructose in high fructose containing environments, avoiding 
the overflow of excessive carbon and lactate. The same clones cultured in glucose 
environments demonstrated high sugar consumption and lactate production. The reduced 
production of lactate in these GLUT5 clones resulted in an increased final cell 
concentration but was only observed for clones that exhibited an appropriate expression 
of this fructose transporter (Wlaschin, Hu 2007). Prolonged culture viability and 
enhanced productivity was observed in the instance of stable overexpression of the 
taurine-transporter (TAUT). Enhanced consumption of particular amino acids was 
evident, taurine and β-alanine, which are known to function as organic osmolytes thus 
inducing apoptosis upon their accumulation (Tabuchi et al. 2010). 
To understand the bioprocess more intimately, a metabolomics-based approach was 
carried out to identify the accumulation or depletion of particular metabolites at specific 
time points within the culture using HPLC and LC/MS (Chong et al. 2009a). These 
findings gave rise to the potential of using such a strategy for guiding media design and 
fed-batch processes. A similar study, focused on the identification of novel metabolites, 
oxidized glutathione, that potentially induced apoptosis through correlation with elevated 
caspase activity (Chong et al. 2011). Metabolite characterisation studies such as these will 
accommodate the controlled manipulation of CHO cell metabolism thus allowing 
maximum performance. 
 
1.1.5.5 Secretion engineering 
Soluble NSF (N-ethylmaleimide-sensitive factor) attachment receptor, SNARE, proteins 
are anchored to both transport vesicles and their target membrane, trigger membrane 
fusion and are crucial in the exocytic pathway (Jahn, Scheller 2006). Vesicle trafficking 
and SNARE-mediated membrane fusion is regulated by the interaction with Sec/Munc18 
(SM). Several efforts have enhanced the production capacity of CHO cells by overcoming 
this bottleneck associated with a saturated secretory pathway. Overexpression of 
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components related to the secretory network such as SNAREs (SNAP-23 and VAMP8) 
and the SM proteins (Sly1 and Munc18c) have been exercised with a positive impact on 
the secretory capacity of rCHO (Peng, Abellan & Fussenegger 2011, Peng, Fussenegger 
2009). An alternative strategy implemented to enhance the secretory capacity of tPA-
producing rCHO cells was the generation of a mutant CHO cell line that possessed a 
phosphorylation-resistant copy of ceramide-transfer protein (CERT), which efficiently 
transfers ceramide from the endoplasmic reticulum (ER) to the Golgi. Specific 
productivity was observed to be elevated by 35% (Rahimpour et al. 2013). 
 
1.1.5.6 Chaperone engineering 
A study identifying the irrelevance of secreted protein levels versus increasing gene copy 
number/strong promoter led to the understanding that the bottleneck in enhancing specific 
productivity lies at the translational and/or post-translational level (Mohan et al. 2008a). 
To relieve the cells of this blockage, engineering of the chaperone machinery networks 
have been undertaken. Protein disulfide isomerise (PDI) is predominantly located in the 
ER and has been found to catalyse disulfide bond formation, assisting in the folding of 
newly synthesised proteins (Freedman, Hirst & Tuite 1994, Gething, Sambrook 1992) 
and acting as a molecular chaperone associated with miss-folded proteins in the ER (Cai, 
Wang & Tsou 1994, Quan, Fan & Wang 1995). From an engineering perspective, 
increased PDI activity in bacterial, yeast and insect hosts has been reported to increase 
the secretion and activity of heterologous proteins containing disulfide bridges (Davis et 
al. 2000). Overexpression of PDI in rCHO was observed to positively influence the 
production capacity of antibody-producing CHO cells, but not in the case of TPO, IL-15 
and tumor necrosis factor receptor:Fc fusion protein (Davis et al. 2000, Borth et al. 2005, 
Mohan et al. 2007). Although antibody productivity was observed to be increased, 
intracellular retention and co localisation in the ER was identified to be the contributing 
factor to the reduction in TNFR:Fc. In a separate study, an isoform of PDI, ERp57, was 
over-expressed to increase the levels of TPO secretion by 2.1 fold without any aberrant 
effects on CHO cell growth (Hwang, Chung & Lee 2003). These reports give a mixed 
view on the benefits of PDI overexpression as an engineering target with cell line, 
expression system and target therapeutic protein playing a significant part. Simultaneous 
overexpression of the chaperones calnexin and calreticulin exhibited a 1.9 fold increase 
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in specific TPO production with no change in it in-vivo biological activity (Chung et al. 
2004). One proposed engineering strategy when exploiting the cells own protein 
chaperone network would be to co-express several chaperones concomitantly in a 
functionally meaningful ratio (Mohan et al. 2008b).  
 
1.1.5.7 Unfolded-protein response engineering 
With the identification of ER-associated chaperones, endoplasmin and PDI, being highly 
correlated with CHO cell productivity (Smales et al. 2004) in addition to shotgun 
proteomics revealing a positive correlation in productivity with the expression of the 
molecular chaperone BiP (Carlage et al. 2009a), it was evident that the ER played a major 
role in protein processing and the transmission of signals. However, accumulation of 
unfolded proteins in the ER lumen induces a response named unfolded-protein response 
(UPR). This response ultimately leads to the transcriptional activation of numerous 
factors involved in the folding process, such as molecular chaperones, foldases (Travers 
et al. 2000) and also genes involved in the ER-associated degradation (ERAD) pathway 
(Casagrande et al. 2000). Prolonged or excessive UPR activation has been observed to 
induce pancreatic beta cell death (Eizirik, Miani & Cardozo 2013) thus possessing the 
potential to interfere with the viable nature of CHO along with offering an engineering 
route to overcome this secretory bottleneck. 
Reprogramming the post-translational processing machinery to overcome production 
bottlenecks was demonstrated by the overexpression, both transient and stable, of X-box 
binding protein 1 in transgenic CHO-K1 (Tigges, Fussenegger 2006). A spliced variant 
(XBP-1s) was revealed to increase the specific production capacity of various therapeutic 
proteins over its non-beneficial unspliced counter-part XBP-1u. Additionally, a further 
study confirmed the utility of XBP-1s overexpression in CHO whereby a secretory 
bottleneck had been reached with a 2.5 fold increase in specific productivity being 
demonstrated for recombinant proteins such as mAb, erythropoietin (EPO) and interferon 
γ (IFNγ) (Ku et al. 2008). Suspension CHO cell cultures maintained in a fed-batch format 
exhibited a 40% increase in antibody titre with appropriate bioactivity and post-
translational modifications under stable XBP-1 expression (Becker et al. 2008).  
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In instances where the overexpression of XBP-1 failed to enhance the production of 
recombinant proteins such as antithrombin III (AT-III), the constitutive activation of the 
transcription factors ATF4 (Activating transcription factor 4) and GADD34 (Growth 
arrest and DNA damage inducible protein 34) demonstrated improved titre of 
recombinant AT-III (Ohya et al. 2008a, Omasa et al. 2008). 
 
1.1.6 Has the maximum productive capacity of CHO reached its climax? 
With such marked advancements in the area of recombinant CHO cell technology being 
seen over the past 25 years, will further improvements in specific and volumetric 
productivity be seen in the near future?  Over the past 25-30 years, volumetric yields for 
recombinant protein production have increased by about 20-fold primarily due to the 
improvements in media and bioprocess design. It has been suggested (De Jesus, Wurm 
2011) that a biological limit has been achieved at about 100 pg/cell/day in the area of 
specific productivity. However, this is by no means routine and volumetric yields could 
still be pushed higher, possibly 2-5-fold, by further increasing the maximal cell density 
achieved within the bioreactor (De Jesus, Wurm 2011). By combining successful 
bioprocess feeding strategies with that of genetically modified rCHO hosts, breaking the 
current limitations of the bioprocess is a tangible goal. Focusing on the lesser explored 
but emerging field of miRNAs, will not only minimise the translational burden associated 
with gene-based genetic engineering strategies (Hackl, Borth & Grillari 2012) but will 
fine tune global gene expression edging the CHO cell towards a more favourable 
phenotype (Clarke et al. 2012). microRNAs (miRNAs) have been suggested as alternative 
engineering tools in the past (Muller, Katinger & Grillari 2008, Wu 2009, Barron et al. 
2011e) and in a short time have come a long way, reviewed in (Jadhav et al. 2013). 
 
1.2 microRNAs: Global regulators of cellular phenotypes 
MicroRNAs (miRNAs) are endogenous, small (~22 nt), single-stranded and non-coding 
RNA (ncRNA) molecules that play an important functional role in the global regulation 
of gene expression (Bartel 2004). Gene expression is exerted at the post-translational level 
whereby mature miRNAs target mRNAs for translational inhibition or mRNA cleavage 
depending on the level of complementarity between the miRNA and the 3’-untranslated 
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region (UTR). In some instances rapid mRNA decay has been attributed to accelerated 
deadenylation via miRNA (Wu, Fan & Belasco 2006) with isolated occurrences of 
enhanced translation of ribosomal proteins through interaction with their 5’UTRs (Orom, 
Nielsen & Lund 2008).  
It is predicted that miRNAs have the potential to target up to ~30% of protein coding 
genes (Filipowicz, Bhattacharyya & Sonenberg 2008). The ability of a single miRNA to 
potentially target hundreds of mRNA transcripts contributes to their complex nature (Chi, 
Hannon & Darnell 2012). Conservation of the “seed” (nucleotides 2-8) sequence dictates 
target specificity. Multiple miRNA-Recognition Elements (MREs) of a single miRNA 
can be found within the 3’ UTR of several mRNA transcripts or several MREs belonging 
to different miRNAs can lie within the same UTR giving rise to synergistic miRNAs 
(Shukla, Singh & Barik 2011).  
As of 2014, over 28,645 miRNAs have been discovered and logged in the miRBase 
database with 1,881 of these being included in the human genome. miRNAs are involved 
in a wide range of molecular pathways such as cellular proliferation (Dong et al. 2012), 
apoptosis (Xie et al. 2012), fat metabolism (Flowers, Froelicher & Aouizerat 2012), 
glucose-induced insulin secretion (Xia et al. 2011) and developmental timing (Carrington, 
Ambros 2003). The conservation of 3’UTR miRNA seed sites across species (Friedman 
et al. 2009) implicate these small RNA based gene regulators as prime targets for CHO 
cell engineering and therapeutic intervention.   
 
 
1.2.1 Discovery of microRNAs 
The very first miRNA, lin-4, was identified in the nematode Caenorhabditis elegans in 
1993 whilst studying its post-embryonic developmental timing. It was observed that the 
transcription of lin-4 negatively regulated the levels of the LIN-14 protein at the L1 stage 
of larval development. Ultimately, non-coding lin-4 transcript encoded for two small 
mRNAs of 22 and 61 nucleotides that possessed complementary sequences to those found 
in the 3’UTR of the lin-14 mRNA (Lee, Feinbaum & Ambros 1993). However, the lack 
of conservation of lin-4 and lin-14 with any species other than nematodes suggested that 
this was a “nematode specific curiosity” (Ambros 2008, Lee, Feinbaum & Ambros 2004, 
Ruvkun, Giusto 1989). 
29 
 
A second and historically significant heterochronic gene switch was identified in the same 
species, let-7, which was shown to code for a 21 nt RNA that possessed complementary 
elements in the 3’UTR of its gene target lin-41 (Reinhart et al. 2000). Binding similarities 
of let-7 to lin-4 was confirmed with imperfect complementary sequence binding located 
within the 3’UTR of the lin-41 mRNA (Vella et al. 2004, Bagga et al. 2005). The 
conservation of let-7 across several species such as vertebrate, ascidian, hemichordate, 
mollusc, annelid and arthropod lead to the characterisation and identification of miRNAs 
as a unique family of short interfering RNAs involved in species development, 
homeostasis and disease (Pasquinelli et al. 2000). The multiple mRNA targets of the lin-
4 miRNA (lin-14 and lin-28) coupled with the predicted crossover target of let-7 with lin-
28 was the first indication that miRNAs could act both synergistically and independently 
in numerous molecular networks (Reinhart et al. 2000, Moss, Lee & Ambros 1997).  
 
1.2.2 miRNA Biogenesis and Processing 
miRNAs are transcribed by RNA polymerase II, or RNA pol III, (Fig. 1.1 1) into long 
primary (pri-) transcripts of several thousand bases, kilo-bases (kbs) (Lee, Feinbaum & 
Ambros 2004, Steel, Sanghvi 2012). The removal of a shorter (~70 nt) hairpin stem loop 
structure termed the preliminary miRNA (pre-miRNA) is performed by the 
Microprocessing complex (Drosha-DGCR8, Fig. 1.1 2). Pri-miRNA processing and 
recognition is mediated by the RNase type III enzyme Drosha and its double-stranded 
RNA-binding adaptor protein DGCR8 (DiGeorge Syndrome Critical Region 8). Drosha 
forms an intramolecular dimer whereby its two RNase III domains cut the 3’ and 5’ strand 
independently of each other yielding a RNase III characteristic 2 nt-3’ overhang (Han et 
al. 2004). Not only do the two double-stranded RNA binding domains of DGCR8 
recognize the single-stranded RNA extensions flanking the base of the stem thereby 
directing Drosha cleavage ~11 bp into the duplex from the ss-RNA/ds-RNA junction 
(Zeng, Cullen 2005, Han et al. 2006) but the protein-protein interactions through 
DGCR8/Drosha in the Microprocessor complex serve to stabilize the Drosha enzyme 
(Han et al. 2006, Yeom et al. 2006).  
Nucleo-cytoplasmic export of these newly processed pre-miRNAs is mediated by the 
nuclear receptor Exportin-5 (Exp5) in a Ran-GTP dependent manner (Wang et al. 2011b), 
(Fig. 1.1 3). Structural recognition of the pre-miRNAs stem duplex is weakly bound by 
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Exportin-5 with the identification of the 2 nt 3’ overhang being the pre-requisite for the 
pre-miRNA recognition by Exp5 (Bohnsack, Czaplinski & Gorlich 2004, Lee et al. 2011). 
In addition to the RNase III-specific 3’ overhang being the determining factor for miRNA 
nuclear export, the pre-miRNA/Expotin-5/Ran-GTP complex also inhibits the 
exonucleolytic degradation of the bound pre-miRNA (Zeng, Cullen 2004) thus stabilizing 
and shuttling efficiently processed and folded miRNAs for further processing.    
Figure 1.1: miRNA Biogenesis and Processing 
 
Figure 1.1: 1) miRNA biogenesis begins with the transcriptional initiation by RNA pol II/III yielding 
a primary miRNA transcript (pri-miRNA). 2) The Microprocessor complex containing 
Drosha/DGCR8 cleaves the overhanging single stranded RNA liberating a ~70 nt Pre-miRNA 
hairpin. 3) Nuclear removal of the pre-miRNA is mediated by Exportin-5 in a Ran-GTP dependent 
fashion. 4) Following export to the cytoplasm, the pre-miRNA is further processed by Dicer removing 
the hairpin loop and generating a ~22 nt RNA duplex. 5) Strand selection takes place upon RISC 
loading where the selected guide strand directs RISC mRNA targeting. 6) Translational repression 
or 7) mRNA degradation takes place based on the level of miRNA: mRNA complementarity and the 
specific Argonaute loaded in the RISC. Figure sourced from (Barron et al. 2011d). 
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In order to achieve target gene binding, the pre-miRNA product is further processed by a 
second RNase III type enzyme, Dicer, which partners with a double-stranded RNA-
binding protein TRBP (TAR RNA binding protein) to remove the loop generating a ~22 
nt RNA duplex (Koscianska, Starega-Roslan & Krzyzosiak 2011), (Fig. 1.1 4). The 
Dicer-TRBP complex closely associates with a member of the Argonaute family (Ago2) 
that mediates gene silencing and is intimately involved in the loading of the mature 
miRNA strand into the (RISC) RNA-Induced Silencing Complex (Chendrimada et al. 
2005) (Fig.1.1 5). Subsequent to physical association of the miRNA duplex with all Ago 
proteins, the rate limiting step in miRNA mediated gene inhibition, is in the conversion 
from inactive RISC complex (Ago associated with RNA duplex) to active RISC complex 
(Ago associated with ssRNA) with thermodynamic stability of the duplex having the 
greatest influence (Gu et al. 2011). This thermodynamic stability in the 5’ end of the 
duplex tips the balance of strand selection (Schwarz et al. 2003, Khvorova, Reynolds & 
Jayasena 2003) with as little a single mismatch in the first four base pairs being enough 
to favour guide strand selection (Hu et al. 2009). Upon strand selection, the passenger 
strand (eg. miRNA-34a*) is rapidly degraded. Passenger strand protection from 
degradation has been observed in species such as C. elegans (Chatterjee et al. 2011). The 
means by which a passenger strand that is not thermodynamically favourable is selected 
is still an unknown process but is likely dependent on co-factors associated with the RISC 
complex. Sporadic selection of the passenger strand completely changes the dynamics of 
miRNA directed gene inhibition by introducing a sequence that will target a separate set 
of mRNAs.  
 
 
1.2.3 Genomic Organisation of microRNA and Nomenclature 
The transcribed primary (pri) miRNA is between 3 and 4kb, and is structurally equivalent 
to that of a transcribed mRNA with flanking 5’ capped and 3’ polyadenylation consensus 
sequences forming defined boundaries (Cai, Hagedorn & Cullen 2004, Saini, Griffiths-
Jones & Enright 2007). Approximately 50% of miRNAs are expressed from the introns 
of protein coding transcripts while the remaining are located within intergenic regions 
(Figure 1.2). The latter intergenic miRNAs are expressed independently from their own 
unique upstream promoter often located within flanking genes coding sequences. 
However, intragenic miRNAs, both intronic and exonic (Olena, Patton 2010), are 
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commonly co-expressed with their host gene and enter the miRNA processing pathway 
following intron splicing. The host gene/miRNA co-expression network has implicated 
these miRNAs in feedback loops with the host gene itself on occasion being the target 
(Ronchetti et al. 2008, Dill et al. 2012). The miRNA cluster miR-17-92 is an example of 
an intronic miRNA under the transcriptional control of its own dedicated transcriptional 
unit (TU) (Ota et al. 2004a).    
Figure 1.2: Genomic Organisation of microRNA 
 
Figure 1.2: Genomic organisation of microRNA. There are four ways in which miRNA can organise 
within the genome. 1) Intergenic miRNA are located within the non-coding “junk” DNA between 
coding genes, are under the transcriptional control of their own TU and can be 1a) monocistronic or 
1b) polycistronic. 2) Intronic miRNA are processed from the intron of protein coding genes 
subsequent to intron splicing and can be 2a) monocistronic, 2b) polycistronic and uncommonly 2c) 
miRtronic whereby the mature pre-miRNA constitutes the entire intron and by-passes cleavage by 
Drosha/DSCR8 through intronic splicing. All intronic miRNA can be expressed under the control of 
their own transcription units (TUs) or be co-expressed with their host gene under its own TU. 3) 
Exonic miRNA are located within the coding exon of a host gene and can be under either its own TU 
or the host genes TU. This figure was sourced from Kelly and colleagues (Manuscript accepted) 
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As of 2008 between 36% and 45% of miRNAs were found to be located in clusters in 
mouse and human (Griffiths-Jones et al. 2008). miRNA clusters are transcribed as a long 
pri-miRNA transcript and cleaved into several pre-miRNAs by the Microprocessor. 
miRNA clusters containing homologous and non-homologous miRNAs can result in 
multiple targeting of a particular mRNA target by several miRNAs (Smith et al. 2012) or 
the co-suppression of multiple mRNA targets (Kim et al. 2009b). The largest miRNA 
cluster identified to date is C19MC which consists of 46 pre-miRNAs expressed in 
tandem from a 100kb primary transcript (Bortolin-Cavaille et al. 2009). An intragenic 
miRNA of interest is the “mirtron” by which the genomic organisation is unique to any 
other type of intronic miRNA. In this instance the full mature pre-miRNA constitutes an 
entire intron between two flanking exons whereby intron splicing serves the role of pre-
miRNA cleavage usually filled by DSCR8/Drosha yielding a mature pre-miRNA with 
the appropriate secondary structure for recognition and removal from the nucleus by 
Exportin-5 (Okamura et al. 2007, Sibley et al. 2012).      
After the discovery of lin-4 and let-7 as a class of small temporal regulatory RNAs, the 
widespread identification of “microRNAs” in both animals and plants shortly followed 
with strong homology across species (Lee, Ambros 2001, Lagos-Quintana et al. 2001, 
Lau et al. 2001). Since the formation of the miRBase database in 2002 over 17,000 mature 
miRNA sequences in over 140 species have been registered (Griffiths-Jones 2004, 
Kozomara, Griffiths-Jones 2011). With the high throughput identification of novel 
miRNAs, it was vital for a nomenclature to be developed that catalogued this diverse 
family of small RNAs. The first criterion in the miRBase catalogue of miRNA 
classification is the species affiliation denoted by a three-four letter prefix of the species 
name. For example, hsa-miR-17 indicates that this miRNA is found in human (Homo 
sapiens) or CHO (Cricetulus Griceus). Additionally, “miR” designates the mature form 
of the miRNA, that being fully processed and RISC loaded, in contrast to “mir” which 
indicates the pri-miRNA or pre-miRNA sequence. miRNAs can give rise to two 
individual mature miRNA that are derived from the same pre-miRNA based on 
thermodynamic stability of the duplex ends, miRNA-17-5p and miRNA-17-3p are 
selected from the 5’ and 3’ ends of the hairpin loop respectively. Designation of the 
mature miRNAs as -5p or -3p over miR/miR* arose from the lack of experimental data 
indicating which arm of the miRNA duplex was predominantly selected, therefore the 
miRNA* species could have been originally named -5p or -3p (Ambros et al. 2003). 
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Considering their small size, a high degree of similarities between unique miRNAs is 
common and for this reason homologous miRNAs are separated into groups. miRNA-
23b and miRNA-23a differ in sequence by a single nucleotide. Given that this nucleotide 
difference may not necessarily be within the seed region, these miRNAs could target 
similar genes, placing them in the same “seed family”. As the evolution of miRNA 
families can be attributed to duplication events (Sun et al. 2012, Ehrenreich, Purugganan 
2008) and subsequent mutagenesis (Lee et al. 2011), a system has been devised that infers 
that two miRNAs are identical, paralogous, but centred in separate chromosomal 
locations (miR-92a-1 and miR-92a-2). The term “isomiR” refers to the identification of 
homologous miRNAs from the same sample source that differs purely by the addition of 
a nucleotide at either end of the mature sequence. This discrepancy in miRNA sequence 
length can be attributed to the variability in Drosha or Dicer cleavage position during 
processing of the pre-miR hairpin (Morin et al. 2008). However the Argonaute protein 
Ago-2 has been hypothesised to be involved in the generation of isomiRs through 
trimming of the 3’-terminal end of the bound miRNA (Juvvuna et al. 2012).  
 
1.2.4 microRNA mode of action 
The catalytic engine driving miRNA-mediated RNA interference is the RISC (RNA-
Induced Silencing Complex) which is composed of two vital components, the single-
stranded mature miRNA that directs RISC targeting and a member of the Argonaute 
family of proteins. Mammals encode four Argonaute paralogs referred to as Ago1-4 with 
characterisation of this family being based on the presence of the N, PAZ, MID and PIWI 
domains (Boland et al. 2011, Ma, Ye & Patel 2004). Despite the overlapping participation 
of the four Argonaute paralogs, Ago-2 has been implicated as the main driving force 
behind miRNA-targeted mRNA cleavage (Liu et al. 2004, Meister et al. 2004) miRNAs 
regulate the transcription of their target mRNAs through base pairing of the “seed” region 
situated at 2-8 nt from the 5’ end (Chi, Hannon & Darnell 2012). High complementarity 
between miRNA: mRNA is more commonly associated with target mRNA cleavage, as 
seen with siRNA, with the more common base-pair mismatching resulting in translational 
inhibition. As mentioned earlier, through the generation of IsomiRs, this degree of 
miRNA: mRNA complementarity can hypothetically be optimized in some cases through 
Ago-2 mediated 3’ terminal trimming of the bound mature miRNA (Juvvuna et al. 2012, 
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Han et al. 2011). Although both the 5’ and 3’ ends of miRNAs can vary widely depending 
on the Drosha/Dicer-dependant addition or deletion of 1-2 nt, alterations in the 5’ 
sequence has the potential to alter the seed sequence greatly resulting in changes in 
miRNA targeting specificity (Krol, Loedige & Filipowicz 2010). Activated RISC 
complexes degrade target mRNAs or inhibit translation through target binding with 
complementary/semi complementary sequences within the 3’UTR with binding sites 
often being found within the 5’ UTR and open reading frame (Kloosterman et al. 2004, 
Lytle, Yario & Steitz 2007). miRNA recognition elements (MREs) within the 3’UTR are 
further underlined by the observation that these functional target sites appear to be under 
evolutionary conservation (Kertesz et al. 2007). The RISC complex has also been 
demonstrated to mediate specific cleavage at the sarcin-ricin loop (SRL) of 28S ribosomal 
RNA eliciting translational suppression by direct ribosomal interaction (Pichinuk, Broday 
& Wreschner 2011). Accelerated mRNA decay through miRNA directed de-adenylation 
has also been observed (Djuranovic, Nahvi & Green 2012, Mishima et al. 2012).  
Despite miRNAs being associated with the fine-tuning of gene expression through 
inhibitory affects, miRNA-10a has been demonstrated to enhance the translation of 
ribosomal proteins through interactions with their 5’ UTR (Orom, Nielsen & Lund 2008). 
 
1.2.5 Target prediction algorithms and online databases/tools 
The potential for an individual miRNA to target a large number of protein coding mRNAs 
has its advantages in relation to cellular homeostasis and as possible targets for genetic 
manipulation but with this carries disadvantages to the researcher. With the small size of 
the seed region being of 6-8 nt in length and the minimum of a 6 bp match causing mRNA 
translational suppression (Brennecke et al. 2005), the challenge of predicting mRNA 
targets with a high degree confidence poses difficult without experimental validation. 
PicTar (Krek et al. 2005), miRanda (John et al. 2004) and TargetScan (Lewis et al. 2003) 
are three algorithms, among others, that utilize the classical method of searching for 
miRNA targets based on the near complementarity between the 5’ miRNA seed region 
and the target mRNAs 3’UTR; conservation of binding sites across species and binding 
energy of the miRNA target duplex. Other prediction algorithms expand on the criteria 
listed above including the incorporation of G: U wobble pairs within the seed region, 
target site accessibility and local concentration of redundant miRNA patterns with a 
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degree of flexibility in computer learning. Variation in the binding criterion applied to 
target prediction across the various databases is shown in table 1.4. Although these in 
silico tools can identify real biological targets, the researcher is presented with a 
substantial list of predicted target genes that must be experimentally verified. 
Table 1.4: Summary of the different software algorithms available for miRNA target 
prediction 
 
Table 1.4: The prediction algorithms available and the binding criteria utilised in miRNA target 
prediction. This table was sourced from a review by Barron et al (Barron et al. 2011d) extensively 
assessing the role of miRNAs as candidates for CHO cell engineering. 
Furthermore, most prediction algorithms rely heavily on the central “seed” dogma of 
miRNA-target binding (all miRNAs contain a 5’-seed region) which is not always the 
case (Lal et al. 2009a). Reducing the number of false-positives is an essential feature for 
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novel prediction algorithms. miRGator encompasses the predictive capacity of three well 
known algorithms (miRanda, PicTar and TargetScanS) providing information on 
expression, functional annotation, pathway and disease (Nam et al. 2008) with an intimate 
link to the Tarbase database for experimentally tested miRNAs across 8 organisms 
(Sethupathy, Corda & Hatzigeorgiou 2006, Vergoulis et al. 2012). Another online 
database, miRWalk, expands the binding criterion outside that of the 3’UTR 
encompassing the 5’-UTR promoter region (Lytle, Yario & Steitz 2007) and nucleotide 
coding sequence (Tay et al. 2008) spanning three species (human, mouse and rat) 
including both predicted, overlapping with predicted binding sites from 8 other prediction 
algorithms, and validated miRNA information sourced from the Pubmed online database 
(Dweep et al. 2011a).  
The reliability of combining multiple prediction algorithms appears questionable over 
one single “accurate” algorithm, reviewed in (Alexiou et al. 2009), however further 
experimental undertakings will provide insights into mechanism of miRNA:mRNA target 
interactions. One such algorithm, mirWIP, utilises experimental data in order to define 
the prediction rules (Hammell et al. 2008) whereas an example of an independent 
approach establishes an in silico prediction model based on an integrative “Omics” study 
of the mammalian inner ear (Elkan-Miller et al. 2011). Here, while studying both mRNA 
and protein levels coupled with a differential expression miRNA profile, subsequent 
crossover with prediction algorithms, including microRNA:Target pathway databases 
(Jiang et al. 2009, Ruepp et al. 2010), will permit the reduction of false positives allowing 
a high confident selection of candidate miRNAs and again enhancing the importance of 
experimental observation in order to better understand the miRNA target binding 
etiquette.  
 
1.2.6    MicroRNAs in Chinese hamster ovary cells – A role in the bioprocess 
The CHO cell is subjected to a number of bio-molecular changes during the bioprocess 
such as mechanical stress, metabolite accumulation, hypoxia, nutrient limitation, 
osmolality, etc., which dampen the capacity for optimal protein production. The use of 
RNA interference (RNAi) technology as an application to improve CHO cell specific 
productivity and recombinant protein quality ushered in the exploration of miRNAs as an 
alternative engineering strategy to target multiple genes in a single pathway or several 
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molecular pathways without impacting on the CHO cells translational machinery, 
reviewed in (Wu 2009).(Wu 2009) The identification of miRNAs in the pathology of 
diseases such as cancer through either their deletion or up-regulation implicated them as 
primary targets for intervention. This stimulated the interest in manipulating the CHO cell 
phenotype using miRNA. 
The pioneering study by (Gammell et al. 2007) explored potential miRNAs involved in 
growth, increased productivity and sustained viability in CHO-K1 during a temperature 
shift to 31˚C, a commonly exercised protocol in order to extend the CHO production 
phase (Kumar, Gammell & Clynes 2007) identifying a novel CHO miRNA involved in 
growth, cgr-miR-21. The exploitation of next-generation sequencing (NGS) technologies 
has led to the identification of over ~400 conserved mature miRNA sequences with 387 
being identified in a single undertaking using small RNAs from 6 biotechnologically 
relevant CHO cell lines (Hackl et al. 2011) with a similar study identifying a plethora of 
miR:miR* homologs in CHO across several species using illumine sequencing (Johnson 
et al. 2011). Upon the release of the CHO-K1 genome sequence (Xu et al. 2011) 
advancements in CHO genetics such as the identification of the genomic loci for over 
~200 miRNA through computational analysis (Hackl et al. 2012) will allow for the 
identification of novel CHO promoters of miRNAs that are temporally stimulated during 
the bioprocess or for the site specific overexpression or deletion of endogenous miRNAs. 
Incorporation of this newly acquired genomic sequence data has been compiled into an 
online data base (www.CHOgenome.org) (Hammond et al. 2012).  
Differential miRNA expression profiles have been carried out on CHO cells in order to 
better understand the miRNA dynamics involved in numerous industrial process such as 
engineered CHO cells (Lin et al. 2010) and CHO cells at different time points (Hernandez 
Bort et al. 2012) including clones with various growth rates (Clarke et al. 2012). A proof-
of-concept study based on a temperature shift differential expression profile, implicated 
the over-expression of the miRNA, miR-7, to have a negative effect on cell growth and a 
positive effect on cell specific productivity with no influence on apoptosis in a CHO-
SEAP cell line (Barron et al. 2011a). Proteomic analysis of miR-7 over-expression 
demonstrated an overlap in proteins up-regulated or down-regulated with the pathways 
that were seen to be manipulated (Meleady et al. 2012a).  
39 
 
Some of the cellular processes central to the bioprocess have been shown to be impacted 
by miRNA regulation in other cell types and turn out to be conserved in CHO, such as 
the impact of miR-7 deregulation (Barron et al. 2011b), whereas others have not been 
described elsewhere, as in the case of miR-466h and its role in inhibiting apoptosis in late 
stage CHO culture (Druz et al. 2013). Stable depletion of miR-7 using a miRNA sponge 
vector improved peak cell density, prolonged culture longevity and boosted secreted 
protein yield by almost 2-fold in a fed-batch process (Sanchez et al. 2013b). Similarly, 
Jadhav and colleagues enhanced the overall yield of an Epo-Fc protein through the stable 
over-expression of miR-17 (Jadhav et al. 2014). Both studies demonstrate the utility of 
miRNA-mediated engineering to improve(Lai, Yang & Ng 2013b) CHO cell growth 
without negatively impacting on specific productivity, a common trade-off for superior 
growth rates and vice versa (Lai, Yang & Ng 2013b). From a product quality perspective, 
Strotbek et al., reported that the glycosylation profile of recombinant IgG1 was not 
compromised in CHO cells engineered to stably co-express miR-557 and miR-1287, 
while inducing increased specific cellular productivity (Strotbek et al. 2013). Besides the 
manipulation of individual miRNAs, it has also been shown that tuning global, cellular 
miRNA levels via the RNAi processing machinery influences bioprocess-relevant 
phenotypes. Hackl et a., (2011) found that overall miRNA expression in CHO cells 
cultured in serum-containing medium was elevated (Hackl et al. 2011) and upon further 
investigation found that Dicer mRNA and protein levels decreased in response to nutrient 
or serum removal. However, attempts to engineer Dicer expression demonstrated a very 
sensitive phenotypic response to the levels of Dicer present in the cells. Knockdown 
below endogenous levels or excessive over-expression both negatively affected growth 
but mild overexpression was found to be beneficial (Hackl et al. 2014b). For this reason, 
fine tuning the expression of single or small numbers of individual miRNAs, such as those 
mentioned previously, is probably a better approach for those interested in targeting a 
specific cellular function or behaviour. A number of groups have reported on miRNA 
expression profiling in CHO cells representing different phenotypes, producing different 
products or grown under different conditions in order to identify potential engineering 
targets. 
Striving to improve the performance of CHO cells in industry has led to the production 
of hundreds of high quality biopharmaceuticals, sequencing of the CHO genome and now 
the identification of hundreds of microRNAs that are highly conserved and endogenously 
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encoded. Efforts to optimise the CHO phenotype using miRNAs are proving promising 
as an alternative to gene based engineering by achieving the same phenotypic outcome 
with a lightened dependency on the cells own translational machinery. Some well-known 
and routinely characterised miRNA families represent a major outlet for CHO cell 
engineering when considering the conserved nature of their mechanistic actions across 
numerous species and disease states, such as cancer, with one family in particular, miR-
34, representing the first miRNA destined to take part in clinical trials (Bader 2012). Two 
miRNA clusters are described below that exhibit considerable interest for CHO cell 
engineering in addition to the wealth of candidates that offer viable engineering targets 
(see table 1.5) 
 
Table 1.5: Candidate miRNA for CHO cell engineering 
Biological 
process 
microRNA Cluster Phenotype Target Reference 
 
 
 
 
 
 
Cell cycle 
miR-7 (CHO) No Tumour 
suppressor 
Skp2 
Psme3 
(Sanchez et al. 
2013a) 
 
miR-34a No Tumour 
suppressor 
CCND1, 
CCNE2, 
CDK4/6 
(Sun et al. 
2008a, He et al. 
2007b) 
miR-24 miR-23a~24-
2 
miR-23b~24-
1 
Tumour 
suppressor 
E2F2 
MYC 
(Lal et al. 
2009b) 
miR-17 
(CHO) 
miR-17~92 Oncogenic CDKN1a/p21 (Ivanovska et 
al. 2008) 
miR-31 No Oncogenic LATS2 
PPP2R2A 
(Liu et al. 
2010b) 
 
 
 
 
 
 
Apoptosis 
Mmu-miR-
466h 
(CHO) 
mmu-mir-
297-669 
Pro-apoptotic Bcl212 
Birc6 
(Druz et al. 
2013) 
miR-34a No Pro-apoptotic Bcl2, 
surviving 
(Bommer et al. 
2007, Shen et 
al. 2012) 
miR-15a/-16 mir-15a~16-1 Pro-apoptotic PDCD4 (Calin et al. 
2008) 
miR-21  No Pro-apoptotic HSP60 
HSP70 
(Itani et al. 
2012) 
miR-133 miR-1/-133 Pro-apoptotic Caspase 9 (Xu et al. 2007) 
 
 
 
 
 
Culture Stress 
miR-126 No Shear Stress Bcl2, 
FOXO3, Irs1 
(Zhou et al. 
2013) 
miR-31 No Hypoxia HIF (Liu et al. 
2010) 
miR-429 miR-
200b~429 
Osmolarity 
responsive 
OSTF1 (Yan et al. 
2012) 
miR-375 No Lactate 
production 
LDHB (Kinoshita et al. 
2012) 
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miR-144 miR-
4732~451a 
Oxidative stress NRF2 (Sangokoya, 
Telen & Chi 
2010) 
 
 
 
 
Energy 
Metabolism 
miR-23a miR-23a~24-
1 
Glutamine 
metabolism 
GLS (Gao et al. 
2009) 
miR-124 No Glycolysis PKM1/2 (Sun et al. 
2012b) 
Let-7 Let-7a/d/f Glucose 
metabolism 
Irs2, INSR (Frost, Olson 
2011) 
miR-23 miR-23a~24-
1 
Mitochondrial 
biogenesis 
TFAM (Jiang et al. 
2013b) 
miR-122 miR-
122~3591 
Lipid  
metabolism 
Cholesterol 
related genes 
(Esau et al. 
2006b) 
 
 
 
Protein 
Quality 
miR-34a No Core 
fucosylation 
FUT8 (Bernardi et al. 
2013b) 
miR-148b No N-Glycosylation C1GALT1 (Serino et al. 
2012) 
miR-30b/d miR-30b/d O-Glycosylation GALNT7 (Gaziel-Sovran, 
Hernando 
2012) 
 
 
 
 
Protein 
productivity/ 
secretion 
miR-33a/33b No GSIS Irs2 (Davalos et al. 
2011) 
miR-30c* No UPR XBP-1 (Byrd, Aragon 
& Brewer 
2012) 
miR-410 mir-
323b~656 
Protein 
secretion 
? (Hennessy et al. 
2010) 
miR-34a No Insulin secretion VAMP2 (Lovis et al. 
2008) 
miR-124 No Insulin 
exocytosis 
SNAP25 
synapsin-1A 
(Lovis, 
Gattesco & 
Regazzi 2008) 
Abbreviations: Bcl2-B-cell lymphoma 2, Birc6-Baculoviral AIP containing repeat 6, C1GALT1- core 1 synthase, 
glycoprotein-N-acetylgalactosimine 3-beta-galactosyltransferase, 1, CCND1/E2-Cyclin D1/E2, CDK4/6-Cyclin-dependent 
kinase 4/6, CDKN1a-cyclin-dependent kinase inhibitor 1a, FOXO3-Forkhead box O3, GALNT7- N-
acetylgalactosaminyltransferase 7, GLS-Glutaminase, GSIS-Glucose stimulated insulin secretion, Heat-shock protein-
60/70,  HIF-Hypoxia inducible factor, Irs2-Insulain receptor substrate 1/2, INSR-Insulin receptor, LDHB-Lactate 
dehydrogenase B,  LATS2-Large tumour suppressor 2, NRF2-Nuclear factor erythroid 2-related factor 2, OSTF1-
Osteoclast stimulating factor 1,  PPP2R2A-PP2A regulatory subunit B alpha isoform, PDCD4-Programmed cell death 4, 
PKM1/2-Pyruvate kinase 1/2, Psme3-Proteomsome activator subunit 3, Skp2-S-phase kinase associated protein 2, 
SNAP25-synaptosomal-associated protein 25, TFAM-Mitochondrial transcription factor A, UPR-Unfolded protein 
response, VAMP2-Vesicular associated membrane protein 2, XBP-1-X-box binding protein-1.  
 
1.2.6.1 miR-17~92 cluster 
One of the best characterised oncogenic miRNAs is miR-17~92, a polycistronic miRNA 
cluster, also known as oncomiR-1, that is among the most potent oncogenic miRNA. The 
precursor transcript for this miRNA contains 6 stem-loop hairpin structures in tandem 
that ultimately generate 6 mature miRNAs: miR-17, miR-18a, miR-19a, miR-20a, miR-
19b-1 and miR-92-1. Human miR-17~92 is located at 13q31.3, a region of the genome 
that is frequently amplified in several hematopoietic malignancies and solid tumours, 
such as diffuse B-cell lymphomas (DLBCLs), follicular lymphomas, Burkitt’s 
lymphomas and lung cancer (Ota et al. 2004b). Studies have revealed that miR-17~92 
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acts pleiotropically during both normal development and malignant transformation to 
promote phenotypes such as proliferation, inhibit differentiation, augment angiogenesis 
and sustain cell survival (Fig 1.3). The anti-apoptotic nature of the miR-17~92 cluster is 
evident in progenitor B-cells whereby c-myc induced apoptosis is suppressed by the 
transcriptional activation of this cluster (Tagawa, Seto 2005). Furthermore, the oncogenic 
transcription factor family E2F (E2F1/E2F3), whose transcription drives the cell through 
to S phase through the activation of S phase genes such as thymidine kinase, DNA 
polymerase and Cyclins E and A, has been demonstrated to be a direct transcriptional 
activator of miR-17~92 (Sylvestre et al. 2007).  Similar to c-myc, the overexpression of 
E2F1 in normal and malignant cell types is sufficient to induce p53-mediated cell cycle 
arrest and apoptosis (Hsieh et al. 1997). 
 
Figure 1.3: Pleiotropic functions of miR-17~92  
 
Figure 1.3: Above demonstrates the Pleiotropic functionality of the miR-17~92 cluster and its 
component members to generate and sustain a more aggressive cancer phenotype. Figure was 
sourced from the review by V. Olive and colleagues, 2010 (Olive, Jiang & He 2010b). 
As E2F1 acts as a transcription factor for itself it is caught in a perpetual positive feedback 
loop. However, through transcriptional activation of the miR-17~92 cluster, not only is 
fine-tuning of its own translation controlled by miR-17-5p (O'Donnell et al. 2005a) but 
entrance into apoptosis is additionally controlled through the interaction of the miRNA 
cluster with apoptotic components such as PTEN and Bim (Ventura et al. 2008). 
Tumourigenicity and aggressiveness has further been demonstrated by Dews and 
colleagues in colonocytes through the promotion of angiogenesis by targeting and 
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repressing anti-angiogenic factors such as thrombospondin-1 (TPS-1) and connective 
tissue growth factor (CTGF) by miR-18a and miR-19 respectively (Dews et al. 2006a). 
Given the wide characterisation of this miRNA cluster, it is not surprising that it has 
shown up on the radar in miRNA research in CHO. Two independent studies revealed the 
potential of the miR-17~92 cluster as an engineering tool for the manipulation of CHO 
cell growth. In the first instance, next-generation sequencing unveiled the presence of 387 
mature miRNA transcripts in CHO with the members of the miR-17~92 cluster being 
among them. Furthermore, cDNA sequencing of 26 previously validated targets (E2F1, 
CCND1, BCL211, MAPK14, PTEN, RB1 and VEGFA) of this cluster demonstrated seed 
target site conservation suggesting conserved functionality of miR-17~92 in CHO (Hackl 
et al. 2011). Transient overexpression of miR-17 was carried out by the same group to 
validate its impact on the proliferation profile of CHO. An increase of 15.4% compared 
to negative controls was reported for this miRNA suggesting the utility of the entire 
cluster as an engineering tool as being functionally viable (Jadhav et al. 2012). Secondly, 
Clarke and colleagues identified the miR-17~92 as being differentially expressed in fast 
growing CHO cells with each of the cluster members exhibiting a positive correlation in 
clones with increasing growth rates (Clarke et al. 2012). 
 
1.2.6.2 miR-23~27~24 clusters 
In humans, the miR-23a~27a~24-2 cluster is intergenic and localised on chromosome 
19p13 while its paralog miR-23b~27b~24-1 is an intronic cluster (Aminopeptidase O, 
AMPO (Sikand, Slane & Shukla 2009)) localised to chromosome 9q22 (Chhabra, Dubey 
& Saini 2010a). The deregulation and aberrant expression of both of these miRNA 
clusters have been associated with numerous cancerous phenotypes such as miR-
23b~27b~24-1 in prostate cancer (Ishteiwy et al. 2012) and miR-23a~27a~24-2 in gastric 
cancer cells (An et al. 2013). Individually however, each member of these clusters has 
been associated with numerous cellular phenotypes including cellular proliferation, cell 
cycle, apoptosis, DNA repair and cellular metabolism. In primary keratinocytes, the 
overexpression of miR-24 was demonstrated to target the cyclin-dependent kinase 
inhibitors (CDKIs) p27Kip1 and p16Ink4a thus promoting cellular proliferation (Giglio et al. 
2013). In contradiction to this mechanism of action, the targeting of key nodes of the cell 
cycle by miR-24 triggered cell cycle arrest in G1 phase through reported gene targets such 
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as MYC and E2F2, as well as their downstream targets CCNB1, CDC2 and CDK4 (Lal et 
al. 2009a). Furthermore, miR-24 levels were determined to be, in one study, highly 
expressed in patient breast carcinoma samples compared to benign breast tissues. Ectopic 
overexpression of miR-24 promoted breast cancer cell invasion and migration while 
overexpression of its direct targets PTPN9 and PTPRF reversed this observed phenotype 
(Du et al. 2013).   
From a metabolic perspective, recent reports have implicated c-Myc to have a role in the 
catabolism of glutamine through the repression of miR-23a and miR-23b (Gao et al. 
2012)(Dang 2010), thereby integrating this transcription factors role in cellular 
proliferation and metabolism. Altered glucose metabolism, also known as the “Warburg 
effect”, is a well-studied metabolic phenotype of cancer. This mechanism of “aerobic 
glycolysis” is characterised by the excessive uptake of glucose and conversion to lactate 
despite the availability of sufficient oxygen levels (Bensinger, Christofk 2012). C-Myc 
also collaborates with hypoxia-inducible factor-1 (HIF-1) to alter mitochondrial 
respiration resulting in the increased rate of glycolysis sufficient for tumour cell 
adaptation to its hypoxic (oxygen deficient) microenvironment, providing a growth 
advantage through the production of ATP and NADPH via excessive turnover of glucose 
and glutamine (Dang 2010). The link between glutamine catabolism and the increase in 
the enzyme glutaminase (GLS) has been associated with the repression of miR-23a/b, 
direct targets of GLS, by c-Myc in neoplastic cells (Gao et al. 2009).   
The third member of these two clusters miR-27a/b has been associated with cellular 
metabolism through adipogenesis regulation via interference of the key regulator PPARγ 
(Lin et al. 2009). Overexpression of miR-27a/b was demonstrated to promote endothelial 
cell sprouting through targeting of the angiogenesis inhibitor semaphoring 6A (SEMA6A) 
(Urbich et al. 2012). Not only has the oncogenic miR-27 been associated as an interfering 
factor in the G2/M check point of the cell cycle in breast cancer (Mertens-Talcott et al. 
2007) but it has additional clinical value as a prognostic marker for breast cancer 
progression and patient survival with anti-correlated expression with its target ZBTB10 
(Tang et al. 2012).  
It can be seen that the component members of the miR-23~27~24 clusters are involved 
in multiple cellular phenotypes from the opportunistic utilisation of carbon sources to 
direct activation or inhibition of pro-/anti- cell cycle regulators. Each member has 
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antagonistic to synergistic functionality, targeting multiple different aspects of cellular 
homeostasis thereby generating a tailor designed, and thriving cancer cell.  The part they 
play in key cellular processes leading to tumorigenesis could also be potentially translated 
to CHO cell engineering.  
 
1.3 microRNAs: Tools for CHO cell engineering 
Various tools exist for the manipulation of miRNAs suitable for CHO cell engineering, 
reviewed in (Barron et al. 2011e). Although, upon publication of this review, miRNAs in 
CHO was still in its infancy, various applications have been published from transient to 
stable miRNA manipulation on a wealth of recombinant CHO cells with a great degree 
of success, reviewed in (Jadhav et al. 2013).  
1.3.1 microRNA identification 
Numerous differential expression profiles have been reported to date in CHO cells under 
various culture conditions such as temperature shift (Gammell et al. 2007, Barron et al. 
2011b), nutrient depletion (Druz et al. 2011), growth rate profiling (Clarke et al. 2012) 
and culture stage profiling (Hernandez Bort et al. 2012). The conservation of mature 
miRNAs has allowed the use of human miRNA arrays to be used for the identification 
global miRNA changes in CHO cells including mouse and rat hybridization. Northern 
blotting has been used for the identification of pre-miRNA and mature miRNA through 
the use of short sequence-specific probes (Chen et al. 2004). More recently however, 
individual miRNAs can be detected based on their mature processed sequence by 
specifically designed reverse transcription (RT) primers containing a 5’-loop structure. 
This quantitative RT-PCR (qPCR) method can be SYBR-Green or Taqman based. qPCR 
based applications can also be used for more “global” large-scale miRNA profiling using 
384-well arrays, each containing single miRNA probes, which gives a significant and 
more comprehensive snapshot of miRNA interaction simultaneously (Weber et al. 2010). 
The use of hybridisation arrays, miRNA bio-arrays generated with probes against human, 
rat and mouse miRNAs, have been exploited to identify expression patterns in a similar 
way to conventional transcriptional profiling methods. This approach identified 26 
differentially expressed miRNAs in CHO subject to temperature shift and was the first 
miRNA profiling study carried out in this cell type (Gammell et al. 2007). With the release 
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of the CHO-K1 genome and the addition of over 400 mature CHO miRNA sequences to 
the miRBase database, it is only a matter of time until CHO-specific arrays are developed 
for the global characterisation of miRNAs intimately involved within different cellular 
processes of biotechnological interest. 
 
1.3.2 Transient microRNA interference  
To verify the utility of predicted miRNAs as engineering tools, phenotypic assessment is 
performed through the increase or decrease of endogenous miRNA levels. In the case of 
gain-of-function, mimics take the form of 22 nt dsRNA duplexes that are similar in 
structure to that of pre-processed or “diced” miRNAs (Fig. 1.1 4) (Ford 2006). This 
introduction of pre-processed miRNAs circumvents the requirement of the utilisation of 
the primary miRNA processing machinery such as Drosha/DGCR8 and Exportin-5 
providing immediate activity with lipid-based delivery remaining the primary method of 
transient introduction (Tseng, Mozumdar & Huang 2009). These mimics take the form of 
short-hairpin (sh) RNAs and do not possess the base-pair mismatches associated with 
natural occurring miRNA duplexes. The benefit of this is that miR* strands can be 
efficiently overexpressed and analysed, despite their “normal” endogenous structures 
favouring selection of the guide due to thermodynamic properties (Schwarz et al. 2003). 
Transient miRNA intervention using mimics has been reported in CHO in the case of 
miR-7 inducing a temperature-shift like phenotype (Barron et al. 2011b) and the library 
screen of 879 miRNAs assessing their role in productivity (Strotbek et al. 2013). 
With the identification of miRNAs being frequently located at fragile chromosomal 
locations susceptible to genomic instability resulting in chromosomal deletions or 
transcriptional attenuation (Lagana et al. 2010) it was important to develop an efficient 
method to evaluate miRNA loss-of-function phenotypes and this has subsequently been 
successfully employed through numerous means, reviewed in (Stenvang et al. 2012). 
Chemically modified antisense oligonucleotides (AON), antimiRs, are a widely 
employed approach to accomplish miRNA loss-of-function by sequestering the mature 
target miRNA, by strong hybridisation, inherently in competition with cellular mRNA 
targets resulting in translational de-repression (Dean 2001). The chemical modification 
of these small RNAs through various methods has been executed in order to prolong the 
stability and subsequently their efficacy within the cellular environment, reviewed in 
47 
 
(Stenvang et al. 2012). These modifications include the 2-OH residue of the ribose of the 
antisense RNA being replaced with 2’-O-methyl (Panzitt et al. 2007), 2’-O-methoxyethyl 
(Esau et al. 2006a), 2’-Fluoro (Lennox, Behlke 2010) and locked nucleic acid (LNA) 
(Chan, Krichevsky & Kosik 2005). Modifications confer enhanced benefits such as 
resistance to nucleases, prolong stability through stable hybridization, increase binding 
affinity without abrogating specificity and enhance melting temperature (Tm). A modified 
version of LNAs, termed 8-mer LNA-antimiRs, has been developed to assess the 
biological functions of entire miRNA seed families (Obad et al. 2011). To reduce off-
target effects such as inhibition of entire seed families, RNAi constructs have been 
designed specific to the primary miRNA sequence allowing a higher degree of specificity 
(Vaistij et al. 2010). Transient miRNA inhibition is routinely used in CHO cell screening 
such as in the case of miR-7 (Barron et al. 2011b) and miR-466h (Druz et al. 2011). 
The large-scale transfection of miRNAs using non-viral delivery has been demonstrated 
for mammalian cell cultures such as CHO in complex protein production media (Fischer 
et al. 2013). This offers new potential for miRNAs to be used in existing approved 
processes via transfection, having less regulatory implications and ultimately avoiding 
stable cell line development (Fig. 1.4). 
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Figure 1.4: Transient miRNA intervention within the bioprocess 
 
Figure 1.4: Large-scale bulk transfection can be performed transiently by introducing small working 
concentrations of either mimics or inhibitors at various culture time points in a bioreactor to achieve 
a multitude of phenotypes such as enhanced quality or yields. This figure was sourced from Kelly et 
al., 2014 (Manuscript accepted). 
Not only does transient overexpression bypass the natural miRNA processing pathways 
but synthetic miRNA stability does not allow the elucidation of prolonged phenotypic 
impacts (Thomson, Bracken & Goodall 2011). For this reason and from the perspective 
of ultimately engineering CHO cell lines for industrial application, stable methods of 
miRNA intervention are required.  
 
1.3.3 Stable microRNA interference 
Stable miRNA intervention is required to overcome the inherent pitfalls of transient 
miRNA assays such as the short half-life of introduced miRNAs, the reduced cytoplasmic 
payload of miRNAs across daughter cells upon cellular division (Song et al. 2003, 
Bartlett, Davis 2006), the saturation of miRNA biogenesis machinery and the titrational 
influence based on the reciprocal relationship between miRNAs and mRNAs (Pasquinelli 
2012). In the case of gain-of-function studies, stable overexpression provides a more 
physiological natural state of miR expression, preventing off-target effects (Grimm et al. 
2006). Furthermore, stable miRNA intervention has been reported to induce a phenotype 
in cases where transient intervention proved unsuccessful such as miR-7 in CHO cells 
(Barron et al. 2011b, Sanchez et al. 2013b). 
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The miRNA hairpin structure has been exploited in order to develop short-hairpin (sh) 
RNA vectors for the validation of gene knockdown studies (Zhu et al. 2007). shRNAs 
driven by a polymerase (pol) III promoter such as U6 (Fig. 1.5 A) are modelled after 
precursor miRNAs (Rossi 2008) containing a sequence of ~22-25 nt, a short loop region 
and the reverse compliment to the 22-25 nt region whereas other systems such as pol II 
act more like primary miRNAs in which the shRNA is flanked by natural miRNA 
sequences (Fig. 1.5 B), termed shRNA-miRs (Meerbrey et al. 2011, Du et al. 2006). The 
natural flanks take the form of miR-30 sequences (125 bases 5’ and 3’) forming the 
second generation of shRNAs (Silva et al. 2005) and have been shown to provide a higher 
knockdown efficiency (Stegmeier et al. 2005) when driven through a pol II promoter. 
shRNA-miRs transcribed in vivo from polymerase II, feed directly into the miRNA 
biogenesis pathway usurping the entire miRNA processing machinery whereby by 
shRNAs driven by pol III circumvent nuclear processing by Drosha acting like a less 
“natural” miRNA system (Lebbink et al. 2011). 
The observation that miR-flanking sequences and pol II promoters enhanced miRNA 
biogenesis in addition to abrogating it upon sequence mutations (Zeng, Cullen 2003) led 
to the final evolutionary step of these vectors to directly use the endogenous miRNA 
sequence itself (Fig. 1.5 C). 100 bp 5’- and 3’- flanks were identified to be sufficient to 
drive miRNA expression in the case of miR-199a (Furukawa et al. 2011). Multi-
expression vectors of miRNAs from various genomics locations (miR-34a, -34b and -
34c), including 60 bp, flanks have demonstrated the possibility of creating artificial 
miRNA clusters (Qiu, Friedman & Liang 2011) presenting a flexible system for “off-the-
shelf” tailored miR construct design. 
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Figure 1.5: Construct of siRNA/miRNA expression vectors 
 
Figure 1.5: A schematic diagram following the evolution of A) first generation shRNA construct 
transcribed from a pol III promoter as a hairpin that bypasses Drosha nuclear processing. B) 
Modified shRNA (shRNA-miR) to include endogenous miR-30 flanking sequences (5’- and 3’-) 
transcribed from pol II to yield a primary miRNA precursor that enters the full biogenesis pathway. 
C) Complete endogenous miRNA sequence including flanks cloned from genomic DNA and under 
the control again of a pol II promoter. 
Stable miRNA expression constructs have also been generated using the miR-155 
flanking motifs and have been successfully employed in CHO cell engineering such as 
miR-17/-21 (Jadhav et al. 2012) and the miR-17~92 cluster (Jadhav et al. 2014). 
Subsequent to the publication of the CHO genome (Xu et al. 2011), pre-miRNA 
sequences and their respective genomic locations were made available (Hackl et al. 2012). 
From this, the use of endogenous CHO sequences has been demonstrated to be more 
efficient when compared to their chimeric counterparts using miR-155 flanks (Klanert et 
al. 2013). A 3-fold increase in mature miRNA expression was observed in the case of 
(Pol III) U6 Promoter
(Pol II) CMV Promoter miR-30 5’ flanking miR-30 3’ flanking
A) First generation shRNA
B) Second generation shRNA (shRNA-miR)
C) Complete microRNA expression construct
(Pol II) CMV Promoter
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miR-221/222 and miR-15b/16 clusters when endogenous CHO clusters were stably 
expressed. The use of endogenous sequences does prove troublesome when attempting to 
overexpress miR* strands due to the thermodynamic favourability towards the guide 
strand (Gu et al. 2011). To navigate around this obstacle, shRNA-based designs have been 
exploited, eliminating natural flanking sequences which contribute a bias in strand 
selection (Yang et al. 2011) and ensuring almost full complementary of the duplex 
partner, as reported for miR-146b-3p (Qu et al. 2012). 
One method to assess prolonged miRNA inhibition has been the introduction of miRNA-
resistant target genes, circumventing miRNA specific deletion, through site-directed 
mutagenesis of the MRE, rendering the miRNA ineffective (Garcia 2008). Global 
interference with miRNA expression through genetic deletions of pivotal miRNA 
biogenesis machinery such as dicer (Ketting et al. 2001) has also been explored. Stable 
knockdown of miRNA through these means, however, proved itself to be challenging and 
ineffective as interference with miRNAs during embryonic development has been 
observed to abrogate the developmental process (Forstemann et al. 2005). The stable 
expression of shRNAs designed specifically to the mature miRNA sequence has been 
demonstrated to be effective such as in the case of miR-466h inhibition in CHO cells 
ultimately extending culture longevity (Druz et al. 2013). To reduce off target effects, 
RNAi constructs can be designed that target the miRNAs primary transcript which would 
have a higher degree of uniqueness ultimately allowing for the inhibition of a single 
miRNA target and not entire seed families (Vaistij et al. 2010). miRNA sponge 
technology offers an attractive option for stable miRNA inhibition as suggested by Barron 
and colleagues (Barron et al. 2011e) and has proved its usefulness in the optimisation of 
pharmaceutical production cells (Sanchez et al. 2013b). 
The increased understanding of miRNAs, their regulatory motifs, their biogenesis and 
processing has allowed for the development of numerous expression constructs allowing 
the researcher to develop, with minimal understanding, shRNA and miRNA vectors, 
making these regulatory molecules easily accessible for industrial applications. 
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1.3.4 microRNA sponge technology 
A recent review by Park and colleagues on genetic knockout studies in mice indicated 
that “genetic ablation of miRNAs may not result in obvious phenotypes” (Park, Choi & 
McManus 2010). This may be attributed in part to the functional redundancy inherent in 
the presence of related miRNA seed families as well as paralogs that share endogenous 
mRNA targets (Bartel 2009). As such, multiple rounds of genetic knockout would 
potentially be necessary to observe any phenotypic impact. Given the genetic complexity 
of miRNA organisation, genetic knockouts also pose problematic as the knockout of 
intronic miRNAs could interfere with host gene transcription or, in the case of clusters, 
interfere with all components instead of one. A means to navigate around this inherent 
genetic fortitude has come from observations in nature of the apparent reciprocal 
relationship between miRNAs and their target genes, reviewed in (Pasquinelli 2012). This 
lead to the hypothesis that miRNA targets could act as competitive inhibitors, competitive 
endogenous RNAs (ceRNAs) of miRNA function (Seitz 2009).  
 
The first observation of an endogenous mRNA impacting on miRNA function was 
discovered in Arabidopsis thaliana and their response to phosphate starvation (Franco-
Zorrilla et al. 2007). Upon deprivation of inorganic phosphate, up-regulation of miR-399 
resulted in the accumulation, rather than depletion, of its predicted target PHO2 (putative-
conjugating enzyme E2). It was discovered that the expected suppression of PHO2 was 
circumvented due to increased expression of the non-coding (nc) gene, IPS1. Thus IPS1 
acted as a miRNA decoy, sequestering or titrating miR-399 function away from its 
endogenous targets. Furthermore, additional mismatches in the duplex formed between 
miR-399 and IPS1 prevented Ago2-mediated slicing of the IPS1 transcript, allowing 
persistence of this “target mimic” in the cell. The presence of common MREs allow these 
ceRNAs to mutually regulate each other in a titration-dependent manner, as observed 
recently for the ZEB2 transcription factor and the tumour suppressor PTEN (Karreth et 
al. 2011, Salmena et al. 2011). Not only did the observation demonstrate that target 
mRNA abundance dilutes miRNA activity, but it identified its presence in a mammalian 
system and in contributing to a disease state (Arvey et al. 2010). Indeed this phenomenon 
was found to go beyond pairs of protein-encoding genes to include long ncRNAs 
(lncRNAs) (Ponting, Oliver & Reik 2009). To support the role of PTEN as a tumour 
suppressor, the pseudogene PTEN1 contains MREs within its 3’UTR similar to that of its 
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coding counterpart PTEN. Expression of this pseudogene transcript retains biological 
activity as a decoy to sequester and fine tune the translation of the coding PTEN through 
competitive binding. Indeed it’s been shown that the PTEN1 locus is frequently lost in 
human cancers (Poliseno et al. 2010).  
 
More recently, the phenomenon of head-to-tail splicing of exons has been shown to 
generate an exciting new class of non-coding RNAs with regulatory potential, known as 
circular RNAs (circRNAs) (Danan et al. 2012, Burd et al. 2010, Hansen et al. 2011). For 
example, an antisense transcript from the cerebellar degeneration-related protein 1 
(CDR1as) (Memczak et al. 2013) was found to generate a circular decoy that harboured 
63 conserved binding sites for the well characterised tumour suppressor miRNA, miR-7 
(Zhang et al. 2013). This class of regulatory RNA offers a viable engineering tool due to 
its superior stability, potentially as a result of its inherent resistance to cytoplasmic 
debranching enzymes and RNA exonucleases (Jeck et al. 2013).   
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Figure 1.6: microRNA sponges divert endogenous miRNA activity 
 
Figure 1.6: microRNA sponges repress microRNA function: A) demonstrates the microRNA 
mediated translational repression of the target gene through Watson-Crick imperfect base-pairing 
to the miRNA target sequence (Black box) resulting in no protein expression. B) Translational 
activation of the endogenous mRNA target through sequestration of the antagonizing miRNA by 
decoy miR-sponge sequences (Green box) transiently expressed form a plasmid vector. C) Similar 
level of microRNA sponging achieved by a chromosomally integrated sponge containing more MBS 
that is expressed at lower levels compared to transient expression from a plasmid in diagram B.  
The discovery of these endogenous miRNA decoys led to the development of “microRNA 
sponge technology” as an experimental tool to evaluate miRNA function (Ebert, Neilson 
& Sharp 2007). Named for their ability to soak up endogenous miRNAs, miRNA sponges 
contain multiple sites of complementarity to the miRNA of interest, usually in an artificial 
3’UTR placed downstream of a reporter gene such as GFP (Fig. 1.6). Drawing from 
lessons in nature, mismatches or “wobble” are introduced as a means to inhibit miRNA-
mediated mRNA cleavage thus prolonging the life-time of the sponge decoy (Kluiver et 
al. 2012b). Introduction of “wobble” has been demonstrated to be more effective at 
diverting endogenous miRNA function than perfect antisense MREs due to the prolonged 
A) mRNA translation repression by miRNA
B) miRNA inhibition through target mimicry: “miR-Sponges”
C) miRNA inhibition through reduced sponge expression with increased MBS
NO PROTEIN PRODUCT
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life-time of the miR-sponge transcript as a result of miRNA/RISC-mediated mRNA 
cleavage inhibtion (Haraguchi, Ozaki & Iba 2009). As seed pairing has been observed to 
be sufficient to drive miRNA-target interactions, miR-sponges have the potential to 
sequester entire miRNA seed families as demonstrated in the case of the let-7 family 
(Yang et al. 2012). Although this can complicate efforts to understand the network of 
downstream molecular events that accompany multi-miRNA inhibition, research has 
proven the miR-sponge approach to be a viable tool for industrial rCHO cell line 
engineering (Sanchez et al. 2013b). In this study, stable diversion of miR-7 through the 
presence of a sponge decoy resulted in increased peak cell density, prolonged viability 
and ultimately enhanced yield in a CHO fed-batch culture.  
Another potential application of this approach is the use of sponge sequences as a means 
of controlling the expression of transgenes in a miRNA-dependent manner. For example 
if there were a situation where overexpression of a particular gene was desirable only at 
a particular point in the culture but otherwise it should be silent. By identifying an 
endogenous miRNA whose expression was anti-correlated with the desired transgene 
expression profile, a sponge for that miRNA placed downstream of the transgene 
sequence would suppress its expression during the chosen culture phase but become de-
repressed later when the miRNA was down-regulated (Fig. 1.7). This application is in 
some ways equivalent to the use of inducible promoters.  
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Figure 1.7: Mechanism of exploiting a miRNA-dependent transgene 
 
Figure 1.7: The above schematic diagram demonstrates the hypothetical utility of miRNA sponge 
technology when implemented within a CHO cell system of whose miRNA expression profile across 
various stages of the culture is known. A plasmid vector expressing the cell cycle inhibitor, p27, 
engineered to contain MREs specific for a given miRNA whose expression profile is known across 
various phases of CHO cell culture (blue line). In early Exponential growth phase p27 expression (red 
line) is maintained at a low level due to the high abundance of mature miRNA specific for the pre-
engineered MREs. Once endogenous miRNA expression is transcriptionally down-regulated, p27 
translation gradually becomes de-repressed ultimately halting the cell cycle mimicking a temperature 
shift-like phenotype. The above figure was sourced from Kelly and colleagues, 2014 (Manuscript 
accepted). 
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1.4 Glyco-engineering 
As of 2012, there were 28 FDA approved recombinant therapeutic antibodies which 
represented 36% of the total market revenue for pharmaceutical biologics (Butler, 
Meneses-Acosta 2012). The development of chimeric and humanised antibodies marked 
a major breakthrough in monoclonal antibody (Mabs) therapy as previous therapeutic 
antibodies were of murine origin thus introducing a foreign, highly immunogenic protein 
demonstrating suboptimal effector functions with short half-lives (Reichert 2010). The 
efficiency of Mabs is due to their antigen specificity and their downstream effector 
functions through the formation and activation of immune complexes. All FDA approved 
therapeutic Mabs (Table 1.6) are of the immunoglobulin G (IgG) class which in itself is 
composed of four subclasses: IgG1, IgG2, IgG3 and IgG4, defined according to their 
relative concentrations in normal serum. It has been demonstrated that each subclass 
elicits a unique profile of effector functions and that selection of each isotype for clinical 
development is dependent on the desired therapeutic outcome and disease type (Jefferis 
2007). The utility of monoclonal antibody therapy is layered and when tailor designed in 
the right way can achieve several outcomes such as: (i) killing cells or organisms, 
cancer/bacteria; (ii) neutralisation of soluble molecules such as cytokines in chronic 
diseases or endotoxins; (iii) act as agonists or antagonists of cellular activity; (iv) induce 
apoptosis, and (v) delivery of a cytotoxic payload such as a chemotherapeutic drug. The 
end point clinical efficacy of therapeutic antibodies is dependent on two mechanisms: 
target-specific binding of the Fab (antigen-binding fragment) domain in addition to the 
availability of cell surface epitopes and the immune-mediated effector functions 
orchestrated through the activation of antibody-dependent cell cytotoxicity (ADCC) 
and/or complement-dependent cytotoxicity (CDC) (Chan et al. 2010, Raju 2008). 
Immune-mediated effector functions are mediated by interactions between the Fc 
(Crystallisable fragment) of the Mab and Fc receptors (FcRs) on various cell types (Siberil 
et al. 2007). Although CHO cells are the primary mammalian cell type for recombinant 
therapeutic protein production due to their similar posttranslational modifications, it has 
now emerged that the variable glycoforms produced in CHO can impose limitations on 
effector functions (Nimmerjahn, Ravetch 2008). Such glycoforms can reduce the potency 
of ADCC activation, requiring higher therapeutic doses per treatment and ultimately 
increase global demand thus placing a strain on biopharma companies to boost product 
titres.     
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Table 1.6: FDA approved therapeutic antibodies and Fc fusion proteins 
Generic 
name 
Format Target Disease MOI Class Effector 
function 
Campath Humanized IgG1κ CD52 CLL Induction of ADCC I High 
 
 
Erbitux 
 
Chimeric 
(murine/human) 
IgG1κ 
 
 
EGFR 
Metastatic 
colorectal 
cancer/head 
and neck 
cancer 
 
Inhibition of EGFR 
signalling, ADCC 
 
 
I 
 
 
High 
Arzerra Human IgG1κ CD20 CLL Induction of CDC 
and ADCC 
I High 
 
Rituxan 
Chimeric 
(murine/human) 
IgG1κ 
 
CD20 
Non-
hodgkin’s 
lymphoma, 
RA and CLL 
Induction of 
apoptosis, CDC and 
ADCC 
 
I 
 
High 
Herceptin Humanized IgG1κ HER2 HER2+ 
breast cancer 
Inhibition of HER2 
signalling, ADCC 
I High 
 
 
Humira 
 
 
Human IgG1κ 
 
 
TNFα 
RA, 
JIA,PA,CD, 
AS and 
plaque 
psoriasis 
 
Neutralisation of 
TNFα activity 
 
 
II 
 
 
Moderate 
 
Simulect 
Chimeric 
(murine/human) 
IgG1κ 
 
CD25 
Acute 
transplant 
rejection 
Inhibition of IL-2-
mediated activation 
of lymphocytes 
 
II 
 
Moderate 
 
Raptiva 
 
Humanized IgG1κ 
 
CD11a 
Plaque 
psoriasis 
Inhibition of CD11a-
associated leukocyte 
adhesion 
 
II 
 
Moderate 
Simponi Human IgG1κ TNFα RA, PA and 
AS 
Neutralisation of 
TNFα activity 
II Moderate 
 
Remicade 
 
Chimeric 
(murine/human) 
IgG1α 
 
 
TNFα 
CD, RA, PA, 
ulcerative 
colitis, AS 
and plaque 
psoriasis 
 
Neutralisation of 
TNFα activity 
 
 
II 
 
 
Moderate 
 
Enbrel 
 
TNFR2 ECD-Fc 
(IgG1) fusion 
 
TNFα 
RA, JIA, 
PA, AS and 
plaque 
psoriasis 
 
Neutralisation of 
TNFα activity 
 
II 
 
Low 
 
Vectibix 
 
Humanized IgG2κ 
 
EGFR 
Metastatic 
colorectal 
carcinoma 
Inhibition of EGFR 
signalling: Induction 
of apoptosis 
 
II 
 
Low 
 
Avastin 
 
Humanized IgG1κ 
 
VEGF 
Metastatic 
colorectal 
cancer 
Neutralisation of 
VEGF activity 
 
III 
Low 
Xolair Humanized IgG1κ IgE Allergic 
Asthma 
Inhibit binding of IgE 
to FcεRI 
III Low 
Table 1.6: Of the list of antibody therapeutics listed, Class refers to the specific mode of action (MOA) 
specified further in figure 1.9. 
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1.4.1 Antibody structure and effector functions 
Antibodies form an intricate part of the adaptive immune system and are responsible for 
the recognition of potentially any antigen (epitope) through the three variable regions 
within both the light and heavy chain that form the complementarity-determining region 
(CDR) (Sela-Culang, Kunik & Ofran 2013) of the antigen-binding fragment (Fab). The 
basic structure of a Mab consists of four polypeptide chains: two identical light chains 
and two identical heavy chains (EDELMAN, BENACERRAF 1962). Figure 1.8 shows 
the association that the four polypeptides demonstrate though covalent and non-covalent 
interactions to form the three independent mature antibody structures. The two Fabs are 
composed of the light chain and the N-terminal domain of the heavy chain harbouring the 
variable regions which determines hyper-variability in antigen specificity along with two 
constant domains (CH1 and CL). Additionally, two domains forming the heavy chains 
are composed of two constant domains (CH2 and CH3) which constitute the crystallisable 
fragment (Fc) and contain moieties that interact with ligands on immune cells that elicit 
effector functions.  
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Figure 1.8: Structure of the immunoglobulin G (IgG) molecule 
 
Figure 1.8: Various domains the makes up a mature IgG molecule. The two heavy chains and two 
light chains are represented as the orange and blue structures, respectively, linked non-covalently by 
the flexible hinge region. Antigen specificity is dictated by the two antigen-binding fragments (Fab) 
made up of covalently linked light and heavy chain. Glycosylated sites are located on the conserved 
Asparagine 297 (Asn297) on each heavy chain CH2 domain.   
Fc receptors (FcRs) are glycoproteins belonging to the immunoglobulin superfamily and 
are composed of the classes FcαR, FcγR and FcεR of which FcγR are mostly expressed 
on immune cells and are fundamental for therapeutic outcome. FcγRs are divided into 
three subtypes – FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) categorised based 
on the their affinity for IgG and the downstream signalling pathways that they trigger 
(Nimmerjahn, Ravetch 2008). As mentioned earlier, antibodies can be exploited to elicit 
a series of therapeutic outcomes such as neutralisation of a soluble signalling molecule 
such as TNFα in Rheumatoid arthritis (Class III), opsonisation and clearance through 
ADCC/CDC via targeting of cell-bound antigens (Class I) and receptor blocking 
interfering with “normal” aberrant signalling (Class II), Figure 1.9. 
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Figure 1.9: Mechanism of action of therapeutic antibodies.  
 
Figure 1.9: Mechanisms of action (MOA) of therapeutic antibodies including targeting and 
subsequent clearance of cell/molecule via antigen binding and ADCC/CDC activation (Class I), 
Interference with aberrant signalling through receptor binding and blocking (Class II) and 
Clearance and deactivation of soluble antigens (Class III). Figure was sourced from (Jiang et al. 
2011). 
Additionally, better understanding of antibody structure and function have allowed for 
the development of Fc-fusion proteins, such as Etanercept (Enbrel), which is a Tumour 
Necrosis factor receptor 2 (TNFR2) fused to the constant Fc-region of an antibody which 
prolongs its half-life in serum via its interaction with the neonatal Fc receptor and appears 
to act independently of glycoforms (Roopenian, Akilesh 2007). The predominant subclass 
of antibody licensed for therapeutic rMab use is the IgG1 isotype (Bruggemann et al. 
1987) largely due to its strong association with the FcγRIIIa, a ligand responsible for 
ADCC activation through natural killer (NK) cells (Bruhns et al. 2009). This affinity is 
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shared by the IgG3 isotype but not with the IgG2 and 4 subclasses. For example, the 
primary pathway of Ritumximab in the treatment of CD20+ B lymphocytes in non-
Hodgkin’s lymphoma appears to be mediated through the activation of ADCC via 
association with NK cells expressing FcγRIIIa receptors (Congy-Jolivet et al. 2007). It is 
interesting that a clinically approved EGF-R antibody, panitumumab of the IgG2 isotype, 
interacts less efficiently with human FcγRs and does not activate the compliment cascade 
(Dechant et al. 2007). It is from these advancements in our understanding of Mab/immune 
system relationship that derivation away from the predominant IgG1 isotype is a growing 
field. Long term exposure to such antibodies in the case of chronic inflammatory diseases 
can, by nature, activate immune cells to release inflammatory cytokines thus contributing 
to the symptoms being targeted. Development of Mabs or fusion proteins specific for 
TNFα but with a low affinity for FcγRIIIa receptors could function to sequester and block 
TNFα signalling without, in this instance, the unwanted immune signalling.  
 
1.4.2 Antibody glycoforms 
Despite the CHO cell being the favoured production vessel of recombinant protein 
therapeutics due to similarities in their post-translational modifications, the recent release 
of the CHO genome sequence has revealed a number of discrepancies in the genomic and 
transcriptomic profile of genes associated with glycan synthesis and degradation (Xu et 
al. 2011). Although only constituting 2-3% of the total antibody mass, glycosylation of 
the IgG-Fc region has been demonstrated to be essential to the activation of the 
downstream biological effector functions. This glycosylation is through covalent 
attachment of an oligosaccharide at the conserved Asparagine 297, Asn297 (Figure 1.8). 
A diantennary type oligosaccharide comprised of a core heptasaccharide and variable 
addition of fucose, galactose, bisecting N-acetylglucosamine and sialic acid contributes 
to the glycoforms of Fc modified Mabs (Fig. 1.10). With the variation in the addition of 
sugars to the core heptasaccharide, a total of 32 unique oligosaccharides can be generated 
from each partner of the heavy chain. Taking into account the duplicity of heavy chains 
in a single Mab there is the potential of ~500 glycoforms to be generated of mature 
antibody (Jefferis 2009a).   
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Figure 1.10: Diantennary-complex oligosaccharide composition of the IgG-Fc 
 
Figure 1.10: A schematic representation of the Diantennary-complex oligosaccharide that is 
covalently attached to the conserved Asparagine 297 (Asn297) on both CH2 domains of the heavy 
chains. The oligosaccharide is composed of a core heptasaccharide (sugars in blue) and outer arm 
sugars (in red) variably attached, Fucose (Fuc), Galactose (Gal), Bisecting N-acetylglucosamine 
(GlcNAc), sialic acid and N-acetylneuraminic acid (Neu5Ac). This figure was sourced from (Jefferis 
2009a).  
Nomenclature for naming the various glycoforms can use G0, G1 and G2 for core 
oligosaccharides bearing zero, one or two galactose residues, respectively. In the event of 
an addition of fucose (Fuc), the notation G0F, G1F and G2F is used. Finally, with the 
addition of a bisecting N-acetylglucosamine (GlcNAc) a B is added to the naming system 
previously described, such as G0B or G0BF (Fig. 1.11). Less than 10% of 
oligosaccharides are sialylated so have not been included in the notation description 
(Mizuochi et al. 1982).  
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Figure 1.11: Diantennary oligosaccharide structure and nomenclature 
 
Figure 1.11: The naming system of the variable oligosaccharides that can be generated on each 
isolated heavy chain and their corresponding glycan structure. Above shows the 16 variants of each 
core heptasaccharide without including the addition of a sialic acid group. Taking into account the 
16 variations on both heavy chains shown above, the total number of unique glycoforms is 128 (16 x 
16) which is divided by two because of the symmetry of the molecule. This figure was sourced and 
modified from (Jefferis 2009a). 
It has been observed that the oligosaccharide present on glycoproteins contribute to their 
stability and solubility (Krapp et al. 2003, Mimura et al. 2000) so it is not surprising that 
a-glycosylated or de-glycosylated IgG forms result in a compromised or ablated effector 
mechanism mediated through FcγRI, FcγRII and FcγRIII.(Sinclair, Elliott 2005). CHO 
cells predominantly produce the top eight glycoforms (a-h) in figure 1.11; however, the 
proportion of galactosylated and non-fucosylated IgG-Fc is relatively low by comparison. 
CHO cells are unable to add the bisecting N-acetylglucosamine as they do not express the 
GnTIII gene but do possess a genomic homolog (Xu et al. 2011). In the absence of these 
A - G0
C – G1
E – G0F
G – G1F
I – G0B
K – G1B
M – G0FB
O – G1FB
B – G1
D – G2
F – G1F
H – G2F
J – G1B
L – G2B
N – G1FB
P – G2FB
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glycan modifications, CHO cells possess the ability to add other sugars that humans do 
not retain thus contributing to immunogenicity such as the addition of galactose in an α(1-
3) linkage. These observations have led to the exploration and development of CHO cells 
engineered to produce specific glycoforms that mediate enhanced effector functions. 
 
1.4.3 Glycan-manipulation 
Present CHO cell production vessels produce rMabs with over 90% fucosylated forms of 
IgG-Fc. Engineered CHO cells to express the GnTIII gene to add the bisecting N-
acetylglucosamine residue on the IgG-Fc bound core heptasaccharide demonstrated a 2-
fold increase in ADCC for a rituximab-like product (Davies et al. 2001). Further 
investigation revealed that this enhanced effector ADCC was mediated through the 
inhibition of the subsequent addition of Fucose to the primary N-acetylglucosamine 
residue through the prior addition of the bisecting GlcNAc in the golgi apparatus (Ferrara 
et al. 2006). Targeting fucosyltation of the primary GlcNAc is now emerging as a viable 
approach for cellular engineering strategies, a process that has been extended to 
encompass the therapeutic antibody Herceptin with a great deal of success in the 
laboratory (Suzuki et al. 2007b).  
A multitude of strategies have been employed in the engineering of CHO cells that 
produced non-fucosylated antibodies such as short-hairpin RNA technology or genetic 
knockouts of the gene responsible for mediating fucosylation, α1,6-fucosylatransferase 
(FUT8) generating Mabs with over 100-fold increased potency in ADCC (Mori et al. 
2004, Malphettes et al. 2010, Yamane-Ohnuki et al. 2004). Alternative strategies have 
attempted to hit the fucosylation process from multiple angles including simultaneous 
knockdown of the enzyme responsible for generating the prerequisite, GDP-fucose, for 
fucosylation GDP-mannose 4,6-dehydratase (GMD), including the GDP-fucose 
transporter and FUT8 with great success (Kanda et al. 2007, Imai-Nishiya et al. 2007). 
An interesting observation was that in the case of GMD-only knockouts, fucosylation was 
revived in the presence of L-Fucose supplementation through a salvage pathway that 
bypassed the glucose-derived GMD-mediated generation of GDM-fucose (Fig. 1.12). 
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Figure 1.12: GDP-fucose salvage pathway for FUT8-mediated fucosylation 
 
Figure 1.12: Antibody fucosylation can be targeted with the addition of compensatory pathways that 
exist through the salvage pathway that generates GDP-fucose through the supplementation of L-
fucose which compensates for GMD knockout. The schematic diagram above was reported in (Kanda 
et al. 2007). 
The increased affinity of non-fucosylated IgG-Fc for FcγRIIIa may be due to the 
reduction or absence of steric inhibition at the receptor-ligand interface. The structure of 
the Fc portion of IgG is flexible and takes the form of a horseshoe-like conformation that 
forms a binding cleft for FcγR interaction. The oligosaccharides covalently linked to 
Asn297 are also flexible in nature and move to accommodate the IgG-Fc-FcγR 
association. Fucosylation has been proposed to reduce the flexibility of the Diantennary 
glycan thus contributing to this stoichiometric interference.  
Despite the advancements in cell line development for the production of tailor designed 
antibody glycoforms eliciting enhanced effector functions, implementing such 
technologies to the manufacture of currently available recombinant Mabs such as 
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Herceptin and Rituxan would be a futile endeavour. The reason for this is that, although 
the process would ultimately generate a more potent product, the resources and time 
required to develop the engineered production CHO cell lines would be extensive. 
Because the glyco-profile of the product being different to its predecessor despite antigen 
specific remaining unchanged, it would be classified as a “New” product thus requiring 
clinical trial testing, at high a cost, before FDA approval. All is not lost however, with the 
patents expiring on many of these blockbuster therapeutics and over 350 novel and 
competing therapeutic Mabs in early development, CHO cell production factories 
genetically engineered to produce specific glycoforms can be implemented from the 
ground up, playing a pivotal part in the generation of “Bio-similar” or hopefully “Bio-
Betters” (Reichert 2013).   
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Aims of thesis 
1 Functional screen of a panel of miRNAs identified in a multi-omics profile of CHO 
cells with varying growth rates  
To: 
 Determine whether the integration of multiple datasets (miRNA, mRNA and 
protein) can allow for the identification of high priority miRNA targets. 
 Evaluate the role miRNAs play in the regulation of CHO cell growth and other 
bioprocess relevant phenotypes (Apoptosis and productivity). 
 Explore the feasibility of screening combinations of miRNAs.  
 Prioritize a short list of mRNA candidates desirable for stable CHO cell 
development. 
 
2 miR-34a as a potential candidate for CHO cell engineering 
To: 
 Explore the stable depletion of miR-34 using miRNA sponge technology on the 
CHO cell phenotype. 
 Determine if miR-34 depletion and miR-34a overexpression alters secreted 
antibody fucosylation profiles. 
 
3 miR-23b* as a potential candidate for CHO cell engineering 
To: 
 Explore the influence of stable depletion of miR-23b* using miR-sponge 
technology on the CHO cell phenotype.  
 
4 miR-23 depletion as an attractive tool for industrial application 
To: 
 Identify the role miR-23 depletion alone plays in CHO-SEAP cells following the 
observation of enhanced growth/productivity under stable cluster inhibition. 
 Determine if miR-23 depletion enhances CHO cell mitochondrial function. 
 Determine the mechanism behind the observation of elevated SEAP activity. 
 Attempt to identify potential targets of miR-23 through label-free mass 
spectrometry. 
 Carry out label-free mass spectrometry on isolated mitochondria. 
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Chapter 2 
 
 
 
 
 
 
 
Materials & Methods 
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2.1 General Techniques of Cell Culture 
2.1.1 Ultrapure water 
Ultrapure water was used in the preparation of all media and solution when specified. For 
ultra-purification, the water was initially pre-treated which involved activated carbon, 
pre-filtration and anti-scaling. This water was then purified by a reverse osmosis system 
(Elga USF Maxima Water Purification System) to a standard of 12 – 18 MΩ/cm 
resistance. 
 
2.1.2 Glassware 
All glassware and lids were soaked in a 2% (v/v) solution of RBS-25 (VWR International) 
for at least 1 h (hr). This is a deproteinising agent, which removes proteineous material 
from the bottles. Glassware was scrubbed and rinsed several times in tap water. The 
bottles were then washed by machine using Neodisher detergent, an organic, phosphate-
based acid detergent. Bottles were then rinsed twice with distilled water, once with 
ultrapure water and sterilised by autoclaving (121˚C for 20 min under a pressure of 1bar). 
The spinner vessels were additionally treated with 1M NaOH solution over night to 
further ensure the elimination of cell debris from the inner surface and were then washed 
twice with ultrapure water. Spinners were sealed in autoclave bags (Stericlin, 0775) and 
autoclaved. Thermo-labile solutions (i.e. 10% DMSO, serum) were filtered through a 0.22 
µm sterile filter (Millipore, millex-gv, SLGV-025BS).  
 
2.1.3 Cell culture cabinet 
All cell culture work carried out in a class II laminar air-flow (LF) cabinet (Holten). 
Before use, the laminar was turned on and the air flow was allowed to acclimatize for 10 
min. Both before and after use, the laminar flow cabinet was cleaned with 70% industrial 
methylated spirits (IMS). Any items brought into the LF cabinet were swabbed down with 
IMS and regular cleaning of gloved hands with IMS was carried out to insure the 
prevention of contamination. Only a single cell line/clone was used in the LF cabinet at 
any one time. If a second cell line/clone was being used a period of 15 min clearance was 
adhered to in order to prevent/minimize cross contamination between cell lines/clones. 
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Weekly cleaning of the LF cabinet included Virkon, a detergent solution (Virkon, Antec 
International; TEGO, TH. Goldschmidt Ltd.), followed by water and IMS. 
 
2.1.4 Incubators 
Adherent cells were maintained at 37 ˚ C, in an atmosphere of 5% CO2 and 80% humidity. 
Cells in suspension were also maintained in these conditions in an ISF1-X (Climo-
Shaker) Kuhner incubator with a speed of 130-170 rpm. Weekly cleaning of the 
incubators was adhered to and followed the same protocol as described for the cell culture 
cabinet. 
2.2 Subculture of cell lines 
Cells were maintained as described above (see 2.1.4: Incubators). Cells were sub-
cultured every 3-4 days in order to maintain them in mid-exponential phase of their 
growth cycle. In the event of temperature shift assays, cells were transferred from ambient 
37 ˚C growth to a 31˚C incubator. All cell lines used and their required culture conditions 
are tabulated below (Table 2.1).  
Table 2.1: Cell lines, Culture conditions, Media types and Selection reagents 
Cell lines and their associated growth conditions 
Cell line 
I.D. 
Cell Type Culture 
Media 
Culture 
Format 
Antibiotic 
Selecting 
Agent 
Antibiotic 
Concentration 
(nM/mL) 
CHO-K1-
SEAP 
rCHO CHO-S-
SFMII 
Suspension Geneticin 
(G418) 
1000 µg  
CHO-K1 CHO ATCC 
+5%FCS 
Monolayer None None 
CHO-
1.14 
IgG-
secreting- 
rCHO 
R5 Suspension Methorexate 
(MTX) 
450 nM 
CHO-
5.18F 
IgG-
secreting- 
rCHO 
AS1 Monolayer MTX 450 nM 
CHO-
11.1S 
IgG-
secreting- 
rCHO 
AS1 Monolayer MTX 450 nM 
CHO-
5.22F 
IgG-
secreting- 
rCHO 
AS1 Monolayer MTX 450 nM 
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2.2.1 Anchorage-dependent cells (Monolayer) 
Spent media was removed from the flask by pipette and discarded into a sterile waste 
bottle. The flask was then rinsed with 2-5 mL of autoclaved/sterile PBS in order to remove 
any residual media. Depending on the size of the culture vessel, 2-5mL of trypsin was 
added to the flask covering the cells and incubated at 37 ˚C for approximately 2-5 min 
until all of the cells have become detached. The level of cell detachment was monitored 
by microscopic observation. A 5mL volume of serum-containing media was added to the 
flask once all the cells were detached in order to deactivate the trypsin. The cell 
suspension was placed into a 30 mL sterile universal container and centrifuged at 1000 
rpm for 5 min. The supernatant was discarded from the universal and the pellet was 
resuspended in fresh complete media. A small aliquot was removed and cell count was 
performed. Another aliquot of this cell suspension was then removed and used to seed a 
fresh culture vessel at the required density. Cells were passaged once 90-100% 
confluency was reached otherwise spent media was removed and fresh media was added 
to the culture flask.   
 
2.2.2 Suspension cells 
Stock cells were maintained in a spinner vessel in a 30-50 mL volume at 37 ˚ C in a Kuhner 
Climo-shaker at 170 rpm. A small aliquot was sampled for counting by trypan blue 
exclusion and the required seeding density of 2 x 105 cells/mL was calculated. If the 
required volume of cells from the working stock exceeds 10% of the culture volume then 
the amount of cells needed is centrifuged at 1000 rpm for 5 min. Conditioned media is 
poured off into a sterile waste container and the cell pellet is resuspended in 30-50 mL of 
media. Some cells lines require the fresh stock flask to be supplemented with 10% 
conditioned media.  
 
2.2.3 Cell counting and viability determination  
2.2.3.1 Trypan blue exclusion method 
Prior to cell counting, an aliquot of sample was extracted from either the subculture of 
adherent cells or a direct sampling from suspension cells as described in (Subculture 
73 
 
2.2.2). An aliquot of cell suspension was added to Trypan Blue (GIBCO, 525) at a ratio 
of 1:1. Prior to the addition of Trypan Blue a dilution can be performed by adding volume 
of media to the sample. The Trypan Blue/Cell sample mixture was incubated at room 
temperature for 2-3 min. A small aliquot (10 µL) was then applied to the chamber of a 
glass cover-slip enclosed haemocytometer. For each of the four corner grids of the 
haemocytometer, cells in the 16 squares were counted under a light microscope (Fig. 2.1). 
Figure 2.1: Haemocytometer Grid Layout  
 
The average of the four grids was multiplied by a factor of 104 (Volume of the grid) and 
the relevant dilution factor to determine the average cell count per mL in the original 
suspension. Viable cells exclude the Trypan Blue dye as their membranes remain intact 
and therefore remain unstained while non-viable cells stain blue.  The percentage viability 
of the culture is calculated by counting non-viable cells and viable cells in the sample and 
dividing the total cell count (viable and non-viable) by the viable cell count. 
 
2.2.3.2 Guava ViaCount® assay 
The Guava ViaCount assay is an efficient alternative to Trypan Blue Exclusion for the 
high throughput determination of cell numbers and viability. The active Guava 
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ViaCount® Reagent (Guava Technologies, 4000-0041) discriminates between viable and 
non-viable cells based on the permeability of two DNA-binding dyes. One dye is 
membrane permeable and stains all nucleated cells producing a fluorescent signal that is 
detected by photomultiplier tube 2 (PM2). The remaining dye penetrates the membrane 
of non-viable cells of which membrane integrity has been lost producing a detectable 
fluorescent signal on photomultiplier tube 1 (PM1). Single positive events of viable cells 
are detected and recorded when the fluorescent signal is accompanied by a signal of 
forward light scatter (FSC) which is of an appropriate intensity to that produced by a cell 
above a particular size. An Event with an accompanying low FSC is counted as cellular 
debris and not included within the live nucleated cell population. Non-viable cells will 
emit a fluorescent signal form the dead cell stain. The read out format for the Guava 
ViaCount assay is a 96-well plate and no less than 100 µL should be used per well. It is 
essential that the cell count present is no less than 10 cells/µL and no more than 500 
cells/µl which could result in inaccurate reads. Cells were diluted in serum free media as 
well as taking into account the addition of 100 µL of Guava ViaCount® Reagent. Plate 
set-up and inclusion of dilution factors is described in section (see 2.2.3.2.1). Guava 
ViaCount® Reagent was allowed to adjust to room temperature. 100 µL of pre-diluted 
sample was added to 100 µL of Guava ViaCount® Reagent and allowed to incubate at 
room temperature for at least 10 min before using the Guava flow cytometer.  
 
2.2.3.2.1 WorkEditTM Software 
The WorkEditTM software programme allows the acquisition command set-up to be 
performed for samples in a 96 well Round Bottom microplate (Corning Inc. COSTAR®, 
10308005) in the sample tray. Figure 2.2 shows the screen layout of the WorkEditTM 
command template. The right hand side of the screen shows the grid template of the 96 
well microplate and allows for the selection of sample wells highlighted in green. The left 
hand side of the screen allows for the selection of the assay type to be performed in this 
case being Guava ViaCount. Acquisition events and acquisition order allows the selection 
of the number of viable cell events per sample and the order in which the microplate will 
be read. Most importantly, entering the dilution factor is necessary for the analysis of each 
samples cell numbers accurately.   
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Figure 2.2: WorkEditTM command screen layout 
 
Figure 2.2: WorkEditTM command screen layout: The right hand side shows the sample well layout 
and allows selection of the well for analysis (highlighted in green). Above it the layout for 10 
microcentrifuge sample tubes along with the 6 well locations required for cleaning. The left hand side 
of the screen allows the selection of assay type, acquisition event number, acquisition order, auto 
saving data files, mid run washing steps, and sample dilution factor.   
 
2.2.3.2.2 EasyFit Analysis     
EastFit analysis allows the software to calculate the results based on its own methodology. 
This type of analysis groups all events into three individual population categories – viable 
cells, dead/apoptotic cells and cellular debris. EasyFit uses its own grouping method that 
clusters data into populations discriminating between the three population types. A 
manual method can be executed alongside this where a gate can be imposed upon the 
“healthy” population by altering the FSC threshold thereby completely discriminating 
between cellular debris and viable cells.   
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2.2.3.3 Cedex XS Analyser  
The Cedex XS Analyser (Roche Innovatis, Bielefeld, Germany) is a semi-automated 
image-based cell analyser based on the Trypan Blue Exclusion method providing 
information about cell concentration and viability. The Cedex XS Smart Slide has eight 
chambers for testing samples. Four sample chambers (e.g. Chambers A1-A4) can be 
measured without turning the Cedex XS Smart Slide. Cell samples for measurement are 
pre-diluted (below 1x107 cells/mL) using and stained using the appropriate amount of 
0.2% Trypan Blue while accounting the addition of Trypan Blue into the dilution factor. 
This solution is mixed thoroughly by pipetting up and down. Pipette 10 µL of sample into 
each chamber of the Cedex Smart Slide for measurement (Figure 2.3 A). The slider 
carrier is pulled out and the Cedex Smart Slide is placed in the slide carrier with the 
chambers containing the samples going in first. The slide carrier is pushed gently in until 
a soft click is felt followed by the illumination of a blue light indicating the first chamber 
is in position, with an additional light for chambers 2, 3 and 4. By clicking on MEASURE 
from the Cedex XS control centre the measurement dialogue box is accessed where 
sample information is entered such as sample ID including replicates and dilution factor 
before taking the final measurement. 
 
Figure 2.3: Cedex Smart Slide & Sample view 
 
Figure 2.3: Cedex smart slide and Sample view: A) Sample loading of 10 µL of pre-diluted sample 
into the chamber of the Cedex Smart Slide. B) Sample view accounting for viable cells circled in 
green, non-viable cells circled in red and aggregates circled in blue. 
 
A B
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Once the sample parameters have been entered the START MEASUREMENT button is 
clicked. The Cedex XS analyser accounts for information such as cell density by taking 
the dilution factor into account, cellular viability and others such as cell size ranging from 
2-180 µm and aggregates (Figure 2.3 B).   
 
2.2.4 Cryopreservation of cells 
Cells being preserved were frozen down in a suitable medium supplemented with 5% 
DMSO (SIGMA-ALDRICH, D5879) and 5% FCS. Given the cytotoxic effects of DMSO 
at warm temperatures a separate solution of suitable medium supplemented with 10% 
DMSO/FCS was made up initially and kept on ice until required. This 10% DMSO/FCS 
solution was filtered using a 0.22 µm bell filter (Gelman, 121-58) before storage on ice. 
Cells for cryopreservation were harvested during their log phase of the growth cycle. 
Generally, cells are frozen down at 1x106 cells/mL in 1mL of media (supplemented with 
5% DMSO/FCS) in a cryovial (Greiner, 201151). After counting and centrifugation, cells 
are resuspended in half the final volume of pre-warmed suitable media giving a cell 
density at 2x106 cells/mL. Finally, this mixture is made up with 1 volume of the 10% 
DMSO/FCS supplemented media yielding a final solution of 5% DMSO/FCS at 1x106 
cells/mL. This suspension was then aliquoted in 1mL volumes to pre-labelled cryovials 
and immediately placed at -20˚C. After 1-2h, cells are transferred to -80˚C for 6-12 h and 
then transferred to the liquid nitrogen tank for long term storage at -196˚C.       
 
2.2.5 Thawing of cryopreserved cells 
Prior to thawing of cells under liquid nitrogen storage, a 10 mL volume of fresh medium 
was pre-warmed in a sterile universal. The cryopreserved cells were removed from the 
liquid nitrogen storage, immediately placed on ice and slightly thawed at 37 ˚C. Cells 
were transferred from the cryo-vial to the aliquoted medium in the sterile universal using 
a pastet. Cells were centrifuged at 1000 rpm for 5 min in order to remove the toxic DMSO. 
The supernatant was decanted and the pellet was resuspended in fresh pre-warmed media. 
Antibiotic selection agent is omitted in the first passage. Thawed cells were then added 
to the appropriate culture vessel, i.e. spinner or T-flask, with the appropriate volume of 
culture medium and allowed to grow at 37 ˚C. In the case of adherent cells, the culture 
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media was removed and cells were re-fed the next day in order to remove and non-viable 
cells and allow the successful proliferation of attached cells.   
 
2.2.6 Apoptosis analysis 
Annexin-V is a calcium-dependent phospholipid binding protein that binds with high 
affinity to phosphotidylserine (PS), which is normally located on the inner face of the cell 
membrane. Annexin V-PE is used to detect PS on the external face of the membrane and 
is a sign of early apoptosis. 7-AAD is also membrane impermeable and is excluded from 
live, healthy cells and early apoptotic cells. 
Non-apoptotic cells: Annexin-V (-) and 7-AAD (-) 
Early Apoptosis: Annexin-V (+) and 7-AAD (-) 
Late stage apoptosis/Dead: Annexin-V (+) and 7-AAD (+) 
Debris: Annexin-V (-) and 7-AAD (+) 
Cells were harvested and resuspended in 200 µL Guava Nexin reagent (Merck-Millipore) 
at 48 h and 96 h after transfection. Cells were incubated for 20 min at room temperature 
in the dark before analysis with a Guava EasyCyte96 (Millipore). It was ensured that at 
least 1% of FCS was added to the cell sample before incubation in cases of serum-free 
culture. 
 
2.3 Other Cell Culture Techniques 
2.3.1 Reconstitution/Rehydration of lyophilized miRNA 
miRNAs were ordered from Applied Biosystems and NBS Biologicals and arrived in a 
lyophilised condition. Reconstitution/Rehydration of miRNA was performed using 
nuclease-free water (Ambion®, AM9932) in sterile conditions in the laminar flow hood. 
miRNAs were resuspended so that their final stock concentration was at 50 µM.  The 
appropriate volume of nuclease-free water was added by pipette and mixed vigorously by 
pipetting up and down and vortex. This mixture was allowed to sit at room temperature 
for 10 min and subsequently centrifuged briefly before storage at -20˚C. Stocks were also 
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subsequently made as low as 5 µM in the event of transfecting small concentrations of 
miRNA, allowing for high volumes being used to avoid pipetting error. 
  
2.3.2 siRNA/miRNA transfection 
2.3.2.1 siSPORTTM NeoFXTM Transfecting Reagent 
Transient transfection of CHO cells was carried out using the AMBION® transfecting 
reagent siSPORTTM NeoFXTM (AMBION®, AM4510) in accordance with the 
manufacturer’s specifications. The following protocol describes the experimental setup 
for a single transfection event at a siRNA/miRNA concentration of 50 nM including a 
10% excess. Each siRNA/miRNA/NeoFX complex volume of 200µl was added to a 2mL 
sample of cells at 1x105 cells/mL. All sample sets were carried out in triplicate with 
appropriate experimental controls. Using serum free media (SFM) such as OPTI-MEM® 
(Life Technologies, 31985-062) or CHO-S-SFM II (GIBCO®, 12052-098), 2.2 µL of a 
50µM miRNA/siRNA was added to 110 µL of SFM previously warmed to 37 ˚C and 
incubated at room temperature for 10 min. The siSPORTTM NeoFXTM transfecting 
reagent was allowed to sit and adjust to room temperature before the addition of 2.2 µL 
to 110 µL of pre-warmed SFM in a separate microcentrifuge tube. Formation of 
siRNA/miRNA complexes was achieved by adding 112.2 µL of siSPORTTM NeoFXTM 
transfecting Reagent/SFM media mixture to the incubated siRNA/miRNA/SFM sample 
and allowed to complex by incubation for 10 min at room temperature. In order to 
inoculate the 2 mL (1x105 cells/mL) culture with a 50nM final concentration of 
siRNA/miRNA 204 µL of the final complex was added with gentle swirling of the culti-
flask disposable bioreactor (Sartorius Stedium Biotech, DF-050MB-SSH). Cells were 
incubated at 37 ˚C in a Kuhner Climo-shaker incubator (Kuhner, Climo-Shaker ISF1-X) 
at 170 rpm. Replacement of the culture media is not necessary as the addition of 
siSPORTTM NeoFXTM transfecting Reagent does not induce cellular stress that can lead 
to cytotoxicity.  
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2.3.2.2 INTERFERinTM transfection reagent 
Transfection of CHO cells was carried out using the PolyPlus-transfectionTM reagent 
INTERFERinTM (PolyPlus-TransfectionTM, PPLU-409-01) as per manufacture’s 
specifications unless otherwise indicated. miRNAs were transfected at a range of 100 nM-
20 nM final concentration per 2 mL volume at 1 x 105 cells/mL. Below describes the 
master mix preparation for one single transfection. Using SFM such as OPTI-MEM® 
(Life Technologies, 31985-062) or CHO-S-SFM II (GIBCO®, 12052-098) 110 µL of pre-
warmed SFM media at 37 ˚C was aliquoted into a sterile cryovial or Eppendorf. All 
reagents such as INTERFERinTM and miRNAs were kept on ice until required, however 
INTERFERinTM was allowed to adjust to room temperature before use. As described in 
section 2.3.1.1, 2.2 µL of the appropriate stock miRNA mimic or inhibitor was added to 
the aliquot of 110 µL SFM and mixed by pipetting up and down gently. From 
optimization results shown in section 3.1.2.4, 1.1 µL of INTERFERinTM was added to 
the SFM containing miRNA mixture and allowed to incubate at room temperature for ~ 
15 min. After this incubation period, 100 µL of complexed miRNA was added directly to 
each 2 mL volume of cells and swirled briefly to mix. Cells were incubated at 37 ˚C in a 
Kuhner Climo-shaker incubator (Kuhner, Climo-Shaker ISF1-X) at 170 rpm. 
Replacement of the culture media is also not necessary as the addition of INTERFERinTM 
transfecting reagent does not induce cellular stress that can lead to cytotoxicity.  
 
2.3.3 Transfection of plasmid DNA 
Plasmid transfection required the use of a separate set of transfection reagents as plasmids 
are required to reach the nuclear membrane thus having to bypass two membranes.  
 
2.3.3.1 Lipofectamine 2000 
Cells were transfected at 5 x 105 attached 24 hs prior to transfection or at 0.5-1 x 106 
cells/mL in suspension culture. DNA to LipofectamineTM (Invitrogen, Cat. No. 11668-
019) was 1:2, respectively. DNA was diluted in 50 µL SFM and mixed gently. 
Transfection reagent was diluted in a separate 50 µL, mixed and incubated for 5 min at 
room temperature. After 5 min, both mixtures were combined, mixed and incubated at 
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RT for 25 min. After 25 min, the 100 µL mixture was added drop-wise to the cells and 
gently rocked to mix. This transfection reagent requires a media change after 4-6 hs of 
incubation.  
 
2.3.3.2 TransIT®-2020 Transfection Reagent        
Cells were transfected at 5 x 105 attached 24 hs prior to transfection or at 0.5-1 x 106 
cells/mL in suspension culture. Transfection complexes were made up in SFM such as 
CHO-S-SFMII or Optim-MEM. For a single transfection, 250 µL of SFM was pre-heated 
to 37°C in a 1.7 mL Eppendorf. 1 µL of TransIT-2020 (Mirus, Cat. No. MIR-5400) was 
used for every 1 µg of plasmid DNA transfected. DNA was added first using a pipette 
and mixed followed by the transfection reagent. Contents were mixed and allowed to 
incubate at room temperature for 20 min. After this time, DNA/transfection reagent 
complex was added drop-wise to the cells. This transfection reagent does not require a 
media change.  
 
2.3.4 Limited-dilution/FACS-based cloning 
Clonal isolation was carried out using a FACS-Aria based on mid-to-high GFP intensity 
or limited dilution single cell cloning. The culture process after isolation was the same 
for both processes. In the case of limited-dilution cloning, a stock solution is made up 
containing 10 cells/mL so that when 100 µL is placed into a well, the well contains a 
single clone. Clones were sorted into 2 separate 96 well plates containing CHO-S-SFM 
II media supplemented with ~30% conditioned media (media previously cultured CHO 
cells and harvested containing secreted growth factors) and 5% serum. Conditioned media 
was harvested 2-3 days into culture with cells removed by centrifugation and filtered 
through a 0.2 µm filter. Single clones were allowed to attach and grow at 37 ˚C for 10-14 
days. After this time, cells were assessed for growth and clonality visually using a bench-
top microscope. Clonal panels were subsequently adapted to suspension culture in a 24-
well suspension plate. 
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2.4 Molecular Biology Techniques  
2.4.1 DNase Treatment of RNA 
DNase treatment of RNA samples is useful for the removal of contaminating genomic 
DNA and for the removal of plasmid DNA from transfection reactions that would have, 
in its high abundance, carry over during the RNA isolation protocol. 
DNase treatment was carried out using the DNase I (RNase-free) kit (M0303S, from New 
England Biolabs®) as per manufacturer’s specifications. Each DNase treatment reaction 
was made up to a reaction volume of 20 µL. 2ug of RNA was added to a 0.5 mL PCR 
tube as well as 2 µL of 10X DNase Buffer (resulting in a 1X DNase Buffer when made 
up to 20 µL with RNase-free water). 2 Units of DNase I (1 µL) was added to the reaction 
resulting in a final reaction volume of 20µl. The reaction mixture was mixed thoroughly 
and incubated at 37 ˚C for 10-15 min. 1 µL of 0.5 M EDTA (to a final concentration of 5 
mM) was added after this incubation step in order to deactivate the DNase I enzyme with 
a subsequent heat inactivation step at 75˚C for 10 min. 
 
2.4.2 High Capacity cDNA reverse transcription  
Reverse transcription of RNA to cDNA was carried out using the High Capacity cDNA 
reverse transcription kit (Applied Biosystems, 4368814) in accordance with the 
manufacturer’s specifications. A maximum of 2 µg RNA was made up to 10 µL in a 0.5 
mL PCR tube using Nuclease-free water. In a separate 0.5 PCR tube reaction vessel, the 
reverse transcription master mix was prepared in accordance with the following table 
(single reaction volumes): 
Component Volume/Reaction (µL) 
 Kit with RNase 
 Inhibitor 
Kit without RNase 
Inhibitor 
10X RT Buffer 2 2 
25X dNTP Mix (100mM) 0.8 0.8 
10X RT Random Primers 2 2 
MultiscribeTM Reverse 
Transcriptase  
1 1 
RNase Inhibitor 1 - 
Nuclease-free H2O 3.2 4.2 
Total per reaction 10.0 10.0 
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10 µL of the RT master mix was added to the 10 µL RNA sample and mixed using a 
pipette. The temperature profile for the reverse transcription reaction carried out using a 
bench top thermocycler G-Storm GS1 PCR machine following the below criteria: 
 Step 1 Step 2 Step 3 Step 4 
Temperature 
(˚C) 
25 37 85 4 
Time 10 min 120 min 5 min ∞ 
 
Reverse transcribed cDNA product is ready to use and is stored at -20˚C until further 
required. 
 
2.4.3 Polymerase Chain Reaction (PCR) 
The DreamTaqTM PCR Master Mix kit (Fermentas Life Sciences, #K1071) was the kit 
used to perform all PCR amplification reactions in accordance with the manufacturer’s 
specification. DreamtaqTM PCR Master Mix was vortexed after thawing and placed on 
ice until further required. Each PCR reaction was made up to a volume of 50 µL. 
Following the component table below, a 25 µL reaction volume was made up in a thin 
walled PCR tube using a maximum concentration range of 1-100 ng of genomic DNA or 
cDNA and 10 pg of forward and reverse PCR primer. Once all components have been 
added, 25 µL of the 2X DreamTaqTM PCR Master Mix was added to each sample creating 
a 50 µL reaction volume.  
Component Volume/Concentration 
DreamTaqTM PCR Master Mix (2X) 25 µl 
Forward Primer 0.1 – 1.0 µM 
Reverse Primer 0.1 – 1.0 µM 
Template DNA 1 – 100 ng 
Nuclease-free water To 50 µL 
Total Volume 50µL 
   
Samples were gently vortexed and quickly spun down. The thermo-cycling conditions are 
shown in the table below with variation lying within the specific melting temperature 
(Tm) of each primer set and length of the Amplicon. A bench top PCR machine was used 
to perform the polymerisation cycle. 
84 
 
Step Temperature, ˚C Time Number of cycles 
Initial Denaturation 95 1-3 min 1 
Denaturation 95 30s  
25-40 Annealing Tm – 5 30s 
Extension 72 1min/kb 
Final Extension 72 5-15 min 1 
HOLD 4 ∞ 1 
 
After completion of the PCR reaction, samples were stored at -20˚C until further required. 
Primer sequences for all PCR reactions are shown in table 2.2. 
Table 2.2: Primer sequences for all genes explored in PCR 
Gene ID Primer For-Rev (5’-3-) Amplicon 
(bp) 
Tm 
(˚C) 
GC% Ann 
Temp 
E2F3 For-
CAGAGGTGCTCAAAGTGCAG 
 
175 
59.4 55  
56 
Rev-
AGCTCGGTCACTTCTTTGGA 
57.3 50 
BCL2 For- 
GGTGGTGGAGGAACTCTTCA 
 
153 
59.4 55  
56 
Rev- 
CGGTTCAGGTACTCGGTCAT 
59.4 55 
CCND1 For- 
ACACCAACCTCCTGAACGAC 
214 59.4 55  
56 
Rev- 
GACAGGAAACGGTCCAGGTA 
59.4 55 
MYCN For- 
CAAGAGCGAGGTTTCTCCAC 
202 59.4 55 56 
Rev- 
AGCCTTCTCGTTCTTCACCA 
57.3 50 
GLS For- 
AAGTGCTTGAATGGGCTGTT 
197 59.7 45 56 
Rev- 
AGCAGTGGGGTGGAGTGTAT 
59.4 55 
TFAM For- 
ATCTGCTCCGGGAAGACTG 
190 60.3 57 56 
Rev- 
GTCTGAGCGTCTCACATTGC 
59.5 55 
DICER1 For-
GGAGAACTTCAGCAGCCAAC 
164 59.4 55  
56 
Rev- 
TCAGGTGGTTCAGGGTTTTC 
57.3 50 
FUT8 For- 
TTCATCCCAGGTCTGTAGGG 
200 59.4 55  
56 
Rev- 
TTCCAGCCACACCAATGATA 
55.3 45 
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CCNE2 For- 
CGCAGTAGCCGTTTACAAGC 
177 59.4 55  
Rev- 
AGTCCACGTCTGCATTACCC 
59.4 55  
CDK4 For- 
GGATTGCCCTCAGAAGATGA 
179 57.3 50  
56 
Rev-
AGGGATTGGAAGGCAGAAAT 
55.3 45 
CDK6 For- 
TCAAATGGCCCTTACCTCAG 
160 57.3 50  
56 
Rev-
CACGTCTGAACTTCCACGAA 
57.3 50 
 
2.4.4 Fast SYBR® Green Real-time qPCR 
Real-time qPCR was performed using the Applied BioSystemsTM Fast SYBR® Green 
Master Mix (Applied BioSystemsTM, Cat. No. 4385612) in accordance with the 
manufacturers’ specifications. Quantification of the target gene is based on the binding 
affinity of SYBR® Green for double-stranded DNA. During PCR amplification by 
AmpliTaq® Fast DNA Polymerase, the target sequence is amplified creating more double-
stranded Amplicon for SYBR® Green to bind to. As the PCR reaction proceeds, the 
fluorescent intensity is proportional to the increase in double-stranded PCR product. 20 
µL reaction mixtures were prepared in a MicroAmpTM Fast Optical 96-well Reaction plate 
with Barcode (4346906). Both primers and cDNA were placed on ice to thaw with 
subsequent vortexing and brief centrifugation. The Fast SYBR® Green Master Mix was 
mixed thoroughly by swirling. Prior to plate setup, a master mix was prepared for all 
samples and technical replicates including a separate master mix for the endogenous 
control (β-actin or GAPDH). For a single reaction, 10 µL of Fast SYBR® Green Master 
Mix (2X) was added to an Eppendorf tube along with 7 µL Nuclease-Free water and 1 
µL of the appropriate forward and reverse primers (200 nM of each primer). Subsequent 
to master mix preparation, 18 µL were added to each well of the MicroAmpTM reaction 
plate. Using a micro pipette designed for small volumes (<10 µL), 2 µL of cDNA template 
was added to each reaction well using a fresh filter tip for each aliquot. It is recommended 
that a maximum of 20 ng of template cDNA be used for each reaction to achieve optimal 
detection. The reaction plate was then sealed using MicroAmpTM Optical adhesive film 
(4311971) to avoid loss of reaction volume during the PCR process. The sample plate 
was read using a 7500 Real-time PCR system. Data analysis was based on the Relative 
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Quatitation (2-ΔΔCt) where the relative expression of the target gene is compared to the 
expression of an internal standard, endogenous control.   
 
2.4.5 Determination of DNA/RNA quantity and quality 
Numerous methods are available for the determination of the quantity and quality of DNA 
and RNA.   
 
2.4.5.1 Bioanalyser/RNA 
The Agilent 2100 Bio-analyser is a microfluidics-based platform used for the analysis of 
proteins, DNA and RNA. The miniature chips are made from glass and contain a network 
of interconnected channels and reservoirs. The RNA 6000 Nano LabChip kit enables 
analysis of samples containing as little as 5 ng of total RNA. To each well, 1µl of each 
sample is loaded along with a fluorescent dye (marker). An RNA ladder is loaded into 
another sample well for size comparison. When all the wells are loaded, the chip is briefly 
vortexed and loaded onto the bio-analyser machine. The machine is fully automated and 
electrophoretically separates the samples by injecting the individual samples contained in 
the wells into a separation chamber.   
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Figure 2.4: RNA 6000 Nano chip and RNA Integrity Number graphs 
 
Figure 2.4: RNA 6000 Nano chip and RNA Integrity Number graphs: A) a picture of the front of the 
RNA Nano chip. B) Upper panel represents the RIN values for high quality RNA while the lower 
panel displays the RIN values for low quality RNA. Diagrams were sourced from 
http://www.agilent.com/chem/labonachip.     
The fluorescence was measured and presented in the form of peaks for 18S and 28S 
ribosomal RNA peaks. In figure 2.4 B, the upper electropherogram and gel-like image 
show the analysis of high quality total RNA resulting in a RNA Integrity Number (RIN) 
of 9.2. The lower electropherogram shows the analysis of a partially degraded total RNA 
sample. Many degradation products appear between the two ribosomal bands and below 
the 18S band resulting in a RIN of 5.8. As RNA degrades, the 28S RNA peaks decrease 
and the smaller fragments appear. 
 
2.4.5.2 NanoDrop® Spectrophotometer 
Purified RNA/DNA samples were quantified using the Nanodrop® ND-1000 
spectrophotometer (NanoDrop Technologies). Before applying the RNA/DNA sample, 
the pedestal was wiped down using a lint-free tissue dampened with UHP. A volume of 
2 µL of UHP was then loaded onto the lower measurement pedestal. The upper arm was 
then lowered down so as to be in contact with the RNA/DNA containing solution. The 
A B
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programme “Nucleic acid” and then “RNA-40” or “DNA-50” was selected on the 
NanoDrop software main screen to read the samples at 260 nm. Upon selection of the 
appropriate programme (RNA-40, DNA-50) the blank option was chosen, after a straight 
line appeared on the screen with zero appearing in all measurement fields the “measure” 
option was selected. Before and after loading each subsequent sample the pedestal was 
repeatedly wiped with a lint-free wiped. The concentration of RNA/DNA was calculated 
by software using the following formula: 
OD260nm x Dilution factor x 40 = ng/µl RNA 
A260/A280 and A260/A230 ratio for each sample was recorded. An A260/A280 ratio ~2 and an 
A260/A230 of ~1.8-2.2 is indicative of a pure RNA/DNA sample with an absorbance 
considerably above or below these values indicating the presence of contaminants such 
as protein or phenol. However, RNA/DNA ratios of as low as 1.86 and 2.24 for A260/A280 
and A260/A230 respectively have been used in subsequent experiments. 
Sample limitation for accurate read outs of RNA/DNA is 2 ng/µL minimum and 3000 
ng/µL maximum without dilution.  
 
2.4.5.3 Gel Electrophoresis/RNA 
Visual determination of RNA integrity can be identified using gel electrophoresis. RNA 
samples were previously diluted in RNase free water with all agarose gel containers being 
cleaned and wiped down with RNase Zap. A 1% agarose gel in 50 mL 1 x TAE with 5 
µL ethidium bromide (EtBr) added for staining the RNA. A DNA ladder was added to 
one well of the gel to estimate the location of the RNA bands. The gel was run for a 
sufficient enough to time to ensure clear separation of the RNA bands. Two RNA bands 
should be visualised, 28S and 18S, with 28S being roughly twice as bright as the 18S 
band. Bands should appear discrete without any leading smear. No bands should appear 
between the 28S and 18S bands indicating genomic contamination and/or RNA 
degradation.      
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2.4.6 Total RNA isolation using TRI ReagentTM 
Isolation of total RNA from cell lysates was performed using the TRI ReagentTM mRNA 
isolation method (SIGMA-ALDRICH®, T9424) in accordance with the manufacturer’s 
specifications. Total RNA was extracted from a maximum of 10 x 106 cells. Suspension 
cells were harvested by determining the appropriate cell count per mL using Trypan Blue 
Exclusion (GIBCO®, 15250-061) and spinning the appropriate volume of culture mixture 
at 2,000 rpm for 5 min. Supernatant was removed from the cell pellet and cells were 
subsequently lysed with the addition of 1 mL TRI ReagentTM, mixed well by pipetting 
and transferred to a microcentrifuge tube. Cell lysates can be stored in TRI ReagentTM at 
-70˚C for up to one month. Samples were allowed to stand for 5 min at room temperature 
to allow complete dissociation of nucleoprotein complexes. Phase separation was 
achieved with the addition of 200 µL of Chloroform (SIGMA-ALDRICH, C2432) to the 
cell lysate in 1 mL of TRI ReagentTM. This mixture was mixed vigorously by vortexing 
at high speed for 15 seconds and allowed to stand at room temperature for 10 min. 
Separation of the three distinct phases (red organic phase containing protein, intermediate 
phase containing DNA and an upper aqueous colourless phase containing RNA), was 
achieved by centrifugation at 12,000 rpm for 15 min at 4˚C. The aqueous phase (upper-
clear) was transferred to a fresh microcentrifuge tube and 500 µL isopropanol (SIGMA-
ALDRICH, I9516) was added and mixed. This mixture was allowed to stand for 10 min 
at room temperature and then subsequently centrifuged at 12,000 rpm for 10 min at 4˚C. 
RNA will form a precipitate along the side/bottom of the tube. The supernatant was 
removed and a wash step was performed using 1 mL of 75% ethanol. Sample was mixed 
well by vortex and centrifuged at 7,500 rpm for 10 min at 4˚C. Decant 75% ethanol as 
best as possible and air dry the RNA pellet by allowing sitting for 10-15 min. The RNA 
pellet was not allowed to dry completely before re-suspension in 30-50 µL nuclease-free 
water.    
 
2.4.7 PCR based miRNA Taqman® Low Density Arrays (TLDA) 
Taqman® Low Density Arrays (Applied Biosystems, 4334812) are 384-well micro fluidic 
cards designed for the analysis of global miRNA expression patterns of up to 8 samples 
in parallel across a defined set of miRNA targets (Fig 2.5). Taqman® Low Density Array 
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is a real-time PCR-based, highly sensitive and reproducible array that contains specific 
probes for human miRNA signatures. 
  
Figure 2.5: Schematic representation of a miRNA Taqman® Low Density Array 
 
 
Given the large number of known human miRNAs, miRNA TLDA cards are split into 
two cards (A + B) with probes for 380 unique miRNA on each card and 8 endogenous 
controls. Total RNA was harvested from cells using the TRI Reagent protocol and cDNA 
was prepared using the MultiplexTM RT Primer kit.  
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2.4.7.1 Reverse transcription 
The Taqman® microRNA Reverse Transcription kit and the MegaplexTM RT Primers Pool 
A and B (4399966 and 4399968) were used to synthesise single-stranded cDNA from 
total RNA. The RT-master mix was prepared as described below: 
 
RT Reaction Mix 
Components 
Volume for One Sample 
(µL) 
Volume for Ten Samples 
(µL) with 12.5% excess 
MegaplexTM RT Primers 0.80 9.00 
100mM dNTPs with dTTP 0.20 2.25 
MultiscribeTM Reverse 
Transcriptase (50 U/µl) 
1.5 16.88 
10 X RT Buffer 0.80 9.00 
MgCl2 (25mM) 0.90 10.12 
RNase Inhibitor (20 U/µl) 0.10 1.12 
Nuclease-Free water 0.20 2.25 
Total 4.50 50.62 
 
The above mixture was combined in a 1.5mL Eppendorf tube depending on the number 
of sample reactions being reverse transcribed. The mixture was mix by inverting the tube 
and briefly centrifuged. In a 96 well MicroAmp® Optical reaction plate (4314320), 4.5 
µL of the RT mixture was added into each well as required. 3 µL of total RNA (100 ng) 
was then added to each reaction well and the plate was sealed using MicroAmp® Clear 
Adhesive Film. The plate was left to incubate on ice for 5 min. Multiplex reverse 
transcription was performed using the thermocycler under the 9600 Emulation mode with 
a final reaction volume of 7.5 µL in the HT7900 RT-PCR machine and programmed as 
follows: 
Step Type Time (min) Temperature (˚C) 
HOLD 30 16 
HOLD 30 42 
HOLD 5 85 
HOLD ∞ 4 
 
cDNA can be stored at -15 to -20˚C for at least one week. 
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2.4.7.2 Pre-amplification 
The Pre-amplification step is required for low concentrations of starting cDNA whereby 
specific cDNA targets are amplified for further Taqman® MicroRNA array analysis. The 
MegaplexTM PreAmp Primers (Pool A and B, 4399233 and 4399201) were thawed on ice, 
mixed by inverting and briefly centrifuged. Master Mix was prepared in a 1.5 mL 
Eppendorf tube in accordance with the following recipe:  
 
PreAmp Reaction Mix 
Components 
Volume for One sample  
(µL) 
Volume for Ten sample 
(µL) with excess of 
12.5% 
Taqman® PreAmp Master 
mix (2X) 
12.5 140.62 
MegaplexTM PreAmp 
Primers (10X) 
2.5 28.13 
Nuclease-free water 7.5 84.37 
Total 22.5 253.12 
 
Invert the master mix six times to mix thoroughly and briefly centrifuge. In a 96-well 
MicroAmp® Optical Reaction Plate place, 22.5 µL of the PreAmp master mix into each 
appropriate well. Pipette 2.5 µL of the RT reaction product into each appropriate well 
brings the final reaction volume to 25 µL. The plate was sealed using MicroAmp® Clear 
Adhesive Film and incubated on ice for 5 min. Pre-Amplification parameters were set up 
in accordance with the following: 
Stage Temp (˚C) Time (min) 
Hold 95 10 
Hold 55 2 
Hold 72 2 
Cycle  
(12 Cycles) 
95 15 sec 
60 4 
Hold 99.9 10 
Hold 4 ∞ 
 
2.4.7.3 PCR  
RT products were diluted using 75 µL nuclease-free water, inverted to mix and spun down 
briefly by centrifugation. The miRNA PCR reaction was carried out using the Taqman® 
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2X Universal PCR Master Mix (No AmpErase® UNG) and in accordance with the below 
protocol in a 1.5 mL Eppendorf tube: 
Component Volume for One array (µL) with 
12.5% excess 
Taqman® 2X Universal PCR Master Mix 
(No AmpErase® UNG) 
450 
Diluted PreAmp Product 9 
Nuclease-Free Water 441 
Total 900 
 
The tube was inverted 6 times to mix and briefly centrifuged. A volume of 100 µL of the 
PCR reaction mix was loaded into each filling port of the Taqman MicroRNA Array 
(Figure 2.5). 
Taqman 
microRNA 
Array 
Filling 
Port 1 
Filling 
Port 2 
Filling 
Port 3 
Filling 
Port 4 
Filling 
Port 5 
Filling 
Port 6 
Filling 
Port 7 
Filling 
Port 8 
Multiplex 
RT 
Primer 
Pool 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
Plate was centrifuged so that all micro fluidic wells are filled with RT reaction mixture 
and then subsequently sealed. Arrays were incubated for 10 min on ice and were loaded 
on HT7900 real time PCR machine and ran under the following protocol: 
Step AmpliTaq Gold® 
Enzyme 
Activation 
PCR 
HOLD CYCLE (40 cycles) 
Denatured Anneal/Extend 
Time (min) 10 15 sec 60 sec 
Temp (˚C) (˚C) 95 95 
 
2.4.7.4 Data Analysis 
Data was analysed using Real-Time StatMinerTM software form Integromics. 
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2.4.8 Singleplex qRT-PCR validation: Taqman® microRNA assays 
Taqman® microRNA assay kits are pre-formulated primer and probe sets designed to 
detect and quantify mature miRNAs in real time. This assay can discriminate mature 
miRNAs from their precursor sequences and quantify small amounts (1-10 ng). Assays 
range for the majority of content found in the miRBase miRNA sequence repository. 
Total RNA was reverse transcribed by specific primers within the miRNA RT kit while 
the PCR reaction is performed using another set of miRNA specific primers together with 
the Taqman® Universal Master mix (Figure 2.6 A). miRNA PCR Amplicon detection is 
based on a DNA probe containing a fluorescent tag (FAMTM) at the 5’ end of the probe 
along with a non-fluorescent quencher (NFQ) at the 3’ end of the probe. The Taqman 
minor groove binding (MGB) probe hybridizes to complementary sequences within the 
forward and reverse primers. This intact probe prior to DNA binding holds the fluorescent 
tag in close proximity to the non-fluorescent quencher resulting in no fluorescence (Fig 
2.6 B).  
Figure 2.6: RT/PCR Mechanism and FAMTM – based detection mechanism 
 
Polymerisation
Strand Displacement
Cleavage
Complete Polymerisation
B) Probe MechanismA) Two-Step RT/PCR Mechanism
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During DNA polymerization, the DNA polymerase cleave only probes that are bound to 
the complementary sequences thus releasing the fluorescent FAMTM tag from the 
suppressive proximity of the quencher. As the number of PCR cycles increases the level 
of probe hybridization/cleavage/fluorescence increases. 
 
2.4.8.1 Reverse transcription 
RT master mix for each sample was prepared separately using the Taqman microRNA 
Reverse Transcription kit (ABI, 4366596) from Applied Biosystems. 
 
Component Master Mix (15 µL-Single 
Reaction) 
100mM dNTPs (with dTTP) 0.15 
MultiScribeTM Reverse Transcriptase, 50 U/µL 1.00 
10X Reverse Transcriptase Buffer 1.5 
5X RT Primer 3 
RNase Inhibitor, 20 U/µL 0.19 
Nuclease-free water 4.16 
Total Volume 10 
 
A separate master mix reaction was prepared without MultiScribeTM RT enzyme for each 
primer set to be used within the assay in order to validate genomic contamination of the 
primers and reaction components. RT-master mix was mixed gently and centrifuged prior 
to distribution. An aliquot of 10 µL of RT-master mix was transferred into a 0.5 mL 
Eppendorf and placed on ice until RNA was prepared. RNA samples were pre-diluted to 
a working concentration of 2 ng/µL in nuclease-free water. For each 15 µL reaction, 5 µL 
of RNA (1-10 ng/reaction) was added to the 10 µL master mix, mixed gentle and 
centrifuged. RT was performed using the following parameters in a G-StormTM 
thermocycler.     
Step  Time (min) Temperature (˚C) 
HOLD 30 16 
HOLD 30 42 
HOLD 5 85 
HOLD ∞ 4 
 
96 
 
cDNA samples were stored at -20˚C until further required. 
2.4.8.2 PCR 
PCR reaction for individual miRNA was performed using the Taqman 2X Universal PCR 
Master Mix (ABI, 4324018) from Applied Biosystems and was prepared in accordance 
with the following table.  
Component 20 µL (Single reaction) 
Taqman MicroRNA Assay (20X) 1.00 
Product from RT reaction (Minimum 1:15 Diltuion 1.33 
Taqman 2X Universal PCR Master Mix, No AmpErase® 
UNG 
10.00 
Nuclease-free water 7.67 
Total Volume 20 
 
To each well of a MicroAmpTM optical reaction plate, 16 µL of PCR-master mix, 
containing appropriate primer, was loaded. From the pre-diluted RT reaction, 5 µL of 
product was added to each PCR-master mix. The plate was sealed with microAmpTM 
optical adhesive film (ABI, 4311971) and then incubated for 10 min on ice. PCR was 
performed using 9600 emulsion mode of thermocycler with reaction volume of 20 µL in 
a HT7600 real time PCR machine. Conditions for the PCR reaction were as follows: 
Step AmpliTaq Gold® 
Enzyme 
Activation 
PCR 
HOLD CYCLE (40 cycles) 
Denatured Anneal/Extend 
Time (min) 10 15 sec 60 sec 
Temp (˚C) (˚C) 95 95 
 
The table below represents all miRNA assay kits used over the course of this Ph.D.  
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Table 2.3: microRNA assay kits (Applied Biosystems) 
Applied BiosystemsTM microRNA assay kits 
miR Cat. No Assay I.D. 
U6 snRNA (Endogenous 
control) 
4427975 001973 
miR-18a 4427975 002422 
miR-23b 4427975 000400 
miR-23b* 4427975 002126 
miR-34a 4427975 000426 
 
2.4.9 MessageAmpTM II aRNA amplification kit 
The MessageAmpTM II aRNA amplification kit is an RNA amplification protocol. The 
procedure consists of reverse transcription with an oligo(dT) primer bearing a T7 
promoter using ArrayScriptTM reverse transcriptase (RT), designed to produce high yields 
of first-strand cDNA. ArrayScript RT mediates the synthesis of virtually full-length 
cDNA, which is the best way to ensure production of reproducible microarray samples. 
The cDNA then undergoes second-strand synthesis and clean-up to become the template 
for in vitro transcription (IVT) with T7 RNA polymerase. To maximise aRNA yield, 
Ambion MEGAscript® IVT technology is used to generate hundreds to thousands of anti-
sense RNA copies of each mRNA in a sample (aRNA is often referred to as cRNA). RNA 
samples of limited amounts (0.1-100 ng) can be put through two rounds of amplification 
if required. Figure 2.7 demonstrates the amplification procedure using MessageAmpTM 
II aRNA amplification kit. 
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Figure 2.7: MessageAmpTM II aRNA amplification procedure 
 
 
Figure 2.7: A schematic flow diagram of the procedure undertaken to amplify low quantities of RNA 
in preparation of carrying out microarray studies requiring a high amount RNA per card. This 
diagram was sourced from http://tools.lifetechnologies.com/content/sfs/manuals/cms_056141.pdf. 
Amplification procedure was carried out in accordance with the manufacturer’s 
specification (Life Technologies, #AM1751). First strand cDNA synthesis was carried 
out on a maximum of 1000 ng of RNA in a maximum volume of 10 µL topped up with 
99 
 
high quality water.  This mixture was vortexed briefly and centrifuged to collect. The 
reverse transcription master mix was prepared at room temperature in nuclease-free 
including a 5% excess to cover pipetting errors according to the following cocktail: 
Reverse Transcription master mix (for a single 20 µL reaction) 
Amount (µL) Component 
1 Nuclease-free water 
1 T7 Oligo(dT) primer 
2 10X First Strand Buffer 
4 dNTP Mix 
1 RNase Inhibitor 
1 ArrayScript 
 
This mixture was gently vortexed and centrifuged briefly to collect and placed on ice until 
required. 10 µL of Reverse Transcription Master Mix was added to each RNA sample 
forming the final 20 µL reaction volume. The mixture was pipetted up and down 2-3 
times, flicked 3-4 times and briefly centrifuged to collect. Samples were placed in a 
thermo cycler and subjected to the following conditions: 
Temp Time Cycles 
42°C (50°C lid) 2 h 1 
4°C Store  
 
Samples were placed on ice immediately after first-strand synthesis. 
Second-strand cDNA synthesis was carried out next. On ice, the second-strand Master 
Mix was prepared in nuclease-free water according to the cocktail below to a final volume 
of 80 µl: 
Second Strand Master Mix (For a single 100 µL reaction) 
Amount (µL) Component 
63 Nuclease-free Water 
10 10X Second Strand Buffer  
4 dNTP Mix 
2 DNA polymerase 
1 RNase H 
 
This reaction included a 5% excess to cover pipetting errors. Master Mix was mixed 
gently by vortexing and centrifuged to collect and placed on ice. 80 µL of second strand 
master mix was transferred to each 20 µL first-strand sample. Mix was pipetted up and 
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down 2-3 times, then flicked 3-4 times and centrifuged to collect. Samples were placed 
on a thermo cycler in accordance with the following steps: 
Temp Time Cycles 
16°C (no heated lid) 2 h 1 
4°C hold  
  
Be sure to deactivate the heated lid and allow thermo cycler to cool to 16°C before 
incubation as temperatures above this can compromise aRNA yield. Samples can be 
placed on ice for no more than 1 h or frozen at -20°C. 
Double-stranded cDNA was then purified. 250 µL of cDNA binding buffer was added to 
each sample, mixed thoroughly by pipetting up and down 2-3 times, flicked 3-4 times 
followed by a quick spin to collect. The entire sample was placed onto the centre of the 
cDNA filter cartridge. Samples were centrifuged for 1 min at 10,000 g or until mixture 
was fully through the filter. The flow-through was discarded and the cDNA filter cartridge 
was replaced into the collection tube. 500 µL of wash buffer was added to each cDNA 
filter cartridge. Samples were centrifuged for 1 min at 10,000 g. The flow-through was 
discarded and the cDNA filter cartridge was centrifuged for an additional minute to 
remove trace amounts. cDNA filter cartridge was transferred to a clean elution tube. 18 
µL of nuclease-free water pre-incubated at 50-55°C was added to the centre of each 
cDNA filter cartridge. This was left to incubate for 2 min and then centrifuged for 1 min 
at 10,000 g. The remaining ~16 µL contains double-stranded cDNA. 
In vitro transcription to synthesise aRNA was carried out using un-modified or biotin-
labelled UTP. The 16 µL of double-stranded cDNA prepared previously was transferred 
to a PCR tube. IVT master mix was prepared for a maximum reaction volume for 40 µL 
to achieve highest aRNA yield in accordance with the following cocktail: 
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Un-modified 40 µL reaction Component 
16 µL Double-stranded cDNA: previous step 
IVT Master Mix for a single reaction 
4 µL T7 ATP 
4 µL T7 CTP 
4 µL T7 GTP 
4 µL T7 UTP 
-- Biotin-11-UTP, 75 mM 
4 µL T7 10X Reaction Buffer 
4 µL T7 Enzyme Miz 
  
Master Mix was mixed well by vortexing and centrifuged to collect the IVT master mix 
at the bottom of the tube and placed on ice. Transfer IVT master mix to each sample and 
thoroughly mix by pipetting 2-3 times, flicking 3-4 times with a brief centrifugation to 
collect. Once mixed, samples were placed in a thermo cycler and processed at the 
following conditions: 
Temp Time Cycles 
37°C (100-105°C heated 
lid) 
14 h 1 
4°C hold  
 
Reaction was stopped by adding Nuclease-free water to each aRNA sample to bring the 
final volume to 100 µL, mixed by vortexing and stored at -20°C. 
aRNA purification was final carried out to remove enzymes, salts, and unincorporated 
nucleotides from the aRNA. 200 µL of nuclease-free water for each samples was pre-
heated to 55°C. For each sample, an aRNA filter cartridge was placed into an aRNA 
collection tube. 350 µL of aRNA binding buffer was added to the 100 µL of aRNA. 250 
µL of 100% ethanol was added to each aRNA sample and mixed by pipetting up and 
down 3 times-DO NOT VORTEX OR CENTRIFUGE. Pipet each sample onto the 
centre of the filter in the aRNA filter cartridge/collection tube. Centrifuge for 1 min at 
10,000 g. Discard flow-through and replace the aRNA filter cartridge back into aRNA 
collection tube. Apply 650 µL wash buffer to each aRNA filter cartridge. Centrifuge for 
1 min at 10,000 g. Discard flow-through and spin aRNA filter cartridge for an additional 
minute to remove trace amounts of wash buffer. Transfer filter cartridge to a fresh aRNA 
collection tube. To the centre of the filter, add 200 µLL pre-heated nuclease-free water 
and incubate samples on a heat block at 55°C for 10 min. Centrifuge for 1.5 min at 10,000 
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g and quantify. 33.3 ng/µL of aRNA is required for microarray processing or a second 
round of amplification can be performed. Samples are stored at -80°C for up to one year. 
 
2.4.10 CHO-specific oligonucleotide arrays 
Following from the amplification using the MessageAmpTM aRNA amplification kit (see 
2.4.9) of the low quantity RNA generated from the biotin-labelled miRNA pull-down, 
100 ng of total RNA from each sample underwent cDNA synthesis, followed by clean-
up, overnight IVT amplification and labelling using the GeneChip 3’ IVT Express Kit 
(#901229, Affymetrix) according to manufacturer’s specifications. cRNA clean-up was 
carried out using the GeneChip Sample Clean-up Module (#900371, Affymetrix) 
according to manufacturer’s specifications. The custom CHO oligonucleotide 
WyeHamster3a microarray (Affymetrix) used in this target identification analysis 
contains a total of 19,809 CHO-specific transcripts, combining library-derived and 
publicly-available hamster sequences. 
 
2.4.11 Gel and LB media/LB agar preparation 
2.4.11.1 Agarose gel preparation 
Depending on the percentage gel desired, agarose (Sigma-Aldrich,  A9539) was added to 
1X TAE (Thermo, #B49) with 2% (w/v) being considered a high percentage for resolution 
of small DNA bands (~ 100 bp). The solution wass heated to boiling until completely 
dissolved and cooled under a running cold tap. 0.5 µg/mL of ethidium bromide was added 
to the gel before pouring. Prior to pouring the gel, gel try was sealed at both ends using 
autoclave tape and left to set in the dark upon pouring.  
 
2.4.11.2 LB media preparation 
For 1 litre of LB media, 10 grams of Tryptone (Sigma-Aldrich, #T7293), 5 grams of Yeast 
(Sigma-Aldrich, #92144) and 10 grams of NaCl (Sigma-Aldrich, S9888) was dissolved 
in 1000 mL of UHP and subsequently autoclaved. 
103 
 
2.4.11.3 LB agar plate preparation 
LB agar preparation follows the same ingredients as LB media with the addition of 15 
grams of agar select (Sigma-Aldrich, A5306) in 1,000 mL of UHP and subsequently 
autoclaved. LB agar is then melted in the microwave and allowed to cool at room 
temperature until bottle is cool enough to handle. It is at this point that antibiotics are to 
be added to the LB agar media mixed well and poured into petri dishes. 
 
2.4.12 Restriction Enzyme Digestion 
Restriction enzymes are enzymes isolated from bacteria that are used as tools in molecular 
cloning techniques to recognise and cut DNA at specific genetic locations to produce 
DNA fragments known as restriction fragments. Restriction enzymes are used to create 
acceptor sites or “sticky ends” within multiple cloning sites (MCS) of plasmid backbones 
and the recombinant DNA insert.  
Digestion reactions were set up in 0.5 mL PCR tubes at a reaction volume of 20 µL. The 
reaction volume can vary depending on the amount of DNA required. The following 
represents the components required for the digestion of 2µg of DNA with a single 
restriction enzyme in a volume of 20µL. 
 
Component Volume (µL) 
Plasmid DNA 2 µg 
NEBuffer 1-4 (10X) 2 
BSA (100X) 0.2 
Restriction enzyme 1U (0.5-1 µL) 
Nuclease-Free water To 20 µL reaction volume 
 
Enzymatic digestions are carried out at a temperature of 37 ˚C on a hot plate until 
complete digestion is achieved. 1 Unit of a restriction enzyme is defined as the digestion 
of 1 µg of λ DNA in 1 h at a total volume of 50 µL (see NEB website 
https://www.neb.com/). Double digests can be carried out within the same reaction vessel 
depending on the compatibility and activity of the respective enzymes in the reaction 
buffers. Enzymatic activity charts can be found on the New England Biolabs website cited 
above. 
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2.4.13 Enzyme modification of linearized plasmid DNA 
2.4.13.1 Alkaline Phosphatase (AP)  
Alkaline Phosphatase treatment is exploited in molecular cloning as a technique to 
remove the 5’-phosphate residue from the DNA backbone after the circularised plasmid 
has been linearized, producing either 3’ or 5’ over hangs with exposed hydroxyl or 
phosphate groups, respectively. The phosphate group on C-6 and the hydroxyl (OH) 
group on C-3 serve as the basis of the chemical reaction of polymerisation of the DNA 
strand through a process known as condensation. 
 
The purpose and function of CIP treatment in molecular cloning is to remove the 5’-
phospate group of the DNA backbone inhibiting self-re-ligation of the linearized plasmid 
unless in the presence of DNA ligase. CIP treatment can be used on the linearized plasmid 
vector whether the exposed termini are incompatible, overhangs are not complementary, 
or compatible, blunt ends, but is more commonly used in the latter.    
 
Alkaline Phosphatase Protocol 
Prior to AP treatment, during the elution step of cleaning up the restriction digest product, 
elution was carried out using 45µL of elution buffer (EB). 4.5 µL of AP Buffer (NEBuffer 
3 (50 mM Tris-HCl, 100 mM NaCl, 10 mM MgCl2, 1 mM Dithiothreitol, pH 7.9 @ 25˚C). 
0.4 µL of Alkaline Phosphatase enzyme (Storage Conditions: 10 mM Tris-HCl, 50 mM 
KCl, 1 mM MgCl2, 0.1 mM ZnCl2, 50% Glycerol, pH 8.2 @ 25˚C) was added to the 
reaction vessel and mixed gently by using a pipette. Reaction was incubated on a hotplate 
at 37 ˚C for 1 h. 45 µL of Chloroform (SIGMA) was added to the reaction mixture 
subsequent to the incubation period and mixed rigorously by vortexing for 1 minute. 
Centrifugation at 13,000 rpm for 4 min was performed to separate both layers. The top 
layer was transferred to a fresh clean Eppendorf tube without any contamination from the 
lower layer. To ensure maximum amount of CIP treated DNA, 10 µL of nuclease-free 
water was added to the previous tube containing the chloroform and centrifuged again at 
13,000 rpm for a further 2 min. Using a lower volume pipette, the top layer was removed 
again and placed into the tube containing the top layer from the previous centrifugation 
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step. DNA was cleaned using the PCR clean-up kit (see 2.6.5) and stored at -20˚C until 
further required.      
 
2.4.13.2 Kinase Treatment 
T4 PNK catalyses the transfer of the terminal gamma (γ) phosphate group from 
Adenosine Tri-phosphate (ATP) to the 5’-hydroxyl termini of DNA and RNA (Fig 2.10). 
This enzyme can be used for the phosphorylation of the 3’-ends of RNA to prevent 
circularisation, phosphorylate the 5’ ends of DNA and RNA in order to provide the 
necessary phosphate backbone required for ligation processes and label 5’-hydorxyl ends 
of DNA with [γ-32P]-ATP (Hui Zhu et al, 2007). In some instances, with the presence of 
an excess of Adenosine Di-Phosphate, the reverse reaction of T4 PNK transfers the 5’-
phosphate from DNA/RNA to ADP thereby fulfilling the role of (CIP) Calf Intestinal 
Phosphatase which prevents linearized plasmids from circularising.  
0.5 µL of both sense and anti-sense strands that were previously annealed were added to 
a 0.5 mL PCR tube. 2 µL of 10 x T4 kinase buffer (500 mM Tris-HCl, 100 mM MgCl2, 
1 mM EDTA, 50 mM dithiothreithol, 1 mM spermidine pH 8.2 (at 25˚C). 0.4 µL of 50 
mM ATP (pH 7.5) was added to this reaction as the source of phosphate. This reaction 
was made up to a volume of 20 µL with the addition of 17 µL nuclease free water 
(Ambion® Cat. AM9932). Lastly 0.4 µL (4U) of Kinase enzyme (ROCHE, storage 
buffer, 50 mM Tris-HCl, 1 mM dithiothreithol, 0.1 mM EDTA, 1 µM ATP, 50% glycerol 
(v/v), pH 7.5 (at 25˚C) was added. Using a heating block this reaction was incubated at 
37 ˚C for 30 min. Upon completion of the 30 minute incubation, the kinase treated 
linearized DNA was ready for ligation and can be used up to one year later and must be 
stored at -20˚C. The T4 PNK supplied by ROCHE must not undergo the 20 minute 
incubation at 65˚C like the SIGMA supplied enzyme.       
 
2.4.13.3 Klenow Treatment 
Escherichia Coli DNA Polymerase I: All DNA polymerase enzymes add 
deoxyribonucleotides to the 3’-hydroxyl terminus of a primed double stranded DNA 
molecule. Synthesis is strictly in a 5’-3’ direction. Many DNA polymerases have a 3’-5’ 
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exonuclease activity associated with the polymerase activity. In the absence of dNTPs, 
this activity will catalyze the degradation from a free 3’hydroxyl end of both single- and 
double-stranded DNA. In the presence of dNTPs, the exonuclease activity on double-
stranded DNA is inhibited by the polymerase activity. Some DNA polymerase enzymes 
(eg., E. Coli DNA polymerase I) have an associated 5’-3’ exonuclease activity. This 
activity degrades double-stranded DNA from a free 5’-hydroxyl end. This allows Nick 
Translation which degrades in the 5’-3’ direction ahead of the polymerizing activity. 
Klenow treatment can be used to trim overhangs to make them compatible with other 
restriction enzymes where combinations are not applicable. Additionally, the klenow 
treatment can also inhibit self-re-ligation (Fig. 2.8). 
Klenow Protocol 
Upon digestion and cleaning of the plasmid/DNA fragment of interest, 1 µg of digested 
product was loaded into a 0.5 mL PCR tube. For a 20 µL reaction volume, 2 µL of 10X 
NEBuffer 2 (10 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl2, 1 mM Dithiothreitol (pH 
7.9 at 25˚C)) is added to the reaction vessel. See table below for variations according to 
final reaction volume. dNTPs were added to a final concentration of 33 µM. 1U of 
Klenow enzyme (Storage Conditions: 25 mM Tris-HCl, 1 mM Dithiothreitol, 0.1 mM 
EDTA, 50% Glycerol (Ph 7.9 at 25˚C)) is added for every 1 µg of DNA in the reaction. 
Reaction volume is made up using Nuclease-free water. Reaction mixture should be 
mixed gently using a pipette before placing on a heating block at 25˚C for 15 min. Klenow 
reaction was stopped by the addition of 10mM EDTA and heating at 75˚C for 20 min.  
Reaction 
Vol. (µL) 
Template 
DNA (µg) 
1xNEBuffer 
2 (µL) 
Klenow dNTPs (33 
µM) (µL) 
H2O 
20 1 µg 2 0.1-0.5 (1-
5U) 
0.5 Up to 20  
µL 
30 1 µg 3 0.1-0.5 (1-
5U) 
0.5 Up to 30 
µL 
50 1 µg 5 0.1-0.5 (1-
5U) 
0.5 Up to 50 
µL 
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Figure 2.8: Cloning process and Klenow treatment 
 
         
 
2.4.14 Gel extraction 
Plasmid DNA fragments of interest containing gene coding sequences were extracted 
from DNA agarose gels using the QIAGEN® QIAquick Gel Extraction kit (QIAGEN®, 
28704). The DNA fragment was excised from a low-melting agarose gel using a clean 
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scalpel. 400 mg of agarose can be processed by the spin column so it is important to 
minimize the size of the gel slice by removing extra agarose. The gel slice was finely 
chopped up and placed into a microcentrifuge tube. The gel slice was then weighed by 
weighing an empty microcentrifuge tube and the one containing the gel slice. 3 volumes 
of Buffer QG was added to 1 volume of gel (100 mg ~ 100 µL). This mixture was 
incubated at 50˚C for 10 min and vortexed every 2-3 min until the gel slice was 
completely dissolved. Once the gel was dissolved, the mixture colour was yellow. If the 
mixture was orange or violet then 10 µL of 3M sodium acetate (Sigma-Aldrich, 
#W302406) was added allowing efficient adsorption of DNA to the QIAquick membrane. 
1 gel volume of isopropanol (Sigma-Aldrich, #190764) was added to the sample and 
mixed using a pipette. A QIAquick spin column was placed into a 2 mL collection tube. 
To bind the DNA, the sample mixture was applied to the QIAquick spin column and 
centrifuged for 1 minute at 13,000 rpm. The flow through was discarded and the 
QIAquick column was placed back into the collection tube. The remaining traces of 
agarose were washed from the column by loading 500 µL of Buffer QG to the QIAquick 
column and spinning at 13,000 rpm for 1 minute. A second wash step was performed by 
applying 750 µL of Buffer PE to the QIAquick column followed by centrifugation at 
13,000 rpm for 1 minute. The flow through was discarded and a second spin for 1 minute 
was performed to dry the column. DNA elution was carried out by placing the QIAquick 
column into a fresh microcentrifuge tube and adding 30-50 µL of Buffer EB or water 
directly onto the QIAquick membrane and left standing for 1 minute at room temperature 
before centrifugation at 13,000 rpm for 1 minute. Eluted DNA was quantified by 
measuring the OD260nm using a NanoDrop spectrophotometer. Plasmid was sorted at -
20˚C for further use.        
 
2.4.15 PCR Purification 
All plasmid DNA was purified using the QIAGEN® QIAquick PCR Purification kit 
(QIAGEN®, 28104) in accordance with the manufacturer’s specifications. This clean up 
kit was necessary for the purification of single-/double-stranded DNA from PCR and all 
other enzymatic reactions such as Kinase/CIP/Klenow. Into the PCR mix, 5 volumes of 
Buffer PB was added and mixed by pipetting. The colour of this mix will turn yellow if a 
pH indicator has been added to Buffer PB. If this solution appears orange or violet then 
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10 µL of 3M Sodium Acetate is added and mixed. A QIAquick spin column was placed 
into a 2 mL collection tube. In order to bind the DNA, the sample mix was applied to the 
QIAquick column and spun by centrifugation at 13,000 rpm for 1 minute. The flow 
though was discarded and the QIAquick column was placed back into the same 2 mL 
collection tube. A wash step was performed by adding 750 µL of Buffer PE to the 
QIAquick column and centrifuged at 13,000 rpm for 1 minute. Flow through was 
discarded and the QIAquick column was placed back into the collection tube and spun 
for a further 1 minute at 13,000 rpm to dry the membrane. Before elution of the purified 
DNA, the QIAquick spin column was placed into a clean microcentrifuge tube. DNA was 
eluted by adding 30-50 µL of Buffer EB or water directly to the QIAquick membrane and 
allowing sitting for 1 minute at room temperature followed by spinning at 13,000 rpm for 
1 minute. Quantification of DNA was determined using a NanoDrop spectrophotometer 
and measuring the OD260nm. Purified DNA was stored at -20˚C until required.        
 
2.4.16 Ligation 
The T4 DNA ligase kit from ROCHE® (Cat. No. 10 481 220 001) was used for all ligation 
reactions carried out. It is recommend that no more than a total of 1 µg of DNA is to be 
used in any given ligation reaction and a range of 1-5 Units of T4 DNA ligase enzyme. 
The online tool LIGATION CALCULATOR (http://www.insilico.uni-
duesseldorf.de/Lig_Input.html) was used to determine the optimum ratio in nanograms 
of insert to vector backbone (Fig 2.9). To insure efficient ligation it is important to have 
a saturation of insert to vector by using the recommended ratios of 1:3 or 1:5. 
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Figure 2.9: Online LIGATION CALCULATOR tool   
 
Figure 2.9: Online LIGATION CALCULATOR tool: All relevant information is to be entered into 
the above fields including vector backbone size (after restriction enzyme digestion) in base pair (bp), 
vector amount in nanograms (ng) after clean-up, insert size in bp and finally the ration of insert to 
vector (1:3 or 1:5). 
A range of ~80-150 ng of vector backbone was used in all ligation protocols depending 
on the yields achieved after the previous two cleaning and CIP treatments beforehand. 
The concentration of insert used was determined based on the fragment size and the 
amount/size of vector being used (Ligation Calculator). All reactions were carried out at 
20 µL but scale up as far as 50 µL can be done if required. 2 µL of 10x T4 DNA ligase 
reaction buffer (660 mM Tris-HCl, 50 mM MgCl2, 10 mM ATP, 50 mM EDTA, pH 7.5 
at 25˚C) was added to the reaction mixture. Nuclease-free water was used to make up the 
reaction volume to 19 µL prior to the addition of the T4 DNA ligase enzyme. Finally 1 
µL (1 U) of T4 DNA ligase enzyme (20 mM Tris-HCl, 60 mM KCl, 5 mM 
Dithioerythritol, 1 mM EDTA, 50% Glycerol, pH 7.5 at 4˚C) was added to the reaction 
mixture creating a reaction volume of 20 µL. This reaction was incubated overnight on 
ice water. This allows the ligation reaction to commence over a temperature gradient. 
Ligated samples were stored at -20˚C. It is important to set up an identical reaction 
containing all components except the fragment to be inserted (no insert control). This 
accounts for the frequency of self-ligation of the DNA backbone and incomplete digestion 
of the vector backbone resulting in non-positive colonies. 
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 2.4.17 Transformation of competent cells 
Two kits supplied by InitrogenTM were used for the transformation of ligated vectors or 
for the amplification of plasmid vector stocks. These kits were the Subcloning 
EfficiencyTM DH5αTM Competent cells (Sigma-Aldrich, Cat. No.18265-017) and MAX 
Efficiency® DH5αTM Competent Cells (Sigma-Aldrich, Cat No. 18258-012). The only 
difference between the two kits above is that the MAX Efficiency® DH5αTM Competent 
Cells kit has a greater transformation efficiency of 1 x 103 transformants/µg pUC19 DNA.   
A 14 mL polypropylene Round-Bottom tube (Falcon®) was placed on ice while the water 
bath (NICKLE-ELECTRO Ltd., Clifton, 14 Litre Unstirred Thermostatic Bath, series 
NEI-14) was pre-heated to 42˚C. 50 µL of competent cells were transferred into each tube 
and kept on ice. ~5 µL of DNA (Ligation product, less for stock plasmid) was added to 
the competent cells and tapped to mix. This mixture was left on ice for ~20 min. The 
competent cells/DNA was heat-shocked by placing in the water bath at 42˚C for 45 
seconds. This step serves to cause contraction of the membrane pores resulting in the 
uptake of DNA from the surrounding environment. Upon heat shock the cells are then 
immediately placed on ice for a further 3 min which serves to constrict the membrane 
pore once again. 500 µL of pre-heated (37 ˚C) S.O.C media (supplied in MAX 
Efficiency® DH5αTM Competent Cells kit) was added to the transformed competent cells. 
Cells were incubated for ~1 h at 37 ˚C on a shaker platform. After an h, the contents were 
transferred into a 1.7 mL microcentrifuge tube (Costar®, Corning Incorporated, Cat. No. 
3620) and centrifuged at 3000 rpm for 4 min. All but 50 µL of SOC media was decanted 
from the bacterial pellet. The pellet was resuspended using a pipette and transferred onto 
a LB agar plate containing the appropriate selection antibiotic (Section 2.4.11). Using a 
sterile microbiological spreader (Copan Innovation, Cat. No. 22-091-241), the 
transformed competent cells were homogenously spread over the LB agar plate 
containing the appropriate antibiotic selecting agent. These plates were then sealed with 
Parafilm® M (SPI Supplies®, Cat. No. 01851-AB) and incubated at 37 ˚C for 16-24 hs.  
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Figure 2.10: Test and Control plate under Ampicillin selection 
 
Figure 2.10: The requirement of carrying out a no-insert control during the ligation process is 
demonstrated. A) Colonies as a result of successful insertion causing circularisation in addition to 
circularised plasmids with no insert as a result of incomplete digestion. B) Colonies formed only as a 
result of incomplete digestion giving an indication of colony number without target inserts.  
After a time period of 16-24 hs of incubation, competent cells that successfully took up 
the plasmid will form single round colonies on the agar plates. The presence of the 
antibiotic selecting agent will select for colonies efficiently expressing the functional 
circularised plasmid that harbours the antibiotic resistance gene. Figure 2.10 A and B 
shows a test and control plate under ampicillin (Sigma-Aldrich, #A9393) selection after 
24 hs of growth. The no-insert control plate was important to account for occurrence of 
incomplete digestion and random circularisation of the vector backbone not containing 
the fragment of interest. By counting the number of colonies on the test and control plate, 
it gives an idea of the number of colonies that is required to be picked and mini-prepped 
(Section 2.6.8) that will contain the plasmid of interest.   
 
2.4.18 DNA mini-prep of plasmid DNA 
The QIAGEN QIAprep Spin Miniprep kit (QIAGEN, 27104) was used according to the 
manufacturer’s instructions for the isolation of plasmid DNA from a 5mL culture. This. 
After incubation, cells were pelleted by centrifugation at 4000 rpm for 10 min. Cell pellets 
A: Test Plate B: No-Insert control Plate
113 
 
were resuspended in 250 µL of buffer P1 and transferred to a microcentrifuge tube. 250 
µL of buffer P2 was added to this solution and mixed gently by inversion. A 350 µL 
volume of buffer N3 was subsequently added to this solution and again mixed gently by 
inversion. This mixture was centrifuged for 10 min at 13,000 rpm. The decanted 
supernatant was applied to the QIAprep spin column and centrifuged for 60 seconds at 
13,000 rpm. This flow though was discarded. The column was washed by adding 500 µL 
of Buffer PB and centrifugation for a further 60 seconds at 13,000 rpm. Again, the flow 
though was discarded. A second wash was performed using 750 µL of Buffer PE and 
centrifuging for 60 seconds. The flow through was discarded and the column was dried 
by an additional centrifugation step for 60 seconds to remove any remaining wash buffer. 
The spin column was then placed into a clean microcentrifuge tube. The DNA was eluted 
by adding 30-50 µL (depending on the desired DNA yield) of Buffer EB or water to the 
spin column. This was allowed to stand for 1 minute at room temperature (RT) before 
centrifugation at 13,000 rpm for 1 minute. The eluted DNA was reapplied to the spin 
column and centrifuged for an additional 60 seconds to collect any remaining plasmid 
DNA. Quantification of the eluted plasmid DNA was determined using a NanoDrop 
spectrophotometer by measuring at OD260nm. Plasmid was stored at -20˚C until required.     
 
2.4.19 DNA midi/Maxi-prep of plasmid DNA 
Stock plasmids were amplified and purified using an Endotoxin-free Plasmid DNA 
Purification Midi/Maxi kit (Nucleobond® Xtra Midi plus EF, Macherey-Nagel, 
740416.50). Typical yield from the Nucleobond® Xtra Midi kit is 250 µg of plasmid DNA 
compared to the 1000 µg from the Nucleobond® Xtra Maxi kit. Both midi and maxi preps 
were carried out according to the manufacturer’s specifications with midi prep being the 
general route of plasmid amplification. 5 mL of inoculated LB media was added to 100 
mL of pre-warmed LB media once again under the selection of antibiotic and incubated 
over night at 37 ˚C on a shaker platform. Pellets were harvested by transferring this 100 
mL to a 250 mL centrifuge flask and spun at 6,000 g for 10 min at 4˚C. Supernatants were 
discarded completely and pellets were either processed immediately or stored at -20˚C 
until required. The Bacterial pellet was resuspended in 8 mL of Buffer RES-EF by 
pipetting up and down until no clumps remained and transferred into a 50 mL Falcon 
tube. Cells were lysed open by adding 8 mL of Buffer LYS-EF and mixed gently by 
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inverting. This mixture was incubated at room temperature (18-25˚C) for 5 min. During 
this incubation period, the Nucleobond® Xtra Column with the inserted column filter was 
equilibrated with the addition of 15 mL Buffer EQU-EF around the rim of the inserted 
column filter. The cell lysate mixture was neutralised with the addition of 8 mL Buffer 
NEU-EF, inverted 10-15 times and incubated on ice for 5 min. The crude lysate was 
homogenised by inverting before applying it directly to the equilibrated Nucleobond® 
Xtra Column Filter and allowed to empty by gravity flow. The first wash consisted of the 
addition of 5 mL Buffer FIL-EF to the rim of the NucleoBond® Xtra Column Filter and 
once again left to empty by gravity flow. Once the column was emptied completely, the 
NucleoBond® Xtra Column Filter was removed and discarded. The second wash step 
washes the NucleoBond® Xtra Column by adding 35 mL of Buffer ENDO-EF directly 
into the column and allowing emptying by gravity flow. The third and final wash requires 
the addition of 15 mL Buffer WASH-EF to the column and emptying by gravity flow. 
Plasmid DNA was eluted into a 20 mL Universal by adding 5 mL of Buffer-ELU-EF to 
the column. For elution of DNA using the NucleoBond® Finalizer the DNA was 
precipitated with the addition of 3.5 mL isopropanol (SIGMA), vortexed well and left to 
sit for 2 min. The plunger was removed from a 30 mL Syringe and the NucleoBond® 
Finalizer was attached. The precipitate was loaded into the syringe and the plunger was 
reinserted into the syringe. Using constant force the precipitate passes through the 
NucleoBond® Finalizer and the flow though is discarded. The Finalizer was removed 
before the removal of the plunger and then reattached. Using the same technique a wash 
step with 2 mL Endotoxin-free 70% EtOH was carried out again discarding the flow 
though. The filter membrane of the NucleoBond® Finalizer was dried by removing the 
plunger and reinserting it into the syringe and expelling the air though the filter. This was 
performed three times. Finally, the plasmid DNA was eluted in 400 µL of Buffer TE-EF 
or H2O-EF by using a 1 mL syringe attached to the NucleoBond
® Finalizer. The 
concentration of eluted plasmid DNA was determined using a NanoDrop 
spectrophotometer by measuring the OD260nm. Plasmid was stored at -20˚C until required.               
 
2.4.20 Plasmid diagnostics 
Plasmid diagnostics requires a combination of the above listed protocols. Restriction 
enzymes are selected that will cut the target insert out of the plasmid constructed in 
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addition to select an enzyme that cuts once at a sequence within the insert. Digestions are 
then ran out on an agarose gel stained with ethidium bromide, including a DNA ladder 
(Life Technologies, 1 kb Plus DNA Ladder, #10787-018), and compare band sizes to an 
appropriate plasmid reference map. 
 
2.5 Mitochondrial studies 
2.5.1 Mitotracker® Deep Red FM 
Mitochondrial content was assessed using the fluorescent dye Mitotracker® Deep Red 
MTDR) FM (InvitrogenTM, M22426). Mitochondrial abundance was determined for 1 x 
106 cells stained with a working concentration of 50 ng. Cells were cultured for 72 hs, 
pelleted and resuspended in a 1 mL volume of culture medium containing the desired 
concentration of MTDR dye and incubated at 37 ˚C for 30 min in a shaker incubator. 
Cells were pelleted and resuspended in fresh culture media and analyzed using a FACS 
flow cytometer (BD). The MTDR emission wavelength of 665 nm did not interfere with 
the emission peak of GFP at 509 nm eliminating the need of compensation in the case of 
stable CHO cell lines expressing the miR-sponge construct. 
 
2.5.2 OROBOROS Oxygraph-2k 
The OROBOROS/Oxgraph-2k, a two chambered respirometer equipped with a peltier 
thermostat and integrated electromagnetic stirrers, was used to determine respirometric 
measurements. The oxygen concentration was recorded using the software DatLab 
(OROBOROS instruments) and specific oxygen consumption rates were represented as 
(pmol O2/s/10
6 cells). Measurements were performed using 1 x 106 cells/mL in 2 mL of 
CHO-S-SFMII for intact cells or in the case of the permeabilised assay, respiration buffer 
Mir05 (Hirsch et al. 2012) at 37 ˚C with continuous stirring.  The following substrate-
uncoupler-inhibitor-titration (SUIT) protocol was applied in both instances.  
In the case of intact cells, oxygen consumption was allowed to stabilise upon inoculation 
and sealing of the chambers which resulted in the acquisition of routine respiration (R). 
Leak respiration (L) was established upon inhibition of ATP synthase through the 
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addition of oligomycin (2 µg/mL). Maximum respiratory capacity in an uncoupled state 
was achieved through addition of FCCP (0.2 µM).  
For the more in depth permeabilised protocol, upon initial stabilisation of oxygen 
consumption, the cell membrane was permeabilised with 3 µL digitonin (30 µg/106 cells). 
Complex I dependent respiration was driven with the addition of glutamate (10 mM) and 
malate (0.5 mM). OXPHOS capacity driven by Complex I was achieved by the addition 
of ADP (1 mM). Cytochrome C (10 µM) was added to test for aberrations in the integrity 
of the outer mitochondrial membrane. Maximal coupled respiration of Complexes I and 
II was stimulated by the addition of a Complex II-specific substrate, succinate (10 mM). 
By uncoupling the mitochondrial membrane and interfering with the proton gradient, 
maximum capacity of the electron transport system (ETS) was obtained using FCCP (0.2 
µM). Inhibition of Complex I with rotenone (0.5 µM) shows the maximal uncoupled 
respiration via Complex II. Complex II and III were inhibited by the addition of Malonic 
acid (5 mM) and Antimycin A (2.5 µM) to estimate the residual oxygen consumption. 
Finally, Complex IV was stimulated by the addition of the artificial electron donor TMPD 
(0.5 mM) and its reducing agent ascorbate (2 mM) with Complex IV inhibition achieved 
through the addition of Azide (100 mM).   
 
2.5.3 Mitochondrial Isolation  
Intact mitochondria were isolated using a Mitochondrial Isolation kit for cultured cells 
(Thermo Scientific, #88794) in accordance with the manufacturers’ specifications. A 
maximum of 6 samples were processed at any one time with 2 x 107 cells being the 
processing limits. Following the reagent-based method, 2 x 107 cells were pelleted by 
centrifugation ~850 g for 2 min and supernatant was discarded. 800 µL of Mitochondria 
Isolation Reagent A was added and vortexed at medium speed for 5 seconds followed by 
a 2 minute incubation on ice. 10 µL of Mitochondria Isolation Reagent B was added and 
vortexed at maximum for 5 seconds followed by incubation on ice for 5 min with 
vortexing at maximum every minute. 800 µL of Mitochondria Isolation Reagent C was 
added followed by inversion of samples. Samples were centrifuged at 700 x g for 10 min 
at 4°C. Supernatant was transferred to a new 2 mL tube and centrifuged at 12,000 x g for 
15 min at 4°C. This contains mitochondria, lysosome and peroxisomes (3,000 x g for 15 
min at 4°C to further reduce by >50%). Transfer the supernatant (cytosol fraction) to a 
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new tube. The pellet contains the isolated mitochondria. 500 µL Mitochondria Isolation 
Reagent C was added to the pellet and centrifuged at 12,000 x g for 5 min. The supernatant 
was discarded. Pellet was maintained on ice until required. Freeze-thawing may 
compromise mitochondria integrity. 
 
2.6 Proteomic analysis 
2.6.1 Bradford assay 
A BSA standard was serially diluted using UHP from a 2 mg/mL stock of Quick startTM 
Bovine Serum albumin Standard (Bio-Rad, #500-0206) starting with 1 mg/mL and 
spanning 0.5, 0.25, 0.125 and 0 mg/mL. Standards and samples were measured in 
triplicates at least by pipetting 5 µl of each into the corner of the base of a well in a 96-
well plate. 250 µL of Quick startTM Bradford 1X Dye Reagent (Bio-Rad, #500-0205) to 
each well and incubate in the dark for 10-15 min. Absorbance readings are measured on 
a bench top spectrophotometer at a wavelength of 595 nm.  
 
2.6.2 Western Blot 
Proteins for analysis by Western Blotting were resolved using SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). Lysis buffer containing urea was added to cell pellet. Cell 
lysis was carried out over 20 min on ice and following vortex, the lysate was spun at 4°C 
for 15 min at maximum speed to remove insoluble debris. Protein was quantified the 
Bradford protocol. Protein samples were diluted in 2X Laemlli buffer (which contains 
loading dye, Sigma-Aldrich, S#3401) and appropriate volumes of lysis buffer. Before 
loading into the gel, samples were boiled for 5 min and cooled on ice. 5-20 µg of protein 
and the molecular weight marker (New England Biolabs) were loaded onto a 4-12% 
NuPAGE Bis Tris precast gradient gel (Life Technolgies, NP0322BOX). Electrophoretic 
transfer, blocking and development of western blots was carried out. Membranes were 
probed with the appropriate antibody of choice diluted in Tris-buffer saline containing 
0.1%-20% Tween (TBS-T). An anti-mouse GAPDH monoclonal antibody (Abcam, 
#ab8245) was used as an internal control.  
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2.6.3 2-D clean up kit 
Lysed protein samples were cleaned up using the ReadyPrepTM 2-D Cleanup Kit (Bio-
Rad, #163-2130) as means of removing any contaminating substances like ionic 
detergents, salts, nucleic acids and lipids as a result of the lysis buffer or residual cellular 
debris. This will reduce streaking, background staining and other artifacts associated with 
substances contaminating 2D/IEF samples. A maximum of 500 µg can be cleaned using 
this kit for any one sample. Sample clean-up volume can be up to a maximum of 100 µL 
in a 1.5 mL microcentrifuge tube with maintenance on ice unless otherwise indicated. 
Always place the centrifuge in the same orientation in the centrifuge. 
1-500 µg of protein was transferred to a final volume of 100 µL of MS-grade water. 300 
µL of precipitating agent 1 was added to the protein sample and mixed by vortexing with 
a 15 minute incubation ice. A further 300 µL of precipitating agent 2 was added to the 
mixture and mixed well by vortexing. This was centrifuged at 12,000 g for 5 min to pellet 
removing tube promptly after spin step. Without disturbing the pellet, supernatant was 
removed using a pipette and discarded. Tube was centrifuged for an additional 15-30 
seconds to collect any residual liquid and carefully removed and discarded. 40 µL of wash 
reagent 1 was added on top of the pellet and centrifuged at 12,000 g for 5 min, this was 
subsequently removed and discarded using a pipette. 25 µL of ReadyPrep proteomic 
grade water of UHP was added on top of the pellet and vortexed for 10-20 seconds. 1 mL 
of wash reagent 2 (pre-chilled at -20°C for at least 1 h) and 5 µL of wash 2 additive was 
added and vortexed for 1 min to mix. Samples were incubated at -20°C overnight. After 
this incubation, tubes were centrifuged at 12,000 g for 5 min to form a tight pellet. 
Supernatant was removed and discarded with an additional centrifuge for 15-30 seconds 
to collect remaining wash. Pellet was air dried at room temperature for no more than 5 
min until the pellet appears translucent. Pellet was resuspended by adding an appropriate 
volume of 2-D rehydration/sample buffer and vortexed for at least 30 seconds. Tube was 
incubated at room temperature for 3-5 min, vortexed again and pipetted up and down a 
few times to fully resuspend. Sample was centrifuged to collect at 12,000 g for 2-5 min. 
Protein is ready for subsequent analysis or treatment and stored long term at -80°C.       
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2.6.4 Label-free sample digestion (Trypsin and Lys-c) 
ProteaseMAXTM Sufactant, Tryspin Enhancer (Promega, #V2072) was used to carry out 
and enhance in-solution digestions in accordance with the manufacturer’s specifications. 
ProteaseMAXTM Surfactant solubilizes proteins including difficult proteins (membrane 
proteins) and enhances protein digestion by providing a denaturing environment prior to 
the addition of protease enzymes. ProteaseMAXTM Surfactant degrades over the course 
of the digestion reaction yielding products that are compatible with downstream processes 
such as mass spectrometry (MS).  10 µg of protein was used for digestion. 2 µL of 1% 
ProteaseMAXTM Surfactant: 50 mM NH4HCO3 and the final reaction volume was made 
up to 100 µL of reaction mixture according to the table below: 
 
Component Volume (µL) 
0.1% ProteaseMAXTM Surfactant:50 mM 
NH4HCO3 
20 
1.0% ProteaseMAXTM Surfactant:50 mM 
NH4HCO3 
2 
50 mM NH4HCO3 58.5 
0.5M DTT 1 
0.55M iodoacetamide  2.7 
Trypsin (1 µg/µL) 1.8 
1% ProteaseMAXTM Surfactant 1 
Final Volume 100 
 
50 mM NH4HCO3 was added to the 10 µg of protein to a final volume of 93.5 µL. 1 µL 
of 0.5M DTT was additionally added and incubated at 56°C for 20 min. 2.7 µL of 0.55M 
iodoacetamide was added and incubated in the dark for 15 min. 1 µL of 1% 
ProteaseMAXTM Surfactant and 0.1 µg of Lys-c (Promega, #V1071) and incubated at 
37°C for 6 hs. Lys-c is a protease that hydrolyses the carboxyl side of Lysine (Lys). After 
this incubation, 1 µg/µL of trypsin (Promega, #V5280) was added to the mixture and 
incubated at 37°C overnight. Trypsin is a protease that specifically hydrolyses arginine 
and lysine residues. The condensate from the walls was collected by centrifugation at 
12,000 g for 10 seconds. A final concentration of 0.5% TFA was added, mixed and 
incubated for 5 min and room temperature. Sample is now ready for cleaning or peptide 
concentration. 
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2.6.5 C-18 spin column peptide concentration 
Peptides were purified using a C-18 spin column (Thermo Scientific, #89870) in 
accordance with the manufacturer’s specifications. Buffer preparation was as follows: 
Activation Solution: 50% Methanol 
Equilibrium Buffer: 0.5% TFA in 5% CAN 
Sample Buffer: 2% TFA in 20% CAN 
Wash Solution: 0.5% TFA in 5% CAN 
Elution Buffer: 70% CAN 
The Column was prepared by tapping until the resin was collected at the bottom. The 
column was placed into a collection tube. 200 µL of activation solution was used to rinse 
the column walls and to wet the resin, centrifuged at 1500 g for 1 minute and flow-through 
was discarded. This was repeated. Next, 200 µL of equilibration buffer was added and 
centrifuged at 1500 g for 1 minute. This step was also repeated. The sample was loaded 
into the resin bed. The column was placed into a receiver and centrifuged at 1500 g for 1 
minute. Flow through was processed again following a repeat step. The column was 
placed into a receiver and 200 µL of wash solution was added and centrifuged for 1 
minute at 1500 g. The flow through was discarded. This wash step was repeated. The 
column was placed into a new receiver tube. 20 µL of elution buffer was placed in top of 
the resin and centrifuged at 1500 g for 1 minute. This step was repeated with an additional 
20 µL of elution buffer to yield a final volume of 40 µL of purified peptides. Samples 
were dried using a vacuum centrifuge until required.  
 
2.6.6 Label-free mass spectrometry 
Nano LC–MS/MS analysis was carried out using an Ultimate 3000 nanoLC system 
(Dionex) coupled to a hybrid linear ion trap/Orbitrap mass spectrometer (LTQ Orbitrap 
XL; Thermo Fisher Scientific).  
A 5 μL injection of digested sample were picked up using an Ultimate 3000 nanoLC 
system (Dionex) autosampler using direct injection pickup onto a 20 μL injection loop.  
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The sample was loaded onto a C18 trap column (C18 PepMap, 300 μm ID × 5 mm, 5 μm 
particle size, 100 Å pore size; Dionex) and desalted for 5 min using a flow rate of 25 
μL/min in loading buffer (0.1% TFA, 2% acetonitrile). The trap column was then 
switched online with the analytical column (PepMap C18, 75 μm ID × 500 mm, 3 μm 
particle and 100 Å pore size; (Dionex)) using a column oven at 35 °C and peptides were 
eluted with the following binary gradients of: 
Mobile phase buffer A (0.1% formic acid in 2% acetonitrile) and mobile phase B (0.08% 
formic acid in 80% acetonitrile) 0-25% B over 280 min and 25-100% for a further 20 
minuntes. 
Data were acquired with Xcalibur software, version 2.0.7 (Thermo Fisher Scientific).  
The Hybrid linear ion trap/Orbitrap mass spectrometer (LTQ Orbitrap XL; Thermo Fisher 
Scientific) was operated in data-dependent mode and externally calibrated.  
Survey MS scans were acquired in the Orbitrap in the 400–1800 m/z range with the 
resolution set to a value of 30,000 at m/z 400. Up to three of the most intense ions (1+, 
2+ and 3+) per scan were CID fragmented in the linear ion trap. A dynamic exclusion 
was enabled with a repeat count of 1, repeat duration of 30 seconds, exclusion list size of 
500 and exclusion duration of 40 seconds. The minimum signal was set to 500.  All 
tandem mass spectra were collected using a normalised collision energy of 35%, an 
isolation window of 2 m/z, activation Q was set to 0.250 with an activation time of 30. 
 
2.6.6.1 Identification of Proteins from Mass Spectrometry Data 
The CHO fasta database was downloaded from: 
ftp://ftp.ncbi.nlm.nih.gov/blast/db/FASTA consisting of 24,383 predicted genes. 
 
2.6.6.2 Progenesis LCMS 
The resulting total ion chromatograms (TIC) of quantitative label-free LC-MS data were 
subjected to statistical analysis using Progenesis LC-MS software (NonLinear 
Dynamics). This programme imports all runs in an “ion intensity map” format which 
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maps the ions discovered in the run, by plotting retention time against the mass/charge 
ratio. All ion maps may be aligned against one reference run which allows for any shift 
in retention time between runs. The intensity of each ion may then be compared against 
that of all other runs, thus generating quantitative data on patterns of differential 
expression between sample sets which may be analysed with statistical analysis tools such 
as ANOVA, and principal component analysis.  
For all experiments, unless stated otherwise, all peptides, and all proteins demonstrated 
ANOVA scores of ≤0.05 for differential analysis between sample sets.  
For all quantitative LC-MS/MS data, Progenesis provides the following information; 
protein accession number, peptide count, number of peptides matched, confidence score, 
an ANOVA value, the maximum fold change, and the average normalised abundance. 
The protein accession number represents the code corresponding to the protein in NCBI-
CHO protein database. “Peptide count” refers to the number of peptides identified and 
“number of peptides matched” refers to the number of peptides which were matched to 
the protein. The MASCOT score (or ion score) is calculated from the combined scores of 
how well each peptide matches to the protein sequence. The significance of the 
differential expression between the two groups is represented by an ANOVA score (p-
value). The fold change, or average ratio, illustrates the greatest fold different in protein 
ion abundance between the two groups. The average normalised abundance is calculated 
from the sum of all peptide abundances from every run for each protein. 
The MASCOT search parameters that were used allowed two missed cleavages, fixed 
modification of cysteine (carbamidomethyl-cysteine) and variable modification of 
methionine (oxidised). Peptide tolerance depended on the instrument used to acquire the 
mass spectrometry data, in this case the Hybrid linear ion trap/Orbitrap mass spectrometer 
used a peptide tolerance of 20 ppm. The MS/MS tolerance was set at 0.6 Da. On 
completion of the database search the peptide results were filtered using MASCOT 
criteria of 95% confidence interval (C.I.) threshold (p<0.05), with a minimum ion score 
of ≥40. Protein identifications were accepted if they had one matched peptide. 
 
 
 
123 
 
2.6.7 SEAP assay 
The enzymatic assay for the quantification of SEAP (secreted alkaline phosphatase) was 
adapted from the method reported by Lipscomb et al., (2005). 50 µL of supernatant was 
transferred to a single well on a 96 well flat bottom plate. To each sample, 50µl of 2X 
SEAP reaction buffer (10.5g diethanolamine (100%), 50 µL of 1M MgCl2 and 226 mg of 
L-homoarginine in a total volume of 50 mL) was added. Plates were incubated at 37 ˚C 
for 10 min in order to increase enzymatic activity. After this time, 10µl of phosphates 
substrate (158 mg of p-nitrophenolphosphate (SIGMA-ALDRICH®, P4744) in 5 mL of 
1 X SEAP reaction buffer, made fresh for each use – adjust to suit number of sample 
wells) was added to each well. A Kinetic absorbance assay was performed and the change 
in absorbance per minute (OD405nm/min) was considered as an indicator of the amount of 
SEAP present in the sample. Mean V was taken as the change in the average of the kinetic 
slope. 
 
2.6.8 Enzyme-linked immunosorbent assay (ELISA) 
CHO-secreted IgG was quantified using the Bethyl Laboratories Human IgG ELISA 
Quantitation Set (Bethyl Laboratories Inc., E80-104) in accordance with the 
manufacturer’s specifications. Initially the amount of samples required including 
replicate number (n = 3), blank samples and standards were calculated to determine the 
number of plates required to perform an assay. 1 µL of Affinity Purified Human IgG 
Coating Antibody (SIGMA-ALDRICH, A80-104A) was diluted in 100 µL of Coating 
Buffer (One capsule of Carbonate-Bicarbonate Buffer (SIGMA-ALDRICH, C3041-
50CAP) in 100 mL of UHP making a 0.05M Carbonate-Bicarbonate coating buffer 
solution) for each well to be coated. Add 100 µL of diluted antibody to each well and 
incubate at 4˚C overnight. Wash plate 3 times using Wash Solution (SIGMA-ALDRICH, 
Tris Buffered Saline, with Tween®, pH 8.0, T9039-10PAK). In order to prevent non-
specific binding, 200 µL of Blocking Solution (SIGMA-ALDRICH, Tris Buffered Saline, 
with BSA, pH 8.0, T6789-10PAK) was added to each well after washing and incubated 
at room temperature for 60 min. During this incubation step, standard and sample 
preparation was performed. Starting from a pre-diluted (using PBS) IgG stock of 1000 
ng/mL, a serial dilution was undertaken creating a range of known IgG concentrations 
from 500 ng/mL-7.8 ng. A blank control of Diluent only (Blocking Solution with 0.5% 
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Tween 20) was run alongside the standards (Fig 2.11). Samples were diluted using 
Diluent based on the expected IgG concentration so that the final concentration/mL fell 
within the range of the standard curve.      
Figure 2.11: Standard Curve Dilutions 
 
After incubation, the blocking buffer was removed by washing 3 times as previously 
described. Into each appropriate well, 100 µL of standard and sample in triplicate was 
loaded and incubated at room temperature for 60 min. After, plates were washed 3 times. 
Prior to addition of the HRP detection antibody (SIGMA-ALDRICH, A80-104P), a 
1/50,000 dilution in Diluent was carried out by adding 1 µL of HRP Detection Antibody 
to 50 mLs of Diluent. 100 µL of pre-diluted HRP detection antibody was transferred to 
each sample/standard well and incubated at room temperature for 60 min. Once again, 
after incubation, the HRP detection antibody was removed and the plate washed 3 times. 
100 µL of the TMB substrate (SIGMA-ALDRICH, 3,3’,5,5’-Tetramethylbenzidine, 
T8665-100mL) was added to each well and the enzymatic reaction was allowed to 
develop at room temperature in the dark for 10-15 min yielding a colour change to a blue 
solution. After 10-15 min, the reaction was stopped with the addition of 100 µL of 0.18M 
(H3PO4) Phosphoric Acid (SIGMA-ALDRICH, 04102-500G) to the TMB previously 
added to each well. The solution should yield a colour change from blue to yellow. Within 
30 min of stopping the reaction, the enzymatic activity should be evaluated by measuring 
the absorbance on an ELISA plate reader at 450 nm. Triplicate absorbance values should 
be within 10% of each other. By plotting a standard curve, the elucidation of IgG content 
of the unknown samples can be calculated based on the curve and taking the dilution 
factor into account. 
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2.6.9 Glutamate assay 
The detection of glutamate was carried out using the Glutamate Assay Kit (Sigma-
Aldrich, #MAK004) in accordance with the manufacturer’s specifications. Absorbance 
readings were performed on a bench top spectrophotometer at a wavelength of 450 nm. 
Glutamate standards were prepared by diluting 10 µL of the 0.1 M Glutamate standard in 
990 µL of the glutamate assay buffer to make a 1 mM standard solution. From this, 0, 2, 
4, 6, 8 and 10 µL into a 96 well plate forming a 0 (blank), 2, 4, 6, 8 and 10 nmole/well. 
Glutamate assay buffer was added to each well to bring the volume to 50 µL. Samples 
were prepared in a similar fashion topping up to 50 µL using glutamate assay buffer. 
Assay reaction mixes were made up according to the scheme below: 
 
Reagent Blank Sample Samples and Standards 
Glutamate Assay Buffer 92 µL 90 µL 
Glutamate Developer 8 µL 8 µL 
Glutamate Enzyme Mix - 2 µL 
 
100 µL of the appropriate Reaction Mix was added to each of the wells, mixed using a 
shaker/pipetting and placed in the dark to incubate for 30 min at 37°C. The plate was 
measured at 450 nm on a spectrophotometer.  
 
2.6.10 Akta Prime IgG purification 
HiTrap Protein A HP column (GE HealthCare-Life Sciences, #17-0402-01) was used for 
the purification of IgG antibodies in conjunction with using the AktaPrime Plus system 
(GE Healthcare). The AktaPrime Plus is a chromatography system that performs single 
purifications of tagged and untagged proteins. The system is compact and comprises of a 
pump, fraction collector, monitors for UV, conductivity and pH. Valves for buffer 
selection, sample injection, gradient formation, and flow diversion are also integrated into 
the system. The AktaPrime was cleaned using 50% ethanol and the system was purged 
with PBS, including the protein A column, before each sample loading. When setting up 
the AktaPrime commands, a flow rate of 1 mL/min (1 mL protein A column) with a 
fraction size of mL and a pressure of 1 MPa. Load position was set to “Pos 1” for 
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equilibration and washing procedures and “Pos 8” in the case of sample loading/washing 
and elution. All elutes were sent to “Waste” except in the case of sample loading, if flow-
through sample was required to be retained, and elution of IgG in which case were sent 
to “load”. Finally, 0% gradient was predominantly selected except in the case of elution 
in which case an 80% gradient of Buffer B (0.5% Acetic Acid) was used. After purging 
the system with PBS and cleaning the protein A column using PBS (Buffer A), IgG 
supernatant sample was loaded through “position 8”. The UV detector will detect all 
secreted proteins as the sample flows through while IgG binds the column prior to UV 
detection. After all sample has been passed though the column, Buffer A (PBS) was used 
to wash the system/Column until the UV absorbance returns to baseline. An 80% gradient 
was then selected for Buffer B (0.5% Acetic Acid) to flow through “position 8” and sent 
to “load”. This elution was collected in waste until there was a spike in the UV detector 
indicating the start of IgG elution from the column (This may take a few min – so don’t 
panic). After the sample was collected, the column was washed with a 100% gradient of 
Buffer B and then the system and column was washed with Buffer B in preparation for 
the next sample. If finished, the system was cleaned with MS grade water loading through 
both “positions 1 and 8” and sending to both “Waste” and “Load” for at least 10 column 
volumes, followed with the same cleaning procedure using 20% ethanol. Once the column 
was cleaned with 20% ethanol, it was also stored in 20% ethanol at 4°C. The eluted IgG 
was buffer exchanged using Amicon Ultra – 4 Ultracal 10kC filters by applying the 
sample to the filter and centrifuging at 4,000 g for 10 min at 4°. Flow through was 
discarded and filters were topped up with 4 mL of PBS and centrifuged again following 
the same conditions. This was repeated about 3-4 times and the remaining ~500 µl of 
IgG-containing PBS was removed, placed in an eppi and stored at -20°C.  
 
2.6.11 Glycomic Characterisation of Antibodies 
Characterisation of antibody glycoforms was determined based on the procedure reported 
by Mittermayr and Bones et al., (Mittermayr et al. 2011). Clones were cultured in a 20 
mL volume spinner flask and cultured for a maximum of 4 days. Cells were removed by 
centrifugation at 1500 rpm for 5 min with a centrifugation step at 4000 rpm for 10 min to 
ensure removal of residual cellular debris. IgG was purified using an IgG-protein A 
column on an AktaPrimeTM Plus system (see section 2.6.10 of Materials and Methods). 
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An in-solution digest was carried out using the PNGase F enzyme to remove any 
asparagine N-linked glycans in addition to serine or threonine O-linked glycans. 500 µg 
of total antibody protein was added to a micro-centrifuge tube in sodium bicarbonate 
(SBC) making up the volume to that of the highest volume sample. As N-glycans usually 
protrude from the external surface, it was not required to reduce or alkylate antibodies. 
PNGase F was added to the final digest at 5% of the total volume and incubated at 37°C 
overnight. A 10 kDa MWCO filter was treated with a 1:1 ethanol water solution and 
centrifuged at 13,000 rpm for 5 min discarding the flow-through. Digested sample was 
added to the filter and spun at 13,000 rpm for 10 min. The digestion tube was washed 
with 200 µL water, added to the filter and spun at 13,000 rpm for 10 min. The filtrate was 
vacuum dehydrated by centrifugation. Once dry, 20 µL of 1% formic acid was added to 
the tube, vortexed briefly and reduced to dryness. This ensures complete conversion of 
glycosamines present back to the reducing aldose. As monosaccharides lack 
chromophores or fluorophores, it was necessary to label monosaccharaides with an 
absorbing group to increase overall analytical sensitivity. To the dried N-glycans, 5 µL 
of labelling solution (50 mg 2-AB, 2-aminobenzoic acid, 60 mg sodium 
cyanoborohydride in 70:30 DMSO acetic acid). Mix by pipetting. An additional 5 µL of 
70:30 DMSO acetic acid was added, vortexed and incubated at 65°C for two hs. 
Following incubation, 90 µL of water was added to the labelling solution, mixed and 
vortexed. 900 µL of acetonitrile was subsequently added, mixed and vortexed with a brief 
spin to collect. Unconjugated 2-AB was removed by aspirating the liquid through a 1 
mL/10 µL PhyNexus Normal Phase PhyTip preconditioned with 95% v/v acetonitrile. At 
least 10 in-out cycles were performed. The tip was washed with 10 in out cycles of 95% 
v/v acetonitrile venting the waste each time. The labelled N-glycans were eluted with 5 x 
200 µL washes of water, collected, combined and reduced to dryness in a vacuum 
centrifuge. Samples were reconstituted in an appropriate volume of water and stored at -
20°C. Ultra-Pure liquid chromatography (UPLC)-fluorescence profiling of N-glycans 
was utilised to the antibody glycoform patterns in antibody samples. Hydrophilic 
interaction liquid chromatography (HILIC) was used as a suitable separation technique 
due to the polar nature of oligosaccharides. 2-AB labelled N-glycans were separated by 
UPLC with fluorescence detection on a Waters Acquity UPLC instrument consisting of 
a binary solvent manager, sample manager and fluorescence detector under the control of 
Empower 2 chromatography workstation software (Water, Milford, MA). Separations 
were performed using Waters BEH glycan columns, 100 x 2.1 mm i.d., 1.7 µm BEH 
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particles, using a linear gradient pf 70-53% acetonitrile at 0.56 mL/min in 16.5 min, 50 
mM ammonium formate pH 4.5 was used as buffer A. An injection volume of 20 µL 
sample prepared in 80% v/v acetonitrile was used throughout. Samples were maintained 
at 5°C prior to injection and the separation temperature was 40°C. The fluorescence 
detection excitation/emission wavelengths were λex = 330 nm and λem = 420 nm, 
respectively.   
     
2.7 Biotinylated miRNA pull-down of mRNA  
The protocol utilised for the target identification of specific microRNAs including the 
comparative analysis of protein complexes associated with miRNA guide and passenger 
strands was based on the method published by Ørum and Lund (Orom, Lund 2007) using 
Biotinylated synthetic miRNAs. Before carrying out the experimental procedure of 
miRNA pull-down, 100 µL of Streptavidin-agarose beads (Sigma-Aldrich, 85881-1ML) 
was incubated with 10 µL of a 10 mg/mL stock of tRNA (Sigma-Aldrich, R8508-1ML) 
and 10 µL of a 10 mg/mL stock of BSA (Sigma-Aldrich, B2518-10MG) in a 1.7 mL 
Eppendorf tube on a rotating platform at 4˚C for ~3 hs. This served to reduce the level of 
non-specific binding. These pre-blocked beads were then washed twice in 300 µL lysis 
buffer by centrifugation at 12,000 g for 30s and subsequently resuspended in 100 µL of 
lysis buffer. This 100 µL of slurry was sufficient for 4 samples. To avoid separation of 
bound mRNAs to our biotin-tagged miRNA as well as associated protein complexes, a 
gentle lysis buffer was prepared in accordance to the recipe below. 
In 100 mL of UHP water: 
20 mM Tris 
200 mM NaCl  
2.5 mM MgCl2 (Sigma-Aldrich, M2670-100G) 
0.05% Igepal (Sigma-Aldrich, 13021-50ML) 
60U/mL RNase Inhibitor, Superase 20U/µL (Life-technologies, AM-2694) 
1 mM DTT 
Halt Protease inhibitor cocktail, EDTA-free (100X) (Thermo-fischer scientific, 87785) 
The addition of the RNase inhibitor, DTT and Protease inhibitor cocktail was carried out 
prior to use of the lysis buffer. For each sample, 25 µL of slurry was transferred to a 1.7 
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mL Eppendorf tube and washed twice with 500 µL of lysis buffer and resuspended in 25 
µL of fresh lysis buffer. Cells were harvested 24-48 hs after transfection and washed once 
with PBS by centrifugation at 1500 g for 5 min. Cells were resuspended in 1 mL lysis 
buffer in a 1.7 mL Eppendorf and placed on ice. Lysed cells were then vortexed 
vigorously for 10s and placed on ice for 10 min and vortexed. The lysate was cleared by 
centrifugation at 12,000 g at 4˚C for 15 min in a microcentrifuge. The supernatant was 
transferred to a new cold tube on ice. At this point, a 50 µL input sample was removed 
from the total volume and placed on ice for further analysis. The remaining lysate was 
then incubated on a rotating platform for 1 h at 4˚C with 25 µL of pre-washed 
streptavidin-agarose beads. Beads incubated in lysate were collected by centrifugation for 
1 minute at 5000 rpm at 4°C. The supernatant was carefully removed and the beads 
washed in 500 µL of ice-cold lysis buffer. This washing step was repeated 3 times. After 
the last wash, 50 µL of lysis buffer was left on the pellet. This final solution contained 
Biotinylated-miRNA bound to the streptavidin-agarose beads with associated 
mRNA/protein complexes ready for further processing such as RNA/Protein isolation.   
 
2.8 Statistical analysis 
A paired t-test was utilised in the case of OROBOROS measurements in miR-23 depleted 
clones (Section 3.4 of results) due to the high through-put constraints within the machine 
itself. Only two samples (test versus control) could be measured at any one time in 
addition to a large degree of innate variance in data output. To account for this variance, 
samples were statistically tested as “unequal variance” with each individual test and 
control being compared individually to each other. Using excel, a paired t-test is a type 1 
t-test. 
A more stringent statistical method was applied for most data analysus throughout this 
thesis, except in the case above. This was an unpaired t-test used to assess weather the 
population means were different. This is a type 2 t-test in excel. 
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of CHO cell growth rate with 
subsequent phenotypic 
characterisation 
 
 
 
 
 
 
 
 
 
132 
 
3.1.1 Identification of microRNAs involved in the regulation of CHO cell growth 
rate and phenotypic characterisation  
This section describes the functional assessment of a panel of miRNAs identified in a 
multi-omics profiling experiment performed in our lab and described in detail in Clarke 
2012 (Clarke et al. 2012). 
 
3.1.1.1 Differential miRNA expression profile of CHO cells with varying growth  
rates using an integrated miRNA, mRNA and protein expression analysis technique 
Briefly, a panel of CHO clones were selected exhibiting a range of growth rates (0.011 to 
0.044 hr-1) (Table 3.1) with a mean productivity of 24 (±3) pg of protein/cell/day. The 
selection of sister clones derived from the same transfection pool differing only in growth 
rate served to remove productivity as a variable within the profile thus enriching for 
variations inherently associated with cellular proliferation.  
Table 3.1: Clonal I.Ds of fast and slow CHO clones 
I.D. Phenotype Specific Growth rate 
X5.13F F  
 
 
 
0.011-0.044 division/hr 
X5.16F F 
X5.18F F 
X5.22F F 
X5.2F F 
X10.2S S 
X11.1S S 
X5.11S S 
X5.1S S 
X7.7S S 
 
Of the clones represented in the table 3.1, the 10 clones were separated into two groups: 
5 “fast” (≥ 0.025 hr-1) and 5 “slow” (≤ 0.023 hr-1) samples. 
The incorporation of multiple “omics” disciplines served to facilitate in the identification 
of non-seed miRNA targets, a problem recurrently encountered when identifying 
potential targets of specific miRNAs, which is reported in greater detail in (Clarke et al. 
2012). Here we focus on only the miRNAs identified within this study and pursue their 
potential application in CHO cell engineering 
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3.1.1.2 Cell Culture and sampling 
Clonal cell lines were grown in batch shake flask suspension culture in AS1 media 
(proprietary serum-free media) at a working volume of 60 mL at 37 ˚C. Cells were 
inoculated at a starting density of 2 x 105 cells/mL. Each clone was grown in triplicate 
and samples were collected during mid/late exponential (log) phase (72 h). Samples were 
separated into three fractions for subsequent analytical profiling of miRNA expression 
using qRT-PCR based Taqman Low-Density Array (TLDA) technology, mRNA 
expression using a proprietary CHO-specific WyeHamster3a oligonucleotide microarray 
and protein expression using label-free LC-MS. The focus of this thesis is the miRNA 
targets identified as potential engineering tools of CHO cell growth. 
 
3.1.1.3 microRNAs associated with growth 
Of the 51 miRNAs found to be DE in this study exhibiting a correlation with CHO cell 
growth rate, a number have previously been associated with cellular proliferation 
including miR-451 (Godlewski et al. 2010), miR-206 (Yan et al. 2009a), miR-23b* (Liu 
et al. 2010a), miR-31 (Laurila et al. 2012) and miR-10a (Tan et al. 2009). Several of the 
miRNAs found to be up-regulated form the miRNA cluster, miR-17 ~ 92 (miR-17, miR-
20a, miR-20b, miR-18a, miR-18b and 106a). This is a well characterised miRNA cluster 
in respect to cancer (Olive, Jiang & He 2010a), having direct oncogenic transcriptional 
activators such as c-myc (O'Donnell et al. 2005b) in addition to being previously 
identified as highly expressed in CHO (Hackl et al. 2011). 
To demonstrate the strength of this profiling strategy in reducing the false 
positive/negative hits generated through utilisation of miRNA: mRNA binding criteria by 
prediction algorithms (see section 1.2.6), the following is an example from the literature 
in support of our findings. An experimentally validated target of miR-451 is the activator 
of tumour suppression, Rab14 (Wang et al. 2011a). miR-451 was shown to be down-
regulated in fast growing CHO cells while the Rab14 protein was up-regulated in addition 
to the level of  expression of its mRNA remaining constant. In the case of Rab14-miR-
451, TargetScan would score Rab14 as a candidate target gene of miR-451 quite poorly 
given the low degree of conservation of the 3’UTR binding site. As a result, sole 
dependence on a prediction algorithm would result in the oversight of true molecular 
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targets but in cases such as this, the availability of datasets generated as described in this 
current profile can aid in the prioritisation of true mRNA targets of miRNAs and 
complement the output hits from prediction algorithms. 
 
3.1.2 Phenotypic validation through transient microRNA screening 
Phenotypic characterisation of a select subgroup of miRNAs derived from the list 
determined to be DE in CHO cells with varying growth rates was carried out transiently 
by the exogenous introduction of an artificial miRNA hairpin or duplex, termed a pre-
miR (mimic), or a single-stranded oligonucleotide fully complementary to the mature 
sequence of the miRNA being targeted, termed an anti-miR/antagomiR or inhibitor (see 
section 1.3.2). To ensure sufficient exogenous levels of a miRNA or adequate knockdown 
of a highly expressed endogenous miRNA, 50-100 nM of mimic/inhibitor was used 
during the screening process. The following section summarises the interesting results 
generated from the primary phenotypic screen of the miRNAs identified from the profile 
(see section 3.1.1) with the inclusion of interesting targets from literature sources/current 
ongoing work.   
 
3.1.2.1 Cell culture and transfection conditions 
All transient transfections were carried out as described in section 2.3.2 of Materials & 
Methods using either the transfecting reagent siSPORTTM NeoFXTM transfecting reagent 
(AMBION®, AM4510) or INTERFERinTM (PolyPlus-TransfectionTM, PPLU-409-01). 
Cells were seeded at a starting density of 1 x 105 cells/mL in a 50 mL aerated culti-flask 
disposable bioreactors (Sartorius Stedium Biotech, DF-050MB-SSH) at a final volume of 
2 mL CHO-S-SFM II (GIBCO®, 12052-098) culture media. A list of all miRNA mimics 
(NBS Biologicals, M-01) and miRNA inhibitors (NBS Biologicals, M-02) used in this 
transient screen are listed in the appendix (Appendix Figure A1). All appropriate 
controls were included: untreated cells, transfection reagent only, a positive control 
(siRNA designed against VCP) and a non-specific negative control (NC). Transfection 
efficiency was based on the transfection of a siRNA designed against the mRNA coding 
sequence of Vasolin-containing protein (VCP). VCP was initially identified as being 
highly expressed in CHO cells with increased growth rates with subsequent siRNA-
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mediated knockdown resulting in the induction of apoptosis and growth arrest (Doolan et 
al. 2010). Inclusion of a NC (NBS Biologicals, M-03) for either a miRNA mimic or 
inhibitor, served to account for the off-target effects on the cells miRNA processing 
machinery. Data represented includes only the negative control and the miRNA under 
investigation, however, assays yielding a poor transfection efficiency, based on siVCP, 
were omitted from analysis.  
Combination transfection of particular miRNAs was undertaken with optimisation carried 
out as a means to determine the concentration to use that would be sufficient to potentially 
mediate a phenotype without losing potency due to titrational effects. 20 nM of pre/anti-
miR was selected with a total of two miRNAs co-transfected at any one time. Each 
miRNA was transfected individually (20 nM) as a means to compare any potential 
synergy taking place while, however to account for the total concentration of 40 nM in 
the case of co-transfected miRNAs, 20 nM of a negative control pre/anti-miR was 
included for each individual miRNA (Data not shown).  
After transfection, cells were cultured for 7 days at 170 rpm in a Kuhner Climo-shaker 
incubator (Kuhner, Climo-shaker, ISF1-X) at 37 ˚C and assessed for growth and 
productivity.  
 
3.1.2.2 Summary of transient miRNA screen 
With the focus of this thesis being that of the exploitation of miRNAs as engineering 
targets to enhance the performance of CHO cells within the bioprocess, this section 
summarises a subset of the list of 51 miRNAs revealed to be DE (section 3.1.1) and their 
impact on the CHO cell phenotype upon transient evaluation. 
From a large panel of miRNAs screened, a small subset of these miRNA was observed to 
exhibit a consistent impact on CHO cell phenotype. This supports previous observations 
within the literature of miRNA acting subtly, buffering cellular networks with few 
miRNAs driving particular phenotypes (Mullokandov et al. 2012). The most interesting 
miRNAs from the screen and their associated CHO cell phenotypes are presented in 
Table 3.1.        
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Several high priority miRNAs, based on phenotypic potency, were identified such as the 
tumour suppressor miR-34a, its passenger strand miR-34a* and the passenger strand of a 
member of another well-known cancer-associated miRNA cluster, miR-23b*. All three 
miRNAs were found to impact negatively on CHO cell viability with potent inhibition of 
cellular proliferation, despite two candidates being demonstrated to be upregulated in fast 
growing CHO cells. In all three instances, volumetric productivity was observed to be 
reduced considerably predominantly attributed to the reduced cell numbers in early-mid 
stage culture, a phenotype recurrent in instances of growth inhibition. 
A large portion of the list of miRNAs screened were observed to elicit either an 
inconsistent or no phenotype across replicates (data not shown). Combinatorial miRNA 
transfections were explored for these inconsistent miR targets in order to exploit potential 
synergy. miRNAs that exhibited mild phenotypes (in both a positive or negative 
direction) or no phenotype at all were co-transfected with a certain degree of success. 
Numerous miRNAs such as miR-455-3p/5p, miR-409-3p and miR-338-3p were observed 
to act negatively upon transient knockdown. However, the mild and inconsistent 
phenotypic shift observed for these miRNAs compared to the potent effects exhibited by 
miR-34a, -34a* and -23b* over-expression resulted in these latter candidates moving to 
the next level of validation as potential CHO cell engineering targets. Following 
experience within our research group with miR-7 (Barron et al. 2011a), stable depletion 
of miR-34a/-34a*/23b* may offer potential benefits based on their potent negative 
phenotype upon their over-expression.  
Despite not pursuing a small number of candidates due to resource and time constraints, 
various miRNAs screened present themselves as viable candidates for stable 
manipulation such as the growth inhibitor miR-206 and miR-639, the growth promoting 
and potentially apoptotic protective miR-15a/-16-1 and the growth inhibitory with 
possible productivity boosting attributes, miR-200a.  
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Table 3.1: Summary of all screening data in CHO-K1-SEAP  
Summary of miRNA screening data in CHO 
miRNA Screening Data Conclusion/Approach 
miR-34a 
(pre-miR) 
Overexpression reduced 
cellular proliferation, 
induced cell death. 
Knockdown improved 
growth inconsistently. 
Transient/stable knockdown 
for the enhancement of 
growth and resistance to 
apoptosis 
miR-23b* 
(pre-miR) 
Reduced cellular 
proliferation, mild 
induction of apoptosis 
Transient/stable knockdown 
for the enhancement of 
growth and the resistance of 
apoptosis 
miR-532 
(pre-miR) 
Overexpression reduces 
volumetric productivity. 
Knockdown improves 
growth rate inconsistently. 
 
Further validation 
miR-200a 
(pre-miR) 
Overexpression reduces 
growth and improves 
volumetric titre 
Stable overexpression under 
inducible promoter to 
enhance productivity/Stable 
inhibition to  improve 
growth 
miR-181d 
(pre-miR) 
Inconsistent Further Validation 
miR-639 
(pre-miR) 
Reduced cell growth Stable knockdown to 
improve growth and 
volumetric titre – Further 
Validation 
miR-455-5p/-455-3p 
(anti-miR) 
Inconsistent with an 
indication towards 
inhibitory growth effects 
Further Validation 
miR-206 
(anti-miR) 
Mild reduction in cell 
growth 
Further Validation 
miR-34a* 
(pre-miR) 
Reduced cellular 
proliferation, induction of 
apoptosis 
Transient/stable knockdown 
for the enhancement of 
growth and resistance to 
apoptosis 
miR-126 Inconsistent Further Validation 
miR-338-3p 
(anti-miR) 
Inconsistent Further Validation 
miR-378 
(anti-miR) 
Inconsistent Further Validation 
miR-409-3p 
(anti-miR) 
Inconsistent Further Validation 
miR-15a/16-1 
(anti-miR) 
Inconsistent/Increases 
growth 
Further Validation/Stable 
knockdown 
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Section 3.2 
 
 
 
 
 
 
The potential of miR-34a as an 
engineering target 
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3.2 Exploring the master “tumour suppressor” miR-34a as a potential CHO 
engineering target 
Both miR-34a and miR-34a* were observed to reduce cell growth and induce apoptosis, 
in CHO-SEAP cells upon their transient overexpression (section 3.1.2.2.2 and 3.1.2.3.1 
of Results). Despite both miR-34a and miR-34a* dramatically reducing volumetric 
protein output, miR-34a was observed to enhance specific productivity. 
This section explores the potential of miR-34a as a candidate for CHO cell engineering 
using miR-sponge technology when taking into account its conserved effect on CHO-
SEAP upon overexpression and its vast number of validated targets (Table 4.1 of 
discussion). 
 
3.2.1 Transient knockdown of miR-34a potentially enhances CHO cell growth  
Given that transient overexpression of miR-34a induced an unfavourable CHO cell 
phenotype it was anticipated that its transient inhibition may mediate the reverse 
phenotype, i.e. accelerated growth and apoptosis resistance. However, the phenotype 
observed upon its transient knockdown using anti-miRs was not as potent as hoped and 
inconsistent over the course of independent assays.  
A mild increase in cell density of ~13% and 30% (p ≤ 0.05) was observed on day 2 and 4 
of culture, respectively (Fig. 3.1 A), with no impact on viability. Normalised productivity 
was reduced by ~13% and ~25% on day 2 and 4, respectively (Fig. 3.1 B).  
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Figure 3.1: Transient miR-34a inhibition in CHO-K1-SEAP cells 
 
Figure 3.1: Transient miR-34a inhibition was achieved using fully complementary antagonists of the 
mature miR-34a commercially designed by NBS biologicals. Phenotypes under investigation were A) 
Cell numbers/mL and B) Normalised productivity. Statistical significance was calculated using a 
standard student t-test (p ≤ 0.05*) with an n = 3. 
 
3.2.2 Transient inhibition of miR-34a mildly inhibits the induction of apoptosis     
The transient nature of exogenously introduced anti-/pre-miRs impedes the assessment 
of late stage culture phenotype such as apoptosis. Given miR-34a’s mild impact on CHO 
cell viability, it was anticipated that reversing its function would positively affect viability 
and prolong cell survival. We sought to induce apoptosis early in culture by mimicking 
late stage culture conditions so that the transient influence of the miR-34a inhibitors has 
not worn off. 
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3.2.2.1 Apoptosis assay development 
Cell death can be induced by the supplementation of reagents such as Sodium butyrate 
(NaBu) (Lee, Lee 2012) or Dimethyl sulfoxide (DMSO). However, we wanted to induce 
a more realistic onset of apoptosis that would resemble the nutrient starved, hypoxic and 
toxin-enriched environment of the bioreactor. This method of inducing apoptosis has been 
previously reported by Druz and colleagues (Druz et al. 2011) which identified a pro-
apoptotic miRNA in CHO, miR-466h.    
We grew CHO-K1-SEAP parental cells seeded at 1 x 105 cells/mL in suspension for 13 
days until cell numbers and viability ceased to decline. By day 13, cultures were 15% 
viable with a cell density of ~2 x 105 cells/mL (Fig. 3.2).  
Figure 3.2: CHO-K1-SEAP growth curve 
 
Figure 3.2: The growth profile for parental CHO-K1-SEAP cells as a means of determining the point 
of culture at which to harvest nutrient depleted (spent) media. Cells were seeded at 1 x 105 cells/mL 
and cultured until cell viability was poor (less than 20%). Cell numbers are represented in blue on 
the left axis while viability is shown in red on the right axis.  
As the most potent impact of a miRNA was often observed at day 4 of culture, we wanted 
to establish an assay that would be monitored over the course of 4 days in an attempt to 
identify the full influence of miR-34a inhibition.  
We wanted to monitor the induction of cell death by culturing CHO-K1-SEAP cells 
seeded at 1 x 105 cells/mL in nutrient depleted media harvested at various time points 
(Fig. 3.2). Cells were cultured in spent media harvested at days 2, 3 and 4 with a fresh 
media control included. It was observed that as the quality of media decreased the level 
0
20
40
60
80
100
120
0.00E+00
1.00E+06
2.00E+06
3.00E+06
4.00E+06
5.00E+06
6.00E+06
0 5 10
C
e
ll
 V
ia
b
il
it
y
 %
C
e
ll
 N
u
m
b
e
r
s/
m
L
Day
CHO-K1-SEAP Growth Curve
Cell 
Numbers/mL
Viability %
142 
 
of exponential cell growth diminished (Fig. 3.3 A). Another interesting observation was 
that culture viability in all three media types declined initially but recovered (Fig. 3.3 A).  
Figure 3.3: Spent medium profiling 
 
Figure 3.3: Various levels of spent media were evaluated under batch conditions in an attempt to 
elicit a mild and gradual impact on CHO cell growth and viability. Cells were seeded at 1 x 105 
cells/mL and cultured in media harvested at A) days 2, 3 and 4 with a fresh media control B) day 6 
and 9 with a fresh media control and C) day 9 media seeded at 4 x 105 cells/mL. 
Next, day 6 and day 9 spent media was assessed. In this instance, cellular proliferation 
was dramatically reduced similar to what was observed for day 4 spent media as well as 
a gradual decline in cellular viability that did not recover (Fig. 3.3 B). Day 9 media 
demonstrated a more defined drop in viability as far as 70% although inconsistent upon 
repeat. 
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Finally, we attempted to increase the initial seeding density to 4 x 105 cell/mL in day 9 
spent media. When this was performed there was a nice decrease in viability to a 
maximum of 70% on day 4 with cell numbers declining to ~1.5 x 105 cells/mL. Upon 
repetition, cells cultured in this format were not observed to revive themselves (Fig. 3.3 
C).  
From these results, we decided to seed at 4 x 106/mL in nutrient depleted media as it gave 
a more consistent decline in both viability and cell density. However, from previous 
experience, transfection at high cell density had proven troublesome. Increasing 
concentrations to 4 µL of transfection reagent containing a negative control pre-miRNA 
generated a similar inhibitory growth phenotype as did for siRNA-VCP (Appendix Fig. 
A3). 50 nM of siRNA against VCP complexed with 4 µL of transfection reagent was the 
only condition to reduce cell viability below 80% (88%) indicating a very low transfection 
efficiency.    
 
3.2.2.2 Transient inhibition of miR-34a mildly inhibits apoptosis in CHO cells 
induced to undergo cell death 
Several aspects of this assay were inspired by the work of Druz et al., 2011 who 
performed viability assays by transfecting cells at high cell density (~106 cells) using 
Lipofectamine and transferring cells into nutrient depleted media 24 h after transfection 
and assayed 24 h later.  
In this instance we transfected CHO cells at 1 x 105 cells/mL in 2 mL of fresh culture 
media including a positive control (siRNA designed against VCP) using INTERFERinTM 
(Fig. 3.4). After 48 h of growth, to allow cell density to build up, cells were pelleted and 
resuspended in 2 mL of day 9 nutrient depleted media except for siRNA-VCP treated 
cells in order to gauge transfection efficiency.  
Transient inhibition of miR-34a in cells induced to undergo apoptosis appeared to mildly 
inhibit the onset of apoptosis by 5-10% (p ≤ 0.01). Interestingly, as previously observed, 
the inhibition of miR-34a also increased cellular proliferation from 1.35-2-fold (p ≤ 
0.001) over numerous replicates.     
 
144 
 
Figure 3.4: miR-34a knockdown using a modified apoptosis assay     
 
Figure 3.4: CHO grown in spent medium were assessed for A) Cell numbers/mL and B) Viability 24 
h subsequent to exposure to spent media, n = 3, t-test were calculated using a standard student t-test. 
 
3.2.3 Stable depletion of miR-34 using a microRNA sponge  
With the previous observation that transient inhibition of miR-34a improved CHO cell 
growth and mildly inhibited apoptosis, we thought it encouraging to explore its stable 
depletion in both SEAP and IgG-secreting CHO cells. miR-34a has been observed to be 
expressed at quite low levels in CHO cells (Hackl et al. 2011) using next-generation 
sequencing while its counterparts miR-34b/c were expressed quite abundantly. With the 
single nucleotide difference lying outside the seed region, both miR-34b and miR-34c are 
members of the same seed family as miR-34a thus potentially targeting the same mRNAs 
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(Bader 2012). Stable depletion of miR-34a using a fully complementary binding sequence 
downstream of a deGFP sponge reporter will effectively target all three miRNAs, miR-
34a/b/c. Hence forth, miR-34a when in reference to its depletion through a sponge decoy 
will be referred to as miR-34. 
 
3.2.3.1 miR-34 sponge design and generation 
The miR-34 miR-sponge sequence was designed to be fully complementary to its specific 
target miRNA with the exception of base-pair mismatches or “wobble” introduced at 
nucleotide locations 10-12 and placed downstream of a deGFP reporter (Fig. 3.5). This 
wobble was introduced to reduce miRNA-RISC-mediate mRNA cleavage that has been 
characterised to occur at nt 9-10 thus prolonging the functional half-life of the sponge 
construct (Kluiver et al. 2012a). 
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Figure 3.5: miR-34 sponge construct and miR interaction 
 
Figure 3.5: The construct that forms the miR-34 sponge, A) a destabilised GFP reporter under the 
transcriptional activation of a CMV promoter and a downstream polyA tail. Sandwiched between 
the deGFP coding sequence and polyA tail is the multiple cloning site (MCS) containing XhoI/EcoRI 
used for insertion of the miR-34 sponge sequence. This sequence contains four concatemeric binding 
sites for the miR-34 family in tandem with 5 nucleotide spacers and forms an artificial 3’UTR of 
deGFP. Wobble is introduced into the sponge sequence across nt 10-12 (highlighted in red) which 
serves to prolong the life time of the sponge mRNA as mRNA cleavage should be inhibited. An 
additional selection gene is incorporated into the sponge construct, Hygromycin resistance (HYGRO 
or HYG), which is used for the generation of stable CHO populations. B) The mature sequence of 
miR-34a with the seed sequence highlighted in blue.  
The sequence of the miR-34 sponge construct including restriction sites is shown in table 
3.2. 
Table 3.2: miRNA sponge sequence design for miR-34 
 
The miR-34 sponge sequence pEX-A-miR-34 (Fig. 3.6 A) was amplified in DH5α cells 
to achieve a working concentration suitable for molecular cloning (see material and 
5’-TCTAGACTCGAG...........acgcgACAACCAGCTCCAACACTGCCAacgcg...........GAATTCTCTAGA-3’
EcoRI
3’-TGTTGGTCGA        TGTGACGGT-5’
TTC
XhoI EcoRI
XbaI XbaI
A
B
5’- TGGCAGTGTCTTAGCTGGTTGT- 3’
5’-3’ microRNA Sponge sequence
miR
Sponge
XbaI
Res.
XhoI
Res.
Sponge seq. EcoRI
Res.
XbaI
Res.
miR-
34a
TCTA
GA
CTCG
AG
acgcgACAACCAGCTCCAACACTGCCAac
gcgACAACCAGCTCCAACACTGCCAacga
gACAACCAGCTCCAACACTGCCAtgacgt
ACAACCAGCTCCAACACTGCCAtcatc
GAA
TTC
TCTA
GA
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methods section 2.4.17 for transformation protocol). Removal of the sponge sequence 
was carried out using the restriction enzymes XhoI/EcoRI. Linearization of the pdeGFP 
plasmid backbone was carried out using the same enzymes to generate “sticky-ends”. 
Both miR-34 sponge insert and backbone were isolated by gel extraction (Fig. 3.7 A and 
B, see Materials and methods section 2.4.14). After ligation of the miR-34 sponge 
sequence into the pd2EGFP-sponge vector, several colonies were picked upon ampicillin 
selection and mini-prepped to isolate plasmid DNA. Two restriction sites NotI and XbaI 
were selected to diagnose successful miR-34 sponge insertion (Fig. 3.7 C). A positive 
colony (1 or 4 from Fig. 3.7 C) was re-amplified to a working stock and diagnosed using 
the same enzymes (Fig. 3.7 D). miR-34 sponge vector was sequenced using the following 
primer: 
EGFP-701-For 5’-GGACGAGCTGTACAAGAAGC-3’ 
Sequence alignment can be seen in appendix figure A4. 
The miR-34 sponge and control sponge plasmid was transfected into SEAP and 1.14 
secreting cells (see Materials and Methods section 2.3.3). 24 h after transfection, cells 
were selected in the presence of 350 µg/mL Hygromycin for 3 passages generating a 
mixed pool (MP) population. Stable cells were adapted to suspension culture in the 
presence of PVA (anti-clumping agent) before characterisation.
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Figure 3.6: Plasmid maps for pEX-A (carrying sponge sequences) and microRNA Sponge backbone 
 
 
 
Figure 3.6: Plasmid maps for pEX-A (carrying miR-sponge sequences) and microRNA sponge backbone: A) Bacterial expression vector harbouring the 
microRNA sponge concatemers with an ampicillin resistance marker (proprietary plasmid from MWG Eurofins) B) microRNA sponge backbone containing 
multiple cloning site (MCS) with cloning restriction sites, GFP reporter construct and Hygromycin (HYGR) resistance marker.   
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Figure 3.7: Diagnostic gels for miR-34 sponge vector preparation  
 
Figure 3.7: Diagnostic gels for miR-sponge preparation A) digests of the sponge backbone and a pre-
made sponge negative control using restriction enzymes XhoI/EcoRI B) miR-34 sponge insert 
extracted using XhoI/EcoRI ran on a 2% agarose gel to confirm is successful extraction C) mini-prep 
digestion of miR-34 sponge bacterial colonies tested using restriction enzymes XbaI/NotI liberating 
successful inserts of ~750 bp. Control sponge digestions using the same restriction enzymes were 
carried out to include no-insert control (NIC), sponge-NC (negative control), raw sponge backbone 
(BB) with no insert and miR-7 sponge. 
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3.2.3.2 Confirmation of miR-34 sponge binding efficacy 
To assess the binding efficiency of the miR-34 sponge for endogenous miR-34 family 
members, we transiently introduced mature miR-34a pre-miRNA into both miR-34 and 
miR-NC sponge mixed pool populations. The varying GFP intensities indicated the 
generation of mixed populations for both plasmids (Random integration) (Fig. 3.8 A). 
Cells expressing the miR-34 sponge exhibited a lower average GFP expression when 
assessed flow cytometry when compared to miR-NC spg (Fig. 3.8 B). This reduced 
average GFP expression was potentially due to endogenous miR-34 interacting with and 
repressing GFP translation. Transient introduction of a pre-miRNA duplex specific for 
miR-34a resulted in a 90% (p ≤ 0.001) reduction in GFP fluorescence in the case of the 
miR-34 sponge mixed pool (Fig. 3.8 B). A reduction in GFP expression was also observed 
in the case of miR-NC sponge upon miR-34a overexpression but not as dramatic as in the 
case of miR-34 sponge, possible a side-effect of miR-34’s known impact on cell growth.  
The average reduced GFP expression in miR-34 sponge cells was reflected again when a 
clonal panel was isolated from both mixed pools potentially due to endogenous miR-34 
(Fig. 3.9). A range in GFP expression can also be observed for all sponge panels due to 
random integration. The GFP intensity was observed to be much higher in CHO-1.14 
cells stably transfected with miR-34 and miR-NC sponge constructs. This could 
potentially be due to a reduced transfection efficiency in the case of CHO-SEAP cells. 
Furthermore, the integration efficiency or transcriptional activity may be higher in the 
case of CHO-1.14s contributing to this significant GFP expression difference.   
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Figure 3.8: miR-34 sponge binding efficiency 
 
 Figure 3.8: The binding efficacy of the miR-34 sponge construct when miR-34a was transiently over 
expressed. A) Visually demonstrates the intensity of GFP in both mixed populations (miR-34 and 
miR-NC sponge) transfected with either pre-miR-NC or pre-miR-34a. B) GFP intensity of both 
mixed pools is further demonstrated using the Guava ExpressPlus programme. Statistical analysis 
was carried out using a standard student t-test (p ≤ 0.001***). 
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Figure 3.9: GFP profile of miR-34 sponge clonal panels in CHO-SEAP and CHO-
1.14 cells 
 
Figure 3.9: The GFP expression of 24 clones isolated from both miR-34 and miR-NC sponge mixed 
populations using FACS sorting in both CHO-K1-SEAP and CHO-1.14 cells. Average GFP 
expression calculated across each panel condition is represented as a broken red line. 
 
3.2.3.3 miR-34a overexpression potentially inhibits conserved targets 
Prior to miR-34 sponge characterisation, we sought to identify potential mRNA targets 
that miR-34a was regulating. A small list of validated miR-34a targets were screened 
upon transient overexpression of miR-34a in CHO-K1-SEAP cells. Targets were 
identified and chosen from the review by Andreas G. Bader (Bader 2012) (Table 4.1 in 
Discussion). Primers were designed based on the CHO sequence genome database 
(http://www.chogenome.org/). Primer sequences are shown in table 2.1 of materials and 
methods section 2.4.3. RNA was harvested 24 h after transfection (see section 2.4.6 of 
Materials and Methods) and reverse transcribed (see section 2.4.2 of Materials and 
Methods). Semi-quantitative PCR was carried out on a small subset of targets including 
E2F3, BCL2, CCND1, DCR-1, CDK4, CDK6 and FUT8 using β-actin as an endogenous 
control (materials and methods section 2.4.3).  
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Cells were assayed 48 h after transfection as a means to confirm both transfection 
efficiency and retention of the miR-34a induced phenotype (Fig. 3.10 A). Gel-based 
visualisation indicated that several cell cycle-related targets were under the influence of 
miR-34a with CCND1 potentially the most dramatic (Fig. 3.10 B). 
Real-time quantitative (qRT)-PCR using SYBR® Green (see section 2.4.4 of Materials 
and Methods) showed a 50% (p ≤ 0.001) reduction in the mRNA abundance of CCND1 
(Fig. 3.10 C).  
Figure 3.10: semi-quantitative and qRT-PCR identification of miR-34a targets 
 
Figure 3.10: Assessment of validated miR-34a targets upon miR-34a over-expression (PM-34a) 
compared to a negative control (PM-NC) in addition to a positive control (siRNA-VCP) A) Influence 
of miR-34a overexpression on proliferation and viability in CHO-SEAP cells 24 h post transfection. 
B) Gel-based semi-quantitative PCR using a panel of primers for validated targets. C) Real-time 
quantitative PCR on CCND1 upon miR-34a overexpression when compared to pre-miR-NC 
transfection. Statistical analysis was calculated based on cyclic threshold (Ct) values using a standard 
student t-test (p ≤ 0.001***).   
E2F3
BCL2
CCND1
DCR-1
CDK4
CDK6
FUT8
0.00E+00
5.00E+04
1.00E+05
1.50E+05
2.00E+05
2.50E+05
3.00E+05
VCP PM-NC miR-34a
C
el
l 
N
u
m
b
er
s/
m
L
Cell Numbers/mL @ 48 hours
miR-34a Overexpression
40
50
60
70
80
90
100
VCP PM-NC miR-34a
V
ia
b
il
o
il
ty
 %
Cell Viability % @ 48 hours
miR-34a Overexpression
***
***
0
0.2
0.4
0.6
0.8
1
1.2
1.4
pre-miR-NC pre-miR-34a
R
Q
CCND1 
CCND1***
0
0.2
0.4
0.6
0.8
1
1.2
1.4
pre-miR-NC pre-miR-34a
R
Q
CCND1 
CCND1***
A
B
C
siRNA-
VCP
siRNA-
VCP PM-NC PM-34a
PM-NC PM-34a
PM- PM-
E2F3
BCL2
CCND1
DCR-1
CDK4
CDK6
FUT8
V
ia
b
il
it
y
 %
C
el
l 
N
u
m
b
er
s/
m
L
154 
 
3.2.3.4 miR-34 sponge influence on endogenous miR-34a and CCND1 
To further explore the influence of the miR-34 sponge on the endogenous levels of miR-
34a, we evaluated the levels of miR-34a in a stable CHO-1.14 clone expressing our miR-
sponge. We further assessed the levels of CCND1, which were shown to be reduced by 
50% upon transient miR-34a overexpression, in the same clone to identify if its levels 
were increased.  
miR-34a abundance was assessed using Singleplex Taqman qRT-PCR (section 2.4.8 of 
Materials and Methods) on three miR-NC-spg clones and three miR-34 spg clones. A 
~5-fold reduction in the mature levels of miR-34a (p ≤ 0.001) was observed in clones 
engineered with the miR-34 sponge when compared to non-specific controls (Fig. 3.11 
A).  
Next siRNA-mediated knockdown of the miR-34 sponge construct was carried out in 
miR-34 sponge clone 21.  
Knockdown of the miR-34 sponge was achieved using a siRNA designed against the GFP 
(siGFP) gene sequence. RNA was harvested 72 h after transfection and qRT-PCR was 
carried out for mature miR-34a expression. As observed before, the miR-34 sponge clone 
exhibited a 5-7-fold reduction in mature miR-34a levels when compared to the miR-NC 
sponge control (Fig. 3.11 B). However, a 2-fold increase in the mature levels of miR-34a 
was observed in the case of miR-34 sponge treated with siGFP compared to miR-NC-
treated miR-34 sponge (Fig. 3.11 B). Knockdown of the miR-34 sponge was 
demonstrated by a 90% (p ≤ 0.001) reduction in GFP expression (Fig. 3.11 B inset). The 
levels of miR-34a however did not return to levels comparable with that of the miR-NC 
sponge control (Fig. 3.11 B) which could potentially be due to the presence of residual 
sponge construct. This does however, indicate that the miR-34 sponge construct is 
specific for miR-34. 
Finally, we attempted to assess the impact that the miR-34 sponge construct exerted on a 
previously validated target of miR-34a, CCND1. The greatest difference was observed in 
the case of miR-34 sponge clone 21 which demonstrated a 1.2-3.5-fold increase in 
endogenous CCND1 levels when compared to all three control sponge clones (Fig. 3.11 
C). However, the abundance of CCND1 in 2 of the 3 miR-34 sponge clones (3 and 4) 
exhibited lower levels when compared to 2 of the 3 control clones (15 and 20).  
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Figure 3.11: The influence of stable miR-34 sponge expression on miR-34a and 
CCND1 abundance  
 
Figure 3.11: Impact of the miR-34 specific sponge on the endogenous levels of mature miR-34a and 
the target CCND1. A) Taqman qRT-PCR for miR-34a in a panel of miR-34 and control sponge 
clones. B) [Inset] The knockdown of the miR-34 sponge construct using siGFP compared to pre-miR-
NC control. Endogenous levels of miR-34a in a miR-34 sponge clone untreated (Cells only) and 
transfected with a control (pre-miR-NC) and siRNA for GFP (siGFP). Endogenous levels of miR-34a 
are also shown for an untreated control sponge clone (miR-NC spg 2) compared to cells only miR-34 
spg 21 C) qRT-PCR for the validated miR-34a target, CCND1. 
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3.2.4 Evaluation of miR-34 depletion in CHO mixed pool populations  
Two CHO cell lines (CHO-SEAP and CHO-1.14) secreting recombinant human-secreted 
alkaline phosphatase (SEAP) and the more industrially relevant antibody (IgG) were 
generated using the miR-34 sponge construct discussed earlier in section 3.2.3.1. Both 
stable mixed pools were evaluated under several culture conditions in an attempt to 
identify the potential benefit of the stable inhibition of miR-34.    
 
3.2.4.1 miR-34 depletion in CHO-K1-SEAP cells 
miR-34 sponge CHO-SEAP mixed pools - Batch 
Stable miR-34 sponge mixed populations were cultured in batch mode over a 6 day period 
and sampled every 48 h along with a non-specific control sponge population. Cells were 
seeded initially at 2 x 105 cells/mL in a 5 mL culture volume of CHO-S-SFM II in the 
absence of Hygromycin selection reagent.  
There was a 55% (p ≤ 0.05) improvement in cell density on day 2 of culture (Fig. 3.12 
A). Repeated experiments demonstrated increased growth over various stages of the 
culture process. Furthermore, cellular viability appeared to be mildly enhanced by 6-15% 
(p ≤ 0.05) late in culture across all three replicates (Fig. 3.12 B).  
No impact was observed on volumetric SEAP yield when both test and controls were 
compared (Fig. 3.12 C). However, the increase in cell numbers on day 2 of culture 
correlated with a reduction in normalised productivity (Fig. 3.12 D). 
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Figure 3.12: Stable miR-34 sponge mixed pool CHO-SEAP under batch conditions  
 
Figure 3.12: The influence of stable miR-34 depletion in batch mode is demonstrated compared to a 
negative control sponge. A) Cells numbers sampled on day 2,4 and 6 B) Cellular viability C) 
Volumetric SEAP yield/mL designated as SEAP Units D) Normalised SEAP activity. 
 
miR-34 sponge CHO-SEAP mixed pool – Fed-batch 
Feeding strategies are commonly implemented in biopharma as a means to further boost 
maximal cell densities and mediate a prolonged viable production phase. An initial feed 
of 15% (v/v) of CD CHO-Efficient Feed A was supplemented on day 0 of culture with 
subsequent feeding of 10% (v/v) every 3 days of culture. Cell growth was dramatically 
enhanced in the case of the non-specific control by almost 2-fold at its apex upon feed 
addition, however, this was not observed in the case of miR-34 pools (Fig. 3.13 A). 
Cellular viability on day 8 of culture was reduced in the miR-34 sponge population by 
~20% (Fig. 3.13 B). However, both volumetric SEAP and specific productivies were 
observed to be enhanced by a range of about 1.6 to 3-fold in miR-34 depleted pools (Fig. 
3.13 C and D).  
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Figure 3.13: Stable miR-34 sponge mixed pool CHO-SEAP under fed-batch 
conditions 
 
Figure 3.13: Fed-batch (feed represented as a broken orange line) results for the miR-34 sponge 
mixed pools alongside a non-specific control sponge assessed over the course of a 6 day culture. A) 
Cell Numbers/mL B) Cellular viability C) Volumetric SEAP yield D) Specific SEAP productivity (n 
= 3), statistics were carried out using a paired student t-test (p ≤ 0.001***).  
 
3.2.4.2 miR-34 depletion in IgG-secreting CHO-1.14 cells 
miR-34 sponge CHO-1.14 mixed population - Batch 
A 40% (p ≤ 0.01) improvement in cell density was recorded on day 2 of culture with a 
20% (p ≤ 0.001) increase observed on day 4 and 6 when compared to controls (Fig. 3.14 
A). Cell density was improved consistently across separate replicates but varied in 
magnitude with viability appearing unaffected (Fig. 3.14 B). Volumetric IgG (see section 
2.6.8 of Materials and Methods) was determined to be unchanged with a small increase 
of about 10% late in culture (Fig. 3.14 C). This could potentially be due to the elevated 
cell numbers, as cell specific productivity was reduced (Fig. 3.14 D).  
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Figure 3.14: Stable miR-34 sponge mixed pool CHO-1.14 under batch conditions 
 
Figure 3.14: CHO-1.14 cells stably engineered to inhibit miR-34 were cultured under batch 
conditions and sampled over the course of a 6 day batch process reporting on the phenotypes, A) Cell 
numbers/mL B) Cellular viability C) Volumetric titres, IgG ng/mL and D) Cell specific productivity. 
 
3.2.5 Generation of miR-34 sponge clones 
As a means of further investigating the phenotype observed within the mixed populations, 
we isolated a panel of clones from the mixed pools using fluorescent activated cell sorting 
(FACS, see section 2.3.4 of Materials and Methods).  
 
3.2.5.1 GFP fluorescence across clonal panels 
Clones were selected that exhibited a medium-to-high GFP intensity as a means to isolate 
clones that expressed the miR-34 sponge at levels sufficient to sequester all endogenous 
miR-34a/b/c. A range of GFP intensities were observed across all clonal panels in both 
cell lines (Fig. 3.9). Both miR-34 sponge clone panels were assessed for performance in 
1 mL batch suspension culture.  
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3.2.5.2 Impact of miR-34 depletion across a CHO-SEAP cell panel 
Previous characterisation in mixed pools indicated that in fed-batch culture, stable miR-
34 inhibition potentially enhanced specific productivity while batch conditions mildly 
enhanced CHO cell growth with no benefit to volumetric SEAP yield. Upon clonal 
isolation, clones were seeded at 1 x 105 cells/mL and cultured over a 6 day suspension 
batch process in parafilm sealed 24-well culture plates. As in the case of previous batch 
processes, samples were taken every 48 h and assessed for the primary phenotypes, 
growth, viability and productivity. Phenotypic characterisation was carried out across the 
entire panel of clones, both test and control, in an effort to assess the average impact of 
miR-34 depletion in addition to isolating exceptional clones.  
When cultured in a 24-well format, miR-34 depleted clones did not display a similar 
phenotype to what was indicated in mixed pool batch culture. Growth was reduced by 
~30% (p ≤ 0.01), ~75% (p ≤ 0.001) and ~80% (p ≤ 0.01) on day 2, 4 and 6, respectively 
(Fig. 3.15). Furthermore, although the average performance was reduced, not a single 
miR-34 depleted clone demonstrated higher growth than the top control performers. This 
reduced growth was observed in 1 mL culture despite mixed pools and subsequently 
selected clones demonstrating “normal” growth patterns in 5 mL.  
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Figure 3.15: CHO-SEAP miR-34 sponge clonal panel – Cell Numbers/mL 
 
Figure 3.15: Growth of individual miR-34 and miR-NC stable sponge clones in 1 mL batch 
conditions. Average panel performance at each time point is represented as a broken red line. Clones 
highlighted in an orange box are clones that were subsequently selected for further characterisation. 
Statistical analysis was carried out using a standard student t-test (p ≤ 0.01** and p ≤ 0.001***). 
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Figure 3.16: CHO-SEAP miR-34 sponge clonal panel – Cellular Viability   
 
Figure 3.16: Clonal viability in both miR-34 and miR-NC sponge stable CHO-SEAP panels on day 6 
of culture. There was no gross difference in clonal cell viability on the preceding time points of day 2 
and 4. Average viability across each clonal panel is represented as a broken red line. Clones selected 
for scale up are highlighted in an orange box. Statistical analysis was carried out using a standard 
student t-test (p ≤ 0.001***).  
The majority of miR-34 depleted clones preformed significantly worse than the panel of 
miR-NC spg clones with a considerable reduction in average viability from 56% in the 
case of the control panel to 29% (p ≤ 0.001) in the case of the miR-34 test panel (Fig. 
3.16).   
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Figure 3.17: CHO-SEAP miR-34 sponge clonal panel – Volumetric SEAP yield/mL 
 
Figure 3.17: Volumetric output of SEAP/mL of each clone in both the miR-34 and miR-NC sponge 
panels. The average SEAP yield across each panel is represented as a broken red line while each 
clone subsequently selected for scale up is highlighted in an orange box. Statistical analysis was 
carried out using a standard student t-test (p ≤ 0.01** and p ≤ 0.001***). 
 
A significant 3.64-fold (p ≤ 0.001), 2.13-fold (p ≤ 0.01) and 1.97-fold (p ≤ 0.001) increase 
was observed when the average volumetric SEAP yields of the miR-34 sponge panel was 
compared to the miR-NC spg panel on days 2, 4 and 6, respectively (Fig. 3.17). 
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Figure 3.18: CHO-SEAP miR-34 sponge clonal panel – Specific SEAP productivity  
 
Figure 3.18: Normalised SEAP productivity per cell for each clone within both miR-34 and miR-NC 
sponge panels. Average normalised productivity is represented as a broken red line while clones 
selected for scale up are highlighted in orange boxes. Normalised productivity was calculated based 
on the value of SEAP produced divided by the number of cells present. The outlier (miR-34 spg clone 
9-day 6 has a value of 7.96 x 10-3. Statistical analysis was calculated using a standard student t-test (p 
≤ 0.05* and p ≤ 0.001***). 
 
An increase of 3.83-fold (p ≤ 0.001), 8.14-fold (p ≤ 0.001) and 14.9-fold (p ≤ 0.05) was 
observed in normalised productivity for the miR-34 sponge panel (Fig. 3.18). 
 
There was no indication that viability was enhanced by the stable depletion of miR-34. 
Furthermore, at this scale, growth appeared to be diminished in comparison to control 
clones. For these reasons, to eliminate bias, clones were selected based on their 
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volumetric productivity attributes, a process that was indicated to be enhanced during the 
fed-batch cultivation in mixed pools. Clones 8, 10 and 18 were selected from the miR-34 
sponge panel while clones 2, 11 and 20 were selected from the miR-NC sponge panel 
(highlighted in orange boxes, Fig. 3.17). The clones selected demonstrated a spread 
within the other phenotypic categories such as viability and growth; however, attempting 
to encompass all performance categories into the one clone would have compromised the 
selection of high SEAP producers and would ultimately give an inappropriate indication 
of performance. The clones selected were progressed for further study in 5 mL culture 
scale up. By selecting clones based on their enhanced productivity attributes, this could 
potentially introduce a bias when clones are scaled up to higher culture volumes. Clones 
have been seen across the literature to perform differently within various culture formats. 
By selecting clones based on phenotypic attributes other than those suggested to be 
enhanced during mixed population assays, a bias can be introduced thereby selecting 
clones whose observed phenotypes are potentially not a result of miRNA intervention. 
This should be considered throughout this thesis for all clones.  
 
3.2.5.3 Impact of miR-34 depletion across a CHO-1.14 cell panel 
We previously showed that the CHO-1.14 mixed pools grew to better cell densities in 
batch culture without any impact on cell viability or product yield. This improvement was 
not maintained when pool-derived clones were cultured in 24-well plates.  
Cell growth across all time points was reduced by 22% (p ≤ 0.05), 8% and 39% (p ≤ 0.01) 
on days 2, 4 and 6, respectively when compared to non-specific controls (Fig. 3.19). 
Additionally, no clone within the miR-34 sponge panel demonstrated a superior growth 
capacity to any of the top performing controls.   
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Figure 3.19: CHO-1.14 (IgG) miR-34 sponge clonal panel – Cell Numbers/mL 
 
Figure 3.19: The individual growth performance of the clones that make up the miR-34 and miR-NC 
sponge panels with the average growth being represented as a broken red line. Clones that were 
subsequently selected for scale up are highlighted in orange boxes. Statistical analysis was carried 
out using a standard student t-test to include all clones (p ≤ 0.05* and p ≤ 0.01**).  
 
Cellular viability remained constant in the early stages of culture (Days 2 and 4, Data not 
included). Within each population there were some poor performers but the average 
viability across miR-NC and miR-34 sponge was 63.4% and 66%, respectively (Fig. 
3.20).  
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Figure 3.20: CHO-1.14 (IgG) miR-34 sponge clonal panel – Cell Viability % 
 
Figure 3.20: The cellular viability of each individual clone of both miR-34 and miR-NC stable sponge 
clonal panels with the average viability across each panel being represented as a broken red line. 
Clones that were selected for scale up are highlighted in orange boxes. 
 
When volumetric IgG levels were assessed, there were a large number of clones that did 
not produce IgG above the detectable limits of the ELISA assay. Although these poor 
performing clones did pull down the average performance across the population, there 
were still some reasonably high performing clones within both groups. There was an 
average reduction of 23%, 36% and 28% observed in volumetric IgG on days 2, 4 and 6 
of culture, respectively (Fig. 3.21). No single clone from the miR-34 sponge panel 
demonstrated a volumetric IgG output above the top performing clone from the control 
group. However, clones that did produce IgG did so above the average level of the control 
panel.  
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Figure 3.21: CHO-1.14 (IgG) miR-34 sponge clonal panel – Volumetric productivity  
 
Figure 3.21: Volumetric IgG secreted product of all individual clones within both the miR-34 and 
miR-NC sponge clonal panels. The average IgG product across each panel is represented as a broken 
red line. Clones subsequently selected for scale up are highlighted in an orange box. 
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It is not surprising that when the specific productivities of each panel was calculated the 
values observed reflected that of the proliferative capacity of each clone versus their 
volumetric output (Fig. 3.22). 
Figure 3.22: CHO-1.14 (IgG) miR-34a sponge clonal panel – specific productivity 
 
Figure 3.22: Specific IgG productivity of each individual clone from both the miR-34 and miR-NC 
sponge panel. The average specific productivity is represented as a broken red line. Clones selected 
for scale up are highlighted in an orange box. 
The performance of the clonal panel did not reflect the phenotype determined within the 
predecessor mixed pool population. From this perspective we decided to select those 
clones that displayed good volumetric IgG characteristics. Clones selected are highlighted 
in orange boxes in all the graphs.  The clones selected from the miR-34 sponge panel 
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were clones 3, 4 and 21. These clones displayed reasonable phenotypes across all 
categories with an emphasis on volumetric productivity. Additionally, miR-NC sponge 
clones 2, 15 and 20 were selected based on similar criteria. 
 
3.2.6 Phenotypic evaluation of miR-34 depleted clones in a 5 mL volume 
miR-34 depletion has been observed to elicit two distinct phenotypes in two recombinant 
CHO cell lines, SEAP and IgG. In CHO-SEAP mixed populations, volumetric SEAP 
yield was enhanced in fed-batch while clones in 1 mL batch displayed enhanced SEAP 
yield. CHO-1.14 mixed pools demonstrated increased growth with reduced specific 
productivity while clone panels showed reduced performance across all traits (Growth, 
yield and specific productivity). This section explores the potential of miR-34 depletion 
in individual clones selected from both the CHO-SEAP and CHO-1.14 panels isolated for 
their production characteristics.  
 
3.2.6.1 Selected miR-34 depleted CHO-SEAP clones 
miR-34 sponge CHO-SEAP clones - Batch 
All miR-34 depleted clones were observed to achieve a reduced maximal cell density of 
between 20-50% when compared to the two control clones (miR-NC spg 2 and 11) that 
reached the highest cell density (Fig. 3.23 A). However, when compared to the worst 
performing control clone, all miR-34 sponge clones demonstrated 1.9-2.3-fold higher cell 
numbers (Fig. 3.23 A). This control clone would be considered an outlier as the “normal” 
growth profile of the CHO-SEAP cell line would be greater than this (~3.5 x 106 cell/mL 
in the case of miR-NC mixed pools). All miR-34 sponge clones demonstrated reduced 
viability on day 6 of culture (Fig.  3.23 B) with two clone in particular (miR-34 spg clone 
9 and 18) exhibiting the lowest viability at ~1%. Furthermore, these miR-34 sponge 
clones appeared to clump early in culture (days 3-4) contributing to a sudden drop in 
apparent cell density. 
 
 
171 
 
Figure 3.23: miR-34 sponge clones culture under batch conditions 
 
Figure 3.23: Batch culture results in a 5 mL volume for miR-34 depleted CHO-SEAP clones selected 
from the clonal panel when compared to non-specific control clones. Phenotypes assessed were A) 
Cell growth, B) Culture viability, C) SEAP yield/mL and D) Normalised productivity. Statistical 
analysis was calculated using a standard student t-test (p ≤ 0.05* and an n = 3). 
All miR-34 sponge clones displayed an enhanced SEAP secretion when compared to the 
two lowest producing control clones (Fig. 3.23 C). One control sponge clone (Clone 11) 
did reach comparable maximal SEAP levels when compared to miR-34 sponge clones 
(Fig. 3.23 C). Two miR-34 sponge clones (9 and 10) demonstrated a high normalised 
productivity potentially due to their propensity to clump and display low cell viability 
resulting in a low cell density on day 6 of culture (Fig. 3.23 D). miR-34 sponge clones 
exhibited a tendency to clump early in culture regardless of the addition of PVA or the 
process of cloning out non-clumping cells from these cultures. At this point, Fed-batch 
was not pursued and assessment of miR-34 depletion in CHO-SEAP cells was terminated. 
 
3.2.6.2 Selected miR-34 depleted CHO-1.14 clones 
miR-34 sponge CHO-1.14 clones - Batch 
3 clones were selected from both control and test panels based on their volumetric 
productivity. However, a growth benefit was observed in the case of mixed pools that was 
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not retained in 1 mL batch culture. When scaled up to a 5 mL volume, all clones 
demonstrated enhanced growth of 1.3-5-fold (p ≤ 0.001) on day 2 and 1.5-3-fold (p ≤ 0.01 
and 0.001) on day 4 (Fig. 3.24 A). While all three clones reached higher cell numbers on 
day 6 when compared to two control clones (miR-NC spg 2 and 15), one control clone 
had increased cell numbers as well as comparable cell viability (Fig. 3.24 A and B). 
Despite the varied performance of the control clones, siRNA-mediated knockdown of the 
miR-34 sponge construct in miR-34 sponge 21 caused a 30% (p ≤ 0.001) reduction in 
density on day 3, suggesting that the presence of the sponge had a growth benefit (Fig. 
3.25). Efficient knockdown of the miR-34 sponge was previously demonstrated (Fig. 3.11 
B). 
All three miR-34 sponge clones demonstrated enhanced viability on day 6 of culture of 
between 65-80% while the miR-NC sponge control clones exhibited viability between 
21-53% (Fig. 3.24 B). However, one control clone (miR-NC spg clone 20) demonstrated 
a viability comparable to miR-34 sponge clones. This would suggest that miR-34 
depletion is conferring a potential benefit by delaying the onset of apoptosis and that miR-
NC clone 20 is displaying high viability due to the nature of clonality, selecting clones 
with inherent beneficial attributes, by chance.  
When volumetric IgG productivity and specific productivity were assessed, there was a 
dramatic reduction in the production capacity of all three miR-34 sponge clones of around 
10-60% across all time points when compared to the range of titres produced by all three 
control clones (Fig. 3.24 C). As cell numbers were observed to be enhanced in the case 
of the miR-34 depleted clones, specific productivity was further reduced to a range of 10-
80% (Fig. 3.24 D). 
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Figure 3.24: CHO-1.14 stable miR-34 sponge clones under batch growth conditions  
 
Figure 3.24: Clones selected from each panel (miR-34 and miR-NC sponge in batch conditions in a 
scaled up 5 mL culture volume. A) Cell numbers/mL B) Cellular viability C) Volumetric IgG 
secretion and D) Specific productivity. Statistical analysis was determined using a standard student 
t-test with each miR-34a sponge clone being compared to all three controls. (p ≤ 0.01** and p ≤ 
0.001***). 
Figure 3.25: sponge knockdown mediates a reversal in the growth phenotype 
 
Figure 3.25: The impact that miR-34 sponge knockdown exerted on the growth profile of a stable 
miR-34a sponge clone (clone 21) upon transient transfection of a siRNA designed against the deGFP 
(siGFP) reporter construct. Cells were sampled on day 3 of culture after transfection with GFP 
fluorescence inhibition reported in Figure 3.11. 
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miR-34 sponge CHO-1.14 clones – Fed-batch 
Clone 3 from the miR-34 sponge panel was omitted from this Fed-batch study as it 
exhibited the poorest growth phenotype. Once again, miR-34 sponge clones achieved an 
increased maximal cell density of 1.5 to 2-fold when compared to two of the three control 
clones (Fig. 3.26 A). Furthermore, both miR-34 depleted clones demonstrated an 
extended productivity phase by maintaining viability above 80% until day 8 (Fig. 3.26 
B). However, as observed in the case of batch culture, one control sponge exhibited a 
comparable phenotype, miR-NC spg clone 20, when both growth and viability were 
assessed.   
A reduction of about 20-40% was observed for both miR-34 depleted clones when 
compared to control clones 15 and 20 while a large reduction of around 80% was observed 
in the case of the high producing clone miR-NC spg 2 in IgG productivity (Fig. 3.26 C). 
When specific productivity was determined, there was a 40-90% reduction in both miR-
34 sponge clones when compared to all three control clones (Fig. 3.26 D).  
Figure 3.26: CHO-1.14 stable miR-34 sponge clones under fed-batch growth 
conditions 
 
Figure 3.26: Fed-batch culture for the selected clones engineered to stably deplete miR-34 and the 
non-specific control. Addition of feed media is represented as a broken orange line. Phenotypes 
reported are A) Cell numbers/mL B) Cell viability C) Volumetric IgG secretion and D) specific 
productivity. 
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From this section it can be seen that the depletion of miR-34 mediated improved growth 
in CHO-1.14 cells. However, this growth benefit did not push the cells to reach higher 
cell densities than previously observed for the parental population with the addition of 
potentially compromising the production capacity of each clone. Although miR-34 
sponge clones did perform better in regards to growth and viability when compared to 2 
of the 3 control clones selected, one control clone exhibited comparable phenotypic 
attributes.  
With miR-34 proving an interesting miRNA but potentially not a viable miRNA for CHO 
engineering, we decided to explore its potential role in influencing the glyocoprofile of 
secreted IgG.  
 
3.2.7 miRNA-mediated interference of CHO cell antibody glycoforms 
Section 1.4 introduced the importance of antibody glycoforms to the functionality and 
potency of antibody-mediated effector functions such as ADCC. Increased ADCC has 
shown to be enhanced for main-stream anti-cancer therapeutics such as Herceptin through 
the manipulation of the core fucose added to the N-acetylglucosamine at the conserved 
Asparagine-297 (Suzuki et al. 2007a)(Li et al. 2013b) and Rituxan (Li et al. 2013b). The 
report that miR-34a could interact with the 3’UTR of FUT8 (Bernardi et al. 2013a) and 
interfere with its mature protein levels led us to explore the stable depletion of miR-34 
contributing to an altered antibody glycoform, fucosylation,  in the case of recombinant 
CHO-1.14 cells. The protocol followed is as described by Mittermayr and Bones et al., 
(Mittermayr et al. 2011) and section 2.6.11 in Materials and Methods. 
Two clones were selected from the CHO-1.14 parental population engineered to stably 
deplete miR-34 including a separate non-specific sponge clone. When the antibody 
glycoform profile was determined for both the selected miR-34 sponge and miR-NC 
sponge clone, it was observed that there was no change in the peak ratios between each 
sample indicating no alteration in the fucosylation profile (G0F, G1F and G2F (see 
section 1.4.2 of Introduction for nomenclature, Fig. 3.27).  
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Figure 3.27: Glyco-profile of a miR-34 sponge clone versus miR-NC sponge clone 
   
Figure 3.27: The peak intensities and elution times (min) for the N-glycans isolated and fluorescently 
labelled with 2-AB (2-aminobenzoic acid) with the core fucosylated N-acetylglucosamine of interest 
being G0F, G1F and G2F, i.e. biantennary N-glycan no, one or two galactose groups on either 
terminal N-acetylglucosamine. GU indicates glucose units    
 
However, one interesting observation was that the intensity of the peak profile was 
considerably higher in the case of the secreted antibody derived from the miR-34 sponge 
clone when compared to the miR-NC sponge clone (Fig. 3.27). 
As a means to ensure that antibody quantification was accurate, potentially contributing 
to the difference in peak intensities, 10 µg of each antibody was run on a 4-12% Bis-Tris 
SDS gel and stained with Coomassie Blue. One antibody pair was reduced using 
iodoacetamide to break apart disulphide bonds, liberating the individual heavy and light 
chains.  
Coomassie blue stained gel showed that there was similar quantities of IgG antibody in 
both miR-NC and miR-34 sponge clone samples (Fig. 3.28). 
 
 
6
miR-34a sponge 
miR-NC sponge
G0F
G1F
G2FG0
G1
G2F+S
G2F+2S
GO = Biantennary with no galactose.
GO = Biantennary with no galactose, no core fucose.
G1, G2 = Plus 1 or 2 galactose residues, respectively.
F = Addition of a fucose.
7 854GU 9 10 11
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Figure 3.28: Coomassie blue semi-quantification of secreted IgG from miR-34 and 
miR-NC sponge clones 
 
Figure 3.28: 10 µg of purified non-reduced and reduced IgG antibody secreted from a miR-NC and 
miR-34 sponge CHO-1.14 clone stained with Coomassie Blue.  
Following these observations, we designed several treatments of the miR-34 sponge clone 
21 as a means to assess the stable depletion of miR-34 on influencing the IgG 
glyocoprofile.  
Firstly, as the intensity of the glyocoprofile peaks were higher in the case of the miR-34 
sponge compared to the control, we assessed the glyocoprofile of the parental CHO-1.14 
from which both sponge clones were derived. It was anticipated that the parental CHO-
1.14 would demonstrate a similar low intensity profile to that of the negative control. 
When this was assessed, both parental and miR-34 sponge clones exhibited a similar 
glyocoprofile of equal intensity (Fig. 3.29 Sample A compared to Sample C or E).   
Secondly, if miR-34 depletion was mediating this increased peak intensity, we attempted 
to knockdown the sponge using a siRNA against GFP with the hope of observing a 
reduced intensity when compared to the control miR-34 sponge treated with pre-miR-
NC. Successful inhibition of the sponge was demonstrated previously for this clone (Fig. 
250
100
55
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25
NC-IgG 34a-IgG NC-IgG 34a-IgG
15
10
Non-reduced Reduced
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3.11 B inset). However, no change in peak intensity was observed (Fig. 3.29 Sample D 
compared to Sample C or E). 
From the perspective of fucosylation, CHO cells secret antibody of which >90% are 
fucosylated (Jefferis 2009a). It is possible that by depleting miR-34 and increasing the 
expression of FUT8, an increase in fucosylation would not be apparent. We next 
transiently over-expressed miR-34a in a stable miR-34 sponge clone with the anticipation 
of observing a shift in the fucosylation profile towards reduced fucosylation. No shift in 
the three peaks associated with fucosylation (G0, G1 and G2) was observed (Fig. 3.29 
Sample B compared to Sample C or E). 
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Figure 3.29: Glyco-profile of IgG produced from a miR-34 sponge clone 21 treated 
with pre-miR-34a and siRNA for GFP 
 
Figure 3.29: The IgG glyco-profiles of various sample conditions including A) CHO-1.14 parentals 
untransfected, B) miR-34a sponge clone 21 transfected with pre-miR-34a, C) miR-34a sponge clone 
21 transfected with a pre-miR-NC control, D) miR-34a sponge clone 21 transfected with a siRNA 
specific for the GFP in the miR-34a sponge construct and E) miR-34a sponge clone 21 transfected 
with a pre-miR-NC control. The primary fucosylated glycan peaks are labelled including G0F, G1F 
and G2F. GU indicates glucose units. 
The focus of CHO cell line engineering towards glyco-manipulation has proven to be a 
promising endeavour from literature reports. Further evaluation of the impact of miR-34a 
on the fucosylation capacity in CHO cells would be required starting by assessing the 
mature protein levels of the FUT8 gene upon overexpression of miR-34a. Additionally, 
several IgG producing cell lines would have to be assessed for their resulting glycoforms 
following miR-34a transfection. Increased miR-34a expression elicits an undesirable 
phenotype such as cell death and growth inhibition. From this perspective, the 
identification of alternative miRNA targets of FUT8 that do not contribute this unwanted 
phenotype would be invaluable.  
CHO 1.14 Parentals
miRNA 34a SPG 21 
(34a Treated)
miRNA 34a SPG 21 
(NC Treated)
miRNA 34a SPG 21 
(siRNA Treated)
miRNA 34a SPG 21 
(NC Treated)
Sample A
Sample B
Sample C
Sample D
Sample E
GU 4 5 6 7 8 9 10 11
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Section 3.3 
 
 
 
 
 
 
 
Stable depletion of independent 
microRNA duplex components: 
miR-23b and miR-23b* 
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3.3. CHO cell engineering using miR-23b and miR-23b* 
Several miRNAs that were screened, such as miR-23b*, impacted negatively on the CHO 
cell phenotype despite their positive correlation with improved growth in the profiling 
experiment. This section describes and characterises two miRNA partners, miR-23b and 
its passenger miR-23b*, selected for stable CHO cell line engineering within both a SEAP 
and IgG-secreting cell line derived from the same CHO-K1 parental background. 
 
3.3.1. Selection of miR-23b and miR-23b* for stable knockdown 
Transient miR-23b* overexpression inhibited growth by 90% and cell viability was 
reduced by 30%. However, it was anticipated that stable inhibition of this miRNA might 
induce a reversed phenotype, enhancing growth and potentially inhibiting cell death. Past 
experience in CHO using miR-7, demonstrated that overexpression of miR-7 caused 
growth inhibition (Barron et al. 2011a) while stable inhibition improved CHO cell growth 
and product yield (Sanchez et al. 2013b).  
The mature guide strand miR-23b was selected based on previous identification and 
evaluation within our research group. A previous study by Gammell et al., (Gammell et 
al. 2007) identified components of the miR-23a~27a~24-2 cluster to be down-regulated 
when subjected to hypothermic growth conditions. Stable depletion of all three miRNA 
members improved both CHO cell growth and volumetric productivity (Data not shown) 
in a CHO-SEAP mixed population. We sought to dissect the role that miR-23 plays in 
mediating the enhanced rCHO-SEAP phenotype by diverting its actions away from its 
endogenous targets. Although specified as miR-23b in this instance, the mature sequence 
of miR-23b and miR-23a only differ by a single nucleotide (Appendix Figure A5), which 
lies outside the miRNA seed region. miRNA sponges have been shown to sequester entire 
seed families (Kluiver et al. 2012a) as miRNA recognition elements (MREs) are fully 
complementary to the mature seed sequence thus effectively targeting both miR-23a and 
miR-23b in our stable cell line (here in referred to as miR-23). 
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3.3.2 miR-sponge vector design and stable CHO cell line generation 
Two individual miRNA sponge vectors were generated for miR-23 and miR-23b* using 
the same miR-sponge construct described for the stable depletion of miR-7 (Sanchez et 
al. 2013b). Both mature miRNA sequences are conserved across human (hsa) and CHO 
(cgr) (Fig. 3.30 A). The miRNA sponge design for miR-23 and miR-23b* follows the 
same vector construct shown in Figure 3.30 B. Molecular cloning and stable cell line 
generation was carried out as described for the miR-34 sponge (section 3.2). 
The miRNA sponge sequences for miR-23 and miR-23b* are shown in Table 3.3 and 
included the same base-pair mis-matches across nucleotides 9-12 (miR-23) and 10-13 
(miR-23b*). Molecular cloning gels for construct preparation and sequence information 
can be found in the appendix (Appendix fig. A6 and A7, respectively). 
Figure 3.30: miR-23b and -23b* sequence conservation and sponge design 
 
Figure 3.30: A) Demonstrates the conservation of miR-23 and miR-23b* across the species of Homo 
sapiens (hsa), Mus musculus (mmu) and Cricetulus griseus (cgr) including the dogmatic “seed” region 
(yellow box). B) Schematic diagram of the miR-sponge vector backbone expressing dEGFP and 
under Hygromycin selection with XhoI and EcoRI restriction sites for insertion of miR-23b* 
sequence carrying fully complementary concatemeric repeats (5’-3’) to each respective microRNAs 
(5’-3’) including base-pair mismatch “Wobble” at nucleotides 9-12 (miR-23) and 10-13 (miR-23b*) 
(red).      
EcoRI
XhoI EcoRI ATG
hsa-miR-23b    AUCACAUUGCCAGGGAUUACC
mmu-miR-23b AUCACAUUGCCAGGGAUUACC
cgr-miR-23b    AUCACAUUGCCAGGGAUUACC
hsa-miR-23b* UGGGUUCCUGGCAUGCUGAUUU
mmu-miR-23b*   GGGUUCCUGGCAUGCUGAUUU
cgr-miR-23b*      GGGUUCCUGGCAUGCUGAUU
TCTAGACTCGAG.....GGTAATCCGCATCAATGTGATtcatcGGTAATCCGCATCAATGTGAT......GAATTCTCTAGA
3’-CCATTAGG         GTTACACTA-5’
GACC
XhoI EcoRI
TCTAGACTCGAG.....AAATCAGCCGTACAGGAACCCAtcatcAAATCAGCCGTACAGGAACCCA....GAATTCTCTAGA
XhoI EcoRI
TACG
3’-TTTAGTCG          GTCCTTGGGT-5’
miR-23b
miR-23b*
A
B
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Table 3.3: miRNA sponge sequence design for miR-23b/-23b* 
5’-3’ microRNA Sponge sequence 
miR 
Sponge 
XbaI 
Res. 
XhoI 
Res. 
Sponge seq. EcoRI 
Res. 
XbaI 
Res. 
miR-
23b* 
TCTA
GA 
CTCGA
G 
acgcgAAATCAGCCGTACAGGAACCCA
tcatcAAATCAGCCGTACAGGAACCCAa
ccgtaAAATCAGCCGTACAGGAACCCAa
cgagAAATCAGCCGTACAGGAACCCAt
catc 
GAA
TTC 
TCTA
GA 
miR-
23b 
TCTA
GA 
CTCCG
A 
acgcgGGTAATCCGCATCAATGTGATtca
tcGGTAATCCGCATCAATGTGATaccgta
GGTAATCCGCATCAATGTGATacgagG
GTAATCCGCATCAATGTGATtcatc 
GAA
TTC 
TCTA
GA 
 
3.3.3 Investigation of GFP fluorescence 
Binding specificity of each miRNA sponge was assessed for its target miRNA. All three 
miRNA sponges were transfected (NC-spg, 23b-spg and 23b*-spg) with their appropriate 
pre-miR and separately with a negative control mimic (pre-miR-NC). A ~90% (p ≤ 0.001) 
reduction in the levels of GFP expression was achieved when pre-miR-23b* and pre-miR-
23b*-mod (pre-miR-23b) were transfected into the appropriate CHO-sponge population 
with the NC-sponge demonstrating little specificity (Fig. 3.31 A and B).  
One point to note was the nomenclature for pre-miR-23b referred to as pre-miR-23b*-
mod. This “mod” implies a modification that we sought when ordering the commercial 
hairpins. Normal pre-miR-23b and pre-miR-23b* take the form of siRNA-like constructs, 
that being a fully complementary duplex with terminal modifications to allow selection 
of the desired strand. In the case of pre-miR-23b*-mod, the hairpin structure mimics that 
of the endogenous miR-23b/23b* duplex (Appendix Fig. A8) thus thermodynamically 
favouring the selection of the mature miR-23b strand while generating the by-product 
passenger strand miR-23b*. The modified version (pre-miR-23b*-mod) repressed GFP 
expression with over 5-fold greater potency than the commercial siRNA-like pre-miR-
23b. This suggested that processing of the commercial pre-miR-23b duplex resulted in a 
lower mature miR-23b copy number.  
The non-specific sponge mixed pool population demonstrated an average higher 
fluorescence when compared to both miR-23 and miR-23b* sponge mixed pools (Fig. 
3.31 B). This reduced GFP fluorescence is likely a reflection of the repression caused by 
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endogenous miR-23/23b*, similar to the observation for the miR-34 sponge, in the 
previous section. 
The heterogeneity within all populations generated is evident from the various GFP 
expression arising from individual clones within the mixed populations (Fig. 3.31 A). 
 
Figure 3.31: miR-23b/23b*spg binding specificity through GFP suppression 
 
Figure 3.31: miR-sponge specificity was carried out for the miR-23 and miR-23b* sponge through 
the transient over-expression pre-miR-23b* and pre-miR-23b. miR-23b*-mod is a specifically 
designed pre-miRNA that is composed of the mature miR-23b and miR-23b* and is processed 
according to their natural thermodynamic properties with the miR-23b* strand being tagged with a 
biotin group. Sponge specificity was determined based on inhibition of GFP expression through 
monitoring with A) Fluorescent microscopy and B) Guava ExpressPlus programme. Non-specific 
stable sponge was transfected in order to identify its lack of specificity. Statistical significance was 
calculated using a standard student t-test (p ≤ 0.001***). 
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3.3.4 Analysis in mixed populations 
The following section assesses the impact both stable miRNA depletion of miR-23 and 
miR-23b* had in both rCHO populations (SEAP and IgG) under various bioprocess 
conditions (Batch and Fed-batch). 
 
3.3.4.1 Impact on bioprocess phenotypes in CHO-K1-SEAP: Batch and Fed-batch 
miR-23 sponge mixed population - Batch 
Mixed pool rCHO-SEAP cells with stable inhibition of miR-23 exhibited no growth or 
viability benefit when compared to NC-spg cells (Fig. 3.32 A and B). However, an 
increase ranging from ~30-50% (p ≤ 0.001) in volumetric SEAP activity was observed 
(Fig. 3.32 C).  
Figure 3.32: Batch process of mixed pool CHO-SEAP cells stably depleting miR-23 
 
Figure 3.32: CHO-SEAP cells engineered to stably deplete miR-23 in a mixed pool population were 
evaluated for bioprocess relevant phenotypes A) Cellular proliferation, B) Cellular viability, C) 
Volumetric SEAP yield/mL and D) specific SEAP productivity/cell over the course of a 6 day batch 
process and compared to a stable mixed pool population expressing a non-specific control sponge 
(miR-NC spg). Statistical analysis was calculated using a standard student t-test (p ≤ 0.01** and ≤ 
0.001***) with an n = 3 of experimental replicates.    
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miR-23 sponge mixed population – Fed-batch 
miR-23 depletion conferred no growth benefit, however, addition of the feed improved 
maximal cell density by 2-fold when compared to batch culture (Fig. 3.33 A). Viability 
was extended a further 3 days above 80% for both miR-23/-NC sponge pools with no 
additional benefit observed in the case of miR-23 depletion (Fig. 3.33 B).   
 
Figure 3.33: Fed-batch process of mixed pool CHO-SEAP cells stably depleting miR-
23 
 
Figure 3.33: Stable miR-23 sponge mixed pool populations were cultured in a fed-batch format over 
the course of an 8 day assay. Nutrient Feed (CD CHO Efficient Feed A) was initially inoculated at 
15% (v/v) on day 0 and subsequent feeds of 10% (v/v) every 72 hs (Feed signified in orange). Stable 
inhibition of miR-23b was assessed for its influence on A) Cellular proliferation, B) Cell viability, C) 
Volumetric SEAP activity and D) Specific SEAP activity. Statistical significance was calculated using 
a standard student t-test (p ≤ 0.05* and ≤ 0.01**) with an experimental replication of n = 3.   
 
A ~50% (p ≤ 0.05 and p ≤ 0.01 at various time points) increase in volumetric SEAP 
activity was achieved across various time points for miR-23 depleted mixed pools (Fig. 
3.33 C). The maximum SEAP units calculated for the mixed pool miR-23 sponge in the 
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fed-batch process was lower when compared to batch. This reduced SEAP activity 
between miR-23 depleted mixed pools under different culture conditions could 
potentially be due to the 2-fold increase in cell growth resulting in an increased demand 
on cellular energy metabolism to be pledged toward cellular division rather than 
productivity. Finally, there was a range of 30-80% enhanced normalised SEAP 
productivity observed for miR-23 depleted mixed pools compared to controls (Fig. 3.33 
D). 
 
miR-23b* sponge mixed population - Batch 
Stable depletion of miR-23b* in an rCHO-SEAP mixed pool demonstrated an average 
increase of 30-40% in the maximal cell density on day 4 of culture with no benefit to 
culture viability when compared to NC-spg pools (Fig. 3.34 A and B). A trend towards 
an enhanced growth phenotype was observed over the course of several replicates 
although not significant. A 40-50% (p ≤ 0.01, p ≤ 0.001) reduced volumetric SEAP 
activity was observed when compared to non-specific control sponge cells (Fig. 3.34 C). 
Normalised productivity was observed to be reduced by ~60% (Fig. 3.34 D). This 
reduction in volumetric/normalised productivity could potentially be due to the enhanced 
proliferation phenotype diverting cellular resources from productivity. 
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Figure 3.34: Batch process of mixed pool CHO-SEAP cells stably depleting miR-
23b* 
 
Figure 3.34: Mixed populations engineered to stably deplete miR-23b* (miR-23b* spg MP) were 
cultured in a batch process over a 6 day time course with a control population expressing a non-
specific miRNA sponge. Phenotypes recorded were A) Cellular proliferation, B) Cellular viability, C) 
Volumetric SEAP activity and D) Specific SEAP activity. Statistical significance was calculated based 
on a standard student t-test (p ≤ 0.01** and ≤ 0.001***) and an experimental repeat of n = 3.  
 
miR-23b* sponge mixed population – Fed-batch 
When the same mixed pool populations were evaluated in a fed-batch format, a 60-70% 
(p ≤ 0.01, p ≤ 0.001) increase in maximal cell density was achieved (Fig. 3.35 A) with no 
impact on cellular viability.  
Volumetric SEAP output was observed to be reduced by 40-75%, as was described for 
batch culture (Fig. 3.35 B). However, at the later time points in culture, volumetric 
productivity achieved comparative levels to that of sponge controls (Fig. 3.35 B). This 
gradual increase in SEAP activity per mL is potentially attributed to the increase in the 
viable cell population. A consistent reduction in normalised productivity of 50-80% 
throughout various time points was observed (Fig. 3.35 C). 
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Figure 3.35: Fed-Batch process of mixed pool CHO-SEAP cells stably depleting 
miR-23b* 
 
 
Figure 3.35: CHO-SEAP mixed populations engineered with a miRNA sponge specific for miR-23b* 
(miR-23b* spg MP) were cultured over a 6 day fed-batch period alongside a non-specific control 
sponge population (miR-NC spg MP). Cultured were fed initially with a nutrient rich feed on day 0 
(15% v/v) and subsequently every 3 days (10% v/v). Bioprocess phenotypes assessed were A) Cellular 
proliferation, B) Cell viability, C) Volumetric SEAP activity and D) Specific SEAP activity. Statistical 
significance was calculated using a standard student t-test (p ≤ 0.01** and ≤ 0.001***) with an 
experimental repeat of n = 3.  
 
3.3.4.2 Impact of miR-23 and -23b* depletion on Mab producing clones 
Both miRNA sponge mixed populations were next evaluated in a cell line secreting an 
IgG antibody.   
miR-23 sponge mixed population - Batch 
The maximal cell density achieved was increased~2-fold (p ≤ 0.001) in miR-23 depleted 
CHO-1.14 cells with an improved viability of 15-20% (p ≤ 0.001) when compared to 
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control sponge cells (Fig. 3.36 A and B). When volumetric IgG concentration was 
determined, a ~60% (p ≤ 0.001) reduction early in culture but only ~30% (p ≤ 0.001) in 
late culture was observed when compared to non-specific sponge controls (Fig. 3.36 C). 
The gradual increase could be a result of the higher viable density of producing cells, 
especially when productivity on a per cell basis was determined to be reduced by ~60% 
across all time points (Fig. 3.36 D). 
 
Figure 3.36: Batch process of a CHO-1.14 mixed pool population with stable 
depletion of miR-23  
 
Figure 3.36: CHO-1.14 cells engineered with a sponge specific for miR-23 and a non-specific control 
sponge were cultured in a batch process over 6 days. Phenotypes assessed were A) Cellular 
proliferation, B) Cellular viability with an 80% viability threshold flagged with a red broken line, C) 
Volumetric IgG concentration and D) Specific IgG concentration. Statistical analysis was determined 
using a standard student t-test (p ≤ 0.01** and ≤ 0.001***) with an experimental repeat of n = 3. 
 
miR-23b* sponge mixed population - Batch 
CHO-1.14 mixed pool populations demonstrated a similar phenotype to what was 
observed in CHO-SEAP mixed pools. An increase in CHO cell growth of 20-50% (p ≤ 
0.01, p ≤ 0.001) was observed for miR-23b* sponge cells when compared to non-specific 
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pools (Fig. 3.37 A). Additionally, an increase in cellular viability of 10-15% (p ≤ 0.001) 
was observed on day 6 of culture (Fig. 3.37 B). When volumetric IgG was assessed, a 30-
40% (p ≤ 0.001) decrease was determined across all time points with a higher decrease in 
cell-specific productivity of 50-60% (Fig. 3.37 C and D).  
 
Figure 3.37: Batch culture for IgG-secreting miR-23b* sponge stable CHO-1.14 
 
Figure 3.37: Stable mixed pool CHO-1.14 population engineered with a sponge specific for miR-23b* 
and a non-specific sponge sequence were cultured over a 6 day batch process.  Bioprocess phenotypes 
under investigation were A) Cellular proliferation, B) Cellular viability with an 80% threshold 
marked with a red broken line, C) Volumetric IgG concentration and D) Specific IgG concentration. 
Statistical significance was calculated using a standard student t-test (p ≤ 0.01** and ≤ 0.001***) and 
an experimental repeat of n = 3. 
 
3.3.5 Analysis of single cell clones in 24-well plate 
Clones from all mixed populations (miR-23, miR-23b* and miR-NC) were selected based 
on a medium-high level of GFP fluorescence to ensure that clones selected were 
expressing the miR-sponge constructs to a degree sufficient enough to meet the minimum 
threshold levels to achieve saturated target miRNA diversion (Fig. 3.38).  
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Figure 3.38: GFP distribution of miR-sponge clones isolated using FACS 
 
Figure 3.38: miR-sponge clones were sorted based on a medium-high range of GFP intensity. Mixed 
populations were gated based on a non-fluorescent parental CHO-K1-SEAP cell line. The average 
GFP intensity is shown in the top right hand corner of the graphs. The percentage of medium-high 
GFP cells is represented as a percentage compared to all cells.  
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Before phenotypic evaluation was performed, all clones were passaged at least 3 time in 
the presence of PVA and pulsed with G418 (Neomycin Phosphotransfarase) and HYG 
(Hygromycin phosphotransfarase).   
 
3.3.5.1 GFP fluorescence across clonal panels 
From the panel of 24 clones in each group (miR-NC-spg, miR-23-spg and miR-23b*-spg) 
in both cell lines (CHO-SEAP and CHO-1.14), GFP fluorescence was determined using 
the Guava ExpressPlus programme on the GuavaTM benchtop cytometer. It revealed that 
there was a spread in GFP expression intensity throughout all clonal panels ranging from 
very high to low expression levels (Fig. 3.39). Similar to what was observed for the miR-
34 sponge, the average GFP intensity of both miR-23 and miR-23b* panels was reduced 
compared to controls and similarly observed in FACS readouts of miR-23/23b* sponge 
mixed pools (Fig. 3.38). It was also observed that the reduced GFP expression in the case 
of the miR-23b* panel was of a lower magnitude when compared to the control panel as 
opposed to miR-23 (Fig. 3.39). This could potentially be attributed to the nature of miR* 
strands being predominantly less abundant in addition to suggesting a potential lesser 
phenotype. The range in GFP intensity across the panel of clones is potentially attributed 
to plasmid integration site within the genome in addition to copy number and not as a 
result of transfection efficiency. Efficiency of transfection would have been assessed 24 
h post-transfection (Data not shown) with a ~70% efficiency in the case of both miR-NC 
and miR-34 sponge mixed pools.  
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Figure 3.39: GFP expression across miR-spg clonal panel (miR-NC, miR-23b and miR-23b*) in both CHO-K1-SEAP and CHO-
1.14 cells 
 
Figure 3.39: GFP expression for each individual clone from all stable miR-sponge populations (miR-NC spg, miR-23b spg and miR-23b* spg) in two different 
CHO cell lines (CHO-K1-SEAP and CHO-1.14). The Median GFP fluorescence for each panel is represented as a broken red line. GFP intensity was analysed 
using the Guava ExpressPlus programme on a Guava EasyCyte benchtop cytometer.  
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3.3.5.2 Impact on bioprocess phenotypes across CHO-K1-SEAP clonal panels 
In the mixed pool populations under various culture conditions, stable depletion of miR-
23 in our rCHO-SEAP cell line demonstrated no impact on CHO cell growth or viability 
yet significantly improved volumetric SEAP production due to enhanced specific 
productivity. On the other hand, miR-23b* depletion appeared to have a subtle beneficial 
effect on CHO cell growth at the expense of specific productivity. Clones isolated from 
both panels were evaluated on a clonal level as a means of assessing the gross phenotype 
as a function of the average panel performance. 
 
miR-23 sponge clonal panel - Batch 
After adaption to suspension culture, clones were grown in a 1 mL volume of serum-free 
medium and cultured in a 24-well suspension plate. The original panel of 24 clones, 
previously assessed for GFP fluorescence, was reduced to a panel of 14 clones due to loss 
during the adaption process as well as a contamination event over the course of several 
passages. The same occurred for miR-NC sponge clones of which 15 clones were 
recovered.  
Both clonal panels were cultured over the course of a 6 day batch period and sampled on 
days 2, 4 and 6.  
The average growth was not observed to differ when clones were assessed on day 2 (Fig. 
3.40Day 2), as observed in the mixed pools. However, clones stably expressing the miR-23 
sponge decoy achieved half the maximal cell density on day 4 when compared to the 
miR-NC sponge panel (Fig. 3.40Day 4), despite a subset of clones reaching “normal” cell 
densities. Cell density was further reduced by ~70% on day 6, potentially attributed to the 
25% drop in cell viability at this late culture time point (Fig. 3.40Day 6, Fig. 3.41). 
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Figure 3.40: CHO-SEAP miR-23 sponge clonal panel – Cell numbers/mL 
 
Figure 3.40: CHO-SEAP clonal panel demonstrating stable depletion of miR-23 and assessed for 
their growth phenotype in 1 mL suspension culture in a 24-well plate format and sampled at days 2, 
4 and 6 in a batch process. Average cell numbers calculated across the entire clonal panels is 
represented by the broken red line with the miR-NC-spg panel represented in dark blue and miR-
23b spg panel in light blue. Yellow boxes highlight the individual sponge clones that were 
subsequently selected from each group for scale up and an n = 2. 
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Figure 3.41: Day 6 cell viability of miR-23b CHO-SEAP sponge panel 
 
Figure 3.41: As cellular viability was comparable between both clonal panels on day 2 and 4, for both 
the miR-23 spg and miR-NC spg panel only the viability of each individual clone form both panel for 
day 6 of culture is presented above. The average viability across each panel is represented as a broken 
red line with the corresponding value enclosed. Clones ultimately selected for scale up are highlighted 
in orange boxes and an n = 2. 
 
An increase of 3.1, 2.9 and 2.5-fold (p ≤ 0.001) in SEAP production per mL was observed 
on days 2, 4 and 6, respectively in the miR-23 depleted panel despite the negative impact 
on cell density (Fig. 3.42). Although some clones from the NC-sponge group possessed 
a high level of SEAP production, 11 of the 15 miR-23 sponge clones outperformed the 
highest performing control clone. In the miR-23 sponge panel, average volumetric SEAP 
activity was observed to be 2.5-fold increased on day 4. This translated to a 5.8-fold (p ≤ 
0.001) increase in normalised productivity due to the reduced cell numbers (Fig. 3.40Day 
4, 3.42Day 4 and 3.43Day 4). This suggests that although miR-23 may be contributing to 
enhanced specific productivity, the extent to which an individual cell will respond relies 
on various cellular processes such as proliferation, an energetically demanding process. 
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Figure 3.42: miR-23 sponge clonal panel – Volumetric SEAP activity 
 
Figure 3.42: Individual volumetric SEAP activity is presented above for both miR-23 sponge and 
NC-sponge clones with the average performance across both panels represented as a red broken line.  
Orange boxes highlight the individual sponge clones that were subsequently selected from each group 
for scale up. Statistical significance was determined using a standard student t-test (p ≤ 0.001***), n 
= 2. 
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Figure 3.43: miR-23 sponge clonal panel – specific SEAP productivity 
 
Figure 3.43: Specific SEAP productivity for all clones in both miR-23 and miR-NC sponge panels. 
Average specific productivity is represented as a red broken line.  Orange boxes highlight the 
individual sponge clones that were subsequently selected for scale up. Statistical analysis was 
calculated using a standard student t-test (p ≤ 0.05*, ≤ 0.01** and ≤ 0.001***), n = 2. The outlier, 
miR-23 clone 6 on day 6, is at a value of 4.98 x 10-2. 
Finally, clones selected from both miR-23 sponge and the miR-NC sponge panels were 
chosen based on volumetric SEAP production, highlighted in orange boxes (Fig. 3.42). 
From the miR-23 sponge panel, the four best producing clones were chosen for scale up 
(miR-23 sponge 2, 4, 6 and 23).  A similar approach was taken for the selection of the 
miR-NC sponge clones (miR-NC sponge 2 and 11) except that miR-NC sponge clone 20 
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was also selected based on its high normalised productivity as well as its high volumetric 
productivity. 
 
miR-23b* sponge clonal panel - Batch 
In 1 mL suspension culture, the miR-23b* sponge clonal panel did not exhibit a beneficial 
growth phenotype as was suggested from previous characterisation in mixed pools. 
Although some individual clones did demonstrate an enhanced growth phenotype early 
into batch culture (miR-23b* spg clone 18 and 22, Fig. 3.44Day 2), on average across the 
entire clonal panel, there was no growth benefit evident with clones behaving similarly 
to that of the miR-NC sponge panel. Furthermore, similar to what was observed for the 
miR-23 sponge panel, there was a 50% reduction in the maximal cell density achieved by 
miR-23b* sponge clones (Fig. 3.44Day 4+6). However, unlike the observation from the 
miR-23 sponge panel, cell viability was similar when compared to the control panel (Fig. 
3.45).  
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Figure 3.44: CHO-SEAP miR-23b* sponge clonal panel – Cell numbers/mL 
 
Figure 3.44: The individual performance of each clone derived from both miR-23b* sponge and miR-
NC sponge mixed pools when cell growth was evaluated over a batch culture process. Average 
performance across all clones is represented by the broken red line with each clone that was 
ultimately selected for further validation highlighted with an orange box.  
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Figure 3.45: Day 6 cell viability of miR-23b* sponge panel 
 
Figure 3.45: Day 6 viability for the miR-23b* and miR-NC sponge panels with average viability 
represented as a broken red line. No impact was observed at the earlier time points of day 2 and 4 
with clones selected highlighted with an orange box. 
 
The drastic impact previously observed on both volumetric and specific SEAP activity 
for the miR-23b* sponge mixed pools was not reflected in the clonal panel. SEAP activity 
remained unchanged on day 2 of culture while a ~20% reduction was observed on day 4 
of culture (Fig. 3.46Day 2+4). Normalised productivity also remained unchanged on day 2 
of culture while being enhanced by ~2-fold (p ≤ 0.05) on day 4 (Fig. 3.47Day 2+4). 
Furthermore, although a 2-fold increase in normalised productivity was observed, this 
coincided with a reduction in volumetric yield by ~20% on day 4. However, on day 6 of 
culture, SEAP yield was measured to be ~35% increased with a further improved 
normalised productivity of ~3.5-fold (Fig. 46Day 6, 47Day 6).  
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Figure 3.46: CHO-SEAP miR-23b* sponge clonal panel – Volumetric SEAP 
 
Figure 3.46: Volumetric SEAP activity for each individual clone from both miR-23b* and miR-NC 
sponge panels is represented above with the average performance across the clonal panels shown as 
a broken red line. Clones selected for scale-up are highlighted in orange boxes with no statistical 
significance observed for phenotypic differences calculated using a standard student t-test. 
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Figure 3.47: CHO-SEAP miR-23b* sponge clonal panel – Specific productivity 
 
Figure 3.47: Specific SEAP productivity was calculated and graphed for each individual clone form 
both miR-23b* and miR-NC sponge clones. Average panel performance is represented as a broken 
red line again with selected clones highlighted in an orange box. Statistical significance was calculated 
using a standard student t-test (p ≤ 0.05*). miR-23b* sponge clone 2 on day 6 has a value of 2.55 x 10-
3 SEAP units/cell.  
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could be contributing to the enhanced normalised productivity observed. SEAP yield was 
observed to be reduced except late in culture where it was increased by 34%. Viability 
was not observed to differ from control clones as opposed to miR-23 sponge clones whose 
viability was reduced despite exhibiting reduced cell numbers. Clones were selected 
based on volumetric productivity.  
 
3.3.5.3 Impact on bioprocess phenotypes across CHO-1.14 clonal panels 
Subsequent to the characterisation of the influence of both miR-23 sponge and miR-23b* 
sponge constructs in an stable mixed pool IgG-secreting rCHO-1.14 cell line, individual 
clones were sorted using FACS under the same selection criteria as was previously 
applied to the selection of both miR-spg SEAP clonal panels. 
 
miR-23 sponge clonal panel - Batch 
CHO-1.14 cell clones stably expressing a sponge specific for miR-23 were cultured in a 
1 mL volume of CHO-S-SFM II media in suspension batch culture over the course of 6 
days. As previously described, a certain number of clones were lost over the course of 
suspension adaptation and suitability to suspension culture. The improved cellular 
growth, as first observed in the predecessor mixed pools, was not as potent in the case of 
clones although, on average, growth was enhanced ~10% on days 2 and 4 with a more 
significant ~40% (p ≤ 0.001) observed on day 6 (Fig. 3.48).    
13 out of 22 miR-23 sponge clones demonstrated higher cell numbers when compared to 
the average cell density of the controls. This less potent growth benefit could potentially 
be attributed to the nature of the 1 mL suspension culture process of which both miR-
23/23b* sponge CHO-SEAP clones demonstrated reduced growth. 
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Figure 3.48: CHO-1.14 (IgG) miR-23 sponge clonal panel – Cell numbers/mL 
 
Figure 3.48: Cellular proliferation for each individual clone within the miR-23 sponge panel is 
represented above with the comparative miR-NC sponge panel in a CHO-1.14 cell line. The average 
cell numbers/mL was calculated across each panel and is represented as a broken red line. Statistical 
significance was calculated using a standard student t-test (p ≤ 0.001***). Each clones ultimately 
selected for scale up is highlighted in an orange box.  
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The enhanced cell density at day 6 was potentially attributed to the increased cell viability 
of 87.7% (p ≤ 0.001) for miR-23 sponge clones when compared to 63.4% for controls 
(Fig. 3.49). The direct impact of miR-23 depletion on viability is potentially reflected in 
the large percentage (18/22 or 81.1%) of clones that maintained a viability of over 80% 
when compared to controls (8/16 or 50%).  
 
Figure 3.49: CHO-1.14 (IgG) miR-23 sponge clonal panel – Cell viability % 
 
Figure 3.49: As viability remained relatively unchanged when comparing miR-23 sponge and miR-
NC sponge clones on day 2 and 4, only day 6 cell viability was reported. The average cellular viability 
across both sponge panels is represented as a broken red line. Statistical significance was calculated 
using a standard student t-test (p ≤ 0.001***) with each clone ultimately selected for scale up being 
highlighted in an orange box. 
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Figure 3.50: CHO-1.14 (IgG) miR-23 sponge clonal panel – Volumetric productivity 
 
Figure 3.50: Volumetric IgG production is represented above for all clones across both sponge panels 
with average performance shown as a red broken line over a 6 day batch culture process. Clones 
selected for scale up are highlighted in orange boxes. Statistical significance was calculated using a 
standard student t-test (p ≤ 0.05*). 
 
It was observed that a significant number of individual clones completely lost IgG 
production, with a higher proportion in miR-23 sponge clones. Statistical analysis was 
performed on all clones. A reduction in volumetric IgG was observed on days 2 (~35%) 
and 4 (~45%), and 6 (~40%, p ≤ 0.05) in miR-23 depleted clone panels (Fig. 3.50). Day 
6 demonstrated the largest reduction in specific productivity (~60%, Fig. 3.51). 
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Figure 3.51: CHO-1.14 (IgG) miR-23b sponge clonal panel – Specific productivity  
 
Figure 3.51: Specific productivity for CHO clones engineered with a sponge specific for miR-23 
versus a control non-specific sponge. Average specific productivity is represented a broken red line. 
Clones selected for scale up are highlighted in an orange box. Statistical analysis was calculated using 
a standard student t-test (p ≤ 0.05* and p ≤ 0.01**). 
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(Fig. 3.48Day 6), only 1 clone (clone 11) remained in the topmost performing group of 
clones when volumetric IgG secretion was assessed, with the remaining 4 clones 
producing below detectable limits. For these reasons clones were chosen based on day 6 
volumetric IgG values (miR-23 sponge clones 6, 9, 14, 17 and 23) as particular clones 
(clone 9 and 23) demonstrated high secreted IgG levels at this time point while producing 
below the ELISA sensitivity on days 2 and 4. Clonal selection from the miR-NC sponge 
panel (clones 2, 15 and 20) was based on similar criteria.   
 
miR-23b* sponge clonal panel - Batch 
Next, the influence of miR-23b* depletion was assessed in clones derived from the stable 
IgG-secreting CHO-1.14 mixed pool. These were observed previously to have an 
enhanced proliferation capacity of 20-50% at the expense of productivity. Furthermore, 
cell viability late into the culture process was increased by 10-15% when compared to 
controls.  
An increase in growth of ~50% (p ≤ 0.001) was observed on day 2 of culture when 
compared to control sponge panels (Fig. 3.52Day 2) with a ~30% (p ≤ 0.01) improved 
maximal cell density. However, it was noted that particular NC-sponge clones (clone 20, 
21 and 16) reached similar cell numbers at this time point (Fig. 3.52Day 4). 20 of 22 (90%) 
of miR-23b* sponge clones exceeded the average growth performance of the control 
panel. Furthermore, an average 50% (p ≤ 0.01) increase in cell density was maintained at 
day 6 of culture potentially resulting from an extended viability (Fig. 3.52Day 6).   
An average additional 25% (p ≤ 0.001) viability was observed when compared to the 
average of the control panel (87.9% versus 63.4%, Fig. 3.53), a phenotype previously 
seen to a lesser extent in mixed pools. 
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Figure 3.52: CHO-1.14 (IgG) miR-23b* sponge clonal panel – Cell numbers/mL 
 
Figure 3.52: The viable cell numbers/mL for clonal miR-23b* and miR-NC sponge populations 
derived from their predecessor mixed pools. Individual clonal performance is represented with the 
average performance across the panel being shown as a broken red line. Clones selected for scale up 
are highlighted in an orange box.  Statistical significance was calculated using a standard student t-
test (p ≤ 0.01** and ≤ 0.001***).  
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Figure 3.53: CHO-1.14 (IgG) miR-23b* sponge clonal panel – Cell viability % 
 
Figure 3.53: Cellular viability status of both miR-23b* and miR-NC rCHO-1.14 clones late in culture. 
Average viability across each clonal panel is represented by a broken red line. Clones that were 
ultimately selected for scale up are highlighted in orange boxes. Statistical significance is was 
calculated using a standard student t-test (p ≤ 0.001***). 
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Figure 3.54: CHO-1.14 (IgG) miR-23b* sponge clonal panel – Volumetric 
productivity 
 
Figure 3.54: Volumetric IgG secreted for each clonal in both miR-23b* and miR-NC sponge panels 
is represented above with the average performance across the panels shown at a broken red line. 
Clones ultimately selected for scale up are highlighted in orange boxes. Statistical significance was 
determined using a standard student t-test (p ≤ 0.05*). 
 
Similarly to the miR-23 sponge panel, a significant number of miR-23b* clones 
completely lost IgG production but were included in statistical analysis. An average 
reduction of 30-45% was observed in volumetric IgG across all time points (Fig. 3.54). 
Cell specific productivity was significantly reduced by ~50% (p ≤ 0.05) on day 2 and 
~60-65% on day 4 and 6 (p ≤ 0.01), respectively (Fig. 3.55).  
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Figure 3.55: CHO-1.14 (IgG) miR-23b* sponge clonal panel – Specific productivity 
 
Figure 3.55: Specific productivity for each clone from both miR-23b* and miR-NC sponge panels are 
shown above with the average performance represented as a broken red line. Statistics were 
calculated using a standard student t-test (p ≤ 0.05* and ≤ 0.01**) with each clone chosen for scale 
up highlighted in an orange box. 
 
The significant number of miR-23b* depleted clones that exhibited a reduced IgG titre 
below the detectable limits of the ELISA is potentially due to the inherent reduction in 
productivity due to the enhanced growth phenotype as previously observed for mixed 
populations in CHO-1.14 and additionally conserved in CHO-SEAP stables (not as 
dramatic a growth impact). Clones ultimately selected for 5 mL scale up were based on 
their viability and cell growth attributes while also maintaining a production capacity. 
Although clonal selection proved difficult, it was anticipated that if miR-23b* depletion 
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mediated apoptosis resistance in selected clones, their inherent reduced specific 
productivity would be overcome by a potential prolonged production phase, potentially 
achieving higher volumetric titres. Clones 6, 15 and 22 were selected from the miR-23b* 
sponge panel and clones 2, 15 and 20 were selected from the miR-NC sponge panel, as 
before for miR-23 sponge comparison.  
 
3.3.6 Investigation of miR-23 and -23b* depletion on selected clones in 5mL Batch, 
Fed-Batch and Fed-batch temperature shift 
This next section characterises the performance of clonal behaviour for both stable miR-
23 and miR-23b* sponge CHO-SEAPs over a serious of commonly implemented 
bioprocess regimes including batch, fed-batch and temperature shift fed-batch. 
 
3.3.6.1 miR-23 and miR-23b* sponge CHO-SEAP clones 
miR-23 sponge clones - Batch 
Clones selected from the clonal panel screen (Clones 2, 4, 6 and 23) were seeded at 2 x 
105 cells/mL in a 5 mL working volume in a 50 mL vented spin tube (37 ˚C at 170 rpm). 
A slight variation in maximal cell density was evident between all clones to within a range 
of 1 x 106 /mL, potentially attributed to clonal variation (Fig. 3.56 A). A range of 
viabilities was observed with a single control clone remaining above 80%, potentially an 
innate clonal benefit (Fig. 3.56 B). 
Productivity was represented as a range with each test clone being compared to the best 
and worst performing control clone. Statistical analysis was calculated for each test clone 
against the pooled values for each control clone. The best performing clones were miR-
23 spg 4 and 6, both demonstrating similar SEAP activity increases of 2-6-fold (p ≤ 0.001) 
while exhibiting a 2-5-fold enhanced normalised productivity as a result of a slightly 
higher cell density (Fig. 3.56 C and D). The lowest performing miR-23 sponge clone 
(miR-23 spg 2) still maintained a higher SEAP activity when compared to the best 
performing control clone ranging from 1.25-3-fold (p ≤ 0.001). 
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A note to make at this point would be the apparent dramatic increase in normalised 
productivity of the control clone, miR-NC spg 20. When cultured in 5 mL volumes, this 
clone had a propensity to clump therefore exhibiting an apparent reduced cell density thus 
resulting in an enhanced normalised productivity calculation. Subsequent bioprocess 
characterisation was carried out with this clone omitted. Additionally, miR-23 sponge 
clone 4 and 6 were retained as they both exhibited similar characteristics. 
 
Figure 3.56: miR-23 sponge clones 2, 4, 6 and 23 under 5 mL batch conditions 
 
Figure 3.56: CHO-SEAP stable clones 2, 4, 6 and 23 stably depleted of miR-23 grown under batch 
condition in a 5 mL volume seeded at 2 x 105 cell/mL are represented above in different shades of red 
while miR-NC clones 2, 11 and 20 are shown in various shades of black (n = 3). Clone performance 
is reported in text as a range compared to the best and worst control clone while statistical 
significance was calculated based on the combined values for all control clones (p ≤ 0.001***, 
standard student t-test). 
 
It is evident that miR-23 depleted clones selected from the mixed pool exhibited a 
maximum 2-fold increase in volumetric SEAP activity when compared to their mixed 
population predecessors under batch conditions (Fig. 3.57), highlighting the benefits of 
clonal isolation. 
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Another interesting observation was that a similar SEAP activity was observed in miR-
23 sponge clones cultured in 1 mL and 5 mL batch culture despite reduced maximal cell 
densities achieved in 1 mL culture. This SEAP activity was attributed to an increased 
normalised productivity (~2-fold) for those clones that reached a lower cell density.  
 
Figure 3.57: Volumetric SEAP performance of miR-23 sponge clones versus miR-23 
sponge mixed pools 
 
Figure 3.57: Various performing clones that make up a mixed population as a result of the nature of 
plasmid integration and expression upon transgenic CHO cell line generation. The SEAP activity is 
compared between the predecessor miR-23 sponge mixed CHO cell population and the subsequently 
isolated clones. 
 
miR-23 sponge clones – Fed-batch 
Next we assessed whether a fed-batch process would further enhance cell density of these 
high SEAP producing clones potentially improving productivity. miR-23 sponge clones 
4 and 6 were evaluated as they both demonstrated similar attributes as well as miR-NC 
spg 2 and 11. Clonal variation was once again evident upon the addition of a feed with a 
range of maximal cell densities being observed (Fig. 3.58 A).      
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Figure 3.58: miR-23 sponge clone 4 and 6 under 5 mL Fed-Batch conditions 
 
Figure 3.58: An 8 day fed-batch culture with a working volume of 5 mL (+ initial feed of 15% v/v, 
represented with a broken orange line) seeded at 2 x 105 cell/mL with subsequent feeding of 10% 
(v/v) every 3 days. A) Cell numbers/mL, B) Cell viability with 80% viability threshold represented as 
a broken red line, C) Volumetric SEAP activity/mL with statistical significance calculated based on 
each test clone versus all three combined control clones (p ≤ 0.001, student t-test) and D) specific 
SEAP activity per cell, n = 2. 
 
Both miR-23 sponge clones 4 and 6 exhibited an enhanced viability of ~20% (p ≤ 0.01) 
on days 6, 7 and 8 of culture when compared to control clones while also maintaining a 
prolonged viability above the 80% threshold for an additional 48 h (Fig. 3.58 B). Both 
miR-23 depleted clones exhibited a 2-6-fold (p ≤ 0.001) increase in SEAP activity when 
compared to controls (Fig. 3.58 C). Given the various growth phenotypes observed, 
normalised productivity was improved but not proportional to volumetric productivity 
(Fig. 3.58 D). It was observed that that maximum SEAP produced was reduced in Fed-
batch for miR-23 depleted clones when compared to batch despite the improved cell 
densities, possibly due to a compromise in normalised SEAP production.  
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miR-23 sponge clones – Fed-batch with Temperature shift 
Another commonly implemented process utilised in industry is hypothermic growth 
conditions (Kumar, Gammell & Clynes 2007). By reducing the culture temperature from 
37 ˚C to ~31 ˚C, specific CHO cell productivity can be enhanced through arrest in the G1-
phase of the cell cycle, the most transcriptionally active phase.  
With the observation that fed-batch boosted both growth and maximum cell density of 
our miR-23 sponge CHO-SEAP clones with the addition of imparting an extended viable 
production phase above 80% for a further 48 h, we sought to overcome the reduced SEAP 
activity when compared to batch culture by inducing a temperature shift thus potentially 
enhancing specific productivity and prolonging culture longevity.  
Fed-batch was carried out as previously described with a temperature shift to 31 ˚C after 
72 h of culture. Both miR-23 and miR-NC sponge clones performed similar over the first 
three days of fed-batch culture reaching cell densities of ~ 6 x 106 cells/mL prior to 
temperature shift, as observed previously. Cellular proliferation was observed to be halted 
upon shift to 31 ˚C three days into culture for all clones except miR-NC spg 2 which 
climbed a further 2 x 106 cell/mL at its maximum (Fig. 3.59 A). A gradual decrease in 
cell density, forming the induced production phase, can be observed upon TS which was 
due to a combination of both cell death and cellular clumping. Another interesting 
observation was that miR-23 sponge clones appeared to be sensitive to TS demonstrating 
a negative response to hypothermic culture conditions dropping below the 80% viability 
threshold on day 5 (Fig. 3.59 B) when compared to day 7 in the absence of TS (Fig. 3.58 
B). However, a viable production phase of ~60% was maintained as far as day 13 of 
culture. Furthermore, miR-NC clones declined faster in viability at very late culture time 
points with a significant separation observed of ~10-20% (p ≤ 0.05) (Fig. 3.59 B). 
Enhanced SEAP productivity of 2-4-fold (Volumetric, p ≤ 0.001) and 2-5-fold 
(Normalised) respectively, was observed for miR-23 depleted clones (Fig. 3.59 C and D).  
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Figure 3.59: miR-23 sponge clones under Fed-batch temperature shift  
 
Figure 3.59: miR-23 sponge clones 4 and 6 were subjected to fed-batch (Orange broken line) 
temperature shift (broken blue line) as a means to exploit the increased cell densities accumulated in 
early culture while subsequently potentially improving specific productivity and reducing the onset 
of apoptosis. Nutrient feeds were as described in the case of a fed-batch. Phenotypes assessed were 
A) Viable cell numbers/mL, B) Cellular viability with an 80% viability threshold represented as a 
broken red line, C) Volumetric SEAP activity and D) specific productivity. Statistics were calculated 
using a standard student t-test (p ≤ 0.05, p ≤ 0.001***) and an n = 2. 
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Normalised productivity was observed to be increased in fed-batch with temperature shift 
when compared to fed-batch only for miR-23 sponge clones, with normalised 
productivity spikes in late culture potentially attributed to clumping (Fig. 3.60).  
 
Figure 3.60: miR-23 sponge 4 and 6 clones specific productivity under Fed-batch 
and fed-batch temperature shift 
 
Figure 3.60:  The influence of a fed-batch versus a fed-batch with temperature shift on specific SEAP 
productivity is compared above for clone 4 and 6 that have been engineered to stably deplete miR-
23. Nutrient feeds are as previously described (15% v/v on Day 0 and 10% v/v every 72 hs) and 
represented as a broken orange line. Temperature shift (TS) to 31˚C is denoted on day 3 as a broken 
blue line. 
 
miR-23b* sponge clones - Batch 
miR-23b* sponge SEAP clones (clone 3,8 and 18) were selected based on their growth 
and productivity phenotype when evaluated under 1 mL suspension.. A range of growth 
phenotypes were observed when clones were cultured under 5 mL batch conditions. One 
clone in particular, miR-23b* spg 18, demonstrated an enhanced growth phenotype on 
day 4 of culture achieving an improved maximum cell concentration of 42% (p ≤ 0.01) 
when compared to the highest performing control clone (Fig. 3.61 A). Furthermore, this 
clone maintained a high viable cell density of 91.1% (p ≤ 0.05) late in culture when 
compared to controls (66.4, 81.6 and 27.8) (Fig. 3.61 B). When normalised productivity 
was compared to miR-NC spg 11, the highest producing control clone, all miR-23b* spg 
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clones demonstrated a reduced output across all time points ranging from 75-35% (Fig. 
3.61 D). However, miR-23b* spg 18 produced an equivalent volumetric SEAP yield on 
day 6 despite this observed reduced normalised SEAP activity (Fig. 3.61 C). This 
observation was potentially due to the enhanced maximal cell density achieved coupled 
with the prolonged viability thus mediating a prolonged viable production phase.  
With the observation of this highly attractive phenotype, miR-23b* spg clone 18 was 
carried on for further validation using various culture conditions.  
 
Figure 3.61: miR-23b* sponge CHO-SEAP clones under batch conditions 
 
Figure 3.61: miR-23b* sponge CHO-SEAP clones cultured under batch conditions are represented 
above for all bioprocess phenotypes including A) Cell numbers/mL, B) Cellular viability, C) 
Volumetric SEAP activity/mL and D) Specific SEAP activity/cell. Statistical significance was 
calculated using the standard student t-test (p ≤ 0.01**) and an n = 3. 
 
miR-23b* sponge clone 18 – Fed-batch 
A similar phenotype was observed when miR-23b* sponge clone 18 was cultured in the 
presence of a feed as had been observed when under batch conditions. The addition of a 
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growth profile was previously observed to be high under batch conditions. This clone 
demonstrated an intermediate growth profile when compared to both miR-NC 2 and miR-
NC 11 (Fig. 3.62 A). An extended viability was observed for clone 18 with a further 48 
hs of culture above 80% viability (p ≤ 0.001) when compared to control clones (Fig. 3.62 
B). The benefit of this extended viable production phase was again reflected in the gradual 
increase in volumetric SEAP activity of miR-23b* spg 18 producing ~10% more than the 
highest producing control clone (Fig. 3.62 C) despite a reduced normalised productivity, 
75-30% (Fig. 3.62 D). 
 
Figure 3.62: miR-23b* sponge clone 18 CHO-SEAP under fed-batch conditions 
 
Figure 3.62: Fed-batch culture results for miR-23b* spg 18 versus two top performing control sponge 
clones (miR-NC spg 2 and 11). Cells were seeded at 2 x 105 cells/mL with an initial feed of 15% (v/v) 
and an additional subsequent feed of 10% (v/v) every 72 h represented as a broken orange line. 
Graphs demonstrate A) Cell numbers/mL, B) Cell viability with an 80% viability threshold shown 
as a broken red line, C) Volumetric SEAP activity/mL and D) Normalised productivity. Statistical 
significance was calculated using the standard student t-test (p ≤ 0.001***), n = 2. 
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miR-23b* sponge clone 18 – Fed-batch with Temperature shift 
With the observation that this miR-23b* sponge clone exhibited a beneficial viability 
phenotype when compared to controls that ultimately improved the production 
phenotype, we sought to further enhance the production phase through the utilisation of 
hypothermic growth conditions.  
miR-23b* spg clone 18 exhibited similar cell densities to controls over the three days 
prior to TS with an immediate growth arrest being observed upon transfer to 31 ˚C (Fig. 
3.63 A). A prolonged viable production phase was observed in the case of miR-23b* 
depletion in clone 18 (p ≤ 0.001-0.05 at various time points) while remaining above 80% 
viability for a further 5 days when compared to controls (Fig. 3.63 B). Volumetric yield 
was boosted by 20-80% (p ≤ 0.001) over various time points (Fig. 3.63 C). Normalised 
productivity was observed to be lower than controls at the early stages of the culture 
process but appeared to be gradually improved later into culture due to the gradual 
reduction in cell numbers and the increase in SEAP activity (Fig. 3.63 D).  
From progressing particular CHO clones generated from both the miR-23 sponge and 
miR-23b* panels through various culture processes, it was evident that both miRNA 
engineering approaches endowed a beneficial CHO cell phenotype although miR-23 
depletion was more consistent than miR-23b*, which allowed for the isolation of a single 
clone (clone 18) with an enhanced viability performance. The observed prolonged 
viability suited this miR-23b* sponge clone to the bioprocess of fed-batch with 
temperature shift. miR-23 sponge clones exhibited an attractive phenotype suitable to 
several production platforms (batch, fed-batch and fed-batch with TS) and for this reason 
was pursued for further validation.   
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Figure 3.63: miR-23b* sponge clone 18 CHO-SEAP under batch conditions 
 
Figure 3.63: Fed-batch (Orange broken line) culture with an additional temperature shift to 31 ˚C 
(Broken blue line) for the CHO-SEAP clone 18 stably depleted of miR-23b* and control sponge 
clones. A) Cell numbers/mL, B) cell viability with an 80% viability threshold represented as a broke 
red line, C) Volumetric SEAP activity/mL and D) Specific SEAP activity. Statistical analysis was 
calculated using the standard student t-test (p ≤ 0.05*, ≤ 0.01** and ≤ 0.001***), n = 2. 
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3.3.6.2 miR-23 sponge CHO-1.14 (IgG) clones 
miR-23 sponge clones - Batch 
As reported previously, miR-23 depletion in the IgG-secreting CHO-1.14 cells was 
different from what was observed in SEAP cells. Growth and viability were enhanced in 
the case of CHO-1.14 to the detriment of productivity. Furthermore, it was observed 
within the clonal panel study that viability was improved by ~20%. Although, volumetric 
and specific productivity was observed to be reduced, miR-23 sponge CHO-1.14 clones 
were selected based on IgG levels, i.e. attempting to isolate the best producers while 
considering both growth and viability traits. From the clones chosen (miR-23 spg 6, 9, 
14, 17 and 23), various bioprocess conditions were tested. 
Enhanced growth of ~1.5-2-fold (p ≤ 0.001) on days 2 and 4 of batch culture was observed 
for all miR-23 sponge clones when compared to all three control clones (Fig. 3.64 A). 
One control clone (miR-NC spg 20) demonstrated a comparable viability (above 80%) to 
that of miR-23 depleted clones unlike its counterparts whose viability on day 6 of culture 
were 54% and 22% (Fig. 3.64 B). Although all 5 miR-23 depleted clones demonstrated 
higher viability than the two lowest performing control clones, only two retained 
enhanced viability over the best performing control clone. It is still evident from the 
number of clones selected that miR-23 depletion does have a positive and beneficial 
impact on CHO cell growth.   
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Figure 3.64: miR-23 depleted CHO-1.14 clones under batch conditions 
 
Figure 3.64: CHO-1.14 clones stably engineered to be depleted of miR-23 under batch culture 
conditions. A) Cell numbers/mL, B) Cellular viability, C) Volumetric productivity (ng/mL) and D) 
Specific productivity. Statistical analysis was determined using a standard student t-test and was 
based on a comparison between each individual test clone and all control clones (p ≤ 0.001***), n = 
3. 
 
All miR-23 sponge clones demonstrated a ~40-60% reduction in volumetric IgG when 
compared to the best performing control clone, miR-NC sponge clone 2 (Fig. 3.64 C). 
When compared to the lower producing controls, there was a less dramatic reduction in 
volumetric IgG titre observed of ~20% as far as +20% in some instances, for all miR-23 
sponge clones. However, all miR-23 depleted clones demonstrated a reduction in specific 
productivity ranging from 25-90% (Fig. 3.64 D) when compared to control clones. It is 
evident that from batch cultivation of a selected panel of miR-23 sponge clones in a 
recombinant IgG-secreting CHO cell line exhibit an enhanced growth phenotype at the 
expense of specific productivity.  
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miR-23 sponge clones – Fed-batch 
We sought to attempt to further boost cell numbers with the addition of a feed and 
potentially mediate a prolonged production phase to ultimately improve volumetric titres 
considering the reduced specific productivity. One immediate observation was that the 
addition of a feed did not appear to enhance cellular proliferation past normal levels, a 
phenotype which had been previously noted in the case of CHO-SEAP during fed-batch. 
miR-23 depleted clones demonstrated an enhanced growth phenotype early into culture 
of ~50% on day 1 and 2 while achieving an increased maximal cell density of ~50-70% 
on day 3 when compared to control clone 2 and 15 (Fig. 3.65 A). One control clone 
however (miR-NC spg 20), as observed in batch culture, demonstrated similar maximal 
cell densities and a superior viability profile (Fig. 3.65 B). Although culture under batch 
conditions suggested a potential viability benefit, there was no discernible improvement 
observed when a feed was added. 
 
Figure 3.65: miR-23 depleted CHO-1.14 clones under fed-batch conditions 
 
Figure 3.65: miR-23 depleted clones secreting IgG under fed-batch conditions with the broken orange 
line indicating the addition of a nutrient feed. Phenotypes monitored were A) cell cumbers/mL, B) 
Cellular viability with an 80% threshold represented as a broken red line, C) Volumetric IgG titres 
and D) Specific productivity (n =2).  
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The three miR-23 sponge clones selected for fed-batch culture demonstrated the highest 
cell densities when grown under batch conditions and demonstrated a potential improved 
volumetric IgG titre at various time points when compared to the two lowest producing 
control clones. In the case of fed-batch, this improved volumetric productivity was more 
potent in the case of miR-23 spg clone 6 and 9 with a maximum increased IgG titre on 
day 9 of ~40-80% and 2-2.6-fold, respectively. miR-23 spg clone 23 exhibited the lowest 
productivity profile of all clones under investigation while miR-NC spg clone 2 surpassed 
all clones when both volumetric and specific productivity were assessed (Fig. 3.65 C and 
D). Specific IgG productivity was observed to be enhanced for 2 out of three clones when 
fed-batch was carried out possibly due to the observation of no dramatic improvement in 
cell growth, potentially resulting in an excess of nutrients available for protein synthesis. 
This demonstrates that miR-23 depletion in our IgG-secreting CHO-1.14 cell line 
improves cellular growth and maximal cell density with a benefit to viability. These 
enhanced phenotypes appear to be at the cost of productivity. However, it is evident that 
the process of clonal selection and the inherent heterogeneity present within CHO cell 
clones can in itself mediate a beneficial phenotype that can be selected for. The selection 
of a larger panel of clones would give a better understanding of the impact that miR-23 
depletion has on this CHO-1.14 cell line.  
At this point however, the depletion of miR-23 in CHO-SEAP cells was more beneficial 
and consistent upon scale up and will be the primary focus for the rest of this thesis. As 
both IgG and SEAP secreting CHO cell lines were derived from the same parental cell 
line, it is possible that the impact of stable miR-23 depletion is product specific with the 
culture format also having an influence. The fact that clones selected throughout the 
various phases of scale-up were selected based on their volumetric productivity could 
have introduced a bias. However, the initial phenotype observed within mixed pools was 
observed to be retained throughout.   
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Section 3.4 
 
 
 
 
 
 
Investigation of the molecular 
impact of miR-23 depletion in 
CHO-SEAP cells 
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3.4.1 miR-23 depletion improves CHO-SEAP specific productivity  
miR-23 depleted clones exhibited an improved SEAP productivity of ~3-fold with a slight 
variation in cellular growth over various culture conditions. This section focuses on the 
elucidation of how the depletion of miR-23 is conferring this advantage on cellular 
productivity. 
 
3.4.2 SEAP transcript levels appear elevated in miR-23 sponge clones 
As all secreted mammalian proteins are translocated to the lumen of the endoplasmic 
reticulum either post- or co-translationally for modification, folded and assembled before 
release to the cis-Golgi compartment (Tigges, Fussenegger 2006), they are susceptible to 
secretory bottlenecks in the event of high protein turnover.  We evaluated the transcript 
levels of SEAP within a small panel of selected clones. Clones were cultured under the 
same batch conditions as reported previously in section 3.3.6.1 and harvested for RNA 
(see section 2.4.6 of Materials and Methods) on day 3 of culture. Semi-quantitative PCR 
indicated that SEAP mRNA levels were elevated in all test clones when compared to 
control (Fig. 3.66 A). 
A more definitive comparison in the levels of SEAP mRNA abundance in our miR-23 
engineered clones was carried out using qRT-PCR (see section 2.4.4 of Materials and 
Methods). The intermediate SEAP producing control clone (miR-NC spg 11) was chosen 
as the calibrator when data was normalised during data analysis. A 2-3-fold increase in 
SEAP transcript (p ≤ 0.05 and 0.01) was observed for all miR-23 sponge clones (Fig. 3.66 
B). Significance was calculated based on Ct (Cyclic threshold) values for each individual 
miR-23 sponge clone versus a combination of all three controls. Although error bars to 
appear to cover a significant portion of the overall dataset, the Ct values were quite tight 
and resulted in significant statistics when a t-test was carried out. Inclusion of a larger 
number of technical replicates would have aided in reducing the level of variation within 
samples ultimately contributing to a reduction in error.  
These results would suggest that the enhanced SEAP yields observed are potentially as a 
result of an elevation in the rate of transcription of the SEAP gene in miR-23 depleted 
cells. 
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Figure 3.66: Semi-quantitative/qPCR for SEAP transcript in miR-23 sponge clones 
 
Figure 3.66: A) Semi-quantitative gel-based PCR and quantitative real-time PCR (qPCR) was 
carried out on miR-23 depleted CHO-SEAP clones in an attempt to assess the potential difference in 
transcript levels. A) Represents the ethidium bromide (EtBr)-stained agarose gel primed for the 
SEAP mRNA transcript in all miR-23b clones and control clones. B) Quantitative real-time PCR was 
carried out to accurately determine the relative fold change in transcript levels of SEAP. miR-NC 
spg 20 was chosen as the clone to calibrate the relative quantity (RQ) of SEAP across all clones while 
statistical analysis was determined for each individual test clone by using a standard student t-test 
for all Ct values across all three controls, (p ≤ 0.05* and p ≤ 0.01**). 
 
When the mature levels of miR-23b were assessed by qRT-PCR (see section 2.4.8 of 
Materials and Methods), there was a 5-fold (p ≤ 0.001***) reduction observed in clones 
expressing a miR-23 specific sponge compared to controls (Fig. 3.67). This reduction in 
mature miR-23 levels was similar to what was observed in the case of miR-34a.  
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Figure 3.67: Endogenous miR-23b levels in miR-23 sponge clones 
 
Figure 3.67: qRT-PCR was utilised to assess mature levels of endogenous miR-23b in miR-23 sponge 
clones when compared to control clones. Significance was calculated for each miR-23 clone across all 
3 miR-NC sponge clones using a standard student t-test (p ≤ 0.001***).  
 
3.4.3 SEAP mRNA stability is not a contributing factor to enhanced productivity 
To further confirm that the elevated SEAP productivity was due to enhanced transcription 
and not increased mRNA stability, we measured the stability of the SEAP mRNA 
transcript in both control and miR-23 sponge clones after Actinomycin-D (Act-D) 
treatment. Actinomycin-D treatment is used as a transcriptional block due to its high 
affinity binding for DNA GC-rich duplexes at transcription initiation complexes and 
preventing elongation by RNA polymerase (Kang, Park 2009). By inhibiting 
transcription, the rate of mRNA decay, i.e. stability, can be determined. The two best 
performing miR-23 sponge clones (4 and 6) and the best control clones (2 and 11) were 
selected for stability assessment. RNA was harvested 6, 18 and 24 hs after the addition of 
Act-D and assessed for SEAP mRNA levels using SYBR Green qPCR with β-actin as the 
endogenous control. The cyclic threshold (Ct) values for each time point of each sample 
is graphed below as a means to best depict the trend in mRNA stability across all 
conditions (Fig. 3.68).  
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Figure 3.68: miR-23 sponge SEAP mRNA stability assay 
     
Figure 3.68: qRT-PCR was used to evaluate the stability of the SEAP mRNA transcript in miR-23 
sponge clones versus miR-NC sponge clones upon the addition of Actinomycin-D. Upon 
transcriptional inhibition RNA was sampled 6, 18 and 24 hs later with the respective Ct values of 
each clone graphed and slopes calculated as a means to assess the rate of decay.  
 
We chose to represent mRNA stability as a function of the Ct from each time point and 
calculate the slope of the line as a means to measure the change over time because 
expressing changes in mRNA levels quantitatively was hindered by the fact that the 
endogenous control (β-actin) displayed an accelerated decay rate to that of the SEAP 
transcript. It can be observed that both miR-NC sponge clones and miR-23 sponge clones 
behaved similarly reflecting both the similar SEAP production capacity previously 
observed and the elevated SEAP transcript exhibited by both miR-23 sponge clones 
indicated by the lower Ct values recorded for each time point. Furthermore, the slope 
calculated for each clone miR-NC sponge 2 and 11 and miR-23 sponge 4 and 6 was 
0.9493, 0.9743, 0.9873 and 0.9828, respectively. This observation indicated that the rate 
of decay of the SEAP transcript was comparable between both the control and the test 
sponge clones and that mRNA stability was not playing a role in the enhanced SEAP 
activity seen in our CHO-SEAP clones engineered to stably deplete miR-23.  
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3.4.4 Cell size is not a contributing factor to clonal differences in productivity 
Cell size has been a variable considered to play a part in the specific production capacity 
of rCHO cells. Larger cells have been shown to possess inherently longer duplication 
times (Kang et al. 2013a). This increased duplication time could correlate with a longer 
period of G1 during the cell cycle or in the case of larger cells without increased genomic 
size, an increased availability of biogenesis machinery.  
Using the Cedex XS analyzer (see section 2.2.3.3 of Materials and Methods), the size 
of the CHO-SEAP sponge clones were evaluated. miR-23 sponge clone 4 and 6 and miR-
NC sponge clone 2 and 11 were selected as these clones exhibited a similar SEAP 
production profile. A size range of 11.3 µm to 12 µm was observed with miR-NC sponge 
clone 11 falling at the higher end of this scale (Fig. 3.69). This indicated that clone cell 
size was not contributing to the increase in productivity in miR-23 depleted clones. 
 
 Figure 3.69: Comparison of miR-23 sponge and miR-NC sponge clonal cell size 
 
Figure 3.69: Using the Cedex XS analyzer, a Trypan blue-based cell imager, miR-23 sponge and miR-
NC sponge clones were assessed for their cell size. Cell size for each clonal population is represented 
as an average value across the entire population.  
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3.4.5 miR-23 depleted CHO clones exhibited elevated Glutamate levels 
Both miR-23a and miR-23b have previously been shown to target the mRNA of 
glutaminase (GLS), an enzyme that mediates the conversion of glutamine to glutamate 
(Gao et al. 2009), which has been proposed to play a role in the Warburg effect through 
anaplerosis, the replenishment of TCA cycle intermediates through glutaminolysis (Dang 
2010) potentially boosting oxidative metabolism, a process previously associated with 
productivity (Templeton et al. 2013). For this reason, we measured the levels of secreted 
glutamate within the supernatants of day 4 cultures (section 2.6.9 of Materials and 
Methods). 
 
Figure 3.70: Glutamate levels across sponge clones 
 
Figure 3.70: Glutamate levels were measured from the supernatants of rCHO-SEAP clones 
engineered with a miR-23 specific sponge (clone 4 and 6) and a non-specific control sponge (clone 2 
and 11). Glutamate levels were calculated based on the average across both test and control groups 
with statistical significance being calculated using a standard student t-test (p ≤ 0.05*). 
 
The average glutamate levels across both clonal groups was observed to be increased by 
65% (p ≤ 0.05, Fig. 3.70). This potentially suggested that glutamate levels were elevated 
through de-repression of translation of the glutaminase enzyme. However, semi-
quantitative and quantitative PCR analysis did not indicate any change in the mRNA 
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levels of glutaminase (GLS), (Fig. 3.77 and Fig. 3.78). This however does not discount 
miR-23 interfering with the translation of GLS. The conversion of glutamine to glutamate 
by GLS generating ammonia (NH4) is not the only source of glutamate. Glutamate 
dehydrogenase (GDH) can catalyse the reversible conversion of glutamate to α-
ketoglutarate (Spanaki, Plaitakis 2012). Glutamate oxaloacetate transaminase also 
mediates the reversible conversion of oxaloacetate and glutamate to aspartate and α-
ketoglutarate (Perez-Mato et al. 2014). This would suggest that the levels of glutamate 
can either contribute to cellular bioenergetics or balance the availability of TCA cycle 
intermediates. It would be expected that the primary source of glutamate generation 
would be intracellular, however, secreted glutamate levels would be expected to reflect 
the internal glutamate levels. 
 
3.4.6 miR-23 depletion impacts positively on CHO cell mitochondrial activity 
Although the observation of increased availability of glutamate could not be definitively 
attributed to enhanced GLS activity without the assessment of its mature protein levels, 
we decided to assess the impact on mitochondrial function in a miR-23 depleted clone by 
using high resolution respirometry (HRR) (see section 2.5.2 of Materials and Methods). 
As glutamate provides essential electron donors (NADH and FADH2) critical to 
mitochondrial function, we speculated that a miR-23 sponge clone would demonstrate an 
increased mitochondrial activity, be it either directly or indirectly through miR-23’s 
influence on GLS. Oxidative phosphorylation (OXPHOS) is a measure of oxygen 
consumption culminating in the synthesis of ATP and the respiratory by-product, water. 
By measuring oxygen consumption using HRR, we were able to compare the 
mitochondrial function of intact cells under normal environmental conditions. 
Additionally, permeabilization assays allowed for the interrogation of individual complex 
components of the electron transport system (ETS, Fig. 3.71). A series of mitochondrial 
substrates, uncouplers and inhibitors are listed in table 3.4. 
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Table 3.4: SUIT protocol substrates, uncouplers and inhibitors  
Substrate Abbreviation Site of action Volume 
(µL) 
Final 
Conc in 
2mL 
Pyruvate P Complex I (CI) 5 5 mM 
Malate M CI 2.5 0.5 mM 
Glutamate G CI 10 10 mM 
Succinate S CI 20 10 mM 
Ascorbate As CIV 5 2 mM 
TMPD Tm CIV 5 0.5 mM 
Cytochrome c C CIV 5 10 µM 
ADP D CV 4 1 mM 
Uncoupler     
 
FCCP 
 
F 
Inner 
Mitochondrial 
membrane 
 
1 µL steps 
 
0.05 µM 
steps 
Inhibitors     
Rotenone Rot CI 1 0.5 µM 
Malonic Acid Mna CII 5 5 mM 
Antimycin A Ama CIII 1 2.5 µM 
Sodium Azide Az CIV 50  100 mM 
Oligomycin Omy CV 1 2 µg/mL 
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Figure 3.71: Schematic diagram of the electron transport system (ETS) and its 
component complexes  
 
Figure 3.71: A schematic diagram showing the components of the electron transport system (complex 
I, II, III and IV) culminating at the generation of ATP through Complex V. These complexes are 
localised to the inner mitochondrial membrane and are responsible for transporting electrons from 
donors (NADH and FADH2) along the chain ending in the generation of water form molecular oxygen 
at complex IV. Additionally, generation of the proton gradient is also contributed to by these 
complexes mediating the transfer of protons from the matrix to the inner membrane space. (Image 
sourced from http://www.robertlfurler.com/category/systems-biology/). 
 
3.4.6.1 Mitochondrial function of intact rCHO cells 
Routine respiration (R) is a measure of mitochondrial oxygen consumption and normal 
cellular homeostasis that is supported by exogenous substrates from the culture media. 
Dissection of mitochondrial activity via the various components that make up the 
mitochondrial electron transport system (ETS) cannot be measured in intact cells as the 
plasma membrane is impermeable to various mitochondrial substrates and ADP.  
Once, R has stabilised, ATP synthesis is inhibited through the addition of oligomycin 
(ATP synthase-Complex V inhibitor). LEAK respiration (L) is a measure of cellular 
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substrate utilisation accommodated by the proton leak (intrinsic uncoupling) at maximum 
mitochondrial potential. As ATP synthase has been inhibited, the electrochemical proton 
gradient is not regulated as proton import into the mitochondrial matrix cannot occur. The 
mitochondrial respiratory control (proton gradient exerting a regulatory electrochemical 
backpressure) system is fully released or uncoupled by the addition of FCCP 
(Carbonilcyanide p-triflouromethoxyphenylhydrazone) which cycles across the inner 
mitochondrial membrane with the transport of protons and dissipates the proton gradient. 
This allows the non-coupled state of ETS capacity to be determined irrespective of the 
contribution from the proton pumps (CI, CIII and CIV). 
Two clonal pairs were compared for their mitochondrial activity as intact cells (miR-NC 
spg 2 and miR-23 spg 4: miR-NC spg 11 and miR-23 spg 6). Cells were cultured at an 
initial density of 2 x 105 cells/mL in a 5 mL volume and grown under batch process 
conditions for 72 h. Cells were counted and resuspended in a 4 mL volume of fresh culture 
media at a final density of 1 x 106 cells/mL. Prior to inoculation of the OROBOROS 
chambers, the oxygen sensors were calibrated using culture media. Given the limited 
nature of the OROBOROS system, only two samples could be assessed at any one time, 
therefore a test and corresponding control clone were assessed with results and statistics 
calculated based on the values obtained from three replicates.  
Routine (R) and LEAK (L) respiration of miR-23 depleted CHO cells was found to be 
increased (p ≤ 0.05) as a function of the maximum ETS (E) determined by the addition 
of FCCP (Fig. 3.72 B). Although the maximum ETS was observed to be lower in the case 
of CHO cells exhibiting an increased volumetric yield (Fig. 3.72 A), respiratory control 
ratios (RCRs) revealed that miR-23 depleted CHO cells produced a higher percentage of 
their maximum energy capability as opposed to NC-sponge cells. This indicated that miR-
23 depleted clones under normal growth conditions have a more efficient mitochondrial 
function. miR-23 sponge clone 4 was observed to perform at 54% of its maximum 
capacity routinely (R) compared to 44% in miR-NC sponge clone 2 while leak was 
observed to be 32% of its maximum compared to 27 (Fig. 3.72 B). 
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Figure 3.72: Mitochondrial function of intact miR-23 depleted rCHO cells clone 4 
and miR-NC sponge 2 
 
Figure 3.72: Comparison of mitochondrial activity based on the rate of oxygen consumption between 
the miR-23 sponge clone 4 and the control sponge clone, miR-NC sponge 2. A) Represents the raw 
values for the rate of oxygen consumption between both miR-sponge clones. B) Flux control ratios 
(FCRs) are normalised to a common reference state after normalisation to residual oxygen (ROX). 
R/E ratio is an expression of how close ROUTINE respiration operates to ETS capacity while L/E 
follows the same trend. All calculations were made based on the individual values obtained over the 
course of three experimental replicates (n = 3) with statistical significance calculated using a type 1 
paired standard student t-test (p ≤ 0.05* and ≤ 0.01**). 
 
Interestingly, when a second set of clones were evaluated for their mitochondrial activity, 
miR-23 sponge clone 6 and miR-NC sponge clone 11, it was observed that there was a 
significantly enhanced routine respiration by 22% (p ≤ 0.01) and maximum ETS by 13% 
(p ≤ 0.05). Although there was an elevated ETS observed in this case, it did not translate 
into a significant increase in the ratio of energy utilisation when normalised to the 
maximum ETS (Fig. 3.73).  
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Figure 3.73: Mitochondrial function of intact miR-23 depleted rCHO cells clone 6 
and miR-NC sponge 11 
 
Figure 3.73: Comparison of mitochondrial activity based on the rate of oxygen consumption between 
the miR-23 sponge clone 6 and the control sponge clone, miR-NC sponge 11. A) Represents the raw 
values for the rate of oxygen consumption between both miR-sponge clones. B) Flux control ratios 
(FCRs) are normalised to a common reference state. R/E ratio is an expression of how close 
ROUTINE respiration operates to ETS capacity while L/E follows the same trend. All calculations 
were made based on the individual values obtained over the course of three experimental replicates 
(n = 3) with statistical significance calculated using a type 1 paired standard student t-test (p ≤ 0.05* 
and ≤ 0.01**). 
 
Both miR-23 depleted clones appeared to demonstrate an enhanced mitochondrial activity 
be it when directly compared to the rate of oxygen consumption in the case of miR-23 
spg clone 6, or be it through the more opportunistic utilisation of energy when compared 
to their maximum ETS capacity, in the case of miR-23 sponge clone 4.  
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Ideally, assessing and comparing the various combinations of test versus control sponge 
clones would have been both desirable and beneficial, however, the limited number of 
chambers in the OROBOROS system would make this a time consuming endeavour 
which unfortunately could not be explored.  
 
3.4.6.2 Mitochondrial function of permeabilised rCHO cells 
Next we sought to evaluate if this enhanced mitochondrial function was as a result of the 
hyperactivity of individual complex components that make up the electron transport 
system (ETS). Permeabilised experimental evaluation of mitochondrial function was 
carried out in mitochondrial respiration media (MiR05) which contains no exogenous 
substrates. As a result, routine mitochondrial respiration cannot be assessed within 
permeabilised mitochondrial assays as this is a natural state of respiration dependent on 
exogenous sources.  
The first exercise was to determine the concentration of Digitonin (Dgt) to achieve full 
membrane permeabilization. Each chamber was inoculated with 2 mL of MiR05 buffer 
containing 1 x 106 cells/mL. Cells were initially treated with 1 µL Rotenone (Complex I 
(C1) inhibitor), 20 µL Succinate (CII substrate) and 4 µL ADP (precursor for ATP 
production – see table 3.4 for final concentrations). In intact cells, CI inhibition via 
rotenone addition suspends respiration through CII because succinate cannot cross the 
cell membrane and succinate production through the TCA cycle is stopped when NADH 
cannot be oxidised. Therefore, inhibition of CI in this instance allows us to assess cell 
membrane permeability with mitochondrial respiration via CII being dependent purely on 
exogenous sources of succinate. After inoculation of both chambers, Digitonin was 
titrated 1 µL at a time with one chamber remaining as a control. As the cell membrane 
becomes permeabilised, succinate moves into the mitochondria thus stimulating oxygen 
consumption through CII activity. After each addition of Dgt, the rate of oxygen 
consumption is allowed to stabilise before the addition of the next µL. We determined 
that our rCHO cells reached a plateaux of permeability upon the addition of 3-4 µL of 
Dgt (Fig. 3.74). Subsequent permeabilization experiments were carried out by initially 
adding 4 µL of digitonin.  
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Figure 3.74: Cell membrane permeabilization optimisation using Digitonin 
 
Figure 3.74: The addition of Digitonin (Dgt) was titrated in order to assess the optimal concentration 
that would fully permeabilise the CHO cell membrane. As succinate cannot cross the cell membrane, 
intact cells are initially dosed with the complex II substrate, succinate (S). Dgt is subsequently titrated 
until maximum oxygen consumption has been achieved through full permeabilization of the cell 
membrane allowing succinate and ADP to fully cross into the mitochondria.  
 
The systematic evaluation of the activity of individual mitochondrial membrane 
components that contribute to cellular respiration was assessed when miR-23 sponge 
clone 4 and miR-NC sponge clone 2 were compared (Fig. 3.75 A and B). Part A of Figure 
3.75 shows the real-time change in oxygen consumption of both control and test clones 
with each substrate/inhibitor/uncoupler being indicated whereas part B demonstrates the 
average values and statistics across a triplicate run.  
A 29% increase in mitochondrial respiration was observed upon addition of 
glutamate/malate as substrates for Complex I. However a significant 26% increase (p ≤ 
0.05) in OXPHOS in miR-23 depleted CHO cells was observed when ADP was no longer 
the limiting factor (Fig. 3.75 BADP).  
The addition of cytochrome c confirmed that in both cases mitochondrial membrane 
integrity was not compromised either through the permeabilization process itself or as a 
result of mitochondrial hyperactivity, in the case of miR-23 sponge cells.  
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OXPHOS maintained the increased of ~ 29% (p ≤ 0.05) upon the addition of succinate, a 
substrate for Complex II, suggesting that complex I was responsible for the observed 
increase in mitochondrial respiration. However, upon acquisition of the ETS, complex I 
was inhibited by the addition of Rotenone (Rot) resulting in a marginal drop in oxygen 
consumption when compared to the addition of succinate (CI and CII). This suggested 
that both complex I and complex II are mediating a ~30% (p ≤ 0.05) increase in cellular 
respiration in miR-23 depleted CHO cells but do not appear to display an additive 
advantage. However, complex II on its own in an uncoupled state maintained a 44% 
higher (p ≤ 0.05) activity upon complex I inhibition (Fig. 3.75 BRot).  
Subsequent inhibition of complex II and III followed by the activation of CIV through 
the addition of the electron donor TMPD resulted in a marginal drop in oxygen 
consumption in miR-23 depleted cells (Fig. 3.75 BTMPD).  
Dissection of the mitochondrial membrane complexes suggested that complex I and II 
contribute to a higher degree of respiration at levels comparable to each other but do not 
display synergy when co-stimulated possibly due to a saturation point centred on the 
downstream electron chaperone complexes III and IV.        
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Figure 3.75: Mitochondrial permeabilization assay on miR-23 sponge clone 4 versus 
miR-NC sponge clone 2 
 
Figure 3.75: Mitochondrial activity of permeabilised rCHO cells (miR-23 sponge clone 4 and miR-
NC sponge clone 2) using a SUIT protocol. A) Is a representation of a real-time read out of oxygen 
consumption from one of the replicates (n = 3) indicating the addition of each 
substrate/inhibitor/uncoupler over the time course (h: min). Oxygen consumption is allowed to 
stabilise before the addition of Dgt. At each step, oxygen consumption is allowed to stabilise before 
the addition of the next substrate/inhibitor/uncoupler. Glutamate/Malate (GM) is added to stimulate 
CI activity while ADP (D) further stimulates OXPHOS through CI by relieving ADP availability as 
a limiting factor. Cytochrome c (C) assessed the integrity of the mitochondrial membrane. Succinate 
(S) additionally stimulates the activity of CII while the uncoupler FCCP (F) assessed the ETS though 
titration at 2 µl intervals. Rotenone (Rot) addition inhibits CI allowing OXPHOS through CII and 
CIII. Malonic acid/Antimycin A (Mna/Ama) inhibits CII and CIII, respectively. CIV is then 
stimulated by the artificial electron donor TMPD in the presence of Ascorbate (AsTm) which serves 
to maintain TMPD in a reduced state. Finally complex CIV is inhibited through the addition of 
Sodium Azide (Az). B) Represents the same data normalised to ROX, with averages across all 
replicates being shown. The states of mitochondrial activity is broken up in LEAK, OXPHOS and 
ETS with statistical analysis calculated using a type 1 paired student t-test (p ≤ 0.05*). 
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3.4.7 Mitochondrial content 
Although mitochondrial function based on oxygen consumption was performed on a fixed 
and equal number of cells (1 x 106 cells/mL) it does not account for the potential intrinsic 
change in mitochondria per cell that could ultimately contribute to the elevated 
mitochondrial activity. Several biomarkers have been assessed for their utility as 
candidates whose activity correlate well with mitochondrial content including cardiolipin, 
citrate synthase (CS) and complex I, in that order (Larsen et al. 2012). However, we 
decided to use a fluorescent-based assay, MitoTracker Deep Red (MTDR, section 2.5.1 
of Material and Methods), which is routinely used to evaluate mitochondrial content 
(Kitami et al. 2012). Cells were cultured in a similar fashion to those that were evaluated 
for mitochondrial activity using the OROBOROS in the previous section.  
Sample fluorescence signals are affected by signal levels, auto-fluorescence, non-specific 
staining, electronic noise, and optical background from other fluorochromes.  These 
factors can contribute to the noise and/or signals observed and increase the width of a 
negative population (i.e. variance or standard deviation).  Stain index (SI) normalization 
was used to adjust for the influence of such factors. SI is defined as D/W, where D is the 
difference between positive and negative populations and W is equal to 2 S.D. of the 
negative population.  
This data indicates that the enhanced mitochondrial function observed in the case of miR-
23 sponge clones is not as a result of increased mitochondrial mass/content (Fig. 3.76). 
FACS-based assessment of mitochondrial content using MitotrackerTM Deep red does not 
discriminate between mitochondrial mass and content. Immuno-histochemical staining 
would provide further information as to the nature of mass being attributed to content 
variation. Furthermore, the emission of MitotrackerTM DR at 665 nm did not interfere 
with the inherent emission signal at 506 nm for the GFP positive sponge clones.    
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Figure 3.76: Mitochondrial mass/content assessment using FACS analysis 
 
Figure 3.76: Assessment of mitochondrial content in stable miRNA sponge expressing CHO cells. 
Mitochondrial content of control miR-NC2, -NC11 sponge and miR-23-6 and miR-24-4 expressing 
CHO cells were examined by MTDR staining and flow cytometry. Data were obtained from ~10,000 
events and stain index used to normalize fluorescent signals for each sample. A representative 
histogram shows MitotrackerTM deep red signals for stained and unstained test and control samples. 
 
3.4.8 Assessment of miR-23 target transcript levels 
Several candidate genes were chosen for evaluation of their endogenous transcript levels 
for two reasons. Firstly, the enzyme glutaminase (GLS) has been validated to be a target 
of miR-23a/b which in the case of our stable miR-23 sponge CHO cells could potentially 
contribute to the elevated glutamate levels (Gao et al. 2009). Furthermore, another 
interesting target of miR-23 is the mitochondrial transcription factor A (TFAM) which 
has been shown to play a critical role in the transcriptional initiation of mitochondrial 
encoded genes (Jiang et al. 2013b). Secondly, increased mitochondrial activity has been 
correlated with enhanced global transcriptional activity (das Neves et al. 2010). From this 
perspective we selected this panel of genes including another validated target of miR-23, 
XIAP (X-linked inhibitor of apoptosis), for the assessment of their mRNA levels (Siegel 
et al. 2011). As miRNA function predominantly lies at the post-transcriptional level, the 
observation of unchanged transcript levels of the aforementioned targets does not 
discount the possibly of miR-23 depletion impact on the mature protein levels. However, 
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if enhanced mitochondrial activity was having an effect on global gene transcription, it 
was suspected that all three genes could be elevated at an mRNA level.  
Semi-quantitative PCR was carried out on all three selected targets of miR-23 using the 
designed primers listed in the appendix (Table 2.2 of Materials and Methods) using 
DreamTaq (Thermo Scientific) following the protocol in section 2.4.3 of Materials and 
Methods. 
 
Figure 3.77: Semi-quantitative PCR for miR-23 targets 
 
Figure 3.77: Semi-quantitative assessment of the mRNA transcript levels for a select panel of 
previously validated targets of miR-23 (GLS, TFAM and XIAP). A moderate number of cycles, 25, 
was used so as not to saturate the amplification signal thus allowing visual identification of potential 
fluorescent changes. Β-actin was used as an endogenous control to ensure efficient sample loading. 
All PCR amplicons were pre-designed to be small, in the range of 150-200 bp, so were ultimately ran 
on a high percentage (2%) agarose gel stained with ethidium bromide and ran slowly for the 
acquisition of clean bands.  
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There appeared to be no apparent changes in the abundance levels of the mRNA 
transcripts for XIAP and TFAM in all rCHO-SEAP clones from both non-specific and 
miR-23 sponge panels that were selected for clonal screening (Fig. 3.77). There did 
appear to be a reduced level of expression for the transcript of glutaminase (GLS). 
However, minute changes in expression can be difficult to observe at best even if an 
optimal number of cycles has been utilised.   
We next sought to evaluate the abundance of transcript levels for the same targets using 
quantitative real-time RT-PCR (see section 2.4.4 of Materials and Methods). Clones 
chosen to take part in this screen were the two best producing miR-23 sponge clone 4 and 
6 and the two best non-specific control clones, miR-NC sponge clone 2 and 11. 
Little to no change was observed for the expression of GLS and TFAM when qPCR was 
carried out (Figure 3.78). A moderate increase in the expression of XIAP was observed 
in the case of miR-23 sponge clone 6 and for a single control miR-NC sponge clone 11 
(Figure 3.78XIAP), potentially a result of clonal variation. This observation does not 
discount the possibility that miR-23 depletion is having an effect on one or all of these 
validated targets due to the nature of miRNA mode of action, translational inhibition.  
To fully understand the potential influence of miR-23 depletion on these target genes, 
analysis on the protein level would have to be carried out through western blot. Label-
free mass-spectrometry will be explored in these stable rCHO-SEAP clones in the next 
section as a means to identify potential targets of miR-23 and to isolate pathways 
potentially contributing to the observed phenotype of enhanced target protein productivity 
with elevated mitochondrial respiration. For this reason, identification of protein 
abundance of the three targets was not explored at this time through western blot analysis. 
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Figure 3.78: qPCR of miR-23 validated targets GLS, TFAM and XIAP 
 
Figure 3.78: Quantitative evaluation of changes in the expression of the mature transcript of a panel 
of validated targets of miR-23, GLS, TFAM and XIAP. Fast SYBR® Green was used to evaluate the 
expression of three targets previously assessed at a semi-quantitative level. Data was normalised to 
one of the two control clones (miR-NC spg 2). Relative quantification was calculated using the 2–ΔΔCt 
method. 
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It has been demonstrated so far that stable depletion of miR-23 improves the productivity 
of SEAP by an average of 3-fold when compared to non-specific controls. Further 
evaluation found that SEAP productivity may be attributed in part to an increase in the 
level of SEAP mRNA. Furthermore, mRNA stability and cell size were ruled out as 
contributing to this.  
miR-23 has been strongly implicated in mitochondrial function both through the 
reprogramming of the “Warburg effect” through anapleurotic replenishment of TCA 
cycle intermediates such as α-ketoglutarate (αKG) via enhanced translation of the enzyme 
glutaminase (GLS) (Liu et al. 2012) and additionally through the post-transcriptional 
attenuation of the mitochondrial transcription factor A (TFAM) (Campbell, Kolesar & 
Kaufman 2012). Although the mRNA levels of these genes remained unchanged in our 
clones, it does not rule out the possibility of their mature protein products being 
influenced especially when considering the elevated glutamate levels observed in the 
miR-23 depleted clones. Using high resolution respirometry (HRR), oxygen consumption 
was assessed as a measure of mitochondrial activity. A ~30% increase in oxygen 
consumption was observed in the miR-23 sponge cells attributed to Complex I and 
Complex II stimulation. Both complexes contributed to this enhanced mitochondrial 
function independently of each other but did not appear to act synergistically, potentially 
suggesting a bottleneck downstream. Using a mitochondria-specific fluorescent dye, we 
managed to rule out an increase in cellular mitochondrial mass/content as a contributing 
factor to this enhanced activity.  
The next section explores the discovery of potential targets of miR-23 that could have a 
role in mediating this observed influence on CHO cell bioenergetics in addition to 
identifying molecular pathways directly or indirectly influenced by miR-23 depletion.    
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Section 3.5 
 
 
 
 
 
 
miR-23 target identification and 
pathway analysis 
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3.5 microRNA target identification 
Previous characterisation has so far identified that stable miR-23 depletion results in 
increased specific SEAP productivity without any impact on cellular growth thus 
ultimately enhancing volumetric SEAP yield. Across a panel of clones the enhanced 
SEAP activity appears to be somewhat attributable to the increase in transcription of the 
SEAP mRNA. Previous characterisation from the literature has implicated miR-23 to be 
involved in cellular bioenergetics through the regulation of targets associated with 
mitochondrial function such as GLS and TFAM. However, analysis of the expression of 
these transcripts using qPCR revealed no difference in the case of miR-23 depletion in 
CHO cells. Given the nature of miRNA, this observation does not rule out the possibility 
that the mechanism of action of miR-23 is being mediated through blocking translation. 
In order to attempt to identify how miR-23 depletion selectively appears to enhance SEAP 
transcription and influence mitochondrial functional, we set out to identify potential 
targets of miR-23 through a novel process of biotin-labelled microRNA mimics and 
Label-free Mass Spectrometry on rCHO-SEAP clones stably engineered to deplete miR-
23. It was hoped that the global mRNA targeting capacity would be identified in the case 
of biotin-tagged mRNA pull down thus indicating potential pathways under miR-23 
regulatory control as well as high priority candidate targets, while proteomic profiling 
was intended to unveil a snap shot of mature molecular pathways under functional 
interference from miR-23, be it either directly or indirectly. 
 
3.5.1 Identification of global mRNA targets through Biotinylated miRNA tags 
A recently described method of identifying miRNA targets is the use of biotinylated-
labelled miRNA mimics (Orom, Lund 2007) and successfully reported for miR-34a (Lal 
et al. 2011). This technique exploits the use of miRNA mimics (pre-miRs) whose 3’-end 
has been covalently modified to carry a biotinylated tag (Fig. 3.79 A). Streptavidin, 
isolated form Streptomyces avidinii and immobilised to sepharose beads has a high 
binding affinity for biotin or biotinylated components (Fig. 3.79 A). 
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Figure 3.79: Schematic diagram of biotin-labelled miRNA-mediated mRNA pull 
down 
 
Figure 3.79: A) Shows a mature miRNA with a chemically modified 3’- end (red arrow) to include a 
linked Biotinylated group as well as the streptavidin-agarose beads with high affinity binding sites 
for biotin B) Represents the general flow diagram for miRNA target enrichment. RNA is isolated 
from streptavidin-agarose beads through the Tri Reagent protocol C) During the incubation period 
of cell lysate with streptavidin-agarose beads mRNAs bound to the biotin labelled miRNA will remain 
bound to the SA beads and enriched for after clearing of the cell lysate. 
 
By incubating CHO cell lysates that have been lysed though the utilisation of a gentle 
lysis buffer so as not to disturb miRNA-RISC bound target mRNAs in the presence of 
streptavidin beads, it is possible to wash away the majority of non-bound mRNAs and 
enrich for those that have a high binding affinity for the mature biotin-tagged miRNA. 
Using microarray technology (section 2.4.10 of Material and Methods), it is possible to 
identify enrichment of a panel of mRNA targets whose identification is potentially a 
function of their association with the pre-tagged miRNA of interest.   
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Both miR-23b and its counterpart passenger strand miR-23b* were selected for mRNA 
target identification through this novel method in an attempt to determine firstly what 
targets and molecular networks are under their influence and secondly if there is 
complementary, antagonistic or unique cellular process under their individual regulation. 
 
3.5.1.1 Evaluation of biotin-miRNA workflow 
Prior to committing to a full scale microarray analysis, validation of the protocol was 
assessed using a validated target as previously reported for the miRNA bantam (Hid gene) 
(Orom, Lund 2007) and miR-34a (CDK4/6) (Lal et al. 2011). 
We undertook some validation steps using qPCR to assess the utility of this method using 
validated miR-23b* targets such as proline dehydrogenase (PRODH) (Liu et al. 2010a). 
However, a challenge presented was the lack of validated targets of miR-23b* other than 
PRODH. A panel of potential targets of miR-23b* was selected by generating a list of 
mRNAs that were anti-correlated to the expression of miR-23b* from the datasets 
acquired during the DE of miRNA in fast and slow growing CHO cells (section 3.1 of 
results and (Clarke et al. 2012)), unveiling 319 mRNAs.  
Next, the miRWalk prediction algorithm was utilised to generate two lists of potential 
miR-23b* targets, one predicted and one validated (Dweep et al. 2011a). From here, both 
lists were analysed for any overlap with the list of mRNAs found to be anti-correlated 
with miR-23b* expression. 11 mRNAs were found to overlap with the list of 856 
predicted targets while none were found to overlap with the list of 98 validated targets 
(Table 3.5). The search criteria for “Validated targets” uses an algorithm that searches 
abstract and paper content for commands such as “miR-23b*” and associated gene names. 
Therefore, this list of 98 validated targets would not necessarily be accurate and reading 
the paper content would be essential to establish if they could truly be considered 
“validated”. 
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Table 3.5: miRWalk Predicted targets of miR-23b* overlapping with targets anti-
correlated to miR-23b* expression 
 
Although PRODH did appear in the list of validated targets, it was not predicted to be a 
target of miR-23b* nor did it appear to be anti-correlated with miR-23b* from the 
miRNA:mRNA profile.  
Biotin-labelled miR-23b* and miR-NC were transfected into CHO-SEAP cells at the 
usual concentration of 50 nM in 1 x 105 cells/mL (see section 2.3.2.2 of Materials and 
Methods). After 72 h, cells were harvested and processed according to the protocol 
described by Ørum and Lund (Orom, Lund 2007) and described in detail in section 2.7 
of Material and Methods. Two miR-23b* biotin –tagged mimics were designed, miR-
23b*-1 and miR-23b*-2 (natural). miR-23b*-1 comprises a duplex miRNA with a 
complementary strand designed to promote strand selection of miR-23b* (Appendix 
Figure A8). miR-23b*-2 (natural) was specifically designed to mimic the wild-type 
hairpin and would result in the selection of the mature miR-23b. When both biotin-tagged 
miRNA were transfected separately, qRT-PCR was carried out for both miR-23b*-1 and 
miR-23b*-2 (natural) (see section 2.4.8 of Materials and Methods) probing for miR-
23b and the miR-23b*.  
When miR-23b* levels were assessed, an increase was observed of ~600-fold for miR-
23b*-1 and ~12,000-fold for miR-23b*-2 (natural) in bead enriched samples (Fig. 3.80 
A). Furthermore, a ~2000-fold increase of miR-23b* was detected for miR-23b*-1 and 
~9,000-fold for miR-23b*-2 (modified) in the input samples prior to bead exposure (Fig. 
3.80 B). Input samples, are samples taken after gentle lysis but prior to incubation with 
streptavidin beads. 
Top 10 predicted targets Overlapping targets Selected Targets
   DNAJC3   Rapgef1 Rapgef1
   GRIP1   BSG CSTA
   CRYBB2   Plod1 DNAJC3
   CTSA   C6orf89 GRIP-1
   HCG9   GGA2 PRODH
   PGK1   BEST1 PGK-1
   SMPD1   ACYL BEST-1
   STX4   YARS CALU
   ACLY   RARRES2 GGA2
   SPRN   CALU YARS
Pomt2
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Figure 3.80: Quantification of miR-23 and miR-23b* by qPCR from streptavidin 
pull-down 
 
Figure 3.80: qRT-PCR data assessing the mature levels of miR-23b and miR-23b* when biotin-
labelled miR-23b*-1 and miR-23b*-2 (modified) were transfected into CHO-SEAP cells. miR-23b* 
is probed for in A) streptavidin captured samples and B) Input samples taken after gentle lysis but 
before incubation in streptavidin beads. miR-23b is probed for in C) streptavidin captured samples 
and D) Input samples. 
 
As an additional level of quality control, miR-23b levels were assessed in the same 
samples. No fold change of miR-23b was observed in either streptavidin captured or input 
samples in the case of miR-23b*-1 as expected as this biotin-labelled pre-miRNA is 
designed to exclusively express miR-23b* as its complementary strand does not contain 
mis-matches therefore has a different sequence to miR-23b (Fig. 3.80 A and B). 
Furthermore, when miR-23b levels were measured in the case of the miR-23b*-2 
(modified) transfectant, a ~14,000-fold and 1,000-fold increase was observed for 
streptavidin captured and input samples, respectively (Fig. 3.80 C and D). This 
enrichment for miR-23b in the case of the tailored miR-23b*-2 (natural) biotin-tagged 
duplex was expected as it should mimic a naturally occurring miR-duplex. The miR-
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23b*-1 biotin-tagged pre-miR was ultimately selected for experimental evaluation as it 
best represents the processing steps that culminate at RISC loading. 
Next, we assessed if successful pull-down of the list of potential miR-23b* targtes could 
be observed in samples transfected with miR-23b*-1 and -2 and exposed to streptavidin 
beads. The amount of RNA pull-down was approaching the sub-nanomolar concentration 
when assessed using a NanoDrop, however, enough template was retrieved that enabled 
reverse transcription and subsequent PCR analysis. Of the list of 10 candidates selected 
for evaluation, Pgk-1 resulted in the most consistent enrichment. miR-23b*-1 proved to 
enrich for Pgk-1 compared to miR-23b*-2 in cell lysates exposed to streptavidin (Fig. 
3.81 Beads). An inconsistency can be observed across input samples possibly due to the 
quality of the RNA harvested. 
 
Figure 3.81: Enrichment for Pgk-1 in miR-23b*-biotin pull-down 
 
Figure 3.81: Analysis of Pgk-1 expression in CHO-SEAP cells transfected with biotin-tagged pre-
miRs, miR-23b*-1 and miR-23b*-2, and incubated with streptavidin beads (Beads). RNA samples 
were taken prior to exposure to streptavidin (Input).  
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Assessment of Pgk-1 pull-down by miR-23b*-1 biotin-tagged pre-miR upon several 
repeats demonstrated inconsistent yet strong indications that Pgk-1 specific binding and 
enrichment was occurring (Fig. 3.82). 
 
Figure 3.82: Enrichment for Pgk-1 in miR-23b*-1 biotin-labelled transfected CHO-
SEAP cells  
 
Figure 3.82: pPCR analysis to measure enrichment of the potential target of miR-23b*, pgk-1 (white 
arrow), in CHO-SEAP cells transfected with miR-23b*-1. “Pull-down” indicates samples incubated 
in streptavidin beads while “input” indicates RNA sampled prior to bead incubation.  
 
3.5.1.2 Microarray identification of mRNA targets specific for miR-23b and miR-
23b* using biotin-labelled mimics 
Following initial optimisation, biotin-labelled miR-23b and miR-23b*-1 pre-miRs were 
transfected into parental CHO-SEAP cells and processed according to section 2.7.5 of 
Materials and Methods. As 12.5 µg of aRNA (antisense RNA) was required for loading 
of CHO-specific microarray chips, an amplification process (MessageAmpTM II aRNA 
amplification, section 2.4.9 of materials and methods) was undertaken prior to 
processing of the aRNA (section 2.4.10 of Materials and Methods).  
Subsequent to generating aRNA, samples were hybridized to CHO-specific microarrays. 
Across all samples (cells only, miR-NC-biotin, miR-23b-biotin and miR-23b*-1-biotin), 
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1933 annotated genes were identified as being present, however, none demonstrated a 
significant fold change or enrichment between conditions. One of the first quality control 
tests undertaken in microarray analysis is the use of hierarchal clustering. This is an 
unbiased means by which a dataset is grouped into sample families based on a similar 
gene expression pattern. This revealed that there were no similarities between samples of 
the same group (Fig. 3.83).     
 
Figure 3.83: Cluster Dendrogram of microarray results  
 
Figure 3.83: Dendrogram demonstrating the unsupervised hierarchal clustering of samples based on 
gene expression. 
 
Any changes observed between biotin-tagged miRNAs compared to biotin-tagged non-
specific controls equated to inherent background noise that would ordinarily be observed 
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between replicate samples. Although this method of miRNA:mRNA identification has 
proved valuable and successful in the past, in this case, no candidates were generated 
from our experiment. 
The reasons for this was not immediately apparent so we decided to check bead-elutes 
for enrichment of both miR-23b and miR-23b* in case the capture step failed.  
  
Figure 3.84: miR-23b/23b* enrichment in main experimental run 
 
Figure 3.84: qRT-PCR analysis using singleplex PCR specific for miR-23b* (blue) and miR-23b (red) 
was carried out on the streptavidin incubated biotin-labelled pre-miRNA for the mature miR-23b 
and miR-23b*. 
 
Singleplex qRT-PCR carried out on samples captured for microarray analysis revealed 
that there was a ~14-fold enrichment of miR-23b* with no apparent enrichment of miR-
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23b (Fig. 3.84). This latter result would explain the lack of clustering observed in figure 
3.83 for miR-23b samples but, miR-23b* at least, seemed to have been successfully 
pulled down although not to as high a magnitude as previously achieved. 
 
3.5.2 Identification of global protein targets using Label-free Mass Spectrometry  
As miRNAs ultimately influence translation, we sought to carry out label-free mass 
spectrometry as a means to identify the potential finite changes in the proteome elicited 
by the stable depletion of miR-23 through sponge intervention. In addition, we attempted 
to identify potential molecular networks and/or biological processes associated with 
mitochondrial function. 
 
3.5.2.1 Differentially expressed proteins in miR-23 depleted clones 
Differential protein expression analysis was performed on two miR-23 sponge clones 
(clone 4 and 6) and two miR-NC sponge clones (clone 2 and 11), the same clones that 
were evaluated for mitochondrial function in section 3.4.6. CHO cells were cultured under 
normal batch conditions in an identical manner as had been previously described for 
mitochondrial function assays and harvested for whole cell proteome analysis after 72 hs. 
A maximum of 500 µg of protein was prepped using a Ready-prep 2D clean-up kit (Bio-
Rad, #163-2130, and see materials and methods section 2.8.3) as a means to further 
concentrate, if necessary, and remove any contaminating salts, reagents and buffers from 
the lysis process. 10 µg of protein was then subsequently digested with Lys-c and trypsin 
overnight to cleave all protein into polypeptides for mass spec identification.  
41 proteins were found to be differentially expressed (25 up-regulated and 16 down-
regulated) in miR-23 depleted CHO-SEAP clones when compared to their non-specific 
control counterparts (Table 3.6). Proteins are listed in order of MASCOT score output 
which overlaps the mass spectral data of the target peptides with that of the reference 
database, including the number of identifications (numbers of peptides associated with a 
single protein). MASCOT also incorporates a false discovery rate (FDR) which compares 
the same mass spectral data of the target peptides to that of a randomised reference 
database of similar length as a means to identify the probability of identifications by 
264 
 
chance. Statistical significance is then assigned to each identified protein after 
normalisation (Anova value) to determine that the observed fold-changes demonstrate 
low variation within replicates and/or pooled clones in the case of our experiment.  
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Table 3.6: DE proteins identified through label-free mass spectrometry in miR-23 (test) depleted CHO-SEAP clones 
 
 
 
Up in Test
Control Test
Down in Test
gi|860908 6 271.74 7.74E-03 1.5 vimentin [Cricetulus griseus] [MASS=44524] VIM 2.91E+06 1.94E+06
0.67
gi|344235837 3 (2) 188 3.36E-05 1.74 Glutathione S-transferase Mu 6 [Cricetulus griseus] [MASS=86559] GSTM6 2.15E+05 3.75E+05
1.74
gi|344236438 3 148.52 6.85E-05 2.07 Bifunctional aminoacyl-tRNA synthetase [Cricetulus griseus] [MASS=154896] EPRS 4.09E+05 1.98E+05
0.48
gi|344257633 2 145.81 2.72E-08 1.98 Lactadherin [Cricetulus griseus] [MASS=16152] MFGE8 1.41E+05 2.79E+05
1.98
gi|344255736 3 144.97 3.12E-04 2.16 Non-muscle caldesmon [Cricetulus griseus] [MASS=61921] CALD1 2.09E+05 4.52E+05
2.16
gi|354487570 2 133.91 6.64E-05 1.85 PREDICTED: ATP-binding cassette sub-family F member 1-like [Cricetulus 
griseus] [MASS=95446]
ABCF1 1.39E+05 7.53E+04
0.54
gi|344237556 2 (1) 132.94 0.02 1.52 Glyceraldehyde-3-phosphate dehydrogenase [Cricetulus griseus] 
[MASS=36889]
GAPDH 4.80E+05 3.15E+05
0.66
gi|354479271 2 118.37 8.74E-07 2.49 PREDICTED: perilipin-4-like [Cricetulus griseus] [MASS=184216] PLIN4 1.06E+05 2.63E+05
2.48
gi|354507545 2 (1) 98.26 4.80E-03 1.56 PREDICTED: glutathione S-transferase Mu 1-like [Cricetulus griseus] GSTM1 1.32E+04 2.07E+04
1.57
gi|344238611 1 91.09 2.48E-03 1.68 Isocitrate dehydrogenase [NADP] cytoplasmic [Cricetulus griseus] 
[MASS=12467]
IDH1 2.58E+04 4.33E+04
1.68
gi|344244293 1 89.46 4.33E-07 2.73 LETM1 and EF-hand domain-containing protein 1, mitochondrial [Cricetulus 
griseus] [MASS=79070]
LETM1 2.71E+04 7.39E+04
2.73
Description Average 
Normalised 
Abundances
Accession Peptides Score Anova 
(p)*
Fold Tags Gene I.D.
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gi|354474417 1 86.11 5.14E-05 1.54 PREDICTED: ras GTPase-activating protein-binding protein 1 [Cricetulus 
griseus] [MASS=51797]
G3BP1 1.07E+05 6.96E+04
0.65
gi|354473301 2 85.25 6.20E-04 1.54 PREDICTED: septin-9 [Cricetulus griseus] SEPT9 1.76E+05 2.71E+05
1.54
gi|344251753 1 85.03 0.02 317.52 Heat shock cognate 71 kDa protein [Cricetulus griseus] [MASS=22696] HSPA8 5.32E+05 1676.73
0.00
gi|4504445 1 78 0.04 2877.1 heterogeneous nuclear ribonucleoprotein A1 isoform a [Homo sapiens] HNRNPA1 2.24E+05 77.98
0.00
gi|344254200 1 77.24 1.48E-04 1.84 Prolyl 4-hydroxylase subunit alpha-1 [Cricetulus griseus] [MASS=58084] P4HA1 7.12E+04 1.31E+05
1.84
gi|354489184 1 72.31 1.05E-03 1.65 PREDICTED: lysosomal alpha-glucosidase-like [Cricetulus griseus] GAA 3.96E+04 6.55E+04
1.65
gi|344255594 1 71.25 4.95E-04 1.76 Calcium/calmodulin-dependent protein kinase type II delta chain [Cricetulus 
griseus] [MASS=25006]
CaMK2D 8.60E+04 1.51E+05
1.76
gi|344248788 1 65.91 0.04 2.50E+04 Eukaryotic translation initiation factor 5A-1 [Cricetulus griseus] 
[MASS=7244]
EIF5A1 3.45E+05 13.79
0.00
gi|344236520 1 61.57 0.02 1.55 40S ribosomal protein S13 [Cricetulus griseus] [MASS=15245] RSP13 1.16E+05 1.79E+05
1.54
gi|354503637 1 61.06 3.85E-03 1.77 PREDICTED: STE20-like serine/threonine-protein kinase isoform 1 [Cricetulus 
griseus] [MASS=142185]
SLK 4.87E+04 2.75E+04
0.56
gi|344247607 1 60.45 9.02E-06 20.57 Suprabasin [Cricetulus griseus] [MASS=63932] SBSN 2685.43 5.52E+04
20.56
gi|346421390 1 58.73 0.02 5.36 C-X-C motif chemokine 3 precursor [Cricetulus griseus] CXC3 1.56E+05 2.91E+04
0.19
gi|344250293 1 57.66 0.01 1.86 rRNA 2'-O-methyltransferase fibrillarin [Cricetulus griseus] [MASS=25970] FBL 4.21E+04 7.84E+04
1.86
gi|71043900 1 56.08 0.03 Infinity 60S ribosomal protein L11 [Rattus norvegicus] RPL11 2.89E+05 0
0.00
gi|354468793 1 53.47 1.96E-06 2.49 PREDICTED: leukocyte elastase inhibitor A [Cricetulus griseus] SERPINB 8.27E+04 2.06E+05
2.49
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Table 3.6: The fold change highlighted in Green or Red denotes the direction in expression of each identified gene in relation to miR-23 sponge clones with 
Green being up and Red being down. Tags indicate the implementation of analytical criteria including fold change above 1.5 and an Anova value below 0.01.  
gi|344249602 1 51.72 1.48E-03 1.64 Ras GTPase-activating-like protein IQGAP1 [Cricetulus griseus] 
[MASS=191377]
IQGAP1 7.88E+04 4.80E+04
0.61
gi|354471687 1 51.7 0.02 1.59 PREDICTED: sorbitol dehydrogenase [Cricetulus griseus] SDH 8.25E+04 1.31E+05
1.59
gi|354504447 1 51.44 1.18E-04 5.77 PREDICTED: hypothetical protein LOC100755523 [Cricetulus griseus] 
[MASS=7910]
SPRR2E 1.95E+04 1.13E+05
5.79
gi|344253587 1 50.88 2.66E-03 1.67 Thioredoxin reductase 1, cytoplasmic [Cricetulus griseus] [MASS=61858] TXNDR1 6.61E+04 1.10E+05
1.66
gi|354479983 1 50.38 2.50E-03 1.67 PREDICTED: malate dehydrogenase, cytoplasmic-like [Cricetulus griseus] MDH 4.07E+05 6.79E+05
1.67
gi|354493216 1 48.45 0.03 1.53 PREDICTED: 26S proteasome non-ATPase regulatory subunit 7-like 
[Cricetulus griseus]
PSMD7 7.40E+04 4.85E+04
0.66
gi|344254748 1 48.09 2.30E-04 1.62 Cytosolic acyl coenzyme A thioester hydrolase [Cricetulus griseus] 
[MASS=35644]
ACOT7 1.44E+05 8.90E+04
0.62
gi|344248399 1 48.08 5.56E-03 1.82 hypothetical protein I79_019528 [Cricetulus griseus] [MASS=271141] PRUNE2 4.81E+04 8.74E+04
1.82
gi|344245117 1 47.43 2.41E-03 1.69 Fermitin family-like 2 [Cricetulus griseus] [MASS=65673] FERMT2 1.95E+05 3.30E+05
1.69
gi|344241413 1 47.22 2.07E-03 1.66 Epidermal growth factor receptor substrate 15-like 1 [Cricetulus griseus] 
[MASS=82827]
EPS15L1 3.26E+04 1.96E+04
0.60
gi|344242484 1 46.57 0.01 1.79 Cytoplasmic dynein 1 light intermediate chain 2 [Cricetulus griseus] 
[MASS=68816]
DYNC1L12 1.54E+04 2.75E+04
1.79
gi|354499825 1 45.47 0.01 2.33 PREDICTED: heme oxygenase 1-like [Cricetulus griseus] HMOX1 3.45E+04 8.05E+04
2.33
gi|354468396 1 43.47 0.02 1.97 PREDICTED: serine/threonine-protein phosphatase PP1-beta catalytic subunit-
like [Cricetulus griseus] [MASS=37328]
PPP1CB 4.02E+04 7.92E+04
1.97
gi|354495432 1 41.82 5.41E-04 2.24 PREDICTED: asparagine synthetase [glutamine-hydrolyzing]-like isoform 1 
[Cricetulus griseus]
ASNS 8.78E+04 3.92E+04
0.45
gi|344244307 1 40.44 5.84E-06 2.77 14-3-3 protein eta [Cricetulus griseus] [MASS=27084] YWHAH 6.50E+04 1.80E+05
2.77
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We conducted our own quality control tests as a means to identify proteins whose 
identification were potentially by chance. The average protein expression of a test group 
is compared to the average protein expression of the control group resulting in identifying 
DE. By un-supervising the samples, large variation within samples contributing to DE 
can be identified. The “6 replicates” of each group (control and test) were stripped of their 
identifiers and randomised, ultimately resulting in two groups for comparison whose 
occupants potentially spanned samples from both control and test groups. When DE 
analysis was carried out in this instance, only two proteins were found to be DE, neither 
of which overlapped with those identified in the list of 41 above (Appendix fig. A9). 
For example, after carrying out the various comparisons, LETM1 was found to be a 
potential target of miR-23 (Fig. 3.85). This figure demonstrates that LETM1 expression 
range is tight and consistent throughout control clones (pink box) and significantly 
increased in expression in miR-23-depleted clones (blue box). Furthermore, the data 
suggests that titrational effects are potentially occurring due to differential sponge 
expression, as two triplicate clusters appear to demonstrate distinct patterns of expression 
within the miR-23 test samples (Fig. 3.85-Black box).    
 
Figure 3.85: Differential expression of LETM1 in control and miR-23 sponge clones 
 
Figure 3.85: Progenesis software output of the protein expression pattern of LETM1 for each of the 
samples replicates within both control (Pink) and test (Blue) groups that ultimately contribute to the 
calculation of both fold change and statistical significance.  
 
Furthermore, when both negative control clones were compared, LETM1 was not found 
to be DE as indicated in Figure 3.85. Additionally, when both miR-23 clones were 
compared, LETM1 was not found to be DE further strengthening that LETM1 is 
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potentially increased as a product of sharing a post-translational controller (miR-23) and 
not as a result of clonal variation.  
When the control clones (miR-NC sponge clone 2 and 11) were compared, 69 proteins 
were found to be DE, compared, to 19 proteins DE between the test clones (miR-23 
sponge clone 4 and 6). Interestingly, 4 proteins determined to be DE in miR-23 depleted 
clones when compared to controls were also found to be DE between control clones 
themselves: Malate dehydrogenase (MDH), heme-oxygenase-1 (HMOX1), non-muscle 
caldesmon (CALD1) and 26S proteosome non-ATPase regulatory subunit 7-like 
(PSMD7). By comparing both control and test clones against each other it examines the 
potential for clonal variation irrespective of the introduction of a miRNA sponge. By 
grouping all clones into their respective groups these inter-clonal differences will 
ultimately be accounted for resulting in a lower statistical significance. Profiling a larger 
panel of clones would be a means to further refine the data output accounting for 
expressional variations that are not a product of or indeed specific to the introduction of 
a sponge specific for miR-23. 
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Figure 3.86: Progenesis output of 4 proteins DE in control clones 
  
Figure 3.86: Progenesis output diagram of the DE of four proteins in miR-23 clones versus miR-NC 
controls. The four proteins listed above, however, were determined to be DE between both control 
clones. 
 
3.5.2.2 High Priority targets of miR-23 
Of the list of 41 proteins found to be DE across the miR-23 depleted CHO-SEAP clones 
when compared to control clones, it was necessary to identify which of these proteins 
were DE as a result of miR-23 diversion and not as a byproduct of the CHO cell 
phenotype. The online resource, miRWalk (Dweep et al. 2011b), was utilised to generate 
a list of potential mRNA targets of miR-23. miRWalk assesses binding potential of a 
selected miRNA for all possible mRNAs by identifying a hetpamer complementary 
PSMD7
HMOX1
MDH
CALD1
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sequence to the miRNA seed region and extending or “walking” in the 3’ direction for 
further complementarity and scored accordingly. Additionally, miRWalk considers 
binding sites within the coding sequences (CDS) and 10kb upstream of the CDS including 
the 5’UTR, a criteria not encompassed in the vast majority of prediction algorithms. 
Furthermore, miRWalk compares the readouts of up to 8 separate prediction algorithms 
(3’UTR only) scoring predicted mRNAs based on the number of algorithms that overlap 
in their prediction. 
Of the 41 proteins found to be DE, 13 were found to overlap with the miRWalk algorithms 
(Table 3.7). These proteins are listed according to their statistical significance (Anova 
value) with the addition of the number of algorithms predicting each protein. Given the 
nature of the miRNA sponge construct and its influence on the cells translatome, it was 
possible to further reduce this list of 13 to a more refined and manageable list of proteins. 
As the presence of the miRNA sponge provides a surplus of binding sites for endogenous 
miR-23, the activity of this miRNA is being sequestered away from its normal cellular 
targets thus ultimately resulting in their translational de-repression. Taking this into 
account, DE proteins from this list of 13 that exhibit an increased-fold change would 
correlate with the diversion of miR-23 away from its natural suppressive role. 
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Table 3.7: Predicted targets of miR-23 using the miRWalk algorithm 
Gene I.D Accession No. FC Anova 
Value 
Algorithm 
overlap 
Biological Process 
Predicted targets demonstrating up-regulation 
LETM1 gi|344244293 2.73 4.33 x 10-7 3 ETS Biogenesis/ 
Mitochondria 
CALD1 gi|344255736 2.16 3.12 x 10-4 1 Calcium Signalling 
CAMK2D gi|344255594 1.76 4.95 x 10-4 2 Calcium binding 
FERMT2 gi|344245117 1.69 2.41 x 10-3 2 Actin assembly 
IDH1 gi|344238611 1.68 2.48 x 10-3 1 TCA cycle / α-KG 
TXNRD1 gi|344253587 1.67 2.66 x 10-3 4 Oxidative stress 
PPP1CB gi|354468396 1.97 2.01 x 10-2 3 Glycogen 
metabolism, protein 
synthesis and 
chromatin structure 
P4HA1 gi|344254200 1.84 1.48 x 10-4 2 Collagen synthesis 
Predicted targets demonstrating down-regulation 
ABCF1 gi|354487570 1.85 6.64 x 10-5 2 ATP binding 
ASNS gi|354495432 2.24 5.41 x 10-4 3 Asparagine 
synthesis 
IQGAP1 gi|344249602 1.64 1.48 x 10-3 1 Cell morphology 
and motility 
CXCL3 gi|346421390 5.36 1.95 x 10-2 1 Cell migration and 
adhesion 
HNRNPA1 gi|4504445 2877.1 4.07 x 10-2 1 pre-mRNA 
processing 
 
Of the shortlist of 7 proteins found to be increased in their levels of expression as a result 
of miR-23 depletion, several appear to be involved in cellular processes that potentially 
reflect the observed phenotype of enhanced mitochondrial function such as LETM1 
(mitochondrial biogenesis), IDH1 (TCA cycle, α-ketoglutarate synthesis) and TXNDR1 
(oxidative stress response).  
Further experiments would be required to validate these proteins as true targets of miR-
23. Western blot could be utilised to determine the sensitivity and accuracy of mass 
spectrometry by selecting a small panel of high priority candidates such as LETM1. 
Ultimately, functional characterisation of priority targets could be explored by siRNA 
273 
 
knockdown of the protein to examine whether their DE could be linked to observed 
phenotype. 
 
3.5.2.3 Gene Ontology analysis of differentially expressed proteins 
To give an indication if the list of DE expressed proteins within the miR-23 clones 
displayed any enrichment for their involvement in similar biological processes, the entire 
list of 42 were analysed using the DAVID (Database for Annotation, Visualisation and 
integrated Discovery: http://david.abcc.ncifcrf.gov/home.jsp) algorithm. From the 
biological processes identified, cellular metabolism was apparent (Table 3.8). 
Table 3.8: Gene Ontology of miR-23 sponge DE proteins 
GO ID GO Term P-value BH adj. 
0015980 Energy derived by oxidation of organic 
compounds 
8.4 x 10-4 2.5 x 10-1 
0006091 Generation of precursor metabolites 1.4 x 10-3 2.2 x 10-1 
0051186 Cofactor catabolic process 1.7 x 10-3 1.8 x 10-1 
0006006 Glucose metabolic process 2.3 x 10-3 1.8 x 10-1 
0055114 Oxidation reduction 3.7 x 10-3 7.3 x 10-1 
0006099 Tricarboxylic acid cycle 4.3 x 10-2 7.5 x 10-1 
0046356 Acetyl-CoA catabolic process 4.5 x 10-2 7.3 x 10-1 
0009060 Aerobic respiration 5.0 x 10-2 7.2 x 10-1 
0006084 Acetyl-CoA metabolic process 5.8 x 10-2 7.2 x 10-1 
 
3.5.3 Identification of differential protein expression in isolated mitochondria 
miR-23 depletion was previously observed to impact on mitochondrial function in 
addition to mitochondrial-associated proteins being identified as increased such as 
LETM1. Mitochondrial extraction was carried out 72 h into culture as before (see section 
2.5.3 of Materials and Methods) and processed for label-free mass spectrometry 
following the same procedure as previously described for proteomic profiling of whole 
cell cultures. 
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3.5.3.1 Differentially expressed proteins 
When label-free mass spectrometry was carried out on the isolated mitochondria of the 
same miR-23 sponge clones (4 and 6) and miR-NC sponge clones (2 and 11), 499 proteins 
were determined to be DE exhibiting a fold change of ≥ 1.2 and a peptide identification 
of ≥ 1 (Appendix fig. A10). When this list was subjected to more stringent analytical 
filters (≥ 1.5 FC in addition to ≥ 2 peptide identifications), a shorter list of 99 proteins 
were found to be DE. Overlap of the entire list of 499 with the 42 found to be DE in the 
whole cell identified 15 proteins common to both lists (Table 3.9) demonstrating the same 
direction of expression in addition to a similar FC in most cases (10 up-regulated and 5 
down-regulated). One interesting observation was the identification of the cytoplasmic 
MDH1 to be upregulated by 1.79-fold in miR-23 sponge clones in the whole cell lysate. 
Whereas the mitochondrial-specific MDH2 and the cytoplasmic MDH1 were identified 
to be up-regulated by 1.3 and 2.7, respectively, in mitochondrial enriched miR-23 sponge 
samples. 
Table 3.9: DE proteins common to both Whole cell and Mitochondrial 
Whole Cell Lysate Mitochondria 
Protein FC Protein FC 
GSTM6 2.73 GSTM6 2.4 
MFGE8 2.49 MFGE8 2.2 
CALD1 2.77 CALD1 1.9 
P4HA1 2.24 P4HA1 1.7 
GAA 1.54 GAA 2.5 
RPS13 1.66 RPS13 1.3 
SBSN 1.68 SBSN 3.6 
TXNRD1 1.86 TXNRD1 1.8 
HMOX1 Infinity HMOX1 2 
MDH1 1.79 MDH1 2.7 
YWHAH 2877.10 YWHAH 1.7 
EPRS 2.49 EPRS 2.6 
ABCF1 20.57 ABCF1 2.4 
GAPDH 1.74 GAPDH 1.4 
HNRNPA1 1.76 HNRNPA1 1.5 
IQGAP1 1.82 IQGAP1 1.6 
 Table 3.9: DE proteins common to both label-free MS list (Whole cell lysates and Mitochondrial 
enriched). Fold-change (FC) comparisons are listed to demonstrate similarities across both lists and 
MS sensitivity in addition to an identical direction of expression (Green – upregulated and Red – 
down regulated). FC and colour-coding refers to the expression in miR-23 depleted clones compared 
to controls. 
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When cell component association of both DE protein lists from the whole cell (42 
proteins) and the mitochondrial enriched (499 proteins) was assessed, there was a 10% 
enrichment for proteins associated with the mitochondria (47 proteins) in the 
mitochondrial enriched samples compared to no apparent mitochondrial association in 
the case of the DE proteins from the whole cell lysate. This indicated a significant 
enrichment over what would be expected by chance. 
 
3.5.3.2: Gene Ontology analysis 
Similar to the case of miR-23 sponge whole cell lysate DE proteins, GO analysis was 
performed for the 499 proteins DE in the mitochondrial enriched samples. Biological 
processes associated with translation, RNA processing, ribosome biogenesis and protein 
folding were found to be enriched. This is potentially in agreement with the miR-23 
depleted associated phenotype of high SEAP production. When all ribosomal proteins 
found to be DE were further analysed, it was found that 26 out of 35 (74.2%) were up-
regulated in miR-23 sponge clones, in keeping with what would be expected in cells with 
an increased protein output. Only one of these ribosomal proteins was determined to be 
specific to the mitochondria (Mitochondrial Ribosomal protein S7 – MRPS7) and was 
decreased in its expression. 
With a far greater degree of statistical significance, GO on the 499 DE proteins also 
indicated biological processes related to cellular respiration including aerobic respiration 
and the Tricarboxylic acid cycle (Table 3.10). 
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Table 3.10: GO for 499 DE proteins 
GO ID GO Term P-value BH adj. 
0006414 Translation elongation 1.8 x 10-34 3.7 x 10-31 
0006412 Translation 2.9 x 10-26 3.0 x 10-23 
0006396 RNA processing 2.4 x 10-12 1.6 x 10-9 
0006397 mRNA processing 1.4 x 10-10 5.7 x 10-8 
0016071 mRNA metabolic process 1.4 x 10-9 4.9 x 10-7 
0006457 Protein folding 5.6 x 10-9 1.7 x 10-6 
0009060 Aerobic respiration 3.9 x 10-7 7.3 x 10-5 
0046356 Acetyl-CoA catabolic process 2.3 x 10-6 3.7 x 10-4 
0006099 Tricarboxylic acid cycle 2.3 x 10-6 3.6 x 10-4 
0042254 Ribosome biogenesis 8.9 x 10-6 1.1 x 10-3 
0006084 Acetyl-CoA metabolic process 2.0 x 10-5 2.1 x 10-3 
Table 3.10: GO categories for DE expressed proteins in mitochondrial enriched miR-23 samples 
versus miR-NC clones using DAVID.  
Finally, of the 47 DE proteins that were found to be associated with the mitochondrion 
when assessed for cell compartment affiliation, gene ontology enrichment was carried out 
as a means to determine which elements of mitochondrial function were predominately 
under regulation (Table 3.11). The highest scoring biological processes found to be 
enriched were aerobic respiration, cellular respiration, Tricarboxylic acid cycle and 
acetyl-CoA catabolic processes indicating that, of the mitochondrial related proteins that 
were DE, a significant proportion of them were influencing pathways responsible for 
cellular energy, as indicated by the observation of enhanced oxygen consumption 
(OXPHOS) by miR-23 depleted clones (Section 3.4.6). 
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Table 3.11: GO analysis of DE proteins associated with the mitochondria 
GO ID GO Term P-value BH adj. 
0009060 Aerobic respiration 1.2 x 10-13 7.8 x 10-11 
0045333 Cellular respiration 1.6 x 10-11 5.3 x 10-9 
0006099 Tricarboxylic acid cycle 7.0 x 10-11 1.6 x 10-8 
0046356 Acetyl-CoA catabolic process 7.0 x 10-11 1.6 x 10-8 
0009109 Coenzyme catabolic process 1.6 x 10-10 2.7 x 10-8 
0006084 Acetyl-CoA catabolic process 5.0 x 10-10 6.7 x 10-8 
0051186 Cofactor catabolic process 5.0 x 10-10 6.7 x 10-8 
0015980 Energy derivation by oxidation of organic 
compounds 
5.7 x 10-10 6.4 x 10-8 
0006732 Coenzyme metabolic process 9.7 x 10-10 9.4 x 10-8 
0055114 Oxidation reduction 5.2 x 10-9 4.4 x 10-7 
0006091 Generation of precursor metabolites 3.7 x 10-8 2.5 x 10-6 
0043648 Dicarboxylic acid metabolic process 3.8 x 10-8 2.4 x 10-4 
0006105 Succinate metabolic process 3.5 x 10-4 2.0 x 10-2 
0022904 Respiratory electron transport chain 1.1 x 10-3 5.5 x 10-2 
0022900 Electron transport chain 5.6 x 10-3 2.4 x 10-1 
0007005 Mitochondrion organisation 9.5 x 10-3 9.5 x 10-1 
Table 3.11: Gene Ontology categories for differentially expressed proteins in mitochondrial enriched 
miR-23 samples versus miR-NC clones using DAVID.  
However, upon further interrogation of the proteins involved in these biological processes 
associated with mitochondrial energy production, several participating candidates were 
found to be decreased in their levels of expression such as IDH3A (Isocitrate 
dehydrogenase [NAD] subunit alpha) and COX5A (Cytochrome c oxidase subunit 5A). 
Further analysis of the proteins related to these processes will be considered later within 
the discussion (Section 4.8).  
 
3.5.3.3: Potential targets of miR-23 
Similar to the exercise carried out in the case of the list of DE proteins from the whole 
cell lysate experiment, the predicted output of targets of miR-23 was overlapped with the 
499 DE proteins in the mitochondrial proteomics profiling experiment. This generated a 
total list of 143 potential targets of miR-23 (64 up-regulated and 79 down-regulated, 
Table 3.11). To further refine this extensive list of potential targets, those that appeared 
in the short list of 99 DE proteins reduced this list to 32 (10 up-regulated and 22 down-
regulated), highlighted in yellow in Table 3.12. Finally, as it would be expected that the 
diversion of miR-23 away from its endogenous targets should result in the translational 
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de-repression of potential targets, only the 10 upregulated proteins from this short list 
were considered high priority. 
Table 3.12: Potential targets of miR-23 from isolated mitochondria  
Gene ID FC Anova (p) Algorithm Overlap 
Genes Upregulated in miR-23 sponge clones 
LIMA1 1.7 1.41E-06 3 
CALD1 1.9 2.30E-06 2 
HMGB2 1.5 5.57E-06 3 
AKAP12 6.9 9.29E-06 4 
SCP2 1.6 1.06E-05 1 
P4HA1 1.7 1.97E-05 2 
CALU 2 2.13E-05 2 
CAPRIN1 1.8 2.25E-05 1 
ITGB1 1.6 2.66E-05 2 
CTSB 1.7 2.70E-05 1 
TXNRD1 1.8 2.92E-05 1 
CLINT1 2 4.73E-05 1 
HSP90B1 1.5 4.78E-05 3 
ALCAM 3.1 7.11E-05 3 
TWSG1 2.5 8.00E-05 3 
CNN2 1.7 8.38E-05 3 
NUFIP2 1.4 0.00034 4 
PSAP 3.5 0.00041 1 
MAP4 1.4 0.00044 3 
ANXA2 1.4 0.00051 2 
BCL9L 2.3 0.00074 2 
CETN3 1.9 0.00076 2 
HDDC2 1.7 0.00112 3 
TPI 1.2 0.00127 2 
WBP2 1.3 0.00172 4 
PRKCSH 1.4 0.00181 3 
AIM2 2 0.00191 2 
SNX1 1.5 0.00217 2 
MAGOH 1.4 0.00231 2 
LAMC1 1.5 0.00381 1 
LAMP1 2.9 0.0042 4 
SET 1.6 0.00451 2 
IDI1 2 0.00466 1 
PDIA6 1.8 0.00534 3 
CACYBP 1.3 0.00543 3 
TMED9 1.4 0.00601 1 
HEXIM1 1.3 0.00685 4 
CRK 1.9 0.00926 2 
PLEKHO2 1.4 0.00936 3 
RAB14 1.4 0.00956 3 
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PPIB 1.4 0.0098 1 
RPL10 1.7 0.01005 4 
BCLAF1 2.2 0.01103 4 
CTSL 1.3 0.0118 1 
SNAP29 1.4 0.01615 2 
FXR1 1.4 0.01785 1 
LMAN2 1.1 0.01836 3 
RRAS2 1.5 0.01912 4 
PEX19 1.3 0.01968 2 
RPL27A 1.7 0.02155 3 
TPI 1.2 0.02234 2 
FKBP10 1.4 0.02374 1 
SEPT7 1.2 0.02385 3 
RCN2 1.6 0.02611 1 
HYPK 2.2 0.0274 2 
DSC1 1.2 0.02788 2 
PRPF40A 1.5 0.03643 3 
FUBP1 1.5 0.03698 2 
RPL31 1.5 0.03785 1 
TMOD3 1.2 0.0386 4 
RPS23 1.5 0.04037 2 
ENO2 1.2 0.04215 4 
GIGYF2 1.1 0.04946 2 
PRDX2 1.3 0.04984 1 
Genes Down-regulated in miR-23 sponge clones 
IQGAP1 1.6 3.40E-05 1 
SKIV2L2 2.1 5.12E-05 3 
TOP2A 1.7 5.99E-05 2 
VCP 1.9 6.71E-05 3 
VCL 1.5 7.35E-05 1 
MYH10 1.5 8.17E-05 2 
PLAA 1.8 0.00011 2 
GRSF1 1.4 0.00012 3 
H2AFV 3 0.00013 2 
FASN 2.8 0.00014 2 
SLC7A1 2 0.00026 3 
RRP15 1.6 0.00027 4 
HDAC2 1.7 0.00028 3 
MCM2 1.8 0.00032 2 
OXCT1 1.5 0.00041 3 
SND1 1.9 0.00041 2 
WDR43 1.8 0.00042 2 
NPM1 1.3 0.00048 1 
HSPH1 2.3 0.00053 2 
RRM1 1.3 0.00056 1 
ABCF1 2.4 0.00057 2 
CLTC 1.7 0.00062 2 
LRPPRC 1.6 0.00069 3 
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FLNB 1.5 0.00073 2 
SLC25A3 1.8 0.00083 1 
LYAR 1.3 0.00088 1 
CAND1 1.9 0.0009 1 
TES 1.4 0.00104 2 
EIF4G1 1.4 0.00108 1 
TMPO 1.3 0.0011 3 
HMGCS1 1.4 0.00121 2 
MAP1B 1.5 0.00165 1 
PPP2R1A 1.3 0.00195 2 
MATR3 1.6 0.00196 1 
SMARCC1 1.3 0.00199 3 
MRPS7 1.4 0.00229 1 
SUCLA2 1.4 0.0023 1 
HAT1 1.5 0.00233 1 
TOP1 1.5 0.00269 4 
RPN1 2.3 0.00309 1 
GATAD2B 1.4 0.00327 1 
SF3B3 2 0.00328 1 
SFPQ 1.3 0.00379 2 
RBM14 1.4 0.00379 1 
DDB1 1.5 0.00511 2 
MKI67 1.5 0.00516 2 
WNK1 1.3 0.00519 4 
SPTBN1 2 0.00575 2 
HNRNPU 1.8 0.0058 3 
DDX21 1.8 0.00583 2 
HNRNPC 3.1 0.00664 1 
MTAP 1.5 0.00757 3 
CPSF6 1.4 0.00803 3 
ILF3 1.4 0.00914 1 
HNRNPA1 1.5 0.01038 1 
KIF5B 1.3 0.01132 1 
SMC1A 1.5 0.01164 4 
DDX5 1.4 0.0128 2 
ZC3HAV1 1.5 0.01293 2 
CTNND1 1.4 0.01374 2 
HIST1H2AG 2.1 0.0142 1 
LBR 1.6 0.01466 2 
SPTBN1 1.8 0.01533 3 
ACTR2 1.2 0.01651 3 
TBL2 1.5 0.01816 4 
HNRNPA2B1 1.2 0.0182 3 
HIST1H2AG 1.4 0.01858 1 
OPA1 1.3 0.01882 2 
KHSRP 1.6 0.02496 3 
SAFB 1.3 0.02618 3 
CSE1L 1.5 0.02706 4 
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RRP12 1.5 0.0278 1 
EZR 1.5 0.02814 2 
VAPA 1.2 0.02995 4 
IRF2BP2 1.2 0.03608 2 
NCAM1 9.4 0.03793 3 
CKAP4 1.2 0.0392 3 
IQCE 1.3 0.04587 3 
MAPRE1 16.6 0.0487 4 
Table 3.12: Potential targets of miR-23 are shown by overlapping the hits generated by the miRWalk 
algorithm with the list of DE proteins from isolated mitochondria. The list is broken up into two, low 
priority targets found to be down-regulated in miR-23 clones and high priority targets found to be 
up-regulated in miR-23 clones. Cells highlighted in yellow passed more stringent criteria of over 1.5-
fold change in expression with the addition of 2 or more peptide identifications.  
Of the two short-lists generated from both label-free MS experiments (DE proteins that 
overlapped with prediction algorithms demonstrating an increased expression) and taking 
into account the two common targets CALD1 and P4HA1, a list of 18 targets were 
identified to be high priority targets of miR-23 that would be subject to further validation. 
These targets are LIMA1, HMGB2, SCP2, CALU, ITGB1, CTSB, SNX1 and PDIA6 in 
the mitochondrial extracted list and LETM1, CaMKIIδ, FERMT2, IDH1, TXNDR1 and 
PPP1CB in the whole cell lysate.  
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4.1 CHO cell engineering using miR-23 
miR-23 depletion presented itself as the most viable candidate for stable miRNA 
intervention when assessed in CHO-K1-SEAP cells. Although not directly derived from 
the initial miRNA profile carried out on CHO cells with varying growth rates, previous 
manipulation of the miR-23~27~24 cluster using miRNA sponge technology proved to 
be an attractive engineering route enhancing both CHO-SEAP cell growth and product 
yield. 
Stable depletion of a single component of this cluster, miR-23, in the same CHO-SEAP 
cell line was observed not to play a role in growth but did elicit an improved product yield 
of ~ 3-fold. These high producing CHO clones were identified to possess an enhanced 
mitochondrial function with an increase in oxidative metabolism of ~ 30% centred on 
complex I and II of the mitochondrial electron transport chain. Protein processing and 
biogenesis has been identified as an energetically demanding process highlighting the 
potential contribution of enhanced mitochondrial activity to accommodate this cellular 
burden. Calcium signalling not only is suggested to be an ATP sensor within the 
endoplasmic reticulum (Kaufman, Malhotra 2014) thus monitoring energy requirements 
but is also implicated in TCA cycle function through the activation of vital enzymes of 
the TCA cycle thus driving energy provisions (Osellame, Blacker & Duchen 2012). It 
was discovered that the increase in SEAP yield was potentially attributed partially to an 
increase in SEAP transcription. This possess the question of whether there lies a 
reciprocal relationship between transcriptional activity/protein processing with enhanced 
OXPHOS or vice versa.  
Label-free mass spectrometry identified various protein targets whose expression was 
increased suggesting potential targets of miR-23 itself that are associated with 
mitochondrial function and cellular metabolism, IDH1/MDH1 and LETM1, in addition to 
proteins implicated in transcriptional control, CaMKIIδ and 14-3-3-η (Fig. 4.1). This 
schematic forms the basis of our hypothesis of the impact miR-23 is having in these CHO-
SEAP clones ultimately boosting productivity of the bioprocess.     
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Figure 4.1: Schematic of miR-23s hypothetical role in rCHO-SEAP cells 
 
Figure 4.1: The depletion of miR-23 could impact directly or indirectly on mitochondrial function given the suggested panel of potential targets from the 
proteomics profiling. Isocitrate dehydrogenase (IDH1) and Malate dehydrogenase (MDH1) provide TCA cycle metabolites. LETM1 is an inner mitochondrial 
membrane (IMM) protein acting as a Ca2+/H+ antiporter with calcium activating TCA cycle enzymes in the matrix while H+ provides energy to the proton 
gradient. Indirectly, increased expression of CaMKIIδ targets HDAC4 for phosphorylation, tagging it for 14-3-3-η thus preventing nuclear localisation. HDAC4 
inhibits transcription through deacetylation. Enhanced SEAP processing in the endoplasmic reticulum (ER) is an energy-demanding process, releasing Ca2+ as 
ATP is used which stimulates mitochondrial oxidative metabolism. 
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4.1.1 Selection of miR-23 for stable depletion 
The pioneering study by Gammell et al., identified a panel of miRNAs to be DE upon 
hypothermic growth conditions such as let-7f and miR-21 (Gammell et al. 2007). Two 
cluster components, miR-27a and miR-24, were found to be up-regulated upon 
temperature shift-induced growth arrest and late culture growth arrest. Despite being 
transcribed from a single transcriptional unit, the levels of miR-23a remained unchanged, 
an outcome influenced by RNA-binding proteins and processing pathway (Chhabra et al. 
2009). Interestingly, these miRNAs demonstrated no change in expression when 
evaluated in CHO cells with varying growth rates (Clarke et al. 2012). Previous 
characterisation within our research group by Dr. Noelia Sanchez demonstrated that 
transient overexpression of miR-23a in CHO-K1-SEAP cells elicited a growth arrest of 
61% whereas its inhibition did not reverse the phenotype. Transient overexpression of 
miR-24 induced a 27% arrest in cell numbers while transient inhibition reversed this 
phenotype to improve cellular growth by the same magnitude. miR-27a overexpression 
in two individual cell lines (CHO-1.14 and CHO2B6) resulted in a growth reduction and 
improvement, respectively, demonstrating a cell specific influence. It was for this reason 
that targeting of the entire miR-23a~27a~24-2 cluster using miRNA-sponge technology 
was explored resulting in a 1.7-fold increase in cell numbers and a 2-fold increase in 
specific productivity. 
This was a beneficial observation in that specific productivity is often observed to be 
compromised during enhanced growth (Sunley, Tharmalingam & Butler 2008a). The co-
existence of a fast growing CHO cell and the retention of increased specific productivity 
in the case of miR-23a~27a~24-2 depletion offers encouragement in terms of a viable and 
robust engineering strategy. CHO cell engineering using decoy technology against miR-
7 (Sanchez et al. 2013b) or stable miR-17 overexpression (Jadhav et al. 2014) have both 
enhanced CHO cell growth without the compromise of specific productivity achieving 2-
3 fold improvements in product yield.  
miR-23 has also been associated with the reprogramming of cellular bioenergetics (Gao 
et al. 2012). The “Warburg effect” describes the propensity of cancer cells to avidly take 
up glucose and almost exclusively convert it to lactate in a process known as aerobic 
glycolysis (Vander Heiden, Cantley & Thompson 2009). Although energetically 
inefficient, it provides critical fuel for biomass production (Catapleurosis) and it 
highlights the role that energy metabolism plays in tumorigenesis (Fig. 4.2).  
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It has however been demonstrated that weakening of the TCA cycle by Acetyl-CoA 
starvation mediated through the Warburg effect (Dell'Antone 2012) can be overcome by 
anapleurotic reactions that resupply mitochondrial intermediates of the TCA cycle such 
as α-ketoglutarate through miR-23s role in glutaminolysis (Gao et al. 2012). 
 
Figure 4.2: Schematic of Aerobic and Anaerobic glycolysis in various cellular 
conditions 
Figure 4.2: A schematic representation of “normal” channelling between Oxidative phosphorylation 
and anaerobic glycolysis under high and low oxygen concentrations, respectively. In addition, the 
utilisation of excess glucose sources via the Warburg effect in both normal and diseased tissues. This 
figure was sourced from (Vander Heiden, Cantley & Thompson 2009). 
 
The primary carbon sources, Glucose and Glutamine, have been extensively considered 
in the area CHO cell research. Monoclonal antibody production has been positively 
correlated with the metabolism of glucose and lactate (Chen et al. 2012). Metabolic by-
product accumulation such as lactate and ammonia from glucose and glutamine 
metabolism, respectively, has been extensively considered for their impact on cell growth 
and productivity, not to mention product quality (Yang, Butler 2000). Studies centred on 
glutamate supplementation have contributed to enhanced productivity and 
galactosylation of recombinant IgG (Hong, Cho & Yoon 2010) and optimisation of fed-
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batch cultures through galactose/glutamate replacement (Altamirano et al. 2000). Various 
CHO cell phenotypes have also been affiliated with particular metabolic states such as 
growth, glycolytic metabolism, productivity and oxidative metabolism (Templeton et al. 
2013). Metabolic re-programming using miR-23 depletion could enhance productivity 
through enhanced mitochondrial function while maintaining growth through an 
unperturbed glycolytic process. 
 
4.1.2 GFP as an effective reporter for clone selection and sponge efficiency  
The utilisation of a reporter construct has enabled the selection of rCHO clones 
demonstrating high specific productivities (Lai, Yang & Ng 2013a). Additionally, they 
have proved useful in the implementation of miRNA-based technology, such as miR-
sponges. We utilised a destabilised GFP (deGFP) reporter construct to monitor miRNA 
sponge efficacy (Kitsera, Khobta & Epe 2007). When expressed at supraphysiological 
levels, miRNA sponges act as decoy transcripts (Mullokandov et al. 2012) but when 
expressed at physiological levels they can be used as miRNA “sensors” allowing for the 
evaluation of endogenous miRNA activity (Mansfield et al. 2004). Despite a wide range 
of GFP intensities, we observed an average reduction in GFP expression across the miR-
23 sponge clonal panel when compared to the miR-NC controls. This reduced GFP 
expression was presumably a result of endogenously expressed miR-23a/b, which should 
not influence the non-specific sponge, as observed by Sanchez and colleagues for miR-7 
(Sanchez et al. 2013b).  
To further confirm the specificity of the miR-23 sponge construct, mixed pools were 
transfected with a miR-23b mimic as a means to repress translation of the GFP reporter. 
One interesting observation however was that transient transfection of the miR-23b 
mimic resulted in a mild repression of GFP (Fig. 3.31 B). One explanation is the reported 
low proficiency of miR-23 derived from its “weak seed”-pairing stability (SPS) due to its 
A+U-rich seed region (Garcia et al. 2011). Furthermore, miRNAs with A+U-rich seeds 
have a greater target abundance due to the A+U-rich composition of 3’UTRs (Grimson 
et al. 2007) ultimately titrating miRNA function (Franco-Zorrilla et al. 2007). With this 
in mind, we attempted to transfect a miRNA that was specifically designed to mimic the 
natural structure of the miR-23b duplex (pre-miR-23b*-mod) meaning that upon 
exogenous introduction into cells, would be processed based on thermodynamic stability 
of the duplex ends giving rise to both miR-23b and miR-23b*. When transfected, both 
288 
 
miR-23 sponge mixed populations and two clones (4 and 6), demonstrated a 90% 
reduction in GFP (Fig. 3.31 Bpre-miR-23b*-mod and Appendix Fig. A14). These 
observations suggested that the first miR-23b mimic was not being processed efficiently 
whereas the modified, pre-miR-23b* mod was, achieving GFP inhibition. miR-23 sponge 
specificity was also explored by assessing the endogenous levels of mature miR-23b in 
clones stably expressing the sponge construct compared to controls. A 5-fold reduction 
in mature miR-23b levels were observed in our clones when compared to clones 
expressing a non-specific sponge (Fig. 3.67). 
The rapid degradation of mature miRNAs have been reported in cases of target 
availability such as miR-27a/b by murine cytomegalovirus (Marcinowski et al. 2012), 
miR-15a/16-1 by hepatitis B virus (HBV) (Liu et al. 2013), miR-122 by HBV (Li et al. 
2013c) and the miR-let-7 family have been observed using a miRNA sponge (Yang et al. 
2012). Although contradictory observations have been reported for miR-7 (Sanchez et al. 
2013b), the mechanism behind the decrease of endogenous miR-23 in stable sponge 
clones remains unceratin.  
 
4.1.3 Stable depletion of miR-23 improves CHO-SEAP productivity 
Specific productivity was enhanced by 30-50% in the case of CHO mixed pools with an 
average 3-fold improved SEAP activity in a clonal panel. Of the four top SEAP producing 
clones selected, 3 demonstrated the highest level of GFP intensity compared to the 
majority of the miR-23 clones suggesting the highest levels of miR-23 depletion. One 
clone in particular however, miR-23 clone 2, possessed the third lowest GFP expression 
yet was the fourth highest producing clone. This would suggest that the intensity of the 
fluorescent signal is not necessarily proportional to the level of productivity. miR-23 
sponge clone 9 for example displayed a high GFP signal compared to miR-23 sponge 
clone 7 (Fig. 3.39) yet its productivity value is one of the lowest. It is possible that by 
selecting clones with mid-high GFP intensities, a titrational influence of miR-23 depletion 
is lost and the productivity differences are due to clonal variation. The selection of clones 
exhibiting a low-medium GFP intensity might allow the assessment of a correlation of 
sponge expression with productivity improvements. 
Protein folding and secretory bottlenecks have been shown to restrict mammalian cells 
from exploiting their physiologic production capacity (Tigges, Fussenegger 2006). As a 
means to investigate whether miR-23 depleted clones possessed an enhanced ability to 
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process and secrete the SEAP protein, we determined there to be a ~2-fold increase in the 
levels of the SEAP mRNA transcript when compared to control clones. This indicated 
that there were no processing bottlenecks in either control or test clones as the levels of 
SEAP transcript reflected SEAP enzymatic activity.  
mRNA stability has been demonstrated to contribute to specific productivity as in the 
case of CHO cells expressing TNFR-Fc subject to hypothermic growth conditions (Kou 
et al. 2011). After translational inhibition through Actinomycin-D treatment, the rate of 
mRNA decay was determined by calculating the slope across the various time points 
when qPCR was carried out. Ideally, a similar decrease at each time when compared to 
time zero would provide information as to the rate of decay independent of varying Ct 
values due to differing transcript concentrations. It was observed that the endogenous 
control (β-actin) displayed an accelerated rate of decay when compared to the SEAP 
transcript, therefore 2-ΔΔCt calculation would not have been suitable. miR-23 sponge 
clones demonstrated no change in decay suggesting there to be no increase in SEAP 
mRNA stability when compared to controls.         
It has been strongly suggested that lessons from nature could aid in the identification of 
attractive engineering targets for the use in CHO cell manipulation, in particular the 
antibody producing B-cell (Dinnis, James 2005). Resting B-cells, once stimulated, 
differentiate into nature’s own antibody factories, plasma cells, and have presented 
engineering targets such as XBP-1 (Tigges, Fussenegger 2006), BiP and PDI (Pybus et 
al. 2013) and ATF4 (Ohya et al. 2008b). In the case of miR-23, its down-regulation has 
been associated with the progression of chronic lymphocytic leukemia (Chhabra, Dubey 
& Saini 2010b). A recent study by Li and colleagues demonstrated that malignant 
transformation of B-cells closely resemble the activation of resting B-cells (Li et al. 
2011a). Among the panel of miRNAs found to be similarly deregulated across both 
phenotypes, miR-23a/b, miR-24 and miR-27b were shown to be down-regulated in 
activated B-cells. Additionally, hematopoietic progenitors expressing the miR-23a cluster 
and cultured in the presence of B-cell promoting conditions were observed to undergo a 
dramatic reduction in B-lymphopoeisis (Kong et al. 2010). The expression of miR-23a 
has also been observed to be negatively associated with the up-regulation of Blimp-1 (B 
lymphocyte-induced maturation protein 1) (Parlato et al. 2013). These studies 
demonstrate that the miR-23a cluster plays a central role not only in regulating the 
molecular frame work of B-cells but also further in their activation. B-cells are of an equal 
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size to that of CHO cells (10-15 µm) with a specific production capability of 100 
pg/cell/day (Dinnis, James 2005), the suggested maximum production capacity of CHO 
(De Jesus, Wurm 2011). As B-cells are considered antibody factories, the implication of 
miR-23 and its cluster components in the activation of B-cells could suggest a similar 
influence in CHO-SEAP cells, specifically stimulating productivity in the case of miR-
23.    
 
4.1.4 miR-23 depletion improves CHO cell growth in a cell type and product-
dependent manner 
Although miR-23 depletion was not observed to impact on the growth of rCHO-SEAP 
cells, it did appear to elicit a positive impact on a second cell line, rCHO-1.14 upon its 
stable depletion, both derived from the same CHO-K1 parent. In both stable mixed 
populations and clonal populations cultured in a 1 mL format, there was an increase in 
cell growth to the detriment of IgG productivity. Various expression patterns of the 
members of miR-23 have been recorded across many cancer states with over-expression 
dominating (Table 4.1). Inhibition in this instance enhanced growth within the CHO-1.14 
cell line. It is possible that this cell line exhibits a completely different set of gene targets 
as its inherent growth is markedly reduced when compared to CHO-SEAP cells. The 
oncogenic transcription factor, c-myc, despite being demonstrated to inhibit the 
expression of miR-23a/b to ultimately alleviate their inhibitory role on glutaminase (Gao 
et al. 2009), has also been shown to up-regulate the miR-23a cluster in mammary 
carcinoma (Li et al. 2013). 
Furthermore, a significant improvement in apoptosis resistance was mediated by the 
depletion of miR-23 in CHO-1.14s in batch culture. miR-23a has been demonstrated to 
directly inhibit the caspase-inhibitor, X-linked inhibitor of apoptosis (XIAP) (Siegel et al. 
2011). XIAP over-expression has been previously explored in CHO cells exposed to 
sodium butyrate treatment as a means to prolong cell survival while exploiting the 
induced high specific productivity phase (Kim, Kim & Lee 2009) offering no viability 
benefit. A prior study demonstrated that stable XIAP over-expression could inhibit CHO 
cell apoptosis upon Sindbis virus infection (Sauerwald, Betenbaugh & Oyler 2002b). This 
suggests that the benefit of XIAP can be both cell line specific and potentially influenced 
by the route of apoptosis activation. As a result, this could be why miR-23 depletion offers 
a protective phenotype in rCHO-1.14 cells but not in rCHO-SEAP cells under batch 
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conditions. Ongoing work by a colleague within our research group has demonstrated that 
miR-23 retains its functionality in targeting XIAP in CHO cells thus validating its capacity 
to regulate the gene but again in a cell type and context-dependent manner.  
It was observed that the improved growth phenotype came hand-in-hand with a reduction 
in specific IgG productivity.  However, upon clonal characterisation, there was a mixture 
in the observed phenotype. Although all clones stably depleted of miR-23 retained a fast 
growing phenotype with increased maximal cell density, volumetric productivity was 
enhanced in the case of 2 out of the three clones. This could have been due to the bias 
introduced during clonal selection, when clones were selected based on their high 
volumetric productivity in addition to growth. Furthermore, a single control clone 
demonstrated an enhanced viable phenotype exposing the natural variation in clones. It is 
possible that the influence on rCHO-SEAP cells in regards to growth is a factor of the 
expressed mRNA targets when compared to the rCHO-1.14. Inducing a faster growth 
phenotype may not be possible due to the limited availability of miR-23s targets in an 
already fast growing cell type.  
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Table 4.1: Table of expression of miR-23 cluster components in various disease 
states 
 
Table 4.1: Deregulated expression of the miR-23 cluster paralogs in various disease states us 
demonstrated above. “u” denotes up regulation whereas “d” denotes down-regulation. The table was 
sourced from the review (Chhabra, Dubey & Saini 2010b). 
 
4.1.5 Clonal variation and culture conditions impact on the CHO cell phenotype 
The process of recombinant cell line generation has its inherent pitfalls depending on the 
context. For example, non-site specific integration of the experimental transgene, in our 
case the miR-23/NC sponge constructs, can result in various genetic phenotypes such as 
copy number variation, intensity of expression due to insert location and potential 
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insertional mutagenesis. Random integration and amplification may also interfere with or 
de-regulate endogenous genes (Winnard, Glackin & Raman 2006) ultimately creating the 
potential for variation in other cellular traits (Kim, Lee 2007). This in particular was 
observed when cellular proliferation was characterised upon the isolation of a panel of 
clones derived by FACS from the original CHO-SEAP mixed pool. Across both miR-23 
and miR-NC sponge clones, a range of growth profiles were identified despite the 
observation of no gross differences in growth of the recombinant mixed pool populations. 
This heterogeneity within clones, as a function of the transgenesis process, is routinely 
exploited in the selection of clones showing an advantage for a particular phenotype 
(Pichler et al. 2011).  
The parental rCHO-SEAP cell used as the basis for stable miR-sponge generation was a 
clonal line and presumed to demonstrate a similar level of SEAP production and genetic 
homogeneity. An additional layer of complexity has been demonstrated in that not only 
are there variations in the performance from clone to clone but that protein expression 
can be heterogeneous within clones themselves. One study demonstrated a 50-70% 
deviation in antibody expression within clones upon 2-11 generations (Pilbrough, Munro 
& Gray 2009). This could have potentially contributed to a production variance, 
originating within the parental CHO-K1-SEAP, across all clones generated irrespective 
of the process of recombinant cell line generation. 
One very interesting observation was that when miR-23 sponge clones were selected and 
cultured in a 1 mL suspension format, the maximum achievable cell density on day 4 was 
less than half of that of miR-NC sponge clones, again in contrast to the similar growth 
profiles observed in the case of mixed pools. The similarity in cell numbers between both 
clonal panels on day 2 of growth suggested that miR-23 depletion itself was not exerting 
a direct impact on the CHO cell growth. Interestingly, of the 4 clones selected from this 
panel demonstrating a range of maximal cell densities (~1 x 106 to ~4 x 106 cells/mL in 
1 mL), each clone exhibited a similar maximal cell density of ~5 x 106 cells/mL upon 
culture in a 5mL volume in a vented spin tube. Cell line behaviour has been previously 
shown to be sensitive to vessel type and process conditions such as pH, temperature and 
dissolved oxygen tension (Trummer et al. 2006, Liu et al. 2011). A comprehensive study 
by Porter and colleagues (Porter et al. 2010) followed the progression of 175 antibody-
secreting clones isolated from the same transfected population throughout various phases 
of cell line characterisation using a “typical strategy” of cell line development (Fig. 4.3). 
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It was evident that clonal performance was dependent on the culture environment which 
ultimately presents a difficult task when empirically selecting clones for phase 
development.  
 
Early stage platforms tend not to have strict regulation on particular environmental 
conditions such as pH and dissolved oxygen tension (DOT). In the case of our miR-23/NC 
sponge screen, the microenvironment of the parafilm-sealed 24-well suspension plate 
potentially possessed a less consistent oxygen environment as opposed to the vented spin 
flasks, potentially contributing to the miR-23 sponge specific growth inhibition. 
Kulshreshtha and colleagues demonstrated a panel of miRNAs responsive to hypoxic 
growth conditions with miR-23/-27 and -24 being upregulated (Kulshreshtha et al. 2007). 
An independent study demonstrated a reduced expression of miR-23a/b and miR-27a/b 
in hypoxia induced apoptosis with an anti-correlation with Apaf-1 (Chen et al. 2014). 
Overexpression of these two miRNAs was further demonstrated to protect against 
apoptosis. Both of these studies suggest a protective role of miR-23 in response to 
hypoxia. It is possible that depletion of miR-23 in CHO-SEAP clones is preventing these 
CHO clones from responding to the potential hypoxic conditions of this culture format 
compared to control clones resulting in the reduced cell viability observed.     
 
Interestingly, despite the reduced maximal cell densities, a similar average 3-fold increase 
in volumetric SEAP productivity was exhibited when compared to individual clones 
selected for 5 mL culture. This retention in volumetric SEAP activity appeared to be as a 
result of enhanced specific productivity in the case of clones cultured at 1 mL volume 
potentially attributed to a prolonged residence in the highly transcriptionally active phase 
of the cell cycle, G1 (Kumar, Gammell & Clynes 2007).  
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Figure 4.3: CHO clone behaviour across multiple phase development platforms 
Figure 4.3: Heterogeneity within clonal populations along with the variations in performance across 
multiple culture conditions ultimately contributing to the complexity in clonal selection during phase 
development. A) Represents the “selected top 10” based on their volumetric productivity in batch 
suspension culture and B) represents the “real top 10” based on their volumetric productivity in fed-
batch suspension culture. From these two categories, clonal ranking was highlighted within all phase 
platforms including (i) spot test, (ii) 24-well plate, (iii) batch culture and (iv) Fed-batch culture. This 
figure was sourced from (Porter et al. 2010). 
 
In the same study by Porter and colleagues (Porter et al. 2010), the addition of a feed 
resulted in the largest variation (25%) in ranking position across all clones. This was 
observed in the case of all miR-23 sponge and miR-NC sponge clones cultured with a 
feed supplement causing larger variations in growth and maximum cell density (Fig. 3.58 
A). Volumetric SEAP production was still retained at 3-fold increase when compared to 
non-specific controls (Fig. 3.58 A). However, when volumetric SEAP activity was 
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compared to that of miR-23 sponge clones cultured under a 6 day batch, it was not 
improved, in fact mildly reduced, (Fig. 3.56 C and 3.58 C) despite the significant increase 
in maximal cell density. One report observed that in the case of CHO cells producing 
tissue plasminogen activator (t-PA), the reduced volumetric yield associated with a 2.5-
fold increase in IVCC was mediated by a possible secretory bottleneck when intracellular 
t-PA mRNA levels were identified to be increased (Dowd, Kwok & Piret 2000). Another 
possibility is that the enhanced cellular growth has resulted in a trade off in CHO cell 
specific productivity conferring no significant production advantage despite the extension 
of 2 days in the culture life time. Both miR-23 sponge clones subject to a nutrient feed 
also retained a viability above 80% for an additional 48 h compared to control clones. 
The introduction of nutrient feeds have greatly improved pharmaceutical recombinant 
protein manufacturing by boosting maximal cell densities, improving cell productivities 
and enhancing viability (Butler, Meneses-Acosta 2012, Huang et al. 2010). This enhanced 
cell viability was evident in both miR-23 and miR-NC sponge clones upon fed-batch 
cultivation when compared to batch, however, stable miR-23 depletion did appear to 
confer a further extended viability (Fig. 3.58 B). 
Low culture temperature results in growth arrest, meaning that cell density is significantly 
reduced at 31°C, nutrients are consumed at a slower rate and the culture can be run for a 
longer period of time prior to the onset of cell death, in a cell-type specific manner. We 
thought it prudent to exploit the potential enhanced viability phenotype of a fed-batch 
with that of a temperature shift as a means to boost volumetric SEAP production. When 
specific productivity was compared between miR-23 sponge clones 4 and 6 cultured 
under fed-batch conditions with or without temperature shift to 33°C (Fig. 3.60), there 
was an average ~2-fold increase in cell specific SEAP productivity in the case of 
hypothermic culture conditions. Furthermore, volumetric productivity was enhanced by 
~30% in the case of clones subject to temperature shift with feed addition (Fig. 3.58 C 
and 3.59 C). A similar observation was made by Fox and colleagues in the case of 
Interferon-γ production (Fox et al. 2004). The highest volumetric SEAP production 
observed in the case of fed-batch with temperature shift may be due to the extended 
production phase. Another possibility that has been reported is that reduced culture 
temperatures can have the added advantage of stabilizing the product and reducing 
intramolecular aggregation (Tharmalingam, Sunley & Butler 2008, Oguchi et al. 2006). 
The highest level of SEAP activity was recorded under hypothermic growth conditions. 
Although, the presence of the miR-23 sponge in fed-batch appeared to delay the onset of 
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apoptosis, the extended production phase under hypothermic growth conditions appeared 
to be maintained below the industry standard of 80%, with the anti-apoptosis benefits 
appearing from day 11 onwards (Fig. 3.59 B).  
It is possible that clones under batch conditions will exhibit a unique transcriptome to a 
clone grown in fed-batch culture. This could ultimately provide a completely new set of 
targets for miR-23 impeding its role in regulating particular phenotypes. It was found that 
cell death in fed-batch was primarily induced via death receptor- and mitochondria-
mediated signalling pathways rather than endoplasmic reticulum-mediated signalling 
compared to batch (Wong et al. 2006) with Fas being demonstrated to be a target of miR-
23a/b (Li et al. 2013a). Despite miR-7 over-expression yielding no negative impact on 
CHO cell viability (Barron et al. 2011b) and being associated with the de-regulation of 
pro/anti-apoptotic genes (Sanchez et al. 2013a), its stable inhibition mediated a prolonged 
viable phenotype under fed-batch conditions (Sanchez et al. 2013b) again suggesting the 
availability of a new cohort of targets. It is possible that fed-batch with temperature shift 
would best suit the stable depletion of miR-23 in our CHO-SEAP population with further 
optimisation such as adapting miR-23 sponge clones to hypothermic growth conditions 
(Sunley, Tharmalingam & Butler 2008b). 
 
4.1.6 miR-23 depletion enhances CHO cell mitochondrial function at Complex I and 
II 
Mitochondria are vital to normal cellular function as they are responsible for energy 
production in eukaryotes, including the synthesis of phospholipids and heme, calcium 
homeostasis and apoptosis activation. Deregulation in mitochondrial activity is often 
associated with numerous disease states such as diabetes mellitus. Furthermore, 
alterations in the metabolic pathways that ultimately feed oxidative phosphorylation 
(OXPHOS) at the electron transport system such as glycolysis and the tricarboxylic acid 
cycle (TCA) can lead to changes in cell fate. The Warburg effect, a process also observed 
in CHO cells (Martinez et al. 2013), has been observed to be reprogrammed through miR-
23’s interaction with glutaminase and sparked the exploration of mitochondrial activity 
(Gao et al. 2009). Each of the enzymes that constitute the glycolytic pathways have been 
found to be over-expressed and/or deregulated in several cancer cell lines and tumours in 
vivo (Pelicano et al. 2006a) ultimately contributing t(Martinez et al. 2013)o enhanced cell 
growth. However, in this instance, miR-23 depletion resulted in enhanced SEAP 
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transcription without contributing to growth. A recent study demonstrated the metabolic 
flux in an antibody producing CHO cell line exposing variations in metabolism during 
growth (Glycolytic) and production (TCA) (Templeton et al. 2013). This has further been 
supported with observations that increased oxidative metabolism can be favoured in 
situations of nutrient depletion and/or reduced growth rate (Young 2013). These studies 
implicate certain metabolic states with particular CHO cell phenotypes, mainly 
productivity with oxidative metabolism encouraging the exploration of miR-23 depletion.  
Eliminating proliferation as a variable, it has been observed that the protein folding 
process consumes much energy, which is provided for by the mitochondria (Bravo et al. 
2011, Simmen et al. 2010). With this in mind, enhanced mitochondrial function could 
further aid miR-23 depleted clones in efficiently processing and turning over the 
additional SEAP mRNA transcripts (Fig. 4.1). 
When intact, non-permeabilised miR-23 clones were assessed for their mitochondrial 
function, one set of clonal pairs exhibited an increased Routine and Leak respiration due 
to the reduced calculated maximum ETS when applying the respiratory control ratios 
(RCRs) (Fig. 3.71 B). RCRs are defined as the O2 flux in different respiratory control 
states normalised for the maximum flux of the ETS capacity. Despite an overall reduced 
maximum ETS in the case of miR-23 sponge clone 4 compared to miR-NC sponge clone 
2, energy turnover is potentially more efficient. Muscle cell mitochondria have 
demonstrated increased RCRs indicating efficient energy production (Larsen et al. 2011). 
The proton gradient is the source of electrochemical energy and regulates electron 
movement across the transport system, electrochemical backpressure (Fig. 4.4). 
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Figure 4.4: Schematic diagram of the mitochondrial proton gradient 
 
Figure 4.4: The propagation of electrons through the ETS is regulated by the electrochemical 
backpressure exerted by the proton gradient. Protons are translocated from the mitochondrial 
matrix to the inner mitochondrial membrane through the various complexes (I, III and IV) as 
electrons are donated from NADH/FADH2. Inner membrane protons are then translocated back into 
the matrix through ATP Synthase generating ATP or lost to proton leak.  
http://hyperphysics.phy-astr.gsu.edu/hbase/biology/etrans.html. 
 
However, both protons and electrons can leak across the membrane without contributing 
to ATP production yet ultimately allowing electron transport from the reducing 
equivalents (NADH and FADH2). Leak respiration is dependent on internal energy 
sources as ATP Synthase has been inhibited by the addition of oligomycin thus preventing 
the translocation of exogenous metabolites into the mitochondrial matrix. Leak 
respiration also accounts for a large proportion of resting metabolic rates (20-25%) (Rolfe 
et al. 1999). The observed increase in leak respiration indicated that internal substrates 
for mitochondrial turnover are more readily available. This is in contrast to the other 
clonal pair, miR-23 sponge clone 6 and miR-NC sponge clone 11, whose RCRs remained 
similar while miR-23 sponge clone 6 demonstrated an enhanced routine respiration and 
ETS capacity (Fig. 3.72). This would suggest that mitochondrial function may not be 
contributing directly to an increase in the transcriptional activity of the SEAP mRNA 
transcript. However, an increase in cellular ATP levels can activate transcription from 
promoters by RNA polymerase II (Conaway, Conaway 1988) indicating a role in 
transcriptional control. To put the change of 5% difference in Leak respiration into 
perspective, a study reported a difference of 5% in leak respiration in skeletal muscle 
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mitochondria in diet resistant and diet responsive patients (Harper et al. 2002), i.e. 5% 
would be considered significant as it does not vary hugely. 
  
Systematic stimulation and inhibition of the various complex components of the electron 
transport system, when cells were permeabilised with Digitonin, revealed that there was 
a 30% increase in oxygen consumption attributed to Complex I and II (Fig. 3.74 B). This 
indicated that there was an increase in the availability of the reducing equivalents NADH 
and FADH2 which provides electrons that drive the pumping of protons from the matrix 
to the inner membrane space contributing to energy production or a more effective and 
efficient assembly of these components on the inner mitochondrial membrane (Fig. 4.5). 
  
Cell-to-cell variation in the rate of transcription has been correlated to higher 
mitochondrial mass or higher membrane potential, with the presence of anti-/pro-oxidants 
and increased ATP substantially improving transcription rates (das Neves et al. 2010), 
indicating the possibility of a contribution to enhanced SEAP transcription. However, this 
enhanced transcription was reported to be on a global level which we investigated by 
probing a set of genes (GLS, XIAP and TFAM). These showed no increase in miR-23 
sponge clones. However, in hindsight, if global gene transcription was enhanced then so 
would the transcription of the endogenous control used for comparison in qPCR 
indicating that no difference would be detected.   
 
A kinetic model of cellular energetics in CHO cells subjected to sodium butyrate exposure 
demonstrated a shift in energy metabolism towards increased efficiency of glucose 
utilisation through the TCA cycle (Ghorbaniaghdam, Henry & Jolicoeur 2013). As 
sodium butyrate treatment is routinely used to artificially induce higher specific 
productivity, the 30% increase in mitochondrial function observed in the miR-23 sponge 
clones supports this notion of oxidative metabolism being linked to specific productivity. 
NaBu treatment has also been observed to stimulate the release of Ca2+ from the ER (Sun 
et al. 2012a) with Ca2+ itself being previously demonstrated to activate enzymes of the 
TCA cycle thus enhancing OXPHOS (Osellame, Blacker & Duchen 2012). It still remains 
difficult to speculate as to how there appears to be a selective increase in SEAP 
transcription. This increase of 30% is significant as reports in the literature of variations 
in mitochondrial function are mild, usually in the range of 5-70% (Hirsch et al. 2012).  
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Figure 4.5: Schematic Diagram linking the TCA cycle to ATP production 
 
Figure 4.5: The schematic representation of the complex components of the electron transport system 
(ETS) in addition to its coupled behaviour with the TCA cycle and the reducing equivalents produced 
(Osellame, Blacker & Duchen 2012). 
 
Despite the potential increase in mitochondrial function, there did not seem to be an 
apparent compromise in mitochondrial membrane integrity. Complex I and III of the 
electron transport system have been described as the primary location of electron loss or 
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leak (Jastroch et al. 2010). This could potentially contribute to the lack of synergy 
observed upon co-stimulation of both complexes I and II when ADP was not the limiting 
factor. Both CI and CII demonstrated a ~30% increase in oxygen consumption 
independently, yet maintained this increase upon co-stimulation. This could potentially 
be attributed to electron leak downstream of both complexes. Mitochondrial membrane 
integrity was demonstrated to be unaffected in miR-23 depleted clones both through the 
addition of cytochrome c during HRR-SUIT permeabilization and the evaluation of 
mitochondrial content/mass using the MitotrackerTM deep red assay. MitotrackerTM deep 
red probes are sensitive to membrane integrity and will diffuse out which we assessed not 
to be a contributing factor.  
Upon inhibition of the activity of complex II and III by Malonic acid and Antimycin A, 
respectively, there was an observed drop in oxygen consumption on complex IV for miR-
23 depleted clone upon its stimulation by the artificial electron donor TMPD. This again 
could potentially be another contributing factor to the lack of synergy between the 
stimulation of complex I and II with electrons potentially reaching a bottle neck at 
complex IV.        
When we assessed the levels of glutamate, there was an observed increase of 65% across 
all clones (Fig. 3.70). Assessment of this metabolite was suggested by the identification 
of the role that miR-23a/b plays in targeting the enzyme glutaminase (Gao et al. 2009). 
The process of glutaminolysis is an anapleurotic reaction that provides that TCA cycle 
with vital intermediates such as α-ketoglutarate (Fig. 4.5). This is a potential mechanism 
in which cancer cells can overcome what’s been termed “the Crabtree effect” in which 
excessive turnover of glucose via the “Warburg effect” can quench and ultimately starve 
the TCA cycle of Acetyl-CoA through exclusive conversion of pyruvate to lactate 
(Dell'Antone 2012). This increase in glutamate availability could explain the increase in 
respiration observed at complex I and II during permeabilised assays as well as the 
increase in routine and leak respiration with the potential of an alternative endogenous 
source of TCA cycle substrates.  
Peak antibody production in CHO cells has been associated with a highly metabolic 
oxidative state while peak cell growth was characterised by a highly glycolytic state 
(Templeton et al. 2013). This would suggest that the observed SEAP productivity could 
be attributed to enhanced mitochondrial function also indicating why cellular 
proliferation was not influenced. However, it would be necessary to assess the glycolytic 
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status of miR-23 sponge clones to rule this a plausible explanation.  Glutamate 
dehydrogenase (GDH) can also convert α-ketoglutarate into glutamate providing an 
alternative source of glutamate that is not derived from glutaminolysis (Friday et al. 
2012). Interestingly, when proteomic analysis was carried out between miR-NC and miR-
23 sponge clones, glutaminase was not identified to be DE suggesting that the formation 
of glutamate could be as a result of catapleurosis derived from downstream sources to 
TCA intermediates.  
These results suggest that miR-23 depletion is potentially playing a role in enhancing 
CHO cell mitochondrial function. The link between oxidative metabolism and 
productivity is a strong indication that the improved mitochondrial function is influencing 
SEAP transcription. Without assessing ATP levels it would be premature to equate this 
increased oxygen consumption to energy synthesis. Furthermore, identifying and 
comparing the presence of lactate would indicate if CHO cells are favouring the glycolytic 
pathway which could be an explanation as to why miR-23 sponge cells demonstrate no 
growth advantage.  
 
4.1.7 Summary of miR-23 depletion in CHO cells 
miR-23 depletion appeared to influence the CHO cell phenotype in a product-dependent 
manner as both SEAP and IgG secreting cell lines were generated from the same CHO-
K1 parent. miR-23 depletion in CHO-1.14 cells improved CHO cell growth and extended 
cell viability at the expense of IgG productivity. This phenotype was maintained as far as 
clonal isolation at which point particular control clones exhibited a comparable 
phenotype. Depletion of miR-23 in CHO-SEAP cells improved SEAP productivity to a 
maximum average of 3-fold without influencing growth. Under fed-batch culture 
conditions, miR-23 depletion was observed to prolong the onset of cell death. Improved 
specific SEAP productivity was shown to be, in part at least, at the transcriptional level 
with cell size and mRNA stability being ruled out as contributing factors. miR-23 sponge 
clones exhibited an enhanced mitochondrial function with permeabilised assays revealing 
a hyperactivity of 30% at Complex I and Complex II. The difference in mitochondrial 
mass/content between miR-23 and miR-NC clones was demonstrated to be negligible. 
However, the specificity of miR-23 depletion influencing SEAP transcription remained 
undetermined at this point despite the indication of oxidative metabolism being associated 
with specific productivity.  
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4.2 Biotinylated miRNA mimics as a novel method for mRNA target identification 
A novel method of isolating and identifying potential miRNA targets was carried out by 
exploiting the use of biotin-labelled miRNAs. Previous studies have demonstrated the 
utility of selective enrichment of target mRNAs associated with a specific miRNA such 
as the immunoprecipitation of epitope-tagged Ago2 in HEK293 cells transfected with 
miR-124a (Karginov et al. 2007). The inherent benefits of using biotin-tagged miRNA 
would be the identification of direct targets, excluding genes whose expression is 
indirectly influenced by changes in miRNA expression, a refinement not possible in 
microarray or proteomics of whole cell lysates. Furthermore, affinity pull-down would 
isolate mRNAs that exhibit a binding affinity for a selected miRNA. Upon assessing the 
utility of this technique using miR-23b*, we carried out pull-down followed by 
microarray target identification, using CHO-specific arrays, for both biotin-tagged miR-
23b and miR-23b*. When both datasets were compared to that of the biotin-tagged non-
specific control, no enrichment was detected (no hierarchal clustering of samples) when 
data were assessed for trends. 
miR:miR* partners have been demonstrated to have complementary functionality be it 
through the same mRNA targets or similar signalling networks (Yang et al. 2013); or 
unique functionality through an independent set of mRNA targets (Shan et al. 2013). By 
comparing the targets pulled down with miR-23 and miR-23b*, we sought to shed light 
on the relationship and potential functional redundancy between both miRNAs. 
Furthermore, we designed a biotin-labelled miR-23b* (miR-23b*-2 modified) whose 
duplex gave rise to both miR-23b and miR-23b* during processing. The biotin-linker was 
located on the miR-23b* passenger strand and was intended to examine the fate of a 
“discarded” passenger strand when compared to a biotin-linked miR-23b* favoured for 
selection and RISC-loading. However, only 12 CHO-specific array cards were available 
and the inclusion of both cells only and biotin-labelled non-specific control was essential 
resulting in the utilisation of both miR-23b and miR-23b* biotin-labelled mimics. 
As previously mentioned, miR-23 possesses an inherently weak seed-pairing due to its 
AT-rich seed region (Garcia et al. 2011). Despite the gentle lysis process, carried out to 
avoid disturbing any ribonucleoprotein complexes that would otherwise fall apart in 
harsher protocols, this weak pairing could have contributed to the poor pull-down of miR-
23-specific mRNAs resulting in the isolation predominantly of non-specific mRNA 
transcripts. When qRT-PCR was carried out, it was observed that there was no enrichment 
305 
 
detected for miR-23b in either streptavidin-bead-incubated lysates as well as input 
samples prior to streptavidin incubation. It was possible that the biotin-tagged miR-23b 
mimic was not being processed efficiently. Keeping in mind the potential for poor 
transfection efficiency on the day, with a 14-fold enrichment of miR-23b*, it was possible 
that this could have further contributed to the absence of enrichment of miR-23b 
ultimately resulting in no capture of target mRNAs.   
The over-expression of biotin-tagged miR-23b*-1 did not mediate the phenotype 
previously observed for the transient expression of miR-23b* during the primary miRNA 
screen reported in section 3.1 of results (reduced cell growth and viability). This 
observation would suggest that the biotin-labelled miR-23b*-1 was not being sufficiently 
processed in the cell to yield the mature biotin-labelled, RISC-loaded, miR-23b* that 
would otherwise interact with endogenous miR-23b*-specific transcripts mediating their 
degradation or translational suppression. Despite this potential lack of cellular processing 
of the miR-23b*-1 miRNA, enrichment and quantification was observed both in the 
optimisation process and the main experimental run. It is possible that regardless of 
efficient processing, the RNA extraction process would separate the exogenously 
introduced miRNA duplex leaving the miR-23b* strand available for qRT-PCR 
amplification and detection. This would explain how a high fold-change of ~600 was 
identified for miR-23b* during optimisation. However, a ~14-fold change was detected 
for samples that were subsequently loaded on to microarrays. It is possible that the 
reduced enrichment of miR-23b* compared to the enrichment achieved during 
optimisation was due to a poor transfection efficiency on the day ultimately contributing 
to no mRNA target enrichment when microarrays were hybridised and analysed. Lal and 
colleagues reported a >40-fold enrichment of miR-34a in a similar experiment where 982 
genes were found to be captured (ranging from 4-10-fold) and common to two cell lines 
including the identification of 14 new targets of miR-34a (Lal et al. 2011). One of the 
genes predicted to be a target of miR-23b* was phosphoglycerokinase (Pgk-1). It was the 
detection of this gene that gave us the most confident indication that we were achieving 
selective enrichment with miR-23b* (Dheda et al. 2004). On the other hand, its role as a 
housekeeping gene and therefore relatively high and consistent expression could have 
contributed to its identification during optimization, when it was potentially a 
contaminant or non-specifically bound.   
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At the time, the lack of characterisation of miR-23b* and the limited knowledge of bona 
fide targets impeded the validation and optimisation of this method of identifying targets 
of miR-23b and miR-23b*. Previous studies implementing this technology had the 
fundamental resource of validated targets in the cell lines under investigation such as the 
miRNA bantam and its gene target Hid in Drosophila (Orom, Lund 2007) and CDK4/6 
for miR-34a in HEK293 cells (Lal et al. 2011). In future, optimisation of this process 
would be essential with a target previously validated in CHO cells or validated prior to 
using this biotin capture approach. Furthermore, if numerous biotin-tagged miRNA were 
being explored, it would be essential to validate each miRNA independently for criteria 
such as efficient cellular processing, execution of an expected phenotype following its 
over-expression, qPCR enrichment for mature miRNA levels and finally mRNA target 
association and enrichment. Although this method was unsuccessful in our case, we 
propose several viable reasons as to the potential reasons behind its failure. Nonetheless, 
it still remains an attractive approach for the identification of miRNA specific mRNA 
interactions. 
 
4.3 Analysis of the whole cell proteome reveals potential miR-23 regulated processes 
As miRNA regulation ultimately culminates at the interference of mature protein levels 
due to post-transcriptional suppression/de-repression, label-free mass spectrometry was 
carried out as a means to identify finite changes in the translatome of miR-23 depleted 
CHO-SEAP clones demonstrating enhanced specific productivity and mitochondrial 
function. 41 proteins were identified to be DE in miR-23 depleted clones when compared 
to control CHO clones. The influence of miR-23 diversion is of importance when 
attempting to identify potential candidates under miR-23s influence in addition to which 
of these candidates are contributing to the observed phenotype. For this reason, a small 
sub-list of DE proteins are discussed below that could potentially be involved in the 
observed elevated SEAP transcription in addition to enhanced mitochondrial activity. 
 
4.3.1 LETM1 
LETM1 (Leucine zipper-EF-hand-containing transmembrane protein) is a nuclear 
encoded mitochondrial inner membrane protein that is involved in respiratory chain 
biogenesis and calcium (Ca2+) homeostasis in mitochondria. It has been implicated in the 
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onset of Wolf-Hirschhorn syndrome in which its deletion mediates an impaired 
mitochondrial ATP generation, reduced glucose oxidation, altered metabolism and 
increased seizures (Jiang et al. 2013a). We identified LETM1 to be up-regulated by 2.73-
fold in CHO-SEAP cells engineered with a sponge specific against miR-23. 
Oxidative phosphorylation is regulated by cross-talk with cellular calcium signalling, so 
that the transfer of Ca2+ into the mitochondrial matrix signals an increased energy demand 
(Jacobson, Duchen 2004). The rise in matrix Ca2+ concentration [Ca2+]m activates the rate 
limiting enzymes of the TCA cycle – pyruvate dehydrogenase, α-ketoglutarate 
dehydrogenase and NAD-isocitrate dehydrogenase as well as ATP synthase although the 
mechanism remains unclear (Osellame, Blacker & Duchen 2012). These processes 
ultimately drive the increase in the availability of NADH to the respiratory chain (a 
substrate for complex I), an increase in respiration and ATP synthesis. LETM1 has been 
characterised as a Ca2+/H+ antiporter contributing to Ca2+ influx into the mitochondria 
along with other Ca2+ regulatory genes such as the mitochondrial calcium uniporter 
(MCU) (Fig. 4.6). 
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Figure 4.6: LETM1s function as a Ca2+/H+ antiporter in the mitochondria  
 
Figure 4.6: Illustration of the various methods exploited by the mitochondria to import cytosolic Ca2+ 
into the mitochondrial matrix with LETM1 acting as a Ca2+/H+ antiporter. This figure was sourced 
from (Pan, Ryu & Sheu 2011). 
 
With the previous observation that Ca2+ drives mitochondrial energy demand, it is 
possible that LETM1 overexpression contributes to the enhanced OXPHOS observed. 
Furthermore, RNAi-mediated inhibition of LETM1 was demonstrated to nearly abolish 
both mitochondrial Ca2+ and pH increases which indicated that LETM1 catalysed the slow 
uptake of Ca2+ into the mitochondria (Jiang, Zhao & Clapham 2009). The study also 
demonstrated a sustained Ca2+ increase upon LETM1 inhibition suggesting that Ca2+ 
efflux is highly regulated by this protein. Additionally, as the formation of the proton 
gradient by Complex I, III and IV is vital for harnessing electrochemical energy for the 
synthesis of ATP, it has further been suggested that the uptake of Ca2+ into the matrix by 
LETM1 not only drives energy demand by the activation of TCA cycle enzymes but also 
contributes to the electrochemical gradient ending at ATP production via the export of H+ 
out of the matrix (Poburko, Demaurex 2012) (Fig. 4.1). 
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Another interesting role of LETM1/mdm38 (its Saccharomyces cerevisiae homolog) is its 
capability to bind mitochondrial ribosomes through a conserved 14-3-3-like ribosomal 
binding domain (RBD) (Lupo et al. 2011). Enhanced respiratory chain biogenesis has 
been observed to be specific to the effective translation and synthesis of the complex III 
component cytochrome b reductase (Cyt-b) and the complex IV component cytochrome 
c oxidase (COX1) (Bauerschmitt et al. 2010) mediated by LETM1/mdm38 while its loss 
leads to respiratory chain defects. Interestingly, when we assessed mitochondrial function 
in permeabilised CHO cells, a ~30% increase in oxygen consumption was observed for 
complex I and II while a drop in oxygen consumption was observed at complex IV in the 
case of the miR-23 sponge clone 4. It has been demonstrated that overexpression of 
LETM1 can abrogate mitochondrial chain biogenesis (Piao et al. 2009) suggesting a 
potential reasoning behind this reduced activity at complex IV and the lack of synergy 
between complex I and II. LETM1 overexpression has additionally been documented in 
various cancerous phenotypes and its inhibition of mitochondrial function has correlated 
with an increase in glycolysis, compensating for ATP production and resulting in a shift 
from NADH to NADPH production (Chen et al. 2007, Pelicano et al. 2006b). Although 
components specific to the mitochondrial transport chain were not found to be DE in miR-
23 depleted clones, it is possible that their assembly is being perturbed. Furthermore, 
mitochondrial enrichment and label-free mass spectrometry was carried out in an attempt 
to identify subtle alterations taking place within the mitochondria that may have been 
missed through whole cell proteomic analysis. The enhanced mitochondrial function may 
be as a result of the activation of particular TCA cycle enzymes as suggested by LETM1s 
role in Ca2+ homeostasis and the observed up-regulation of metabolic enzymes such as 
isocitrate dehydrogenase (IDH1) and malate dehydrogenase (MDH) (Fig. 4.1). With 
reference to the literature, LETM1 appears to have a regulatory influence in mitochondrial 
function both directly and indirectly spanning the majority of the respiratory chain 
complex components.    
 
4.3.2 14-3-3-eta (YWHAH) 
The 14-3-3 protein family is a well conserved family of heterogeneous dimeric proteins 
whose activation is dependent upon calcium and the cAMP-dependent kinase or 
Calmodulin-dependent protein kinase. They are involved in cell signalling, regulation of 
cell cycle progression, intracellular trafficking/targeting, cytoskeletal structure and 
310 
 
transcription and commonly require the phosphorylation of a serine or threonine residue 
in their target sequences (Ferl, Manak & Reyes 2002). There are 7 known isoforms in 
mammalians (α/β, ε, η, γ, τ/θ, δ/ζ, and σ) suggesting that each exert a distinct function. 
However, knockout studies have demonstrated no definite phenotype which may reflect 
the fact that in many cases isoforms can compensate for each other (Aitken 2006).  
14-3-3-eta (14-3-3-η) was found to be elevated in its abundance in miR-23 depleted CHO-
SEAP cells by 2.7 fold. The regular functions of 14-3-3 proteins encompasses activation, 
inhibition, stabilization or orientation of their binding partners (Gardino, Smerdon & 
Yaffe 2006). This is through the sequestration of target proteins in the cytoplasm 
ultimately inhibiting nuclear or mitochondrial localisation of specific binding partners 
and includes cellular functions such as metabolism (Kleppe et al. 2011) and insulin 
secretion (Chen et al. 2011b).  
Although we are not observing a tumour-like phenotype as previously demonstrated for 
this family of proteins, one interesting role is their involvement in the regulation of gene 
expression, reviewed in (Healy, Khan & Davie 2011). 14-3-3-epsilon’s expression in 
CHO has been previously demonstrated to be induced upon the induction of hypothermic 
growth conditions (Thaisuchat et al. 2011) potentially implicating a role in increased 
specific productivity (Kumar, Gammell & Clynes 2007). Additionally, 14-3-3-epsilon, 
among other 14-3-3 family members, was identified to be increased in their 
expression/translation upon transient transfection with pre-miR-7 (Meleady et al. 2012a) 
whose transient overexpression was also found to mimic a temperature-shift-like 
phenotype including enhanced specific productivity (Barron et al. 2011b). This would 
suggest that the expression of this family of 14-3-3 proteins is involved in enhancing 
transcription in a temperature-dependent and independent manner.  
It has been further demonstrated that the 14-3-3 family of proteins can interfere with gene 
expression at an epigenetic level by binding to and sequestering (Shahbazian, Grunstein 
2007)HDAC4 activity (Wang et al. 2000) and HDAC5 (Grozinger, Schreiber 2000). 
Histone deacetyltranferases (HDACs) regulate gene expression by the phosphorylation of 
H3 of the histone complex rendering surrounding DNA inaccessible. Although the 
association with HDAC4 and 14-3-3 does not interfere with HDAC4s activity, retention 
within the cytoplasm prevents its nuclear localisation and ultimately inhibition of 
transcriptional repression mediated through deacetylation (Fig. 4.1). Additionally, 
prevention of nuclear entry of HDAC4 via 14-3-3 was demonstrated to be activated upon 
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Ca2+/Calmodulin signalling, a biological process found to be activated within miR-23 
depleted CHO clones (Guan et al. 2012) including CaMKIIδ found also to be increased 
in expression in miR-23 depleted CHO clones (Zhang et al. 2007). HDACs lack intrinsic 
DNA-binding activity and are therefore recruited to target sites by their direct association 
with transcriptional activators and repressors (Shahbazian, Grunstein 2007). Target site 
specificity to the SEAP CMV-promoter and enhanced SEAP transcription in the case of 
miR-23 sponge clones is partially suggested when considering the binding specificity can 
be dictated by endogenous transcriptional activators that would be cell type specific yet 
potentially similar within our rCHO-SEAP cell line. To explore the possibility of 14-3-3 
mediating specific transcriptional enhancement of the SEAP gene further validation 
would be required such as siRNA-mediated knockdown of the 14-3-3-eta gene expecting 
to observe reduction in SEAP secretion and transcription or immunoprecipitation of 14-
3-3-eta as means to identify its binding partners, HDAC4 potentially being one. 
Interestingly, a recent paper by Yang and colleagues demonstrated that the addition of the 
small molecule inhibitor of HDACs, Valporic acid (VPA), enhanced antibody titres by 
>20% in numerous cell lines without impacting on glyco-profiles (Yang et al. 2014).  
Several miRNA have been previously demonstrated to regulate the translation of 14-3-3 
proteins in various types of cancer such as miR-193b in MCF7 cells (Leivonen et al. 2011) 
and miR-375 in gastric cancer (Tsukamoto et al. 2010). Interestingly, miR-375 has been 
widely implicated in the regulation of glucose-stimulated insulin secretion through 
targeting multiple factors such as PDK1 and myotrophin in pancreatic β-cells (Li 2014). 
Its previously characterised impact on 14-3-3 proteins expression offers a potential and 
alternative explanation to how it mediates elevated levels of insulin transcript. Despite 
the large regulatory capabilities of this family of proteins, it is possible that 14-3-3 is 
mediating the enhanced SEAP transcription phenotype be it through direct de-repression 
due to miR-23 diversion or as a result of other targets more dramatically de-repressed 
such as CaMKIIδ. 
 
4.3.3 Calcium signalling 
This ubiquitous second messenger, Calcium (Ca2+), is intricately involved in numerous 
cellular processes including signal transduction, muscle contraction, secretion of 
proteins/hormones and gene expression. Within the cell, Ca2+ is stored in specialised 
compartments (endosomes, lysosomes and golgi) as well as within the endoplasmic 
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reticulum (ER)/sarcoplasmic reticulum (SR) (Rizzuto, Pozzan 2006). Protein folding in 
the ER is a very energy-demanding process as many of the molecular chaperones (BiP 
and GP94) hydrolyse ATP during their binding/release cycles. It has been suggested that 
the depletion of intraluminal ER ATP may be an energy deprivation signal to stimulate 
Ca2+ release for uptake by the mitochondria ultimately stimulating OXPHOS as described 
earlier through the activation of TCA cycle enzymes (Kaufman, Malhotra 2014). This 
would suggest that enhanced transcription of the SEAP gene within our miR-23 depleted 
clones is exerting a high energy demand on the ER for efficient folding and processing 
ultimately driving energy demand through Ca2+ release and mitochondrial stimulation 
(Fig. 4.1). Excessive cytosolic/mitochondrial Ca2+ can result in mitochondrial swelling, 
pore opening and collapse of the mitochondrial membrane potential resulting in apoptosis 
by cyt-c release (Osellame, Blacker & Duchen 2012). This would suggest that if 
mitochondrial function is being stimulated by Ca2+ influx, it is as a result of energy 
demand and not the direct influence of miR-23 intervention providing unphysiological 
amounts of Ca2+ through the over-activity of LETM1, for example. An additional layer or 
Ca2+-mediated OXPHOS regulation comes from the observation that extra-mitochondrial 
Ca2+ can influence the transport of glutamate into the mitochondria (Gellerich et al. 2010), 
suggesting the observed increased availability of glutamate is being channelled into the 
mitochondria for utilisation. 
CaMKs (Ca2+/Calmodulin-dependant protein kinases) are a family of serine/threonine 
kinases regulated by calcium and Calmodulin. One member, CaMKIIδ, was observed to 
be increased in expression by 1.75-fold in miR-23 depleted clones. Another protein found 
to be up-regulated and activated by CaMKs was Caldesmon (CALD), an actin binding 
protein (2.16-fold). Both CaMKIIδ and CALD presented themselves as potential targets 
of miR-23 and both are responsive to calcium signalling. 
CaMKIIδ has previously been found to be expressed at relatively high levels in β-cells 
(Easom 1999)  in addition to its activation upon glucose stimulation following the entry 
of Ca2+ (Norling et al. 1994, Wenham, Landt & Easom 1994). Furthermore, CaMKIIδ 
was found to be directly related to the metabolic control of insulin secretion at a 
transcriptional level (Osterhoff et al. 2003). As mentioned previously, CaMKIIδ has been 
demonstrated to phosphorylate the two conserved phosphorylation sites, ser-246/467 in 
HDAC4, ultimately flagging it for the mobilisation of 14-3-3-eta which recognises 
phosphorylated serine/threonine residues (Little et al. 2007). Retention of HDAC4 in the 
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cytosol prevents histone deacetylation maintaining DNA in a relaxed and 
transcriptionally accessible state (Fig. 4.1) Furthermore, CaMKIIδ possesses two splice 
variants (δB and δC) the former of which contains a nuclear localisation signal (NLS) 
(Zhang, Brown 2004) further suggesting its potential role in enhancing SEAP 
transcription. Perhaps elevated SEAP productivity could be as a result of this process with 
mitochondrial function being a by-product of calcium signalling stimulated by ATP-
depleted ER-release. It would be interesting to evaluate the levels of intracellular calcium 
in our miR-23 stable clones in addition to inhibiting CaMKIIδ.  
 
4.3.4 TCA cycle and metabolism 
Several proteins were found to be DE in CHO-SEAP-sponge-23 that could potentially be 
playing a role in cellular metabolism including isocitrate dehydrogenase 1 (IDH1-1.68-
fold up regulated), malate dehydrogenase (MDH – 1.67-fold up regulated), Lysosomal 
alpha glucosidase (1.65-fold up regulated) and prolyl-4-hydroylase (P4HA1 – 1.84-fold 
up-regulated). It’s been suggested that some of these candidates can be activated by an 
influx of Ca2+ into the mitochondrial matrix suggesting their function to be responsive to 
internal cellular cues and potentially not causative. Nevertheless, their increased 
abundance could be responsible for the increase in mitochondrial OXPHOS previously 
observed in miR-23 depleted CHO-SEAP cells (Fig. 4.1). 
Lysosomal alpha glycosidase is an enzyme encoded by the GAA gene that mediates the 
degradation of glycogen to glucose from lysosomes. Lysosomal alpha-glucosidase is 
known to be responsible for a lysosomal storage disease, Pompe(Manganelli, Ruggiero 
2013) disease, whereby a build-up of lysosomal glycogen results in the inhibition of 
lysosome activity, aberration of autophagy and ultimately muscle wasting characterised 
by the build-up of cellular debris (Manganelli, Ruggiero 2013). Mitochondrial 
dysfunction has also been implicated in the onset of Pompe disease, however, this lull in 
mitochondria function is potentially coupled to the inhibited autophagic turnover of 
cellular organelles in addition to broken cristae due to the accumulation of membrane 
bound glycogen particles within the mitochondria (Raben et al. 2012). Increased 
expression of this enzyme in miR-23 depleted CHO cell could potentially supply excess 
glucose through glycolysis into the TCA cycle resulting in the observed increase in 
OXPHOS in addition to ensuring effective and optimal lysosome function.    
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IDH is a family of enzymes that include three distinct enzymes: IDH1, IDH2 and IDH3. 
All three enzymes catalyse the conversion of isocitrate to α-KG, a central metabolite for 
the TCA cycle. IDH1 and 2 use NADP+ while IDH3 uses NAD+ with IDH1 being located 
in the cytosol and the latter two being localised to the mitochondria (Yang et al. 2012). 
As NADH is a reducing equivalent providing electrons to the ETS and IDH3s reaction 
being irreversible, this isoform is considered central to oxidative phosphorylation (Fig. 
4.7). 
 
Figure 4.7: The role of IDH in cellular metabolism 
 
Figure 4.7: The role of the IDH family of enzymes in cellular metabolism including the central role 
IDH3 plays in the TCA cycle and both the compensatory roles IDH1/2 play in the TCA cycle in 
addition to downstream molecular pathways. This figure was sourced from (Yang et al. 2012). 
 
NADPH on the other hand is involved in many cellular processes including defence 
against oxidative stress, fatty acid synthesis and cholesterol biosynthesis (Kim et al. 
2007). It is possible that the cytosolic IDH1 enzyme reaction might compensate for the 
loss of the mitochondrial IDH2/3 by producing metabolites in the cytosol that can be 
transported into the mitochondria as it has previously been observed that rapid transport 
of metabolites can take place between the cytosol and the mitochondria such as citrate, 
isocitrate and α-ketoglutarate (Fig. 4.8). 
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Figure 4.8: The role of IDH1 in supplementing the TCA cycle 
 
Figure 4.8: The potential role of IDH1 in rCHO-SEAP cells inducing an increased OXPHOS. IDH1 
catalysis the reversible conversion of isocitrate to α-KG with the forward reaction being 
predominant. This reaction takes place in the cytoplasm whereby α-KG is then transported into the 
mitochondria for entrance into the TCA cycle in what’s known as anaplerosis.   
 
Mitochondrial export of citrate/isocitrate was demonstrated to be an important step in 
glucose-stimulated insulin secretion with the overexpression of citrate/isocitrate carriers 
(CICs) enhancing GSIS (Joseph et al. 2006). Furthermore, siRNA knockdown of 
cytosolic IDH1 inhibited GSIS by 59% (Ronnebaum et al. 2006). This observation 
reinforces the suggested function of α-KG as a co-factor for other cellular pathways such 
as the activation of α-KG-dependent dioxygenases and that the predominant mutations in 
IDH1/2 isotypes influence these alternative molecular pathways. Although IDH1 is 
redundant for the IDH2/3 interconversion of isocitrate to α-KG, its knockdown impacting 
on insulin secretion suggests a non-redundant role in this pathway. Elevated expression 
of IDH1, for example as a result of miR-23 diversion, could potentially provide the cell 
with excess α-KG ultimately providing elevated NADH through TCA cycle processing. 
However, the exclusive production of NADPH in the cytosol, through export of TCA 
cycle intermediates via excess downstream sources, could possibly be playing a part in 
signalling networks such as its interaction with dioxygenases and its role in oxidative 
stress as IDH1 mutations have been associated with increased oxidative stress in gliomas 
(Gilbert et al. 2014). Furthermore, IDH1 is one of the key genes found to be up-regulated 
in breast cancer stem cells, which were identified to have lower levels of reactive oxygen 
species (ROS) (Diehn et al. 2009). The overabundance of α-KG in addition to Fe2+ serve 
Isocitrate α-ketoglutarate
NADP+ NADPH
IDH1
TCA
cycle Anaplerosis
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as cofactors for the activity of histone demethylases such as Jumonji C ultimately 
switching gene expression on (Horbinski 2013).  
Prolyl-4-hydroxylase is an intracellular enzyme required for the synthesis of all types of 
collagens and is stimulated by the levels of α-KG, potentially provided for by IDH1 in 
miR-23 depleted CHO cells. The functional roles of prolyl-hydroxylases or 2-OG 
oxygenases (2-OG is 2-oxoglutarate also known as α-ketoglutarate or α-KG) have a wide 
range of functional roles including hypoxic response (oxygen sensing), nucleic acid repair 
and modification, fatty acid metabolism and chromatin modification (Loenarz, Schofield 
2008). Prolyl-hydroxylase catalyses the conversion of proline and α-KG into 
hydroxyproline, succinate and CO2 in the presence of iron and dioxygen. Prolyl-4-
hydroxylase has been demonstrated to have a higher affinity of α-KG than other PDHs. 
This high affinity would suggest that the cell would possess an inherent increased 
sensitivity in responding to TCA cycle defects. It is possible that the α-KG being 
produced exclusively in the cytosol by IDH1 is being sensed and processed by P4HA1 
into its products hydoxyproline and succinate. Succinate could be shuttled into the 
mitochondria where it serves as a substrate for succinate dehydrogenase (complex II) 
resulting in the increased oxygen consumption observed at this complex. A study by Zhao 
et al (Zhao et al. 2009) demonstrated that ectopic expression of an IDH1 mutant was 
found to result in the inhibition of the activity of prolyl hydroxylase (PDH) which could 
be restored by feeding cells with α-KG. Various pathways are under the influence of these 
hydroxylases including collagen synthesis, histone modification and transcription. It is 
estimated that there are over 60 α-KG-dependent dioxygenases (Rose et al. 2011) 
suggesting that changes in IDH1 levels could potentially affect multiple pathways.   
With the observation of glutaminase not being elevated in its translation due to miR-23 
depletion, the increase in the glutamate concentration of 65% across all miR-23 depleted 
clones could be as a result of the catapleurotic export of α-ketoglutarate due to elevated 
IDH1 (increased synthesis of α-KG from isocitrate) and its conversion into glutamate 
(Owen, Kalhan & Hanson 2002).     
Malate dehydrogenase (MDH) catalyses the conversion of malate to oxaloacetate in a 
NAD+-dependent manner generating the reducing equivalent NADH, contributing to the 
electron transport chain. It is considered the second rate limiting step in the TCA cycle as 
oxaloacetate is the terminal substrate required to produce citrate in the presence of acetyl-
CoA to start the cycle over again. MDH was found to be increased in its expression in 
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miR-23 depleted CHO-SEAP clones. This increase in MDH expression could be 
providing surplus NADH reducing equivalent for electron donation at complex I thus 
contributing to the elevated OXPHOS previously observed. As an aside, interference at 
these rate limiting steps can be responsible for mitochondrial dysfunction due to 
metabolite starvation such as the “Crabtree effect” whereby exclusive conversion of 
glucose to lactate inhibits TCA cycle recycling by reducing Acetyl-CoA production from 
pyruvate (Dell'Antone 2012) (Fig. 4.9). 
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Figure 4.9: The “Warburg” and “Crabtree” effect 
 
Figure 4.9: The “Warburg effect” (Red Box) demonstrates the high consumption of glucose by 
cancer/CHO cells with exclusive conversion to lactate. Although energetically inefficient, 
intermediates provide key substrates for biomass production to actively proliferating cells. As 
pyruvate is converted to lactate and not Acetyl-CoA, the TCA cycle is starved of essential starting 
metabolites (Acetyl-CoA and oxaloacetate) causing TCA cycle weakening termed the “Crabtree 
effects” (Green box). However, the overexpression of certain enzyme such as IDH1 and MDH, in 
addition to the increased abundance of glutamate, can supplement and strengthen the TCA cycle by 
providing key intermediates such as α-KG and encouraging forward reactions. 
 
Overexpression of MDH II in CHO resulted in increases in intracellular ATP and NADH 
with a corresponding 1.9-fold improvement in integral viable cell density (Chong et al. 
2010). Growth improvement was not an observed benefit in our miR-23 depleted stable 
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SEAP cell line despite NADH concentration being correlated with cellular proliferation. 
It would be interesting to assess miR-23 depleted clones for their metabolic profiles 
including ATP, NADH, NADPH, as well as TCA intermediate metabolites such as 
malate, α-KG, citrate and isocitrate.    
 
4.3.5 Combating oxidative stress 
Evidence suggests that protein folding and the generation of reactive oxygen species 
(ROS) is a byproduct of protein oxidation in the ER. Additionally, one of the main cellular 
organelles involved in the production of ROS is the mitochondria which, in a state of 
chronic nutrient/energy overload, the flux of nutrients through the mitochondrial ETS can 
result in enhanced ROS production and ultimately oxidative stress (Malhotra, Kaufman 
2007). The observation of elevated transcription of the SEAP gene as well as increased 
oxidative phosphorylation within miR-23 depleted clones, in addition to metabolic 
enzymes of the TCA cycle fuelling OXPHOS, suggests that miR-23 sponge clones by 
comparison to their control counterparts have a higher degree of oxidative stress. 
Numerous proteins were found to be up-regulated that have been shown to respond to 
oxidative stress including Thioredoxin reductase 1 (TXNRD1: 1.66-fold), Heme 
oxygenase-1 (HMOX-1 or HO-1: 2.33-fold), glutathione-s-transferase Mu-1 and 
glutathione-s-transferase Mu-6 (GSTM1/GSTM6 – 1.56/1.74-fold up-regulated 
respectively). 
Thioredoxin reductase-1 is a cytosolic antioxidant which is known to reduce various 
cellular compounds including Thioredoxin using NADPH. Reduction of thioredoxin 
(TXN) activates it allowing for the reduction of oxidised cysteins in cellular proteins and 
scavenge peroxides by peroxidredoxins (PRDX), thus protecting the cell against oxidative 
stress (Cadenas et al. 2010). Thioredoxin reductase does appear to be able to directly 
remove ROS by reducing oxidants and hydrogen peroxide due to its highly reactive 
selenocystein (Cenas et al. 2004). Activated thioredoxin has a redox-active cystein pair 
through which it interacts with other proteins to regenerate proteins damaged by ROS for 
example H2O2-inactivated GAPDH (Fernando et al. 1992). Thioredoxin is also a co-factor 
for methionine sulfoxide reductase, whereby it can reduce methionine sulfoxide residues 
in oxidised proteins caused by ROS (Watson et al. 2004). Thioredoxin reductase deficient 
cells demonstrated a decreased basal mitochondrial oxygen consumption rates (Lopert, 
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Day & Patel 2012) suggesting its role in maintaining efficient mitochondrial function 
under harsh oxidative stressful conditions.    
Heme oxygenase 1 is a ubiquitous inducible cellular antioxidant stress protein that 
catalyses the conversion of the pro-oxidant molecule heme into the products biliverdin, 
iron and CO. HMOX1 is up-regulated in response to cellular stress such as hydrogen 
peroxide. Mitochondrial localisation of HMOX1 has been demonstrated to confer 
resistance to oxidative stress, correct mitochondrial dysfunction and inhibit apoptosis and 
gastric injury (Bindu et al. 2011). Interestingly, Thioredoxin reductase has been 
demonstrated to regulate the induction of heme-oxygenase-1 expression (Trigona et al. 
2006) suggesting a synergistic link between both pathways and that the increased 
expression of HMOX1 in miR-23 depleted CHO-SEAP cells could be a result of oxidative 
stress and not as a function of miR-23 diversion. 
The ubiquitin-proteasome pathway (UPP) is the primary cytosolic proteolytic machinery 
for the selective degradation and removal of damaged proteins. Studies have 
demonstrated that the 26S proteosome is highly susceptible to inactivation during 
oxidative stress whereas the 20S proteasome is relatively stable under a variety of 
oxidative stresses (Reinheckel et al. 1998). The 26S proteosome has been found to be 
responsible for the unfolding and degradation of most normal ubiquitinylated proteins 
(missense mutations) but shows poor selectively for oxidised proteins (Ding, Dimayuga 
& Keller 2006). Unlike the 26S proteasome, the 20S exhibits a high degree of selectivity 
for degrading oxidised or otherwise damaged proteins resulting from oxidative stress 
(Pickering, Davies 2012). The 26S proteosome is composed of a 20S and two 19S 
subunits. Cellular adaptation to oxidative stress has revealed that dissociation of the 26S 
proteome liberates the oxidative-damaged specific 20S subunit as a means of combatting 
potential cellular damage in a transcriptional-independent manner (Grune et al. 2011). It 
is possible that the down-regulation of PSMD7 (26S proteosome non-ATPase regulatory 
subunit 7-like) which is a component of the 19S subunit is reducing the association and 
formation of the 26S proteosome thus providing increased availability of the 20S subunit 
potentially providing assistance for mitochondrial/ER derived oxidative stress. 
In addition to their role in cellular metabolism and other molecular pathways such as 
biosynthesis, IDH1/2 have been observed to play a vital role in cell protection against a 
variety of insults that produce oxidative stress (Chang, Xu & Shu 2011). Reduced 
expression of both IDH1 and IDH2 was observed to result in higher levels of ROS and a 
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greater oxidative damage in response to an oxidative insult (Jo et al. 2001, Lee et al. 
2002). Additionally, several reports have demonstrated that the overexpression of IDH1/2 
can offer cellular protection against oxidative stress (Kim et al. 2007, Shin et al. 2004). 
For examples, NADPH produced by IDH1/2 can be utilised by glutathione reductase to 
convert the oxidised form of glutathione (GSSG) to the reduced form (GSH) which can 
neutralise free radicals and ROS species (Lee et al. 2002). 
Following from this, two glutathione-s-transferase of the Mu (µ) isoform (1 and 6) were 
found to be up-regulated in miR-23 depleted CHO cells. Maintenance of the cellular 
antioxidant glutathione (GSH) in different cellular compartments is under the critical 
regulation of GSTs. GSTs function in cellular detoxification of endogenous toxic 
metabolites, superoxide radicals and exogenous toxic chemicals (Raza 2011). Reports 
have documented the presence of the mu class of GSTs in rat and mouse mitochondria in 
addition to rat brain mitochondria (Addya et al. 1994, Raza et al. 2002, Bhagwat et al. 
1998). The reduced expression of GSTM2 was observed to increase oxidative stress in 
spontaneously hypertensive rats (Zhou et al. 2008). The observation of the elevated 
abundance of these antioxidant proteins further suggests that cellular and molecular 
pathways, mediating an enhanced SEAP productivity are inducing oxidative stress which 
is being compensated for by numerous cellular responses. Glutathione (GSH) and 
Thioredoxin are considered the most important out of the four antioxidant systems in the 
cell. The observation of both of these systems potentially being overactive again suggest 
that miR-23 depleted CHO cells are under oxidative stress which is being adequately dealt 
with. Without measuring the internal levels of ROS, it is premature to assume that the 
elevated expression of these oxidative stress responding proteins are activated as a result 
of elevated mitochondrial function and SEAP production, in addition to their expression 
(TXNDR1) being a result of miR-23 depletion or responsive to cellular cues.  
 
4.4 Proteomic analysis of enriched mitochondria   
Cell fractionation to isolate mitochondria and profile them directly not only serves to 
identify low abundant proteins that would be otherwise over-shadowed by high abundant 
proteins, but also serves to refine the localisation of previously identified proteins as 
functioning specifically in the mitochondria (Drissi, Dubois & Boisvert 2013). 
The previous link between miR-23 and cellular bioenergetics through glutaminolysis 
(Gao et al. 2009) highlights its potential role in our enhanced mitochondrial function 
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through other pathways such as the various proteins mentioned previously. Another 
mitochondrial-related gene found to be under the translational control of miR-23 is the 
mitochondrial transcription factor A (TFAM) (Jiang et al. 2013b). This gene is involved 
in the transcriptional initiation of the mitochondrial genome (Campbell, Kolesar & 
Kaufman 2012) in addition to mtDNA packaging and copy number (Uchiumi, Kang 
2012). Although several of these validated gene targets of miR-23 (GLS, TFAM and 
XIAP) did not appear to be DE when label-free mass spectrometry was carried out, it is 
possible that miR-23 can influence cellular metabolism through various molecular means. 
However, given the previous association of high CHO cell specific productivity with 
oxidative metabolism (Young 2013) and the ability of the endoplasmic reticulum to 
increase energy provisions through calcium signalling (Kaufman, Malhotra 2014), it is 
possible that this enhanced mitochondrial function is not causative but symptomatic of 
the enhanced production phenotype of miR-23 sponge CHO-SEAP cells.  
  
4.4.1 A deeper insight into mitochondrial function 
Lactate dehydrogenase (LDH) directly catalyses the interconversion of pyruvate to lactate 
with the concurrent interconversion of NAHD and NAD+. LDH-A was observed to be 
down-regulated in miR-23 sponge clones by 1.3-fold. Although lactate is considered the 
lesser of two evils when compared to ammonia (Kim do et al. 2013), the propensity of 
CHO cells to act like some cancers with respect to the Warburg effect, excessive 
accumulation of lactate is an issue. Inhibition of LDH-A has been demonstrated to 
decrease glucose flux in the glycolytic pathway (Chen et al. 2001) and has further been 
demonstrated in CHO, upon siRNA-mediated inhibition, to increase hTPO production by 
2.2-fold without influencing growth or viability (Kim, Lee 2007). These authors 
suggested that the viability benefit of reduced LDH-A activity may be more apparent 
under fed-batch conditions whereby a high glucose feed would result in faster 
accumulation of lactate. Although measurement of lactate levels would be required within 
our miR-23 sponge clones, this could be a potential explanation for the extended viability 
phase observed under fed-batch conditions that was not apparent when in batch culture.  
 
It has been suggested that the increase in recombinant protein production may drive 
pyruvate into the TCA cycle or divert glucose towards the pentose phosphate pathway 
(Sengupta, Rose & Morgan 2011). With the observation of enhanced mitochondrial 
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function in miR-23 depleted clones, it is likely that oxidative metabolism is favoured. The 
reduced expression of LDH-A could also make pyruvate transiently more abundant for 
channelling into the TCA cycle (Fig. 4.9). With the observation that glycolytic 
metabolism and oxidative metabolism being associated with growth and productivity, 
respectively (Young 2013), the potential reduced glycolysis not impacting on miR-23 
sponge clone growth is interesting. It has been reported that a 20% reduction in glucose 
consumption in a CHO cell engineered with reduced LDH-A and enhanced Bcl2 
expression, had no impact on growth (Jeon, Yu & Lee 2011). Another interesting report 
demonstrated that the co-inhibition of LDH-A and pyruvate dehydrogenase kinase 
(PDHK, the enzyme responsible for PDH inhibition) resulted in the 90% increase in IgG 
specific productivity without any appreciable impact on CHO cell growth (Zhou et al. 
2011a).  
The enzyme pyruvate kinase (PKM) was found to be down-regulated in miR-23 sponge 
clones by 1.9-fold. This enzyme is responsible for the generation of pyruvate from 
phosoenolpyruvic acid and is a key regulator of the metabolic fate of the glycolytic 
intermediates (Iqbal et al. 2014). Its expression has been demonstrated to promote the 
Warburg effect and tumour growth (Sun et al. 2011). Down-regulation of this gene could 
be mediating a reduced dependency on glycolytic metabolism in miR-23 depleted clones 
starving the TCA cycle of its perquisite metabolite Acetyl-CoA. Acetyl-CoA catabolic 
processes were also found to be enriched for in GO assessment. Oxidative metabolism is 
possibly supplemented, as indicated by the enhanced mitochondrial function, through the 
various isotypes of TCA cycle enzyme such as IDH1 and MDH1. This is irrespective of 
the potential enhanced activity of various TCA cycle enzymes through calcium signalling 
suggested by the increased expression of LETM1 and the energy requirements of the ER 
(Fig. 4.1). However, without assessing the specific consumption rate of glucose, it would 
be premature to conclude that glycolytic metabolism is being perturbed in our miR-23 
sponge clones or if they are simply eliciting an enhanced mitochondrial function.  
Both MDH isotypes were identified as being overexpressed in miR-23 depleted CHO 
cells indicating that the isolation of mitochondria was successful in unveiling 
mitochondrial specific proteins such as the mitochondrial specific MDH2. These 
enzymes mediate the conversion of malate to oxaloacetate in addition to generating the 
reducing equivalent NADH (Marín-García 2012) 
. Overexpression of MDH2 in CHO cells has been demonstrated to increase intracellular 
ATP and NADH levels by 1.9-fold contributing to an increase in IVCC (Chong et al. 
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2009b). Weakening of the TCA cycle has been observed due to the export of vital 
intermediates such as α-ketoglutarate and malate out of the mitochondrial matrix 
(Dell'Antone 2012). The constant supply of oxaloacetate via MDH1 and 2 may allow for 
the efficient energy turn over as indicated when respiratory control ratios were calculated 
for miR-23 sponge clones, as no bottleneck is provided in addition to the reduced LDH-
A activity potentially providing excess pyruvate. The restoration of oxaloacetate has been 
observed to drive continued TCA cycle function (DeBerardinis et al. 2007). Another rate 
limiting metabolite α-ketoglutarate could be in constant supply through the elevated 
abundance of IDH1, identified in both whole cell and mitochondria enriched experiments. 
This could potentially compensate for the observation of the reduced expression of the 
mitochondrial-specific isotype, IDH3A, the predominant isotype involved in the TCA 
cycle (Yang et al. 2012). It was also observed that other enzymes involved in the TCA 
cycle were found to be down-regulated such as 2-oxoglutarate dehydrogenase (KGD1) 
and aconitate hydrotase (ACO2). However, it is possible that the small changes in 
abundance may not be impacting significantly on mitochondrial function as indicated in 
intact and permeabilise assays. 
Enzymes involved in combatting oxidative stress were found to be increased in miR-23 
sponge clones including those previously identified in the whole lysate experiment such 
as TXNDR1, HMOX1 and GSTM1/6. Mitochondrial Glutathione reductase (GSR) was 
found to be upregulated 1.3-fold and serves as a key enzyme that converts oxidised 
glutathione (GSSG) to its reduced form (GSH) which ultimately scavenges ROS (Gill et 
al. 2013). Peroxiredoxin-2 (PRDX2) was also found to be increased in expression and has 
been linked with protecting proteins against oxidative damage (Rhee et al. 2012). The 
observation of the increase in expression of additional proteins involved in conferring 
resistance to oxidative stress further suggest the increase in mitochondrial function 
despite certain TCA cycle members being reduced.(Li et al. 2005) 
Several proteins found to be associated with the electron transport system were found to 
be DE in mitochondrial enriched miR-23 sponge clone extracts. Cytochrome c oxidase 
(COX), also known as Complex IV, is the terminal enzyme complex of the mitochondrial 
electron transport system that couples the transfer of electrons from reduced cytochrome 
c to molecular oxygen and is composed of 13 subunits of both nuclear and mitochondrial 
origin. The subunit COX5A, nuclear in origin, was found to be down-regulated in miR-
23 sponge clones by 1.8-fold. This complex has been associated with efficient assembly 
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of the COX supercomplex. The first step in COX assembly is the membrane integration 
of COX1 followed by COX4-COX5A (Stiburek et al. 2005). Furthermore, direct depletion 
of COX5A resulted in the decreased levels of assembly of the COX enzyme with a parallel 
accumulation of COX sub-(Fornuskova et al. 2010)complexes and unassembled subunits 
(Fornuskova et al. 2010). Another mitochondrial complex associated protein UQCRC1 
(ubiquinol-cytochrome b-c1 reductase) was found to be down-regulated by 1.5-fold in 
miR-23 sponge clones. This enzyme is responsible for transferring electrons form QH2 to 
ferricytochrome c. Specific loss of UQCRC1 has been demonstrated to be induced upon 
exposure to oxidative stress (Shibanuma et al. 2011). The reduction in abundance of both 
these Complex III and IV related proteins could potentially explain the bottleneck in 
electron transfer suggested earlier for the lack of synergy upon stimulation of Complex I 
and II in permeabilised assays. Furthermore, stimulation of Complex IV by TMPD 
demonstrated a reduction in oxygen consumption in miR-23 sponge clones potentially 
due to the reduced expression of COX5A and associated assembly of COX. The continued 
healthy phenotype of miR-23 deplete clones would suggest that the reduced expression 
of these mitochondrial related proteins is not detrimental to the cell.  
The protein NDUFA1 was once thought to be associated with complex I is now emerging 
as having a role with complex IV (Carroll et al. 2006). NDUFA4 has been shown to be 
associated with COX function but not in its assembly (Pitceathly et al. 2013) suggesting 
that, despite its increased expression, will not enhance COX function. One observation 
however indicates that enhanced mitochondrial function maybe due to the increased 
abundance of metabolites providing excess quantities of the reducing equivalent NADH 
and FADH2. This observation was the reduction in abundance of two components of 
Complex II, Succinate dehydrogenase (SDH), A and B. SDH catalyses the oxidation of 
succinate to fumarate in addition to the reduction of ubiquinone to ubiquinol (Kim et al. 
2013). The dual role this enzyme plays links the oxidation of glucose in the TCA cycle 
with the production of ATP. The reduced expression of two components does not 
correlate the increased oxygen consumption previously observed at complex II during 
permeabilised assays. However, this could be due to the mild reduction in abundance of 
1.3 and 1.4 for SDHA and SDHB, respectively, potentially not abrogating enzymatic 
function. Furthermore, the enhanced activity of other TCA cycle enzymes such as IDH 
and MDH could provide excess metabolites mediating the observed enhanced activity.   
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The indication towards enhanced mitochondrial function with elevated SEAP 
productivity as a result of stable miR-23 depletion begs the question: Is SEAP 
productivity enhanced as a function of oxidative metabolism or is oxidative metabolism 
elevated as a result of enhanced SEAP transcription and processing? Previous studies 
have documented the ability of MYC to induce mitochondrial biogenesis, function and 
enhanced oxygen consumption (Li et al. 2005). Metabolic reprogramming in activated B-
cells has also been recently reported with both an increase in glycolytic and oxidative 
metabolism being observed (Le et al. 2012). The ability of MYC to regulate the 
expression of several(O'Donnell et al. 2005b) miRNAs (O'Donnell et al. 2005b), miR-
23a/b included (Gao et al. 2009), including its role in metabolic reprogramming (Eilers, 
Eisenman 2008) and the association of miR-23 with B-cell differentiation (Li et al. 
2011a), further strengthens the potential of miR-23 playing a direct role in cellular 
metabolism.   
 
4.5 Potential bona-fide targets of miR-23 
Identification of true miRNA targets is a cumbersome and trialling task, which without 
appropriate validation, leaves the researcher with an extensive list of potential targets all 
of which have question marks over them. Earlier, we demonstrated that by integrating 
multiple “omics” datasets, low scoring in-silico predicted targets that would otherwise be 
discounted can ultimately be discovered. However, when posed with a list of DE proteins 
from a single dataset, prediction algorithms are still the number one source for narrowing 
down the potential target list. Of the 41 protein targets found to be DE in the whole cell 
lysates of stable miR-23 depleted clones, 13 were found to overlap with the list generated 
from the miRWalk algorithm. Given that the miR-23 sponge clones divert miR-23 away 
from its endogenous mRNA targets, mRNA transcripts under direct influence of miR-23 
should demonstrate an increase in their level of translation. When this was considered, 8 
protein targets (LETM1, CALM1, CaMKIIδ, FERMT2, IDH1, TXNRD1, PPP1CB and 
P4HA1) of the 13 overlapping targets were found to be up-regulated. These eight targets 
present themselves as priority targets of miR-23a/b. miRNAs impact on an endogenous 
target is generally accepted to be modest, mediating an impact of ~ 2-fold 
increase/decrease in the level of translation of the target protein (Meleady et al. 2012b). 
All of these candidates demonstrate this modest change in translation ranging from 1.67-
2.73 with LETM1 exhibiting the highest level of translational de-repression. Of course 
327 
 
using the term de-repression is premature at this point as further validation would be 
required as a means to assess the totality of miR-23s influence on these targets. 
 
Detecting translational de-repression has been observed in the past to be easier than 
translational inhibition despite both eliciting modest impacts on the translatome 
(Martinez-Sanchez, Murphy 2013). From this perspective, it would be worth carrying out 
label-free mass spectrometry on the parental CHO-SEAP cell line upon the transient 
overexpression of miR-23 such as in the case of miR-7 overexpression with subsequent 
proteomic analysis (Meleady et al. 2012a). Transient over-expression of miR-23a/b with 
subsequent analysis of each of the above targets on both the mRNA and protein levels 
would be the next step in elucidating their potential as true targets. Furthermore, siRNA 
inhibition of each target in stable CHO clones engineered to deplete miR-23 would be a 
means to determine which of the panel of targets is mediating the observed phenotype of 
enhanced SEAP mRNA transcription contributing to elevated specific productivity and 
those candidates whose expression is potentially symptomatic and not causative of the 
induced phenotype. Lastly, cloning the 3’UTR of the highest priority targets downstream 
of a reporter gene would be required to validate the potential suppressive role of miR-
23a/b.   
LETM1 presents itself as the most attractive and high priority candidate in relation to 
being a target of miR-23. As a means to account for variation between clones, all clones 
were grouped together i.e. triplicate samples of miR-23 sponge clone 4 and 6 being 
analysed as 6 miR-23 replicates. This would allow for the variation within clones 
themselves to be accounted for with only protein candidates under the influence of miR-
23 demonstrating significant differences between the control groups. When replicates 
from both miR-23 and miR-NC groups were randomised and compared, two proteins 
were found to be DE that did not overlap with the final DE list. This was performed to 
assess whether identifications were a result of random chance. LETM1 demonstrated no 
DE between control groups while not exhibiting DE when both miR-23 sponge clones 
were compared. To further refine the list and potentially eliminate clonal variation and 
background noise, more miR-23 sponge clones and control clones could be selected and 
assessed for differential protein expression.  
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4.6 Integrated “omics” profile of CHO cells with varying growth rates 
The use of miRNAs in CHO cell engineering has flourished in the past few years and 
have been secured in the toolbox of viable engineering strategies (reviewed recently in 
(Jadhav et al. 2013)) and highlighted in the stable manipulation of miR-23 in CHO-SEAP 
cells. Numerous DE profiles have been carried out to date in an attempt to identify 
miRNAs involved in the regulation of bioprocess relevant phenotypes including 
temperature shift (TS) (Gammell et al. 2007, Barron et al. 2011a), growth phases 
(Hernandez Bort et al. 2012), apoptosis induction (Druz et al. 2011) and CHO cells grown 
in serum-containing medium (Jadhav et al. 2013). These profiles have resulted in stable 
CHO cell manipulation of candidates such as miR-7 (Sanchez et al. 2013b) and miR-466h 
(Druz et al. 2013) enhancing bioprocess phenotypes.  
With the advent of biphasic culture, accumulation of cell density is crucial before entering 
the “production phase” whereby growth is compromised to the benefit of specific 
productivity. We sought to potentially enhance growth early in culture using miRNAs 
derived from this profile with an application in temperature shift culture, published in 
BMC Genomics in 2012 (Clarke et al. 2012).  
Additionally, by acquiring transcriptomic data, mRNA and protein, a systems level 
perspective of the molecular networks surrounding CHO cell growth was revealed, 
demonstrating gene ontology enrichment for cellular processes such as translation and 
RNA splicing. Furthermore, the integration of all three datasets facilitated the 
identification of potential mRNA targets under the direct regulatory control of the DE 
miRNAs. This approach also highlighted targets that can be scored poorly by prediction 
algorithms, Rab14-miR451 (Wang et al. 2011a), in addition to identifying “non-seed” 
mRNA targets whose miRNA: mRNA interaction does not follow the binding criteria by 
which most prediction algorithms are based upon (Pasquinelli 2012). 
 
Given the large inherent genetic heterogeneity between CHO cell lines, demonstrated 
when comparing the genomes of 6 CHO cell lines including CHO-K1, DG-44 and CHO-
S against the ancestral sequenced CHO-K1 genome (Lewis et al. 2013), it was essential 
to minimise variation through the careful selection of CHO cells that would form the basis 
of the DE profile. Chromosomal heterogeneity has also been observed even among cells 
within a clonal population (Wurm, Hacker 2011), not to mention the genetic 
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heterogeneity associated with recombinant CHO cell line development (Matasci et al. 
2011).  
All things considered, the study sought to minimise variation through the careful selection 
of mAb-secreting CHO cell lines that were derived from the same transfection pool, 
exhibiting a range of growth rates spanning from 0.011-0.044 hr-1. To further eliminate 
biological noise and expose variations related to the proliferation phenotype, sister clones 
selected demonstrated a similar level of cell specific productivity of 24 pg/cell/day (±3), 
an attribute that commonly varies with growth rate (Barron et al. 2011a)  
      
4.6.1 Identification of miRNAs associated with cellular growth rate 
Of the 51 DE miRNAs identified within this study, a number of them have previously 
been associated with cell growth. Several miRNAs that were found to be upregulated 
form part of a well-studied oncogenic cluster, miR-17~92 (e.g. miR-17, miR-18a, miR-
18b, miR-20a, miR-20b and miR-106a) (Olive, Li & He 2013). This cluster has been 
shown to be directly activated by the oncogenic transcription factor Myc (Dews et al. 
2006b) and E2F1 (O'Donnell et al. 2005a). Its repression has also been demonstrated to 
be influenced by p53 (Yan et al. 2009b). Individual cluster components contribute to the 
clusters pleiotropic function through the regulation of various phenotypes such as 
proliferation (p21), apoptosis (Bim) and angiogenesis (Tsp1) (Olive, Jiang & He 2010a) 
(Fig. 1.3 of the Introduction). This miRNA cluster has previously been identified in 
CHO (Hernandez Bort et al. 2012). Functional redundancy has been suggested by Hackl 
et al., by identifying the conservation of MREs within 26 validated targets of this cluster 
through next-generation sequencing (such as E2F1, CCND1, BCL211 and PTEN) in CHO 
(Hackl et al. 2011).  
Among the 51 miRNAs DE within fast growing CHO cells, 15 make up the lesser 
characterised miR-passenger (miR*) strands. Thought initially to be a by-product or 
carrier (Guo, Lu 2010) of miRNA processing, it is now emerging that miRNA* strands 
accumulate to substantial levels in-vivo, indicating a functional role (Chiang et al. 2010). 
Bioinformatics’ analysis has demonstrated that a substantial fraction of miR* species are 
conserved throughout vertebrate evolution with the greatest degree of conservation lying 
within their seed regions and MREs (Yang et al. 2011). Growing evidence has supported 
the functional role miR* strands play in genetic regulation such as target reporter gene 
suppression as a function of endogenous miR: miR* reads (Yang et al. 2011), the 
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generation of mature miRNAs from both arms of a miRNA precursor (Okamura et al. 
2008), the sporadic switch from the dominantly selected miRNA (Griffiths-Jones et al. 
2011), the capacity of particular miRNA precursors to generate comparable levels of 
mature miRNAs from both arms (miR-3p/5p) and ultimately their role in various disease 
states such as arthritis (Niederer et al. 2012) and cancer (Chang et al. 2013).  
13 of the 15 miR* strands DE in fast growing CHO cells were observed to be upregulated. 
In some cases (miR-34a* and miR-23b*), this apparent increase in miR* strand 
accumulation was not accompanied by an increase in transcription based-on the constant 
levels of the mature guide miRNA strand. This could be as a result of a phenomenon 
known as target-mediated miRNA protection (TMMP), a proposed mechanism by which 
increased target availability can lead to the accumulation of miRNAs protected by 
exoribonuclease turnover through target association (Chatterjee et al. 2011, Chatterjee, 
Grosshans 2009).  
miR-34a* has been observed to be down-regulated in Rheumatoid arthritis increasing 
apoptosis resistance in synovial fibroblasts through the regulation of XIAP with its 
overexpression inducing apoptosis (Niederer et al. 2012). This is in contrast to the 
observation of its increased expression in fast growing CHO cells. However, the transient 
overexpression of miR-34a* in CHO did correlate with this observation. Other miR* 
strands over-represented are part of the well characterised miRNA clusters such as the 
miR-17~92 and miR-23b~27b/miR-23a~27a clusters. There have been observations of 
functional redundancy between partner strands through target sharing or pathway overlap. 
One study demonstrated the induction of prostate tumour growth through co-ordinated 
suppression of TIMP3 by both the guide miRNA, miR-17-5p, and the passenger miR-17-
3p (Yang et al. 2013). The miR: miR* relationship is further exemplified with the 
observation that both miR-17-5p and miR-17-3p act synergistically to induce 
hepatocellular carcinoma through the interference of independent signalling pathways via 
knockdown of PTEN (-5p), GalNT7 and vimentin (-3p) (Shan et al. 2013). This would 
suggest that miR* strands identified as DE could mimic their guide counterparts.  
 
Several miRNAs found to be down-regulated as growth rate increased included miR-338-
3p, miR-204, miR-206 and miR-30e. One interesting observation was the down-
regulation of miR-30e in fast growing CHO cells and its up-regulation in CHO cells 
subject to temperature shift growth arrest (Barron et al. 2011b). miR-451 has been shown 
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to inhibit growth (Li et al. 2013) and induce apoptosis (Bian et al. 2011) upon its 
overexpression whereby it was observed to be down-regulated in fast growing CHO cells.  
It is extensively reported within the literature that miRNAs are both species and cell 
type/tissue specific. The nature of this variance is dependent on the availability of miRNA 
targets and the sensitivity of the molecular pathways subjected to translational influence. 
Several miRNAs play a recurring role within the literature, such as miR-34a and the 
oncogenic cluster miR-17~92, earning themselves an almost p53-like status. From the list 
of miRNAs found to be DE in our fast growing CHO cell phenotype, many correlated 
well with reported function in the literature in addition to a subset of miRNAs previously 
studied in CHO such as members of the miR-17~92 cluster (Jadhav et al. 2014) and miR-
30e (Barron et al. 2011a). 
 
4.6.2 Transient screening of miRNA  
Numerous miRNA profiling experiments have been carried out in CHO cells to include 
subsequent screening strategies (Barron et al. 2011b, Jadhav et al. 2014, Strotbek et al. 
2013, Jadhav et al. 2012). One such strategy began with an initial screen of 879 miRNA 
mimics at a high concentration of 1 µM isolating candidates based on improved 
volumetric productivity (Strotbek et al. 2013). Although this study identified that the 
stable overexpression of miR-557/-1287 improved viable CHO cell density and specific 
productivity, it highlights the potential loss of information because of the assessment of 
a single phenotype (volumetric productivity) or the screening of only miRNA mimics. 
Selection of the host cell line that will form the basis of a screening project will also 
contribute to the outcome of the screen. This primarily is due to the variation in the 
miRNA/mRNA expression across species, tissues and cell types. This is a critical factor 
to consider when the cell system forming the basis of the DE profile is different to that of 
the cell type exposed to transient evaluation. This potential variation was evident within 
our primary screen with candidates such as miR-23b*, miR-34a*, miR-206 and miR-639 
inducing a contrary phenotype.  
The absence of phenotypic conservation within the CHO-SEAP screen could be due to 
various reasons. One study demonstrated that predicted mRNA targets of highly 
conserved tissue-specific miRNAs were expressed at low abundance in comparison to 
tissues that did not express these tissue specific miRNAs. It also highlighted that highly 
expressed genes were enriched that do not contain MREs within their 3’UTR for certain 
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tissue specific miRNAs (Sood et al. 2006). A study using a miRNA decoy library found 
that over 60% of miRNAs had no discernible activity which indicated that the functional 
“miRNome” may be quite limited and that only the most abundant miRNAs mediate 
target suppression (Mullokandov et al. 2012). It has been identified that a “threshold” 
relationship is apparent between miRNAs and their cognate mRNA targets (Pasquinelli 
2012) and that a non-linear trend exists between a targets transcription and translation 
(Mukherji et al. 2011). Published screens as mentioned previously have reported a small 
numbers of impactful miRNAs which is in keeping with the results observed during 
transient evaluation. 
The fundamental point to take from these observations is that a miRNAs influence is 
complex, to say the least. The observation that many miRNA candidates did not elicit the 
anticipated phenotype as suggested from the profile does not rule out the potential for 
these miRNA candidates to control CHO cell growth in a different CHO cell type. It is 
possible that the molecular make-up of the CHO-K1-SEAP cell line used for transient 
screening is different to that of the fast and slow CHO clones, thereby presenting a wealth 
of differing molecular targets. 
 
4.6.2.1 miR-23b* 
Of the 15 miR passenger strands found to be DE in fast growing CHO cells, miR-23b* 
exhibited the highest increased fold change of 121.Very little is known about the specific 
role that miR-23b* plays. However, a recent report has identified it to be elevated in renal 
cancers (Liu et al. 2010a) mediating its function through inhibition of the mitochondrial 
tumour suppressor Proline Oxidase (POX) or alternatively Proline Dehydrogenase 
(PRODH), correlating with its increased abundance in fast-growing CHO cells. Transient 
overexpression, however, of miR-23b* demonstrated contrary results to both the 
literature and the profile, with miR-23b* inhibition being demonstrated to elicit a similar 
outcome (Liu et al. 2010a). A maximal inhibition of ~70% peak cell density was observed 
upon miR-23b* overexpression with a mild induction of cell death. A more in-depth 
analysis using the Guava Nexin assay was carried out to determine the degree of influence 
this miRNA played in apoptosis. It was noted that there was an almost 2-fold increase of 
cells entering early apoptosis (p ≤ 0.05) at both 48 and 96 h. The results are in contrast to 
the reports above and suggests that the apparent increase in miR-23b* expression is a by-
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product of the changing molecular environment and not a causative influence on the fast 
growing phenotype. 
One potential mechanism for the increased levels of this passenger strand in fast growing 
CHO cells is the recently hypothesised target-mediated miRNA protection (TMMP). 
Although the reciprocal relationship between miRNAs and their targets is not a new 
concept (Pasquinelli 2012), TMMP is an experimentally validated mechanism by which 
mRNAs, once thought to be passive targets of miRNAs, prevent the active turnover and 
degradation of miRNA duplex components by cytoplasmic exoribonucleotlyic enzymes 
such as XRN-2 in Caenorhabditis elegans (Chatterjee, Grosshans 2009) and XRN-1 in 
humans (Bail et al. 2010) (Fig. 4.10). Target availability has been shown to be a 
stabilizing factor for Ago-bound mature miRNAs (Chi et al. 2009). Chatterjee et al., has 
demonstrated that target availability can also exhibit a protective effect on certain miR: 
miR* strands (Chatterjee et al. 2011) (Fig 4.10 C). It potentially plays a role in RISC and 
non-RISC bound miRNAs adding further complexity to the regulatory role that mRNAs 
can elicit on endogenous miRNAs. 
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Figure 4.10: Enzyme-mediated microRNA turnover with miR* strand TMMP 
 
Figure 4.10: A) Shows a pre-miRNA duplex with 3’ 2 nt overhangs being loaded into the Ago/RISC 
protein complex with selection of the miRNA guide/passenger strand based on thermodynamic 
stability of the 5’ end B) mRNA target binding by RISC directed by the miRNA guide strand with 
exonuclease decay of the free passenger (miR*) strand by XRN-2 C) mRNA target availability 
prevents decay of miR* strands through this TMMP process. 
 
From the raw TLDA profiling data of the expression patterns of miR-23b and miR-23b* 
(Appendix Fig. A10), it was observed that in slow growing CHO cells, a classical 
expressional relationship between star and guide strand existed, one strand present at high 
levels (miR-23b) and one strand at low levels (miR-23b*). However, in Fast-growing 
cells, expression levels of both strands were comparable. It has been shown that some 
miRNA precursors can be processed to produce significant amounts of mature miRNAs 
from both arms (Okamura et al. 2008), in addition to arm-switching being tissue specific 
(Griffiths-Jones et al. 2011). The increase in miR-23b* levels in fast growing CHO cells 
versus slow with no associated change in the levels of mature miR-23b suggests that arm-
switching is not taking place in this instance. However, without assessing the 
transcriptional levels of the precursor pre-miRNA, it cannot be concluded whether an 
increase in transcription is compensating for the steady mature miR-23b levels or if arm-
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A
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switching was taking place. A recent report has suggested that the abundance of target 
transcript is primarily more selective at “protecting or mediating arm-switching” of miR* 
strands over their more abundant guides (Kang et al. 2013b), perhaps due to the inherently 
low miR* copy number. This dramatic impact on miR* strands was demonstrated by 
Kang and colleagues whereby a 10-fold increase of miR-7b was observed compared to 
~250-fold for miR-7b* in stable sponge models (Kang et al. 2013b). One major factor for 
consideration from the perspective of “does the level of miR-23b* contribute to this fast 
growing phenotype?” is whether the apparent elevated levels of miR-23b* are associated 
with a functionally active RISC or are they merely a by-product of miRNA processing? 
Stable depletion of miR-23b* in a fast growing clone from the profile was observed to 
elicit a reduction in growth (Data not shown) suggesting that in this cell, miR-23b* may 
contribute functionally. 
From a productivity perspective, miR-23b* overexpression resulted in a maximum 
reduction in SEAP production of 55%. This was attributed to the reduced cell density, 
similar to transient miR-7 overexpression in the same CHO-K1-SEAP cell line (Barron 
et al. 2011b). Although an increase in cell specific productivity is often observed upon 
growth arrest, miR-23b*-mediated growth arrest did not generate such a phenotype. As 
miR-23b* has been linked with the G2-phase of the cell cycle through POX interaction 
(Liu et al. 2009), it is possible that no significant increase in specific productivity is a 
result of the potential arrest in G2 whereas high specific productivity is often associated 
with G1 phase arrest (Bi, Shuttleworth & Al-Rubeai 2004, Carvalhal, Marcelino & 
Carrondo 2003).  
Although miR-23b* overexpression did not present itself as an attractive option for CHO 
cell engineering, a reversal of this observed phenotype would be desirable. Evidence 
supporting reversing CHO cell phenotype was observed by Sanchez and colleagues 
(Sanchez et al. 2013b) upon the stable depletion of miR-7 despite its overexpression 
resulting in cell cycle arrest with reduced product yields (Sanchez et al. 2013a, Meleady 
et al. 2012b, Barron et al. 2011c). Although little is known about the functionality of miR-
23b*, it is part of a well characterised miRNA cluster implicated in human disease, miR-
23a~27a~24-2 and its paralog miR-23b~27b~24-1 (Discussed briefly in the Introduction). 
The pleiotropic functionality of this miRNA cluster is evident from the multiple processes 
regulated by its members such as metabolism, oncogenesis, proliferation or 
differentiation, with the additional observation from profiling studies in various disease 
336 
 
conditions that all three miRNA members are simultaneously deregulated (Chhabra, 
Dubey & Saini 2010b). Individual members have been documented as potent modulators 
of cellular processes such as miR-23b; found to regulate a plethora of phenotypes 
including apoptosis, angiogenesis and invasion (Zhang et al. 2011). Interestingly, both 
miR-23b and miR-23b* have been implicated in mitochondrial function, ultimately 
contributing to metabolite introduction to the TCA cycle under the regulation of the 
oncogenic c-MYC (Fig. 4.11).  
In the case of miR-23a/b, c-MYC suppresses their expression thus derepressing inhibition 
of glutaminase (GLS) and mediating the conversion of glutamine to glutamate (Dang 
2010). In the case of miR-23b*, c-MYC enhances its expression levels thereby decreasing 
POX expression (Liu et al. 2009). Genetic alternations linking the regulation of glucose 
metabolism in cancers are evident by the aberrant expression of the oncogenic 
transcription factor, c-myc, which directly regulates the expression of glucose metabolic 
enzymes and additionally genes involved in mitochondrial biogenesis (Li et al. 2005, 
Eilers, Eisenman 2008). Mitochondrial dysfunction has been observed in various 
metabolic diseases including obesity, aging, diabetes and cancer, with miRNAs emerging 
as key regulators of mitochondrial proteins encoded by nuclear genes (Tomasetti, Neuzil 
& Dong 2013). Re-programming of mitochondrial metabolism to depend on glutamine 
catabolism circumvents the requirement of glucose as a primary carbon source, starving 
the TCA cycle of essential metabolites as observed via the “Warburg effect” (Dell'Antone 
2012). Glutaminolysis, conversion of glutamine to glutamate, is mediated by the enzyme 
glutaminase (GLS) of which miR-23a/b have been shown to target of whose transcription 
is repressed by c-myc (Gao et al. 2009). The implication of miR-23a/b in cellular 
bioenergetics encouraged the exploration of its stable inhibition in CHO cells.   
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Figure 4.11: Mitochondrial metabolic contribution of miR-23b and miR-23b* 
 
Figure 4.11: The influence that miR-23a/b suppression plays in the release of Glutaminase under c-
MYC suppression thus alternatively feeding mitochondrial respiration through glutamate 
metabolism independent of glucose. Additionally, as an alternative fuel source to glucose, miR-23b* 
also contributes to mitochondrial function through proline metabolism. Figure was sourced and 
modified from (Dang 2010) and (Liu et al. 2009).  
 
4.6.2.2 miR-34a/34a* 
miR-34a* was found to be elevated in fast growing CHO cells and displayed a similar but 
less dramatic expression pattern with its partner strand miR-34a as miR-23b* 
demonstrated with its counterpart. Given the extensive characterisation of miR-34a in the 
literature, we thought it prudent to evaluate the phenotypic impact of both miRNAs on 
the CHO cell despite only the star strand being DE. Transient transfection of either 
miRNA resulted in a similar phenotype: i.e. detriment to cellular proliferation and 
viability. This also supported a previous notion of miR:miR* components demonstrating 
functional redundancy. miR-34a has been shown to be transcriptionally activated by the 
“master tumour suppressor” p53 (Hermeking 2009), a transcription factor capable of 
halting cell cycle progression or ultimately activating programmed cell death (PCD) 
(Hermeking 2007). Ectopic expression of miR-34a has been observed to induce G1/S-
miR-23b*
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phase arrest through direct inhibition of pro-cell cycle targets such as CCND1 and its 
binding partner CDK6 (Sun et al. 2008b). Its counterpart on the other hand, miR-34a*, is 
less well characterised and has been validated to target a member of the family of 
apoptosis inhibitors, X-linked inhibitor of apoptosis (XIAP) (Niederer et al. 2012). 
Reduced expression of XIAP has been correlated with a reduction in the level of 
expression of CCND1 (Cao et al. 2013) inducing G1-phase arrest while another study 
demonstrated that selective inhibition of XIAP arrested cells in S and G2/M-phase with an 
associated deregulation of targets such as cyclin-B1 and CDK1/2 (Wang et al. 2013). 
The small molecule inhibitor of XIAP, Embelin, induced the shift in expression of 
apoptosis related proteins Bcl-1, Bax and Bcl-xL destabilising the mitochondrial 
membrane potential allowing for the release of cytochrome c (Wang et al. 2013), 
supporting the 30% reduction in cell viability reported for miR-34a* overexpression in 
CHO in addition to a similar observation of its overexpression in synovial fibroblasts 
(Niederer et al. 2012). Numerous anti-apoptotic genes have been validated within the 
literature as direct targets of miR-34a including Bcl2 (Cole et al. 2008) and the inhibitor 
of apoptosis (IAP) member, survivin (Shen et al. 2012) supporting its impact on CHO cell 
viability, similar to miR-34a*. A recent study has identified XIAP to be a target of miR-
34a to add to the extensive list of validated targets (see table 4.2) (Truettner, Motti & 
Dietrich 2013). On top of this, despite limited studies of miR-34a*, the realisation that 
transient overexpression of both pre-miRs mediate similar phenotypes, it is possible that 
both miRNAs share more common targets, beyond XIAP, associated with proliferation 
and apoptosis than is currently known.  
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Table 4.2: Validated targets of miR-34a 
Cellular 
process 
Gene Gene name Reference 
 
Cell cycle 
CDK4 
CCNE2 
CCND1 
CDK6 
Cyclin-dependent kinase 4 
Cyclin E2 
Cyclin D1 
Cyclin-dependent kinase 6 
(He et al. 2007a) 
(He et al. 2007a) 
(Sun et al. 2008b) 
(Sun et al. 2008b) 
 
 
Apoptosis/ 
p53 pathway 
BCL2 
 
SIRT1 
 
YY1 
 
BIRC5 
B-cell leukemia/lymphoma 2 
 
Sirtuin, silent information regulator 1 
 
Ying yang 1 transcription factor (TF) 
 
Survivin 
(Cole et al. 2008) 
(Yamakuchi, Ferlito & 
Lowenstein 2008) 
(Chen et al. 2011a) 
(Shen et al. 2012) 
 
 
 
 
 
Wnt 
signalling/ 
metastasis 
JAG1 
WNT1 
NOTCH1 
LEF1 
WNT3* 
CTNNB1* 
LRP6* 
MTA2+ 
TPD52+ 
AXL+ 
Jagged 1 
Wingless-related MMTV integration site member 1 
Notch homolog 1, translocation-associated 
Lymphoid enhancer binding factor 1 
Wingless-type MMTV integration site member 3 
Beta-catenin 
Low density lipoprotein receptor-related protein 6 
Metastasis associated 1 family member 2 
Tumor protein D52 
AXL receptor tyrosine kinase 
(Hashimi et al. 2009) 
(Hashimi et al. 2009) 
(Du et al. 2012) 
(Kim et al. 2011) * 
(Kaller et al. 2011b) + 
 
 
 
Cancer  
MYCN 
 
CD44 
NANOG 
 
SOX2 
v-myc myelocytomatosis viral related oncogen N 
 
Heparan sulphate proteoglycan 
NANOG homeobox transcription factor 
 
SRY (sex determining region Y)-box 2 TF 
(Cole et al. 2008) 
(Liu et al. 2011) 
(Choi et al. 2011) 
(Choi et al. 2011) 
 
 
Mitotic 
signalling 
MET 
MAP2K1 
(Silber et 
al. 2012) 
RRAS 
 
PDGFRA 
Met proto-oncogen (hepatocyte growth factor receptor) 
Mitogen-activated protein kinase 1 (MEK1) 
 
Related RAS viral (r-ras) oncogen homolog 
 
Platelet-derived growth factor receptor, alpha 
(He et al. 2007c) 
(Ichimura et al. 2010) 
(Kaller et al. 2011b) 
(Silber et al. 2012) 
 
 
Oncogenic 
Transcription 
E2F3 
 
MYB 
 
MYC 
E2F transcription factor 3 
 
v-myb myeloblastosis viral oncogen homolog 
 
v-myc myelocytomatosis viral oncogen homolog 
(Welch, Chen & 
Stallings 2007) 
(Navarro et al. 2009) 
(Christoffersen et al. 
2010) 
 
 
Metabolism 
ACSL1 
 
LDHA 
 
IMPDH 
Acyl-CoA synthetase long-chain family member 
 
Lactate dehydrogenase A 
 
IMP (inosine 5’-monophosphate) dehydrogenase 
(Li et al. 2011b) 
(Kaller et al. 2011b) 
(Kim et al. 2012) 
Post-
translational 
modifications 
 
FUT8 
 
 
α-1,6-Fucosytransferase 
(Bernardi et al. 2013a) 
Table sourced and modified from (Bader 2012) 
 
A maximum reduction of ~75-80% in SEAP activity was observed which was in parallel 
with an almost 90% drop in maximal cell density upon overexpression of both miR-34a/-
34a*. As seen before, this decrease in yield is due to the limited number of actively 
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producing cells within the bioprocess. One interesting observation however was the 
increase in normalised productivity for cultures treated with pre-miR-34a (section 
3.1.2.3.1) compared to those treated with pre-miR-34a* (section 3.1.2.2.2). The 
maximum increase of ~80% in normalised productivity in CHO-SEAP cells may be 
perhaps due to the role that miR-34a plays in G1-phase arrest (Sun et al. 2008b) compared 
to the association of miR-34a* with G2 (Wang et al. 2013).  
 
4.6.2.3 miR-181d/200a 
We pursued miR-200a to assess its possible functional conservation, low in relapsed 
patients subsequent to prostatectomy (Barron et al. 2012), in CHO cells and observed a 
reduction in cell density of 20-65% upon its overexpression (n = 7). This reduced cellular 
proliferation coincided with improved normalised productivity, however, in some 
instances volumetric SEAP yields were enhanced, suggesting that normalised 
productivity was improved irrespective of growth. A study by Hennessy and colleagues 
(Hennessy et al. 2010) found miR-200a to be down-regulated in glucose non-responsive 
MIN6 cells. Transient inhibition of miR-200a decreased glucose-stimulated insulin 
secretion (GSIS) which seems in keeping with the observation that its overexpression in 
CHO cells potentially enhances SEAP production. The tumour suppressive nature of 
miR-200a is exemplified in the study by Saydam and colleagues (Saydam et al. 2009) 
whereby the expression of miR-200a was found to be ~25-fold down-regulated in 
meningiomas with targets such as Cyclin-D1 and β-catenin (Su et al. 2012). Previous 
characterisation of this miRNA to regulate CCND1 coincides with our observation of 
reduced cell growth with enhanced normalised productivity (Kumar, Gammell & Clynes 
2007). This would further suggest that miR-200a knockdown might improve CHO cell 
growth thus allowing for the rapid accumulation of cellular biomass. Interestingly, miR-
200a was observed to be involved in a positive-feedback loop through the translational 
inhibition of histone deacetylase 4 (HDAC4) in human hepatocellular carcinoma 
implicating a role in transcription (Yuan et al. 2011). The specificity of HDACs is an area 
of continuous research as to whether a set panel of genes or global gene expression is 
influenced by their mechanism of action (Haberland, Montgomery & Olson 2009). The 
potential of miR-200a to interfere with the translation of HDAC4 could potentially 
contribute to the increased specific productivity independent of growth, if its panel of 
targets excluded growth related genes for example. 
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The transient over-expression of miR-181d demonstrated a less potent and consistent 
phenotype than miR-200a when screened in CHO-SEAP cells. Although selected for its 
potential tumour suppressor influence, overexpression resulted in a varied suppressive 
influence on CHO cell growth. One study reported that miR-181d, miR-34a and miR-
193b were down-regulated subsequent to MAPK activity (Ikeda et al. 2012).  Although 
miR-181d and the miR-181 family have been validated to target various cancer associated 
genes such as k-ras, bcl2 (Wang et al. 2012), Mcl-1 (Ouyang et al. 2012) and Tcl1 in 
chronic lymphocytic leukemia (Pekarsky et al. 2006), the expression profile of these 
targets and fundamentally the retention of target conservation will dictate the potency of 
this miRNA to elicit an effect in CHO. Of the two miRNAs screened, miR-181d and miR-
200a, it would be interesting to explore the potential synergy between the two however; 
miR-200a would be a prime candidate for stable inhibition, in the future.   
 
4.6.2.4 miR-532-5p 
It has been suggested that lessons can be learned from nature such as mimicking the 
differentiation of B-lymphocytes into plasma cells (Dinnis, James 2005) with a view to 
potentially improving the secretory capacity of host rCHO cells. Numerous miRNAs have 
been identified to be directly involved in glucose-stimulated insulin secretion (GSIS) such 
as miR-375 (Poy et al. 2004) and miR-124a (Lovis, Gattesco & Regazzi 2008) in 
pancreatic islet β-cells. miR-532-5p was found to be down-regulated in glucose non-
responsive MIN6 β-cells and was explored for its potential role in CHO cell productivity 
(Hennessy et al. 2010).  
Transient overexpression of miR-532-5p (Guide strand) had no impact on cellular 
proliferation or viability but did impact negatively on specific productivity, ranging from 
a ~20-30% reduction. Without assessing intracellular SEAP levels, it would be premature 
to attribute this observed phenotype to a reduction in the secretory capacity of treated 
cells or an impact on rSEAP transcription. In an attempt to reverse this phenotype, anti-
miRs designed against miR-532-5p were transiently transfected into CHO-K1-SEAP 
cells with no impact on volumetric productivity. It was noted that the expression of miR-
532-5p in fast growing CHO cell clones was low (Appendix fig. A11) upon analysis of 
the raw CT values from the original profiling study. It is possible that if miR-532-5p is 
related to a fast growing phenotype then its low level of expression could be similar in 
CHO-K1-SEAP. If that was the case, further inhibition may not yield a measurable 
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phenotype. However, upon exploring transient knockdown of this miRNA to mediate 
enhanced SEAP secretion, there was a mild increase of around 20-30%, at its highest, in 
cell numbers on day 2-4 of culture, suggesting that stable inhibition might be an 
interesting route to pursue.      
 
4.6.2.5 miR-639 
miR-639 expression was increased in fast growing CHO cells, yet when over expressed 
in our model CHO-K1-SEAP cell line, it caused a contrary but consistent reduction in 
cellular growth  with an associated increased normalised productivity. One study showed 
miR-639 to be upregulated in the serum samples of patients with bladder cancer in an 
attempt to evaluate the potential of miRNAs as candidates to assess prognosis and as 
diagnostic biomarkers (Scheffer et al. 2012). This suggests it could act as an oncogene in 
addition to a report of it targeting the tumour suppressor p21 (Wu et al. 2010). Despite 
the suggestion from the literature, the transient overexpression of miR-639 induced a 
reduction in CHO cell proliferation. It is possible that the increased expression of miR-
639 is a result of the phenotype and not a cause of it. The increase in normalised 
productivity indicates that the observed reduced growth could be due to an arrest in G1 
phase of the cell cycle potentially inducing an associated highly transcriptionally active 
production phase (Kumar, Gammell & Clynes 2007). Despite its lack of characterisation, 
miR-639 presents itself as an attractive candidate for stable depletion. 
 
4.6.2.6 miR-206 
Reduced expression of miR-206 in fast growing CHO cells agreed with numerous studies 
reporting its decreased expression in gastric cancer samples and cell lines (Zhang et al. 
2013), estrogen-dependent ERα-positive breast cancer (Kondo et al. 2008), melanoma 
cell lines (Georgantas et al. 2014) and laryngeal cancer (Zhang et al. 2011). Several 
characterised targets of this miRNA support its tumour suppressive capacity such as 
CCND2 (Kondo et al. 2008), CCND1, CDK4 (Georgantas et al. 2014), VEGF (Zhang et 
al. 2011) and Notch3 (Song, Zhang & Wang 2009). It was interesting to observe that 
transient inhibition of miR-206 in CHO-K1-SEAP cells mediated a reduction in CHO cell 
proliferation by 30% with an associated elevated normalised productivity of 15% on day 
4 of culture. 
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The reason for its negative impact on CHO cell growth upon its transient inhibition 
remains elusive. Reports of this miRNA in apoptosis suggests the potential for it to 
prolong a viable production phase upon its inhibition (Wang et al. 2012). The observation 
of enhanced normalised productivity suggests that cell cycle interference may be at the 
G1 phase. It would be interesting to pursue its transient overexpression as a means of 
assessing any conserved impact on CHO cell growth through targets such as CCND1/2 
or CDK4.  
 
4.6.3 Final miRNA screen comments 
Several candidate miRNAs were highlighted from the transient screening process, 
including miR-34a/34a*, miR-23b*, miR-200a, miR-206 and miR-639, some of which 
were more potent than others and all of which demonstrated growth inhibition. The 
observation that numerous miRNAs selected for screening either had no phenotypic 
impact or the opposite of what was expected could be due to a point made earlier in that 
over 60% of miRNAs expressed in any given cell type have no apparent functional 
influence (Mullokandov et al. 2012). Additionally, the varied expression pattern of 
miRNAs and mRNAs across various cell lines would suggest that miRNAs screened in 
the CHO-K1-SEAP cell line could elicit a varied phenotype given the potential 
differences in the expression profile of its mRNA targets. In essence, a miRNAs function 
is dependent on the abundance and sensitivity of its gene targets.  
The non-linear relationship between miRNA abundance and mRNA expression 
(Mukherji et al. 2011) potentially contributes to a layer of complexity when assessing 
miRNA function. When screening miRNAs in combination, a compromise has to be made 
when selecting the concentration of each miRNA under investigation. Exogenously 
introducing a high concentration, as in our transient screening process (50 nM), could 
potentially saturate the miRNA biogenesis machinery when assessing multiple miRNAs 
in combination leading to a potential transfection concentration of 150 nM and upward. 
Aberrant expression of miRNA biogenesis components have been associated with 
negative cellular phenotypes, for example Dicer knockdown inducing G1 arrest in MCF-
7 breast carcinoma cells (Bu et al. 2009) and the induction of mouse embryonic lethality 
(Bernstein et al. 2003). We demonstrated that siRNA-mediated dicer knockdown was 
detrimental to the CHO cell phenotype both inducing apoptosis and inhibiting cellular 
proliferation, an observation also made by others in CHO (Hackl et al. 2014a). A CHO 
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specific observation was made that both Dicer expression and global miRNA abundance 
were enhanced in CHO cells cultured in serum containing media (Hackl et al. 2011, Hackl 
et al. 2014a). These observations not only exemplify the beneficial role that miRNAs play 
in sustaining and maintaining cellular homeostasis but also that interference in global 
miRNA processing can be detrimental to the cell. Compromising miRNA concentration 
when screening multiples can potentially dilute miRNA activity to a point where a 
phenotype is not perturbed which ties into this titrational effect that was previously 
mentioned. Several miRNA candidates from the fast versus slow profile were assessed in 
combination such as miR-338-3p, miR-455-3p/5p and miR-409-3p, members from the 
panel screened that did not generate a significant/consistent phenotype. Additionally, in 
combination with each other, a more consistent or potent phenotype was observed.  
Not observing a phenotype upon transient manipulation of these miRNAs does not prove 
that they do not play a role in the phenotype in which they were implicated. However, it 
is possible that a large number of DE miRNAs in any profile are a result of the phenotype 
and not the cause of it. The CHO-SEAP cell line is innately a fast growing cell line by 
comparison to the fast growing clones used in the original profiling experiment. This 
would suggest that a similar miRNA profile could be shared between both cell lines in 
relation to growth. As a result, further manipulation of particular candidates may not elicit 
a phenotype. Furthermore, the CHO-SEAP cell line could potentially demonstrate a 
completely unique miRNA and mRNA profile thus not expressing targets of these 
miRNAs. This suggests the benefit of profiling a panel of CHO cell lines from an 
industrial point of view to determine the diversity of a particular targets across a range of 
cell and product types. It would also suggest that profiling of candidates from a profile 
should be carried out in the same cell line as used in the original profiling such as in the 
case of miR-7 (Barron et al. 2011b) and miR-466 (Druz et al. 2011) in CHO. 
By assessing and understanding the miRNA/mRNA expression patterns of CHO cell lines 
two things can potentially be achieved. The first is the prediction of CHO cell 
performance if miRNA/mRNA expression patterns are correlated with production 
phenotypes such as growth or productivity. A study like this was carried out by Clarke 
and colleagues which predicted CHO cell specific productivity to within 4.44 pg/cell/day 
by using microarray technology generating a panel of 287 genes associated with 
productivity (Clarke et al. 2011b). miRNA profiles across various CHO cell types, could 
help to predict which CHO cells will respond to miRNA intervention.  
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Secondly, rudimentary inducible systems could be developed if miRNA expression 
profiling data has been catalogued. For example, the cell cycle inhibitor p27 could be 
engineered to include a miRNA sponge that contains MREs for a miRNA whose temporal 
expression profile is confidently understood within a given CHO cell. If this miRNA has 
a high expression early into culture then p27 will not be translated thus allowing for the 
propagation of exponential growth (Fig. 1.7 of Introduction). If this miRNA is naturally 
switched off or down-regulated in mid-late exponential growth then p27 translation 
would be de-repressed inducing a growth arrest in G1 mediating an artificial, high 
producing, temperature-shift like phenotype. This system could potentially provide 
industry with an alternative to the use of exogenously inducible systems or the exploration 
of temperature sensitive promoters. Profiling of tens or hundreds of CHO cell lines may 
be costly but could present itself with numerous benefits such as those mentioned above. 
The screening process also highlights the importance of selecting an appropriate cell line 
for transient screening or suggests the necessity of carrying out screens in multiple cell 
lines as a means of pin-pointing master miRNAs that possess conserved function across 
various CHO cell types.  
 
4.7 CHO cell engineering using miR-34 
Our transient screening assay revealed potent suppression of CHO cell growth when miR-
34a was overexpressed. This observation prompted us to attempt a stable depletion 
approach in anticipation of having the opposite outcome i.e. improved cell densities 
and/or increased culture longevity.  
 
4.7.1 miR-34’s depletion on various CHO cell types 
The impact of a miRNA on a late stage culture phenotype such as apoptosis is difficult to 
evaluate due to their short life-time. This can be caused by the stability of the exogenously 
introduced miRNA in addition to cellular proliferation diluting cytoplasmic miRNAs 
across daughter cells ultimately titrating their effect (Song et al. 2003, Bartlett, Davis 
2006). To navigate around this, we cultured CHO-SEAP cells in nutrient-depleted media 
and transiently inhibited miR-34a function resulting in a ~10% reduction in cell death. 
This mild improvement in cell viability was similar to an observation by Druz and 
colleagues upon transient inhibition of miR-466h in nutrient depleted cells (Druz et al. 
2011). The inconsistent improvement in cell viability observed in the case of CHO-SEAP 
346 
 
cells could be attributed to the low endogenous levels of miR-34a in CHO cells reported 
by next-generation sequencing (Hackl et al. 2011). Additionally, the successful profiling 
of miR-466h by Druz and colleagues could be due to the same cell type being used in 
both profiling and miRNA transient/stable inhibition (Druz et al. 2013). Transient 
inhibition of miR-34a also demonstrated an inconsistent improvement of 30% in maximal 
cell density. This increase in cell numbers could have contributed to the apparent increase 
of 10% in culture viability.  
 
The mild and inconsistent impact of miR-34a upon its inhibition may also be due to a 
multitude of reasons: 1) the transient inhibition of miRNAs being less potent on 
endogenous targets compared to their overexpression (Martinez-Sanchez, Murphy 2013), 
2) the potential absence of molecular targets for miR-34a in combination with its low 
abundance in CHO cells (Hackl et al. 2011) and 3) the dilution effect of miR-34a inhibitor 
through multiple rounds of cellular proliferation. Stable inhibition of miR-34 was based 
on previous observations in our group (Barron et al. 2011b), whereby stable depletion of 
miR-7 enhanced cell density and boosted volumetric SEAP yield (Sanchez et al. 2013b) 
despite increased apparent normalised productivity. Similar to miR-466h, miR-7 was 
identified, characterised and stably engineered in the same cell line again highlighting the 
selection of cell line having a contribution to outcome. Of course, from the perspective 
of identifying a high priority miRNA candidate for industrial application, the effect 
should be verified in several CHO cell lines. 
When miR-34 depletion was assessed in a CHO-SEAP stable mixed population, there 
was an increase in growth observed with an elevated viable cell density of 6-15% (Fig. 
3.12 A and B). No benefit was observed in SEAP yield. However, when these cells were 
cultured under fed-batch conditions, a considerable increase in SEAP yield was observed 
(Fig. 3.13 C and D). This increase in productivity could have been attributed to the 
reduced proliferation of miR-34 depleted cells when compared to controls, suggesting a 
longer residence in the highly transcriptionally active G1-phase of the cell cycle (Kumar, 
Gammell & Clynes 2007). When clones were assessed as a panel, volumetric SEAP 
productivity was enhanced across all time points (Fig. 3.17). Cellular proliferation in 1 
mL batch culture was reduced, possibly explaining the considerable increase in specific 
productivity. Studies have demonstrated that CHO clones not only behave differently to 
each other in respect to a certain phenotype but vary under differing bioprocess conditions 
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(Porter et al. 2010). Clones were selected based on their productivity and when cultured 
in batch conditions continued to demonstrate an enhanced volumetric yield as observed 
within the clonal screen. Interestingly, miR-34 clones exhibited a propensity to clump 
when compared to controls and other miR-sponge clones generated (miR-23 and -23b*). 
miR-34a has previously been associated with biological processes contributing to cell 
adhesion (Jo et al. 2011), potentially explain this increased cellular interaction resulting 
in clumping when clones were derived.  
On the other hand, when miR-34 was stably depleted in IgG-secreting CHO-1.14 cells, 
mixed populations grew better (Fig. 3.14 A). This agrees with numerous reports of loss 
of miR-34a expression influencing cancer cell proliferation through mediating the 
increased expression of numerous oncogenes such as CCND1, CCNE2 and CDK4/6 (He 
et al. 2007b, Sun et al. 2008b). Loss of miR-34a function has been observed in a range of 
cancers such as prostate (Fujita et al. 2008), breast (Vogt et al. 2011), pancreas (Chang et 
al. 2007) and ovary (Corney et al. 2010) due to epigenetic mechanisms and genomic 
instability (Calin et al. 2008, Vogt et al. 2011, Lodygin et al. 2008). The observation that 
miR-34a overexpression reduced the mRNA levels of CCND1 in CHO suggested its 
potential role in mediating a beneficial growth phenotype. However, the expression of 
CCND1 in miR-34 depleted CHO clones varied considerably when compared to controls 
(Fig. 3.11 C). It has been reported that mild changes of as little as 1.23-fold in the 
expression levels of miR-34a targets have been sufficient to drive tumorigenesis (Kaller 
et al. 2011a). It is possible that other targets both known and unknown are mediating this 
enhanced proliferation such as CDK4/6. Additionally, siRNA knockdown of the miR-34 
sponge did reduce growth suggesting that miR-34 depletion was eliciting an enhanced 
growth phenotype.  
Specific productivity was reduced across all time points in these mixed pool CHO-1.14 
populations potentially as a result of enhanced proliferation. It has been suggested that 
energy provisions can be redirected in fast growing cells from productivity to 
proliferation and accumulation of biomass (Clarke et al. 2012). Furthermore, miR-34a 
has been implicated in the arrest of cells in the G1-phase of the cell cycle upon its 
expression (Navarro et al. 2009) ultimately prolonging their residence in this highly 
transcriptionally active phase (Kumar, Gammell & Clynes 2007). Swift propagation 
through the cell cycle could be contributing to the observed reduced specific productivity. 
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When miR-34 sponge clones were selected through FACS, the GFP expression pattern 
across both CHO-SEAP and CHO-1.14 panels was suggestive that endogenous miR-34 
was targeting the sponge as there was an average drop in GFP fluorescence across the 
miR-34 sponge panels compared to controls, an observation made previously by Sanchez 
and colleagues for miR-7 sponge clones (Sanchez et al. 2013b). Furthermore, it was 
demonstrated that mature miR-34a levels when assessed in a set of miR-34a clones 
exhibited a 5-fold reduction (Fig. 3.11 A). siRNA inhibition of the miR-34a sponge was 
also shown to increase levels of endogenous miR-34a though not to resting levels when 
compared to control sponges. This is possibly as a result of incomplete knockdown of the 
sponge.  
The enhanced growth phenotype observed in the case of CHO-1.14 mixed populations 
was not retained when miR-34 clones were cultured in a 1 mL volume. However, once 
introduced back into 5 mL volumes, miR-34 sponge clones showed an improved growth 
phenotype over all control clones except one, which maintained high cell density and 
viability. Volumetric IgG and specific productivity was observed to be reduced 
considerably in the case of miR-34 sponge clones. This could be due to the more potent 
increase in growth exerted by the miR-34 sponge thus contributing more significantly to 
reduced specific productivity. When fed-batch was carried out, a similar trend was 
observed in the case of miR-34 sponge clones, i.e. enhanced growth to the detriment of 
productivity. However, individual miR-NC clones also performed well, showing high cell 
densities and viability, miR-NC sponge clone 20, and high productivity, miR-NC sponge 
2. This could be as a result of clonal selection, isolating individual clones that exhibit 
desirable phenotypes potentially mediated by insertional mutagenesis resulting from 
plasmid integrating or inherent heterogeneity.      
From assessing miR-34a depletion across various culture formats within two cell lines, it 
can be seen that it enhanced the specific production capacity of CHO-SEAP cells but 
possibly caused these cells to clump mid-culture. This observation of miR-34 depletion 
to improve productivity in selected clones suggests its potential use under an inducible 
promoter, whereby a high specific production phase could be induced through depletion 
of miR-34 mid-culture after biomass has accumulated. In the IgG-secreting CHO-1.14 
cell line, miR-34 depletion potentially enhanced CHO cell growth at the expense of 
productivity. However, the selection of a large clonal panel would be required before 
concluding the miR-34 does confer a growth benefit to these cells. It is also possible that 
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in the case of the CHO-SEAP cell line, whose growth characteristics are far superior to 
that of the CHO-1.14s, miR-34 depletion did not mediate an enhanced growth phenotype 
as the potential molecular targets of miR-34 in this cell line would not mediate a further 
improvement upon their deregulation.  However, by investigating the potential role that 
miR-34 could play in the bioprocess, the process of glyco-engineering would not have 
been highlighted nor would the significant impact this engineering process would have 
on industry be appreciated. 
 
4.7.2 miRNA-based glycoform engineering of recombinant antibodies 
It has been suggested that the maximum specific production capacity of CHO has been 
achieved at 100 pg/cell/day (De Jesus, Wurm 2011), although not routinely accomplished. 
An alternative means of indirectly increasing yield to meet the global demand for these 
products could be offered through enhancing antibody effector function, ADCC, thus 
reducing patient doses. The addition of a biantennary glycan (heptasaccharide) to the 
conserved asparagine-297 considerably influences antibody effector functions (Jefferis 
2009b). In fact, when the glycosylation is eliminated, binding of the target antigen has 
been observed to decrease or not take place at all (Walsh, Jefferis 2006). The proportion 
of non-fucosylated IgG-Fc produced in CHO is low with >90% of N-linked glycans 
containing a core fucose group. It is possible that this high frequency of fucosylation 
stems from their inability to add a bisecting N-acetylglucosamine as they do not express 
despite containing a genomic homolog of the gene, β-1-4-N-
acetylglucosaminlytransferase III (GnTIII) (Xu et al. 2011). This was suggested by a 
study whereby CHO cells engineered to express the GnTIII gene produced a non-
fucosylated Rituximab-like antibody product with enhanced ADCC due to prior addition 
of a bisecting-GlcNAc (Ferrara et al. 2006).  
shRNA technology designed against the FUT8 gene resulted in an 88% reduction in 
fucosylation of an IGF-1R antibody with enhanced ADCC and little impact on 
productivity in a CHO-DG44 clone (Beuger et al. 2009). Several studies have reported 
improved ADCC function of CHO-produced antibodies for clinically relevant products 
such as Herceptin and Rituxan exploring routes such as genetic knockout of FUT8 
(Yamane-Ohnuki et al. 2004), GMD knockout (GDP-fucose 4, 6-deydratase (Kanda et al. 
2007), siRNA-double knockdown of both FUT8/GMD (Imai-Nishiya et al. 2007) and 
siRNA inhibition of FUT8 alone (Mori et al. 2004). 
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Having found that the stable depletion of miR-34 did not generally mediate a beneficial 
phenotype, despite enhancing cell growth in the IgG-secreting CHO-1.14 cell line, we 
explored its potential impact on the fucosylation of secreted antibodies following the 
observation by Bernardi and colleagues that miR-34a could regulate the translation of 
FUT8 (Bernardi et al. 2013a). 
CHO cells produce predominantly fucosylated glycans (Kanda et al. 2006) with the main 
glycoforms being GOF, G1F and G2F (Ucakturk 2012). It is possible that the increased 
expression of FUT8, potentially as a result of miR-34 depletion, does not increase 
antibody fucosylation. This is potentially due to the high abundance of fucosylated 
antibodies (>90%) already produced by CHO. However, despite no change in 
fucosylation being observed, there was a considerable reduction in peak intensity for the 
miR-NC sponge clone when compared to miR-34 sponge clone possibly indicating a 
reduced frequency in the post-translational addition of the N-Glycan at asparagine-297 
(Fig. 3.27 in Results). Discrepancies have been observed in the glycosylation patterns of 
clones derived from the same cell line indicating that clonal variation can contribute to 
differences in post-translational modifications (Singh 2011). However, we were hopeful 
that the depletion of miR-34 was enhancing the post-translational process occurring in 
the CHO-1.14 cells. Little literature support could be found regarding the frequency at 
which monoclonal antibodies are successfully glycosylated, however, we evaluated the 
peak intensities of the parental CHO-1.14 cells and anticipated that a similarity would be 
observed when compared to miR-NC sponge clones, i.e. reduced intensity by comparison 
to miR-34 depleted clones. Both miR-34 sponge and parental CHO-1.14 demonstrated a 
similar glyco-profile of comparable intensity (Fig. 3.29 in Results). Furthermore, siRNA 
knockdown of the miR-34 sponge did not lower the peak intensity of the glyocoprofile 
suggesting that the presence of the miR-34-specific sponge was not influencing the 
frequency of N-glycan addition. 
Interestingly, we observed no change in the glyocoprofile (Fig. 3.28 in Results) of the 
miR-34 sponge clone 21 transfected with miR-34a mimic. This was carried out in an 
effort to reduce FUT8 levels in the hope of reducing core fucosylation. In hindsight, this 
was not the most ideal experimental setup as it is possible that the presence of a highly 
expressed sponge specific for miR-34 could dilute miR-34a away from its endogenous 
targets, including FUT8, in this instance (Mullokandov et al. 2012). When the miR-34 
sponge clone 21 was transfected with miR-34a, there was a significant reduction in 
351 
 
maximum cell density observed (Data not shown). However, no decline in cellular 
viability was observed, as had been previously induced in parental cell lines. This would 
suggest that the presence of the miR-34 sponge competed for exogenously introduced 
miR-34a preventing its suppression of genes involved in apoptosis resistance for example 
Bcl2 (Yang et al. 2014) or XIAP (Truettner, Motti & Dietrich 2013). Although its potent 
inhibition on cell growth was maintained, this could be due to the multitude of validated 
targets of miR-34a involved in cellular proliferation such as CCND1, CCNE2, CDK4, 
CDK6 and E2F1 thus hitting this phenotype from multiple angles. Transfection of miR-
34a into an IgG-secreting cell line not containing a sponge specific for miR-34a would 
be a more desirable approach.  
miR-34a function upon its overexpression in CHO appears to be conserved, as indicated 
from the literature, in regards to reducing proliferation and inducing cell death (section 
3.1.2.3.1). If its influence on FUT8 was also demonstrated to be conserved in CHO 
resulting in reduced antibody fucosylation, as an engineering target it would still not 
prove viable. As miR-34a overexpression would be required to reduce FUT8 
translational, this could also result in it eliciting other phenotypes such as reduced cell 
growth and cell death. As miRNAs are renowned for their ability to bind multiple mRNA 
targets, it is possible that multiple miRNAs target the FUT8 gene. A method to identify 
bound miRNAs to specific mRNAs has been reported and offers an attractive option to 
achieve this goal (Hassan et al. 2013). By identifying novel miRNA targets of FUT8, 
subsequent screening could identify those that mediate a potent inhibition of FUT8 
translation without negatively impacting on other cellular processes such as growth or 
apoptosis.   
The benefit of exploring miRNA/siRNA inhibition of FUT8 in antibody producing CHO 
cells would potentially navigate around the generation of multiple cell lines, i.e. the 
primary or parental FUT8 knockout CHO cell lines and the subsequent introduction of 
the specific antibody for large-scale production. A bi-cistronic expression vector has been 
reported for the co-expression of the miR-183 family and a protein coding gene 
(GFP/Atoh1) by exploiting the naturally occurring intronic pathway of miRNA 
processing (Stoller, Chang & Fekete 2013). This technology would allow for the 
simultaneous engineering of target therapeutic and miRNA. Although the generation of a 
FUT8 genetic knockout cell line, as demonstrated by complete de-fucosylation of a 
Rituxan antibody with enhanced ADCC (Yamane-Ohnuki et al. 2004), would be an 
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attractive option for industrial implementation, the availability of a co-expression system 
could accommodate engineering of the multiple cell types suited for particular 
bioprocesses and certain “hard-to-process” recombinant proteins. Glycoform engineering 
offers industry a new option to produce highly active, less immunogenic and controlled 
(Mode-of-action executed to suit treatment) antibodies that can indirectly address the 
strain of global demand. As mentioned previously, current blockbuster antibodies such as 
Herceptin and Rituxan will more than likely not be manufactured in these FUT8 
engineered cell lines due to the costs involved in characterising their new structure in 
clinical testing. The technology will, however, provide a viable platform for the 
production and large-scale manufacture of the 350 antibodies currently in development 
(Reichert 2013).  Additionally, as patents expire, new parental cell lines will have to be 
generated allowing for the introduction and implementation of this highly beneficial 
engineering strategy. In addition, increasing the effector function of current antibodies 
could also mediate the development of “Bio-betters”. 
 
4.8 CHO cell engineering using miR-23b* 
Previous characterisation of this miRNA in CHO-K1-SEAP cells demonstrated it to be 
detrimental to the CHO cell phenotype upon its overexpression, resulting in reduced 
maximum cell densities and the induction of apoptosis. This observation was in contrast 
to that indicated from the profile. As previously suggested, the phenomenon of target-
mediated miRNA protection (TMMP) (Chatterjee et al. 2011) is potentially causing the 
apparent increase in mature miR-23b* although the nature of it exerting a phenotypic 
influence remains in question.  
When miR-23b* levels were measured in miR-23b* sponge clones, there was no apparent 
change when compared to non-specific controls (Appendix Fig. A13). This was in 
contrast to the reduced levels of endogenous miR-34a and miR-23b in their respective 
sponge clones as well as reports of miR-7 being up in its sponge cell line (Sanchez et al. 
2013b). Despite an observed phenotype upon miR-23b* depletion and the demonstration 
of the sponges specificity for miR-23b* via GFP inhibition, it was interesting to observe 
no influence on endogenous miR-23b* levels. It has been demonstrated in HeLa cells that 
miRNAs are expressed in a 13-fold excess relative to that of Ago1-4 indicating that there 
are more freely available miRNAs than RISC-bound.  Additionally, there is a 7-fold 
excess of free miRNAs associated with mRNA targets compared to Ago-bound miRNAs 
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demonstrating that free miRNAs can associate with mRNAs and do so in excess to RISC-
bound miRNAs (Janas et al. 2012). This would also suggest that free miRNAs can 
compete for and interfere with the regulatory capacity of their RISC-bound counterparts 
also suggesting that TMMP can influence any miRNA within the transcriptome. On the 
other hand, if there are more RISC-bound miRNAs than free, the interaction with mRNAs 
could accelerate the turnover of these RISC-bound miRNAs upon dissociation from the 
mRNA target. The fate of the miRNA-RISC complex is not something reported on in the 
literature so the reduction in miR-23b/-34a levels through this increased instability upon 
mRNA dissociation is purely speculative. By sequentially assessing numerous miR-
sponge constructs specific to miR-34a/23/23b* with various mismatches within the 
MREs, it could be possible to evaluate if finite changes in complementarity will dictate 
the observation of TMMP or reduced mature miR levels. The above questions the 
influence of TMMP in both influencing apparent miRNA abundance and additionally in 
the regulation of a miRNAs phenotypic influence.    
miR-23b* depletion in CHO-SEAP mixed pools enhanced growth in both batch and fed-
batch conditions at the cost of specific productivity, resulting ultimately in reduced 
volumetric SEAP output. This phenotype was conserved when assessed in the IgG-
secreting CHO-1.14 cell line with the addition of improved cell viability. Only one 
validated target of miR-23b* has been reported, Proline Oxidase (POX) or Proline 
Dehydrogenase (PRODH) (Liu et al. 2010a). This is a mitochondrial inner-membrane 
tumour suppressor gene involved in proline catabolism. The absence or reduction of 
PRODH has been observed in a variety of human tumours (Liu et al. 2010a, Liu et al. 
2009) with its induction being observed to be regulated by p53 (Polyak et al. 1997) 
resulting in cell cycle arrest in G2-M (Donald et al. 2001) and the initiation of apoptosis 
through its ability to generate ROS (Liu et al. 2006). In miR-23b* depleted clones, the 
enhanced growth was potentially associated with an increase in the target PRODH, 
contradicting the reports mentioned. It is possible that the enhanced growth phenotype is 
being mediated by a variety of potential miR-23b* targets that have not yet been identified 
due to the little attention previously paid to miR* strands. Enhanced growth was not 
observed when clones were assessed in a 1 mL volume, an observation made in the case 
of miR-23 depleted CHO-SEAP clones also. As specific productivity and cell density 
appeared to be equivalent on day 2 of culture, it is possible that the reduced cell numbers 
observed on day 4 contributed to the increased specific productivity. However, in the case 
of the IgG-secreting CHO-1.14 cells (mixed pool, clonal panel and clones), cell density 
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was enhanced at the cost of productivity. The phenotype mediated by miR-23b* was 
observed to be retained in the CHO-1.14 cell line. 
  
Upon selection of miR-23b* depleted CHO-SEAP clones, a range of growth phenotypes 
were observed with clone 18 demonstrating the highest cell density and culture longevity. 
miR-23b* sponge clones demonstrated a higher productivity then previously documented 
for mixed pools but still lower when compared to controls. This potentially could have 
resulted from the selection of clones based on productivity values thus introducing a bias. 
Clone 18 produced a comparative amount of SEAP on D6 of batch culture despite its 
reduced specific productivity. This may have been as a consequence of extended viability 
towards the latter part of the culture compared to controls. This comparative productivity 
was retained under fed-batch conditions with viability being maintained above 80% for a 
further 72 h. Temperature shift was explored with the aim of improving specific 
productivity and further delaying the induction of apoptosis which ultimately resulted in 
improved SEAP yield of 50%.  
One observation was that, upon subsequent experimental repeat of miR-23b* sponge 
clone 18 in CHO-SEAP cells in fed-batch conditions including a temperature shift, a 
reduction in GFP expression was observed which coincided with a decrease in viability 
at an earlier time point in culture (Data not shown). This potentially implicates the 
presence of the sponge in mediating the observed phenotype. Given the variation 
observed within clones themselves over several generations (Pilbrough, Munro & Gray 
2009), this reduction in GFP expression could also be attributed to an increase in 
endogenous miR-23b* expression. Of the three miR-23b* sponge CHO-SEAP clones 
selected from the panel screen, clone 18 demonstrated the lowest level of GFP expression 
with clone 8 being the highest and clone 3 falling in between. Only clone 18 demonstrated 
enhanced viability in 5 mL scale up suggesting that the presence of the sponge is not 
influencing extended viability and may be a result of mutagenesis in addition to the 
influence of the culture format (Porter et al. 2010). This type of forward genetic 
characterisation has been explored to identify genes involved in cancer onset by using a 
transposon, Sleeping Beauty (Dupuy, Jenkins & Copeland 2006) supporting the 
possibility of beneficial CHO phenotypes induced by plasmid integration. No viability 
benefit was observed across the panel of miR-23b* sponge clones indicating that this is a 
phenotype not effected by miR-23b* depletion. Selection of a larger number of clones 
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carried over into the various culture formats would have given a better indication as to 
whether this prolonged culture longevity observed for clone 18 was more than a by-
product of the cloning process. Regardless, the phenotype observed in miR-23b* sponge 
clone 18 would be desirable under perfusion culture conditions. This bioprocess 
configuration has been shown to compensate for low specific activity, as in the case of 
miR-23b* depletion, due to the maintenance of high viable cell densities (Clincke et al. 
2013) and demonstrates the utility of process selection for exploiting innate CHO cell 
characteristics.      
Although it would be pre-mature to conclude that miR-23b* depletion is mediating the 
observed phenotype, it is evident that by selecting and adapting particular bioprocess 
regimes to suit a clonal attributes, a desirable outcome can be achieved.  
 
4.9 miRNAs place in the bioprocess 
Although the specific production capacity of CHO cells has been proposed to have 
reached its natural limit at 100 pg/cell/day (De Jesus, Wurm 2011), acquisition of this is 
not routinely achieved and further drives the requirement for alternative engineering 
approaches. One such alternative is boosting CHO cell densities and/or prolonging culture 
viability without compromising specific productivity. It is for this reason that miRNA 
profiling of CHO cells with varying growth rates but similar specific productivities was 
explored (Clarke et al. 2012) identifying miRNAs associated with growth such as the 
miR-17~92 cluster (Olive, Li & He 2013). This miRNA has already demonstrated 
promising results in the manipulation of the CHO cell phenotype including the 
overexpression of miR-17 enhancing growth performance, increasing specific 
productivity 2-fold and boosting yield 3-fold of an EPO-Fc protein (Jadhav et al. 2014). 
More recently, miR-17, -19b and -92a overexpression was observed to enhance antibody 
titres by 130-140% in clonal cells without interfering with product quality (Loh et al. 
2014). Other reports have demonstrated beneficial outcomes as a function of miRNA 
intervention including miR-7 depletion (Sanchez et al. 2013b), miR-466h inhibition 
(Druz et al. 2013) and miR-557/-1287 overexpression (Strotbek et al. 2013) all resulting 
in enhanced product titres in SEAP and IgG producing cell lines. Characterisation of the 
benefits of miRNAs over a range of recombinant products further enhances their utility 
as engineering targets. Furthermore, several of the above reports demonstrate the 
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improvement in cell growth without compromising specific productivity, a common 
trade-off often reported (Lai, Yang & Ng 2013a).  
To add to this list, miR-23 depletion in CHO-SEAP cells was observed to enhance 
specific productivity ~3-fold without impacting cell growth. However, pursuit of 
inhibition of the entire miR-23~27~24 cluster could offer a more adventitious phenotype, 
given its association with B-cell differentiation, and preliminary data in mixed pools 
demonstrating both enhanced growth and specific SEAP productivity. 
In the 7 years since the first miRNA differential expression profile of CHO cells subjected 
to temperature shift (Gammell et al. 2007), numerous reviews have been published that 
have documented the progress in the field and further speculating on miRNAs future in 
the bioprocess (Wu 2009b, Jadhav et al. 2013, Muller, Katinger & Grillari 2008, Barron 
et al. 2011d). Significant efforts have been invested to the understanding and control of 
CHO cells and the molecular tools available for their engineering including the release of 
the CHO genome (Xu et al. 2011), the utility of endogenous CHO miRNA clusters 
(Klanert et al. 2013) and the large-scale transfection of CHO cultures with miRNAs 
(Fischer et al. 2013) (Fig. 1.4 of the introduction). 
Furthermore, the ongoing profiling strategies (Barron et al. 2011b, Hernandez Bort et al. 
2012, Druz et al. 2011) in CHO have been suggested to benefit the bioprocess in the form 
of inducible systems dependent on the innate expression profile of miRNAs over the 
culture process (Fig. 1.7).  
The possibility for miRNAs potential in bioprocess engineering does not end here. An 
exciting area of research has been in the manipulation and control of particular antibody 
glycoforms produced by CHO cells with the goal of enhancing antibody effector 
functions such as ADCC (Jefferis 2009b). We explored the potential of miR-34a to retain 
its function of suppressing the translation of the FUT8 gene (Bernardi et al. 2013b) as a 
means of reducing the level of fucosylated IgG antibody. Although we were unsuccessful 
in demonstrating miR-34a to impact on antibody fucosylation, this particular area of 
research will have vast implications for the industry. By enhancing antibody effector 
functions, therapeutic dosages can be reduced which could ultimately aid in achieving 
global demands. This indirect route of meeting demand, or bringing the demand down, 
will reduce costs involved in bioprocess design, allow for the derivation away from the 
construction of large-scale pharmaceutical production plants and ultimately reduce 
consumer costs.  
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With patents of major blockbuster therapeutics coming to an end, the drive for the 
development of “bio-similars” and “bio-betters” is in full swing with over 350 antibody 
products alone currently in pre-clinical development (Reichert 2013), a new era of cell 
line development will be opened allowing for the re-optimisation of the parental 
production cell lines for industrial scale manufacture. The various success stories reported 
for miRNAs, miR-23 included, effectively enhancing CHO cell performance across a 
range of recombinant products, implicates these small molecules as additional tools to 
compliment other approaches.     
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Conclusions 
1 Integrated microRNA profile of CHO cells with varying degrees of growth rates 
and subsequent phenotypic characterisation through transient screening 
 51 miRNAs were found to be differentially expressed (DE) demonstrating a 
positive or negative correlation with increasing CHO cell growth rate such as the 
oncogenic miR-17~92 cluster.   
 Transient screening revealed miR-34a/34a* and miR-23b* to negatively impact 
cell growth and viability: miR-206, miR-639 and miR-200a to negatively impact 
growth with potential improved productivity in the case of miR-200a: and miR-
532-5p and miR-15a~16-1 to positively influence CHO cell growth. 
 Target-mediated miRNA protection (TMMP) could influence and reshape the 
apparent miRNA transcriptome ultimately contributing to a symptomatic change 
in mature miRNA levels, as indicated in the case of miR-23b*.  
 
2 miR-34a as a potential candidate for CHO cell engineering 
 miR-34a overexpression was demonstrated to arrest cellular proliferation and to 
induce cell death with concomitant improved specific SEAP productivity. 
 miR-34a was observed to enhance CHO cell specific productivity when stably 
depleted in CHO-K1-SEAP cells but appeared to cause clones to clump mid-late 
exponential phase of culture with clones demonstrating reduced culture viability. 
 In IgG-secreting CHO-1.14 clones, miR-34 depletion was observed to enhance 
CHO cell growth at the expense of specific productivity potentially through the 
regulation of targets such as CCND1. 
 Stable depletion of miR-34 did not appear to further increase antibody 
fucosylation potentially attributed to the inherently high (>90%) level of 
fucosylated IgG secreted by CHO. 
 Overexpression of miR-34a did not reduce the level of antibody fucosylation 
potentially resulting from the presence of the miR-34 sponge titrating miR-34a 
function away from FUT8. 
 
3 miR-23b* as a potential candidate for CHO cell engineering 
 The over-expression of miR-23b* inhibited cell growth and induced cell death in 
CHO-SEAP cells.  
 Stable depletion of miR-23b* appeared to enhance CHO cell growth at the 
expense of productivity in both CHO-SEAP and CHO-1.14 cells.  
 In a stable CHO-SEAP clone, miR-23b* sponge clone 18, was observed to 
produce ~50% more SEAP in a fed-batch temperature shift, despite its reduced 
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specific productivity compared to controls. This enhanced phenotype was 
attributed to a prolonged production phase due to its enhanced culture longevity.  
 
4 miR-23 depletion as an attractive tool for industrial application 
 miR-23 depletion using a miRNA sponge enhanced CHO-SEAP cell productivity 
by an average of ~3-fold without affecting cell growth.  
 Productivity was demonstrated to be enhanced at the transcriptional level with no 
influence on post-translational/secretory bottlenecks and mRNA stability. 
 Stable depletion of miR-23 in IgG-secreting CHO-1.14 cells enhanced cell growth 
and appeared to prolong viability at the expense of productivity.  
 The variation of miR-23’s impact on two separate CHO cell lines, both derived 
from the same parent, suggests that this variation is product-specific. 
 Mitochondrial function appeared to be enhanced in miR-23 depleted CHO-SEAP 
clones. 
 Proteomic profiling of whole cell lysates identified a high priority target LETM1 
(associated with mitochondrial function) to be elevated in miR-23 sponge clones 
by 2.7-fold.  
 Elevated SEAP transcription is enhanced in miR-23 sponge clones possibly due 
to the increased expression of CaMKIIδ and 14-3-3η which have been 
demonstrated to interact with HDAC4/5 sequestering them in the cytoplasm 
resulting in elevated transcriptional activation through reduced deacetylation in a 
co-factor dependent manner.  
 Whole cell proteomic analysis further identified 8 potential targets of miR-23 
which were found to overlap with predicted targets using the miRWalk algorithm 
including LETM1, CALD1, CaMKIIδ, FERMT2, IDH1, TXNDR1, PPP1CB and 
P4HA1. 
 Several proteins found to be enriched in both whole cell lysate and mitochondrial 
extracts have been previously associated with cellular bioenergetics and 
mitochondrial metabolism including MDH, SDH, GAA and IDH1 in addition to 
proteins involved in oxidative stress such as TXNRD1, GSTM1/6, IDH1, PSMD7 
and HMOX1 further indicating that CHO cell mitochondrial function is 
potentially elevated as indicated through miR-23 depletion. 
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Future work 
1 Identify additional miRNA targets for stable CHO cell engineering  
 It would be interesting to screen the full panel of DE miRNAs from the profile in 
both a slow growing clone and the model CHO-SEAP cell line. 
 Explore the potential of TMMP playing a role in the apparent increase of miR-
23b* levels in fast growing CHO clones and if miR-23b* is itself influencing this 
fast growing phenotype.  
 
2 Validate the selectivity for enhanced SEAP transcription in CHO-SEAP cells upon 
stable depletion of miR-23 
 siRNA-mediated inhibition of a selection of potential targets of miR-23 derived 
from label-free MS such as LETM1, CaMKIIδ and IDH1 including other 
interesting targets such as 14-3-3-η would assess whether these targets are playing 
a role in the enhanced SEAP productivity phenotype. 
 Immunoprecipitation of candidates such as 14-3-3-η and LETM1 followed by 
label-free mass spectrometry would give an indication of the cohort of proteins 
associated with these upregulated targets such as the hypothesised family of 
HDACs. 
 Over-expression of miR-23a/b in CHO-SEAP cells and western blot analysis of 
the 8 high priority predicted targets (LETM1, CADL1, CaMKIIδ, FERMT2, 
IDH1, TXNDR1, PPP1CB and P4HA1) would further prioritize their candidacy 
as targets of miR-23 with the expectation of reduced translation. Following this, 
3’UTR cloning of miR-23 responsive targets placed downstream of a GFP 
reporter would confirm them as bona fide targets upon miR-23 overexpression. 
 Assess transcript levels of IgG (heavy/light chain) in miR-23-depletd CHO-1.14 
clones to determine enhanced transcription with a potential down-stream 
processing bottleneck. 
 
3 Investigate the impact miR-23 depletion is exerting on mitochondrial function 
 Select a larger number of miR-23 and miR-NC sponge clones and assess 
mitochondrial function using the OROBOROS under both intact and 
permeabilised conditions. Furthermore, it would be interesting to assess variation 
within clonal groups for differences in mitochondrial function. 
 siRNA-mediated sponge knockdown of both miR-23 and miR-NC sponges within 
selected clones and subsequent mitochondrial function characterisation using the 
OROBOROS. 
 siRNA-mediated knockdown of the SEAP transcript with subsequent 
OROBOROS assessment could potentially determine if protein processing is 
driving energy demand. 
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 Carry out the quantification of the various metabolites such as isocitrate, α-
ketoglutarate, malate, oxaloacetate, lactate and ammonia in miR-23 sponge CHO-
SEAP clones versus controls. Additionally, determining the availability of NADH 
and FADH2 could indicate the direction of metabolic reactions. Ultimately, 
evaluating the levels of ATP will provide insight as to whether the enhanced 
mitochondrial function is contributing to an increased energy provision. 
 
4 Investigation of the role of miR-23~27~24 depletion in a panel of CHO cells 
producing a range of recombinant products 
 With the previous observation that depletion of the entire miR-23~27~24 cluster 
enhanced both cell growth and productivity without compromising specific SEAP 
productivity, stable depletion and generation of CHO-SEAP (various recombinant 
products) clones exhibiting stable cluster diversion could further enhance 
volumetric titres due to increased cell densities. 
 
5 Further explore the manipulation of antibody glycoforms using miRNAs 
 Assess the capability of miR-34a to interfere with the fucosylation of antibodies 
produced in rCHO cells. Transiently transfect antibody-secreting cells with miR-
34a followed by western blot analysis of the α-1,6-fucosyltransferase (FUT8) to 
determine effective targeting of FUT8 itself. Following this, glyco-profiling will 
be explored to confirm reduced core fucosylation.  
 As miR-34a overexpression does not present itself as a viable option for CHO cell 
engineering given its widely conserved phenotypic influence of reduced cell 
growth and induction of apoptosis, additional miRNAs that target FUT8 will be 
explored. The use of biotin-labelled anti-sense DNA oligonucleotides will be used 
to pull down FUT8 with any associated miRNAs followed by miRNA target 
identification using miRNA arrays. 
 From a practical application perspective, identified miRNAs will be validated as 
bona fide targets of FUT8 in addition to interfering with core fucosylation. 
Furthermore, overexpression of these miRNAs will be screened for any potential 
adverse effects such as a negative impact on cell growth, viability and/or 
productivity.  
 Finally, ADCC studies with the antibody products of these stable engineered 
miRNA cells will be essential to confirm the enhanced benefits of antibody 
effector functions.  
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6 miRNA profiling of the natural antibody producing B-cell  
 It has already been suggested that lessons from nature can be explored in the 
identification of attractive engineering targets for CHO cell manipulation, B-cells 
being one. Differential miRNA expression profiling could be explored on resting 
B-cells and activated B-cells with subsequent screening of these identified 
miRNA candidates in CHO.  
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Appendix 
Figure A1: microRNAs used in primary screen 
microRNA Pre-miR/Inhibitor (PM/AM) 
miR-10a AM 
miR-15a AM 
miR-15b AM 
miR-16-1 AM 
miR-18a PM 
miR-23b PM 
miR-23b* PM 
miR-25 AM 
miR-27a AM 
miR-29a AM 
miR-34a PM 
miR-34a AM 
miR-34a* PM 
miR-93 AM 
miR-106b AM 
miR-126 AM 
miR-143 AM 
miR-181d PM 
mir-184 AM 
miR-200a PM 
miR-206 AM 
miR-219 PM 
miR-320 PM 
miR-320a PM 
miR-320a AM 
miR-338-3p AM 
miR-378 AM 
miR-409-3p AM 
miR-450 PM 
miR-455-3p AM 
miR-455-5p AM 
miR-532-5p PM 
miR-532-5p AM 
miR-639 PM 
miR-874 AM 
AM = anti-miR for transient inhibition  
PM = pre-miR (mimic) for transient over-expression
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Figure A2: Relative data for transient transfection of anti-miR 126, -338-3p, -378 and -409-3p in CHO-K1-SEAP cells 
Day 2 Day 4 Day 7 Day 2 Day 4 Day 7 Day 2 Day 4 Day 7
miR-126 1.03 1.06 0.8 0.95 1.1 0.88 0.92 1.04 1.09
1.22 0.86 0.86 1.02 0.97 0.79 0.83 1.11 0.92
1.06 1.4 1 0.93 1.03 1.07 0.87 0.73 0.99
0.6 0.47 1.33 0.76 0.82 1.1 1.25 1.43 0.82
0.57 0.49 1.07 0.69 0.74 1.19 1.19 1.48 1.11
1.18 1.13 1.59 0.96 0.9 1.03 0.81 0.8 0.64
0.88 0.9 0.66 0.96 0.92 0.87 1.09 1.02 1.3
0.77 0.59 0.83 0.72 0.86 1.21 0.92 1.45 1.12
0.99 1.05 0.99 0.91 0.95 1.15 0.92 0.9 1.16
0.9 0.8 1.18 0.92 0.83 0.93 1.02 1.03 0.78
1.29 1.97 1.12 0.83 1.16 0.93 0.64 0.59 0.83
0.87 0.87 1.22 0.89 1.04 1.11 1.02 1.19 0.91
1.19 0.87 0.83 1.22 1.36 1.44 1.01 1.55 1.71
1.08 1.27 0.95 1.09 1.09 1.08 1.01 0.85 1.13
0.99 1.26 1.5 0.92 0.96 1.09 0.89 0.76 0.73
0.86 0.98 0.6 0.94 0.97 0.95 1.09 1.09 1.57
0.92 0.9 0.65 0.98 1.16 0.84 1.06 1.28 1.29
miR-409-3p
Cell numbers/mL Protein Yield/mL Cell specific Productivity
miRNA
miR-338-3p
miR-378
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Figure A3: High cell density transfection optimisation using siRNA against VCP 
 
Figure A3: cells were transfected at a density of 4 x 105 cells/mL using 50 nM pre-miR-NC and siRNA 
designed against VCP using a range of concentrations of INTERFERinTM of 1, 2 and 4 µl. Part A 
shows cell numbers/mL while part B shows cell viability. 
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Figure A4: clustal alignment for miR-34 sponge sequence 
 
Figure A4: Clustal alignment to confirm insertion of the miR-34 sponge sequence. Seq1 = template 
sequence, Seq2 = sequence results from MWG Operon sequencing service. Star denotes a perfect 
match. 
 
Figure A5: single nucleotide difference between miR-23a and miR-23b 
 
 
Figure A5: Sequence similarity between the mature miR-23a and miR-23b sequences. A single 
nucleotide difference is indicated by a star (*) with the seed region of both miRNAs being highlighted 
in a yellow box (nt 2-8). 
 
 
 
 
 
 
 
 
 
 
 
miR-23b     5’-aucacauugccagggauuacc-3’
miR-23a      5’-aucacauugccagggauuucc-3’
*
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Figure A6: Diagnostic gels for miR-23b/-23b* sponge vector preparation  
 
Figure A6: Diagnostic gels for miR-sponge preparation A) stock plasmid containing miR-23b/-23b* 
(pEX-A) suitable for bacterial culture only B) Digestion of empty and negative control (NC) pd2-
EGFP-sponge with XhoI/EcoRI C) Extracted miR-23b/-23b* sequence inserts D) Mini-prep 
diagnostic panel of miR-23b/-23b* sponge vectors E) Final diagnostic of Maxi-prep sponge vectors. 
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Figure A7: Sequence alignment for miR-23b and miR-23b* sponge vectors 
 
Figure A7: The Clustal sequence alignments for both miR-23b* (A) and miR-23b (B) sponge 
sequences referenced against the original sequence designed. Seq1 denotes the original sequence 
designed while Seq2 denotes the sequence information from MWG Operon. Perfect matches are 
flagged with stars (*) while just the sponge sequence is highlighted in green.  
 
Figure A8: pre-miR-23b hairpin with base-pair mismatches  
Figure A8: This diagram was sourced from the miRBase database (http://www.mirbase.org/cgi-
bin/mirna_entry.pl?acc=MI0000439) and demonstrates the structure of the pre-miR-23b hairpin upon 
Drosha-mediated processing of the long pri-miRNA. We had specifically requested a tailor designed 
miRNA (pre-miR-23b* mod) in which instead of an siRNA-like design of complete complementarity, 
the base-pair mismatches are retained within its structure.  
 
 
 
 
A miR-23b* sponge vector
B miR-23b sponge vector
miR-23b* (23b-5p)
miR-23b (23b-3p)
5’-
3’-
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Figure A9: List of differentially expressed proteins when miR-23 and miR-NC 
samples were randomised 
 
Figure A9: When all clones were randomised and compared for differential protein expression, two 
proteins were found to be DE. This was a quality control test as a means to determine the likelihood 
of randomly identifying DE
Control Test FC
gi|344243859 2 120.07 0.02 1.86 Retinoic acid-induced protein 3 [Cricetulus griseus] 
[MASS=39746]
8.74E+04 1.62E+05
1.853547
gi|344257799 1 53.63 0.03 5.66 Keratin, type II cytoskeletal 1b [Cricetulus griseus] 
[MASS=93520]
1.22E+04 6.93E+04
5.680328
Description Average 
Normalised 
Abundances
Accessio
n
Peptides Score Anova 
(p)*
Fold Tags
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Figure A10: Differentially Expressed proteins from enriched mitochondrial (miR-23 sponge CHO-SEAP versus miR-NC sponge) 
CS 
Anova 
(p) FC Gene I.D Description 
65.21 9.61E-09 2.6 KIAA1881 Protein KIAA1881 [Cricetulus griseus] [MASS=39959] 
473.97 2.52E-08 3.6 SBSN Suprabasin [Cricetulus griseus] [MASS=63932] 
96.35 6.13E-07 3.7 GRN Granulins [Cricetulus griseus] [MASS=63924] 
158.9 1.41E-06 1.7 LIMA1 LIM domain and actin-binding protein 1 [Cricetulus griseus] [MASS=84545] 
76.55 1.52E-06 6.2 AHNAK2 Protein AHNAK2 [Cricetulus griseus] [MASS=81741] 
204.15 2.19E-06 2.6 EPRS Bifunctional aminoacyl-tRNA synthetase [Cricetulus griseus] [MASS=154896] 
290.49 2.30E-06 1.9 CALD1 Non-muscle caldesmon [Cricetulus griseus] [MASS=61921] 
77.33 2.38E-06 1.5 HTATSF1 HIV Tat-specific factor 1-like [Cricetulus griseus] [MASS=60645] 
62.16 2.49E-06 2.5 HSPG Basement membrane-specific heparan sulfate proteoglycan core protein [Cricetulus griseus] [MASS=334137] 
47.16 3.08E-06 2.2 NIP7 60S ribosome subunit biogenesis protein NIP7-like [Cricetulus griseus] [MASS=10402] 
42.96 3.50E-06 2.9 ADA Adenosine deaminase [Cricetulus griseus] [MASS=40940] 
110.25 5.57E-06 1.5 HMGB2 High mobility group protein B2 [Cricetulus griseus] [MASS=18197] 
216.74 6.04E-06 1.7 NOP2 Putative ribosomal RNA methyltransferase NOP2 [Cricetulus griseus] [MASS=86249] 
42.91 6.49E-06 2.2 MCM3 DNA replication licensing factor MCM3 [Cricetulus griseus] [MASS=90790] 
83.37 7.49E-06 2.3 DLGAP5 Disks large-associated protein 5 [Cricetulus griseus] [MASS=63127] 
60.3 9.07E-06 2.8 ZCCHC3 Zinc finger CCHC domain-containing protein 3 [Cricetulus griseus] [MASS=30279] 
112.46 9.29E-06 6.9 AKAP12 A-kinase anchor protein 12 [Cricetulus griseus] [MASS=91046] 
499.19 9.69E-06 2.1 RCN1 Reticulocalbin-3 [Cricetulus griseus] [MASS=34399] 
172.09 1.06E-05 1.6 SCP2 Non-specific lipid-transfer protein [Cricetulus griseus] [MASS=58892] 
528.27 1.09E-05 2.4 GSTM6 Glutathione S-transferase Mu 6 [Cricetulus griseus] [MASS=86559] 
85.95 1.19E-05 2.4 KIF2C Kinesin-like protein KIF2C  
107.61 1.97E-05 1.7 P4HA1 Prolyl 4-hydroxylase subunit alpha-1 [Cricetulus griseus] [MASS=58084] 
293.89 2.13E-05 2 CALU Calumenin [Cricetulus griseus] [MASS=87917] 
84.54 2.25E-05 1.8 CAPRIN1 Caprin-1 [Cricetulus griseus] [MASS=73689] 
40.54 2.28E-05 2.9 PTER Phosphotriesterase-related protein [Cricetulus griseus] [MASS=39278] 
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284.33 2.41E-05 2.5 GAA Lysosomal alpha-glucosidase [Cricetulus griseus] [MASS=105847] 
56.39 2.55E-05 1.8 UAP1L1 UDP-N-acetylhexosamine pyrophosphorylase-like protein 1 [Cricetulus griseus] [MASS=58175] 
44.26 2.57E-05 23.2 FABP4 Fatty acid-binding protein, adipocyte [Cricetulus griseus] [MASS=14753] 
415.32 2.66E-05 1.6 ITGB1 Integrin beta-1 [Cricetulus griseus] [MASS=88342] 
96.32 2.70E-05 1.7 CTSB Cathepsin B [Cricetulus griseus] [MASS=37504] 
40.09 2.92E-05 1.8 TXNRD1 Thioredoxin reductase 1, cytoplasmic [Cricetulus griseus] [MASS=61858] 
50.25 3.29E-05 2.7 MDH1 Malate dehydrogenase, cytoplasmic [Cricetulus griseus] [MASS=36466] 
419.27 3.33E-05 1.6 GP50 GP50 [Cricetulus griseus] [MASS=46598] 
152.86 3.40E-05 1.6 IQGAP1 Ras GTPase-activating-like protein IQGAP1 [Cricetulus griseus] [MASS=191377] 
160.75 3.46E-05 1.6 SMARCA5 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5  
57.31 3.49E-05 2.5 DPP2 Dipeptidyl-peptidase 2 [Cricetulus griseus] [MASS=56397] 
99.72 4.63E-05 2 IPO5 Importin-5 [Cricetulus griseus] [MASS=89713] 
85.75 4.73E-05 2 CLINT1 Clathrin interactor 1 [Cricetulus griseus] [MASS=68215] 
576.94 4.78E-05 1.5 HSP90B1 Endoplasmin [Cricetulus griseus] [MASS=92622] 
85.86 5.00E-05 1.9 SH3BGRL3 SH3 domain-binding glutamic acid-rich-like protein [Cricetulus griseus] [MASS=12747] 
134.41 5.03E-05 1.6 RRBP1 Ribosome-binding protein 1 [Cricetulus griseus] [MASS=216696] 
42.91 5.12E-05 2.1 SKIV2L2 Superkiller viralicidic activity 2-like 2 [Cricetulus griseus] [MASS=96202] 
43.27 5.35E-05 1.4 EIF3H Eukaryotic translation initiation factor 3 subunit H [Cricetulus griseus] [MASS=34239] 
173.71 5.48E-05 1.6 LPH Lactase-phlorizin hydrolase [Cricetulus griseus] [MASS=301280] 
155.61 5.81E-05 1.7 SHMT Serine hydroxymethyltransferase, mitochondrial [Cricetulus griseus] [MASS=55908] 
420.16 5.99E-05 1.7 TOP2A RecName: Full=DNA topoisomerase 2-alpha; AltName: Full=DNA topoisomerase II, alpha isozyme 
48.89 6.04E-05 3.6 GUSB Beta-glucuronidase [Cricetulus griseus] [MASS=74804] 
60.27 6.20E-05 1.9 PRPF8 Pre-mRNA-processing-splicing factor 8 [Cricetulus griseus] [MASS=30142] 
287.95 6.33E-05 1.4 STIP1 Stress-induced-phosphoprotein 1 
461.22 6.40E-05 1.4 ANXA1 Annexin A1 [Cricetulus griseus] [MASS=38861] 
991.99 6.58E-05 1.8 CALR Calreticulin [Cricetulus griseus] [MASS=48241] 
155.37 6.71E-05 1.9 VCP Transitional endoplasmic reticulum ATPase [Cricetulus griseus] [MASS=237642] 
780.39 6.72E-05 1.4 GAPDH Glyceraldehyde-3-phosphate dehydrogenase  
48.83 7.11E-05 3.1 ALCAM CD166 antigen [Cricetulus griseus] [MASS=65083] 
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42.71 7.35E-05 1.5 VCL Vinculin [Cricetulus griseus] [MASS=124877] 
534.81 7.65E-05 1.8 PDIA4 Protein disulfide-isomerase A4 [Cricetulus griseus] [MASS=72586] 
43.2 8.00E-05 2.5 TWSG1 Twisted gastrulation protein-like 1 [Cricetulus griseus] [MASS=24747] 
177.24 8.07E-05 1.7 HP1 heterochromatin protein 1 alpha [Cricetulus griseus] 
485.82 8.17E-05 1.5 MYH10 Myosin-10 [Cricetulus griseus] [MASS=229037] 
77.41 8.38E-05 1.7 CNN2 Calponin-2 [Cricetulus griseus] [MASS=32507] 
42.27 8.41E-05 1.4 EHD3 EH domain-containing protein 3 [Cricetulus griseus] [MASS=60915] 
69.02 8.73E-05 6 RPL7 60S ribosomal protein L7 [Cricetulus griseus] [MASS=29237] 
998.19 9.15E-05 1.6 NUMA1 Nuclear mitotic apparatus protein 1 [Cricetulus griseus] [MASS=340229] 
67.81 0.000104 1.6   Proline synthetase co-transcribed bacterial-like protein [Cricetulus griseus] [MASS=24790] 
130.72 0.000106 2 PFDN6 prefoldin subunit 6 [Mus musculus] 
106.24 0.000108 1.7 TXNDC5 Thioredoxin domain-containing protein 5 [Cricetulus griseus] [MASS=46354] 
86.63 0.00011 1.8 PLAA Phospholipase A-2-activating protein [Cricetulus griseus] [MASS=87183] 
74.08 0.000117 1.5 NCAPH Condensin complex subunit 2 [Cricetulus griseus] [MASS=81308] 
652.03 0.000121 1.6 PDIA3 ERP57 protein [Cricetulus griseus] [MASS=56796] 
47.4 0.000122 1.4 GRSF1 G-rich sequence factor 1 [Cricetulus griseus] [MASS=70369] 
83.65 0.000128 3 H2AFV histone H2A.V isoform 1 [Homo sapiens] 
40.47 0.000135 1.6 HLAA MHC class I antigen Hm1-C1 [Cricetulus griseus] [MASS=38752] 
154.98 0.000136 2 HMOX1 Heme oxygenase 1 [Cricetulus griseus] [MASS=33023] 
313.51 0.00014 2.8 FASN Fatty acid synthase [Cricetulus griseus] [MASS=271857] 
42.21 0.000144 1.9 ZNF593 Zinc finger protein 593 [Cricetulus griseus] [MASS=15247] 
113.62 0.00018 2.1 MCM5 DNA replication licensing factor MCM5 [Cricetulus griseus] [MASS=82347] 
261.37 0.000194 1.4 CBX3 chromobox protein homolog 3 [Homo sapiens] 
94.68 0.000198 1.3 AK2 Adenylate kinase 2, mitochondrial [Cricetulus griseus] [MASS=15424] 
135.15 0.000205 2.2 MFGE8 Lactadherin [Cricetulus griseus] [MASS=16152] 
40.63 0.000211 2.3 GNGT2 guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2 precursor [Mus musculus] 
80.18 0.000223 1.8 FUS RNA-binding protein FUS [Cricetulus griseus] [MASS=21204] 
53.68 0.000229 1.2 RPS27L ribosomal protein S27-like, isoform CRA_a [Homo sapiens] 
119.96 0.000234 1.4 SRSF3 Splicing factor, arginine/serine-rich 3 [Cricetulus griseus] [MASS=19310] 
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60.94 0.000236 3.1 KIF4 Chromosome-associated kinesin KIF4 [Cricetulus griseus] [MASS=185097] 
524.15 0.000241 1.6 PDIA3 Protein disulfide-isomerase A3 [Cricetulus griseus] [MASS=50051] 
632.16 0.000241 1.7 MYBBP1A Myb-binding protein 1A [Cricetulus griseus] [MASS=105149] 
53.85 0.000255 2 SLC7A1 High affinity cationic amino acid transporter 1 [Cricetulus griseus] [MASS=67614] 
62.52 0.000264 2.9 HSPB1 Heat shock protein beta-1 [Cricetulus griseus] [MASS=8903] 
106.62 0.000265 1.6 RRP15 RRP15-like protein [Cricetulus griseus] [MASS=42329] 
1075.25 0.000265 1.4 GRP78 78 kDa glucose-regulated protein binding  
756.55 0.000268 1.3 HSP60 60 kDa heat shock protein, mitochondrial  
57.17 0.000269 1.5 COPB1 Coatomer subunit beta' [Cricetulus griseus] [MASS=89506] 
105.9 0.000275 1.7 HDAC2 Histone deacetylase 2 [Cricetulus griseus] [MASS=51941] 
107.47 0.000316 1.8 MCM2 DNA replication licensing factor MCM2 [Cricetulus griseus] [MASS=102184] 
107.76 0.000326 1.5 VAPB Vesicle-associated membrane protein-associated protein B [Cricetulus griseus] [MASS=27502] 
128.89 0.000329 1.4 DNTTIP2 Deoxynucleotidyltransferase terminal-interacting protein 2 [Cricetulus griseus] [MASS=85134] 
136.67 0.000342 1.4 NUFIP2 Nuclear fragile X mental retardation-interacting protein 2 [Cricetulus griseus] [MASS=56644] 
67.07 0.00035 1.5 NUP93 Nuclear pore complex protein Nup93 [Cricetulus griseus] [MASS=89109] 
47.74 0.00035 1.7 KIF15 Kinesin-like protein KIF15 [Cricetulus griseus] [MASS=125621] 
123.84 0.000367 1.9 CAD CAD protein [Cricetulus griseus] [MASS=243029] 
145.15 0.000398 1.3 CTTN Src substrate cortactin [Cricetulus griseus] [MASS=61469] 
109.1 0.000407 1.5 OXCT1 Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, mitochondrial [Cricetulus griseus] [MASS=56218] 
46.59 0.000411 3.5 PSAP Sulfated glycoprotein 1 [Cricetulus griseus] [MASS=27374] 
319.39 0.000414 1.9 SND1 nuclease domain-containing protein 1 [Cricetulus griseus] [MASS=99748] 
96.49 0.000417 1.8 WDR43 WD repeat-containing protein 43 [Cricetulus griseus] [MASS=55890] 
180.99 0.000423 1.6 ATP1A1 Sodium/potassium-transporting ATPase subunit alpha-1 [Cricetulus griseus] [MASS=84781] 
120.34 0.000436 1.4 MAP4 Microtubule-associated protein 4 [Cricetulus griseus] [MASS=138221] 
221.57 0.000439 1.4 NSFL1C NSFL1 cofactor p47 [Cricetulus griseus] [MASS=41009] 
121 0.000454 2.1 PLS3 RecName: Full=Plastin-3; AltName: Full=T-plastin 
87.48 0.00046 1.6 CYF1P1 Cytoplasmic FMR1-interacting protein 1 [Cricetulus griseus] [MASS=145275] 
71.91 0.00046 1.7 ATP2A3 Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 [Cricetulus griseus] [MASS=103607] 
52.46 0.000473 1.8 UHRF1 E3 ubiquitin-protein ligase UHRF1 [Cricetulus griseus] [MASS=88095] 
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45.14 0.000476 1.6 GMPS GMP synthase [glutamine-hydrolyzing] [Cricetulus griseus] [MASS=130016] 
109.81 0.000483 1.3 NPM1 Nucleophosmin [Cricetulus griseus] [MASS=31052] 
97.59 0.000487 1.5 MTHFD2 Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial [Cricetulus griseus]  
69.28 0.000491 1.4 DDX6 PREDICTED: probable ATP-dependent RNA helicase DDX6 isoform 1 [Sus scrofa] 
110.09 0.000492 1.4 PSMD2 26S proteasome non-ATPase regulatory subunit 2 [Cricetulus griseus] [MASS=72983] 
197.29 0.000505 1.4 ANXA2 Annexin A2 [Cricetulus griseus] [MASS=27037] 
65.4 0.000535 2.3 HSPH1 RecName: Full=Heat shock protein 105 kDa; AltName: Full=Heat shock 110 kDa protein 
493.84 0.000553 1.4 SDHA Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial [Cricetulus griseus] [MASS=71658] 
56.16 0.000556 1.3 RRM1 Ribonucleoside-diphosphate reductase large subunit [Cricetulus griseus] [MASS=90217] 
324.58 0.000565 2.2 MYH11 Myosin-11 [Cricetulus griseus] [MASS=227190] 
71.8 0.000572 2.2 GSTA3 Glutathione S-transferase alpha-3 [Cricetulus griseus] [MASS=14752] 
93.72 0.000575 2.4 ABCF1 ATP-binding cassette sub-family F member 1 [Cricetulus griseus] [MASS=65859] 
121.17 0.000581 1.5 PSME1 Proteasome activator complex subunit 1 [Cricetulus griseus] [MASS=24514] 
434.44 0.000603 1.7 DDX1 RNA helicase [Mesocricetus auratus] 
269.45 0.000617 1.7 CLTC Clathrin heavy chain 1 [Cricetulus griseus] [MASS=223961] 
80.08 0.000637 1.6 SLC7A8 Large neutral amino acids transporter small subunit 1 [Cricetulus griseus] [MASS=55205] 
168.98 0.00067 1.6 HYOU1 Hypoxia up-regulated protein 1  
274.94 0.000693 1.6 LRPPRC Leucine-rich PPR motif-containing protein, mitochondrial [Cricetulus griseus] [MASS=158425] 
40.28 0.000698 1.6 HNRNPUL1 Heterogeneous nuclear ribonucleoprotein U-like protein 2 [Cricetulus griseus] [MASS=72420] 
294.31 0.000726 1.5 FLNB Filamin-B [Cricetulus griseus] [MASS=277844] 
60.42 0.000737 2.3 BCL9L B-cell CLL/lymphoma 9-like protein [Cricetulus griseus] [MASS=156723] 
77.91 0.000745 1.4 RHOA transforming protein RhoA precursor [Rattus norvegicus] 
103.35 0.000751 1.5 RAB7A Ras-related protein Rab-7a [Cricetulus griseus] [MASS=23518] 
51.97 0.000763 1.9 CETN3 Centrin-3 [Cricetulus griseus] [MASS=19558] 
58.48 0.000795 1.3 CCT7 T-complex protein 1 subunit eta [Cricetulus griseus] [MASS=54906] 
77.13 0.000817 1.4 PFDN4 Prefoldin subunit 4 [Cricetulus griseus] [MASS=15226] 
276.02 0.000827 1.3 KIF27 Kinesin-like protein KIF27 [Cricetulus griseus] [MASS=185707] 
183.23 0.000829 1.8 SLC25A3 Phosphate carrier protein, mitochondrial [Cricetulus griseus] [MASS=26018] 
113.17 0.000839 2.6 SPRR1A Cornifin-A [Cricetulus griseus] [MASS=12457] 
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50.66 0.000873 1.6 EIF1AY eukaryotic translation initiation factor 1A [Mus musculus] 
121.03 0.000876 1.3 LYAR Cell growth-regulating nucleolar protein [Cricetulus griseus] [MASS=43169] 
55.92 0.000896 1.9 PPA1 Inorganic pyrophosphatase [Cricetulus griseus] [MASS=36997] 
40.96 0.0009 1.9 CAND1 Cullin-associated NEDD8-dissociated protein 1 [Cricetulus griseus] [MASS=133622] 
173.13 0.000923 1.4 RPL6 60S ribosomal protein L6 [Cricetulus griseus] [MASS=32777] 
47.96 0.000938 1.9 L7RN6 lethal, Chr 7, Rinchik 6 [Mus musculus] 
175.92 0.000989 1.4 YWHAZ 14-3-3 protein zeta/delta [Cricetulus griseus] [MASS=27715] 
336.44 0.001001 1.3 ALDOA Fructose-bisphosphate aldolase A [Cricetulus griseus] [MASS=39382] 
160.65 0.001043 1.4 TES Testin [Cricetulus griseus] [MASS=47209] 
249.77 0.001078 1.4 EIF4G1 Eukaryotic translation initiation factor 4 gamma 1 [Cricetulus griseus] [MASS=175081] 
211.82 0.001097 1.3 TMPO Lamina-associated polypeptide 2, isoforms alpha/zeta [Cricetulus griseus] [MASS=34881] 
141.92 0.001111 1.6 KPNB1 Importin subunit beta-1 [Cricetulus griseus] [MASS=211197] 
42.51 0.001122 1.7 YWHAH 14-3-3 protein eta [Cricetulus griseus] [MASS=27084] 
41.01 0.001125 1.7 HDDC2 HD domain-containing protein 3 [Cricetulus griseus] [MASS=20271] 
49.9 0.001205 1.8 SLC3A2 putative CD98 protein [Cricetulus griseus] [MASS=58926] 
200.38 0.001206 1.3 LDHA LDH-A [Cricetulus griseus] [MASS=36519] 
234.43 0.001211 1.4 HMGCS1 Hydroxymethylglutaryl-CoA synthase, cytoplasmic 
48.07 0.001228 1.7 HSPA4 Heat shock 70 kDa protein 4 [Cricetulus griseus] [MASS=62990] 
753.03 0.001268 1.4 EEF2 elongation factor 2 [Cricetulus griseus] [MASS=95323] 
306.33 0.001271 1.2 TPI Triosephosphate isomerase [Cricetulus griseus] [MASS=20407] 
371.2 0.001338 1.3 HSPA9 Stress-70 protein, mitochondrial 
74.66 0.001374 1.5 HGPRT RecName: Full=Hypoxanthine-guanine phosphoribosyltransferase; Short=HGPRT; Short=HGPRTase 
369.15 0.001428 1.4 GSTP1 RecName: Full=Glutathione S-transferase P; AltName: Full=GST class-pi 
114.51 0.001441 1.7 MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic [Cricetulus griseus] [MASS=101286] 
146.47 0.001474 1.4 RCN1 Reticulocalbin-1 [Cricetulus griseus] [MASS=29316] 
56.71 0.001485 1.4 ANLN Actin-binding protein anillin [Cricetulus griseus] [MASS=122923] 
230.11 0.001584 1.7 NOLC1 Nucleolar phosphoprotein p130 [Cricetulus griseus] [MASS=73455] 
61.69 0.001609 1.6 TCOF1 Treacle protein [Cricetulus griseus] [MASS=127813] 
263.85 0.001643 1.4 NUDC Nuclear migration protein nudC [Cricetulus griseus] [MASS=32771] 
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160.48 0.001645 1.5 MAP1B Microtubule-associated protein 1B [Cricetulus griseus] [MASS=260385] 
152.73 0.001718 1.3 WBP2 WW domain-binding protein 2 [Cricetulus griseus] [MASS=27992] 
639.78 0.001771 1.4 PDI Prolyl 4-hydroxylase subunit beta 
117.81 0.00179 1.3 IDH3A Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial [Cricetulus griseus] [MASS=39684] 
87.63 0.001806 1.5 LGALS1 Galectin-1 
188.09 0.001807 1.4 PRKCSH Glucosidase 2 subunit beta [Cricetulus griseus] [MASS=62353] 
177.85 0.001833 1.3 BST2 Bone marrow stromal antigen 2 
70.34 0.001869 1.3 TRIM28 Transcription intermediary factor 1-beta [Cricetulus griseus] [MASS=58046] 
63.76 0.001889 1.3 DDX10 putative ATP-dependent RNA helicase DDX10 [Cricetulus griseus] [MASS=101337] 
69.21 0.001909 2 AIM2 Interferon-inducible protein [Cricetulus griseus] [MASS=14990] 
315.2 0.001918 1.2 ACTB Actin, cytoplasmic 1 
84.3 0.001949 1.3 PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform [Cricetulus griseus]  
63.6 0.001956 1.6 MATR3 Matrin-3 [Cricetulus griseus] [MASS=94625] 
53.37 0.001985 1.3 SMARCC1 SWI/SNF complex subunit SMARCC1 [Cricetulus griseus] [MASS=154765] 
143.8 0.001998 1.2 HNRNPAB Heterogeneous nuclear ribonucleoprotein A/B [Cricetulus griseus] [MASS=23754] 
240.68 0.002132 1.5 ACO2 Aconitate hydratase, mitochondrial [Cricetulus griseus] [MASS=85466] 
85.16 0.002167 1.5 SNX1 Sorting nexin-1 [Cricetulus griseus] [MASS=58922] 
56.33 0.002223 1.8 LEPRE1 Prolyl 3-hydroxylase 1 [Cricetulus griseus] [MASS=73130] 
89.12 0.002264 2.3 HMGN1 Nucleosome-binding protein 1 [Cricetulus griseus] [MASS=33339] 
85 0.002286 1.4 MRPS7 28S ribosomal protein S7, mitochondrial [Cricetulus griseus] [MASS=17257] 
53.95 0.002298 1.4 SUCLA2 Succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial [Cricetulus griseus] [MASS=25797] 
59.63 0.002313 1.4 MAGOH protein mago nashi homolog [Homo sapiens] 
94.58 0.002324 1.4 DDX56 putative ATP-dependent RNA helicase DDX56 [Cricetulus griseus] [MASS=61201] 
41.04 0.002333 1.5 HAT1 Histone acetyltransferase type B catalytic subunit [Cricetulus griseus] [MASS=21390] 
41.44 0.002371 1.4 ERP29 Endoplasmic reticulum protein ERp29 [Cricetulus griseus] [MASS=28603] 
215.81 0.002435 1.3 NME2 Nucleoside diphosphate kinase B [Cricetulus griseus] [MASS=17340] 
71.77 0.002584 1.5 GB2 growth factor receptor-bound protein 2 isoform 1 [Homo sapiens] 
46.64 0.002633 1.6 NUP205 Nuclear pore complex protein Nup205 [Cricetulus griseus] [MASS=223157] 
53.37 0.002636 1.4 TALDO1 RecName: Full=Transaldolase 
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189.83 0.002673 1.3 RPS15 40S ribosomal protein S15 [Cricetulus griseus] [MASS=12990] 
164.35 0.00269 1.5 TOP1 DNA topoisomerase I [Cricetulus griseus] [MASS=90837] 
146.99 0.002708 1.5 HDGF Hepatoma-derived growth factor [Cricetulus griseus] [MASS=22716] 
48.73 0.002736 1.5 SUMF2 Sulfatase-modifying factor 2 [Cricetulus griseus] [MASS=7750] 
46.99 0.002781 1.5 SRSF7 Splicing factor, arginine/serine-rich 7 [Cricetulus griseus] [MASS=26153] 
89.77 0.002846 2.3 CMAS N-acylneuraminate cytidylyltransferase [Cricetulus griseus] [MASS=31274] 
96.89 0.002873 6.6 SLC25A5 ADP/ATP translocase 2 [Cricetulus griseus] [MASS=46576] 
206.18 0.002913 1.3 RPSA 40S ribosomal protein SA 
86.59 0.002921 1.5 RANGAP1 Ran GTPase-activating protein 1 [Cricetulus griseus] [MASS=63142] 
263.02 0.003013 1.5 ARHGDIA Rho GDP-dissociation inhibitor 1 [Cricetulus griseus] [MASS=23423] 
231.19 0.003016 1.3 HSD17B10 3-hydroxyacyl-CoA dehydrogenase type-2 [Cricetulus griseus] [MASS=27174] 
203.53 0.003086 2.3 RPN1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 [Cricetulus griseus] [MASS=68577] 
832.3 0.003147 1.4 MYH9 Myosin-9 [Cricetulus griseus] [MASS=225794] 
203.2 0.003181 1.2 TPR Nucleoprotein TPR [Cricetulus griseus] [MASS=238753] 
57.3 0.003233 1.3 ARD1 hypothetical protein I79_013960 [Cricetulus griseus] [MASS=25829] 
108.67 0.00327 1.4 GATAD2B Transcriptional repressor p66-beta [Cricetulus griseus] [MASS=64918] 
136.53 0.003279 2 SF3B3 splicing factor 3B subunit 3 [Mus musculus] 
111.74 0.003378 1.3 RPS18 40S ribosomal protein S18 [Cricetulus griseus] [MASS=17763] 
58.08 0.003381 1.6 KHDRBS1 KH domain-containing, RNA-binding, signal transduction-associated protein 1 [Cricetulus griseus] [MASS=48326] 
75.88 0.003612 1.4 UBXN1 UBX domain-containing protein 1 [Cricetulus griseus] [MASS=23179] 
75.04 0.003631 1.7 MFGE8 Lactadherin [Cricetulus griseus] [MASS=22114] 
52.21 0.003653 1.6 SDF2L1 Stromal cell-derived factor 2-like protein 1 [Cricetulus griseus] [MASS=19011] 
45.27 0.003722 1.8 COX5A Cytochrome c oxidase subunit 5A, mitochondrial [Cricetulus griseus] [MASS=8603] 
171.03 0.003763 1.5 SPTAN1 Spectrin alpha chain, brain [Cricetulus griseus] [MASS=258831] 
271.84 0.003789 1.3 SFPQ splicing factor proline/glutamine rich (polypyrimidine tract binding protein associated) [Rattus norvegicus] 
196.86 0.003789 1.4 RBM14 RNA-binding protein 14 [Cricetulus griseus] [MASS=50151] 
48.78 0.003814 1.5 LAMC1 Laminin subunit gamma-1 [Cricetulus griseus] [MASS=172121] 
47.43 0.003845 1.5 SLC1A5 Neutral amino acid transporter B(0) [Cricetulus griseus] [MASS=17378] 
78.34 0.003922 1.3 ADPRH [Protein ADP-ribosylarginine] hydrolase [Cricetulus griseus] [MASS=38789] 
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195.07 0.003951 1.5 LRPAP1 Alpha-2-macroglobulin receptor-associated protein [Cricetulus griseus] [MASS=41173] 
280.78 0.004029 1.2 HDLBP Vigilin [Cricetulus griseus] [MASS=141720] 
43.14 0.004073 1.9 Cab45 45 kDa calcium-binding protein [Cricetulus griseus] [MASS=41237] 
140.74 0.00413 1.9 RPL3 60S ribosomal protein L3 [Cricetulus griseus] [MASS=46152] 
87.27 0.004148 1.3 SF3B1 splicing factor 3B subunit 1 isoform 1 [Homo sapiens] 
304.02 0.004163 1.3 DDX17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17, isoform CRA_a [Rattus norvegicus] 
140.66 0.004164 1.3 GANAB Neutral alpha-glucosidase AB [Cricetulus griseus] [MASS=106977] 
40.99 0.004195 2.9 LAMP1 Lysosome-associated membrane glycoprotein 1 
162.94 0.004226 1.3 BAG3 BAG family molecular chaperone regulator 3 [Cricetulus griseus] [MASS=61111] 
101.43 0.00423 1.4 ATX10 Ataxin-10 [Cricetulus griseus] [MASS=34265] 
131.59 0.004301 1.3 MDH2 Malate dehydrogenase, mitochondrial [Cricetulus griseus] [MASS=28696] 
91.91 0.004348 1.6 ABCG3 ATP-binding cassette sub-family G member 3 [Cricetulus griseus] [MASS=69556] 
139.2 0.004449 1.3 HNRNPM Heterogeneous nuclear ribonucleoprotein M [Cricetulus griseus] [MASS=60304] 
80.15 0.004493 1.4 EWSR1 RNA-binding protein EWS [Cricetulus griseus] [MASS=68536] 
41.01 0.004497 1.3 RAB1B ras-related protein Rab-1B [Mus musculus] 
65.48 0.00451 1.6 SET Protein SET [Cricetulus griseus] [MASS=44274] 
195.18 0.004615 1.5 FKBP4 FK506-binding protein 4 [Cricetulus griseus] [MASS=46625] 
44.57 0.004662 2 IDI1 Isopentenyl-diphosphate Delta-isomerase 1 [Cricetulus griseus] [MASS=32694] 
123.1 0.004826 1.5 UQCRC1 Cytochrome b-c1 complex subunit 1, mitochondrial [Cricetulus griseus] [MASS=40615] 
199.47 0.004925 1.4 RPL7A 60S ribosomal protein L7a [Cricetulus griseus] [MASS=22240] 
43.78 0.005069 1.4 DNAJC8 DnaJ-like subfamily C member 8 [Cricetulus griseus] [MASS=29840] 
185.23 0.005078 1.6 EEF1B2 Elongation factor 1-beta [Cricetulus griseus] [MASS=24687] 
142.75 0.005097 1.8 PSMD12 26S proteasome non-ATPase regulatory subunit 12 [Cricetulus griseus] [MASS=52978] 
56.01 0.005112 1.5 DDB1 DNA damage-binding protein 1 [Cricetulus griseus] [MASS=126926] 
150.21 0.005145 1.3 RPS13 RecName: Full=40S ribosomal protein S13 
379.43 0.005165 1.5 MKI67 Antigen KI-67 [Cricetulus griseus] [MASS=356150] 
59.13 0.005188 1.6 PGAM1 Phosphoglycerate mutase 1 [Cricetulus griseus] [MASS=20205] 
57.83 0.005192 1.3 WNK1 Serine/threonine-protein kinase WNK1 [Cricetulus griseus] [MASS=157436] 
124.49 0.005193 1.5 GFM1 Elongation factor G, mitochondrial [Cricetulus griseus] [MASS=83298] 
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1139.28 0.005193 1.5 LMNA Lamin-A/C [Cricetulus griseus] [MASS=64041] 
57.24 0.005195 1.5 CEBPZ CCAAT/enhancer-binding protein zeta [Cricetulus griseus] [MASS=120496] 
112.2 0.005225 1.4 KGD1 2-oxoglutarate dehydrogenase E1 component, mitochondrial [Cricetulus griseus] [MASS=104514] 
64.63 0.005231 1.4 SYAP1 Synapse-associated protein 1 [Cricetulus griseus] [MASS=35619] 
394.01 0.005336 1.8 PDIA6 Protein disulfide-isomerase A6 [Cricetulus griseus] [MASS=28401] 
121.4 0.005428 1.3 CACYBP Calcyclin-binding protein [Cricetulus griseus] [MASS=21260] 
57.72 0.005504 8.6 HIST2H2AA3 histone H2A type 2-A [Homo sapiens] 
41.28 0.005535 1.3 RPS16 40S ribosomal protein S16 [Cricetulus griseus] [MASS=15699] 
120.44 0.005659 1.3 EIF3G Eukaryotic translation initiation factor 3 subunit G [Cricetulus griseus] [MASS=35716] 
72.63 0.005743 1.2 AIFM1 Apoptosis-inducing factor 1, mitochondrial [Cricetulus griseus] [MASS=66780] 
40.65 0.005753 2 SPTBN1 Spectrin beta chain, brain 1 [Cricetulus griseus] [MASS=94523] 
251.05 0.005771 1.4 UBA1 Ubiquitin-like modifier-activating enzyme 1 [Cricetulus griseus] [MASS=117697] 
95.07 0.005797 1.8 HNRNPU Heterogeneous nuclear ribonucleoprotein U [Cricetulus griseus] [MASS=57620] 
102.32 0.005826 1.8 DDX21 Nucleolar RNA helicase 2 [Cricetulus griseus] [MASS=80626] 
94.1 0.005877 1.4 RPL7 60S ribosomal protein L7 [Cricetulus griseus] [MASS=17054] 
51.38 0.005887 1.5 RPL29 60S ribosomal protein L29 [Cricetulus griseus] [MASS=12365] 
43.74 0.005956 1.4 PMPCB Mitochondrial-processing peptidase subunit beta [Cricetulus griseus] [MASS=40055] 
42.85 0.005957 1.3 ANXA5 Annexin A5 [Cricetulus griseus] [MASS=36065] 
398.31 0.005973 1.4 LAML1 Lamin-L(I) [Cricetulus griseus] [MASS=55093] 
76.63 0.006009 1.4 TMED9 Transmembrane emp24 domain-containing protein 9 [Cricetulus griseus] [MASS=26765] 
48.69 0.006101 13.9 TPM2 Tropomyosin beta chain [Cricetulus griseus] [MASS=30686] 
91.36 0.006151 1.3 EBP2 putative rRNA-processing protein EBP2 [Cricetulus griseus] [MASS=35026] 
189.08 0.006175 1.3 ATAD3A ATPase family AAA domain-containing protein 3 [Cricetulus griseus] [MASS=66291] 
73.25 0.006177 2.1 SGTA Small glutamine-rich tetratricopeptide repeat-containing protein alpha [Cricetulus griseus] [MASS=34090] 
56.98 0.006188 1.7 EIF2S3 Eukaryotic translation initiation factor 2 subunit 3 [Cricetulus griseus] [MASS=51107] 
44.36 0.006279 1.4 DDX39A ATP-dependent RNA helicase DDX39 [Cricetulus griseus] [MASS=48709] 
68.25 0.006284 1.3 RPS2 40S ribosomal protein S2 [Cricetulus griseus] [MASS=8599] 
88.54 0.006377 1.5 PSMD6 26S proteasome non-ATPase regulatory subunit 6 [Cricetulus griseus] [MASS=45566] 
55.02 0.006636 3.1 HNRNPC Heterogeneous nuclear ribonucleoproteins C1/C2 [Cricetulus griseus] [MASS=24495] 
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55.1 0.006649 1.5 UBXN4 UBX domain-containing protein 4 [Cricetulus griseus] [MASS=56719] 
107.31 0.006721 1.2 ICAM1 intracellular adhesion molecule 1 [Cricetulus griseus] 
73.61 0.006835 1.3 UBE2V1 ubiquitin-conjugating enzyme E2 K isoform 1 [Homo sapiens] 
72.75 0.006847 1.3 HEXIM1 Protein HEXIM1 [Cricetulus griseus] [MASS=40208] 
81.13 0.006848 1.4 PSAT1 Phosphoserine aminotransferase [Cricetulus griseus] [MASS=33926] 
195.33 0.007068 3.5 PABPC1 Polyadenylate-binding protein 1 [Cricetulus griseus] [MASS=62714] 
249.85 0.007155 3 HSP90AA1 Heat shock protein HSP 90-alpha [Cricetulus griseus] [MASS=38095] 
164.82 0.007238 1.4 NCL nucleolin, C23 [Cricetulus griseus] [MASS=73289] 
86.37 0.007316 1.5 G6PD RecName: Full=Glucose-6-phosphate 1-dehydrogenase; Short=G6PD 
67.1 0.007333 1.2 6PGD 6-phosphogluconate dehydrogenase, decarboxylating [Cricetulus griseus] [MASS=53376] 
160.83 0.007423 1.4 TCP1 T-complex protein 1 subunit alpha 
135.5 0.007429 1.2 RPL9 60S ribosomal protein L9 [Cricetulus griseus] [MASS=22652] 
73.09 0.007567 1.5 MTAP S-methyl-5'-thioadenosine phosphorylase [Cricetulus griseus] [MASS=35587] 
344.42 0.00761 1.4 HSP90AB1 Heat shock protein HSP 90-beta [Cricetulus griseus] [MASS=47807] 
48.81 0.007636 1.5 PUR3 phosphoribosylglycinamide transformylase [Cricetulus griseus] [MASS=107446] 
136.73 0.007637 1.2 SF3B1 Splicing factor 3 subunit 1 [Cricetulus griseus] [MASS=88710] 
79.02 0.007671 1.1 RPL19 60S ribosomal protein L19 [Cricetulus griseus] [MASS=6891] 
144.98 0.007927 1.3 SRRM2 Serine/arginine repetitive matrix protein 2 [Cricetulus griseus] [MASS=304044] 
40.1 0.00794 7.6 RPL7A 60S ribosomal protein L7a [Cricetulus griseus] [MASS=15698] 
46.96 0.008026 1.4 CPSF6 Cleavage and polyadenylation specificity factor subunit 6 [Cricetulus griseus] [MASS=53622] 
90.99 0.008104 1.6 ARCN1 coatomer subunit delta [Mus musculus] 
110.87 0.008124 1.4 ACTN4 Alpha-actinin-4 [Cricetulus griseus] [MASS=26219] 
105.25 0.008335 1.8 HNRNPH2 heterogeneous nuclear ribonucleoprotein H2 [Mus musculus] 
61.77 0.008415 1.3 CCT3 T-complex protein 1 subunit gamma [Cricetulus griseus] [MASS=60620] 
44.31 0.008612 2.2 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 [Cricetulus griseus] [MASS=526782] 
60.58 0.008695 3 PSMD14 26S proteasome non-ATPase regulatory subunit 14 [Homo sapiens] 
145.99 0.008978 1.5 RPS17 40S ribosomal protein S17 [Mus musculus] 
137.39 0.009137 1.4 ILF3 Interleukin enhancer-binding factor 3 [Cricetulus griseus] [MASS=97550] 
109.8 0.009137 1.4 VARS Valyl-tRNA synthetase [Cricetulus griseus] [MASS=166356] 
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42.45 0.009183 1.5 DTYMK Thymidylate kinase [Cricetulus griseus] [MASS=8404] 
54.54 0.009237 1.4 CCT4 T-complex protein 1 subunit delta [Cricetulus griseus] [MASS=42136] 
87.01 0.009261 1.9 CRK Proto-oncogene C-crk [Cricetulus griseus] [MASS=36171] 
87.63 0.009353 1.4 RPS21 40S ribosomal protein S21 [Cricetulus griseus] [MASS=9143] 
49.08 0.009364 1.4 PLEKHO2 Pleckstrin-likey domain-containing family O member 2 [Cricetulus griseus] [MASS=54045] 
468.75 0.009537 1.4 HSP90AA1 RecName: Full=Heat shock protein HSP 90-alpha 
45.68 0.009552 1.7 MTA1 Metastasis-associated protein MTA1 [Cricetulus griseus] [MASS=79077] 
45.42 0.009559 1.4 RAB14 ras-related protein Rab-14 [Mus musculus] 
112.55 0.009801 1.4 PPIB Peptidyl-prolyl cis-trans isomerase B [Cricetulus griseus] [MASS=23634] 
50.37 0.010036 1.4 NACA Nascent polypeptide-associated complex subunit alpha, muscle-specific form [Cricetulus griseus] [MASS=34787] 
47.59 0.010052 1.7 RPL10 60S ribosomal protein L10 [Cricetulus griseus] [MASS=23428] 
103 0.010084 1.6 RPL5 60S ribosomal protein L5 [Cricetulus griseus] [MASS=34413] 
117.94 0.010379 1.5 HNRNPA1 Putative heterogeneous nuclear ribonucleoprotein A1-like protein 3 [Cricetulus griseus] [MASS=35945] 
231.34 0.010501 1.3 MSN Moesin [Cricetulus griseus] [MASS=34529] 
49.53 0.011035 2.2 BCLAF1 Bcl-2-associated transcription factor 1 [Cricetulus griseus] [MASS=47008] 
66.36 0.011279 1.2 RPS18 40S ribosomal protein S18 [Cricetulus griseus] [MASS=18872] 
72.87 0.011304 1.3 LGALS3 Galectin-3 
105.82 0.011314 1.3 RPS26 40S ribosomal protein S26 [Rattus norvegicus] 
56.93 0.011323 1.3 KIF5B Kinesin-1 heavy chain [Cricetulus griseus] [MASS=87850] 
62.94 0.011644 1.5 SMC1A Structural maintenance of chromosomes protein 1A [Cricetulus griseus] [MASS=143220] 
79.67 0.011724 2.1 GPRC5A Retinoic acid-induced protein 3 [Cricetulus griseus] [MASS=39746] 
44.13 0.011798 1.3 CTSL Cathepsin L1 [Cricetulus griseus] [MASS=37248] 
54.27 0.011871 1.1 PSMD4 26S proteasome non-ATPase regulatory subunit 4 [Cricetulus griseus] [MASS=41091] 
43.31 0.011876 2.8 CAT Catalase [Cricetulus griseus] [MASS=63099] 
53.31 0.01223 1.3 GSR Glutathione reductase, mitochondrial [Cricetulus griseus] [MASS=44949] 
46.24 0.012371 1.5 ACTN4 Alpha-actinin-4 [Cricetulus griseus] [MASS=37673] 
243.53 0.012419 1.5 NME1 Nucleoside diphosphate kinase A [Cricetulus griseus] [MASS=17195] 
77.74 0.012505 1.4 CHMP4B Charged multivesicular body protein 4b [Cricetulus griseus] [MASS=21459] 
62.52 0.01279 1.4 AGFG1 Arf-GAP domain and FG repeats-containing protein 1 [Cricetulus griseus] [MASS=50397] 
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250.63 0.012804 1.4 DDX5 probable ATP-dependent RNA helicase DDX5 [Rattus norvegicus] 
60.6 0.012926 1.5 ZC3HAV1 Zinc finger CCCH-type antiviral protein 1 [Cricetulus griseus] [MASS=110826] 
81.25 0.013009 1.9 EFTUD2 116 kDa U5 small nuclear ribonucleoprotein component [Cricetulus griseus] [MASS=109491] 
101.18 0.013245 1.3 PES1 Pescadillo-like [Cricetulus griseus] [MASS=41566] 
57.81 0.013468 1.3 RPS14 40S ribosomal protein S14 [Homo sapiens] 
47.92 0.013665 2.4 NPTN Neuroplastin [Cricetulus griseus] [MASS=25086] 
51.4 0.013744 1.4 CTNND1 Catenin delta-1 [Cricetulus griseus] [MASS=104051] 
522.43 0.014198 2.1 HIST1H2AG Histone H2A type 1 [Cricetulus griseus] [MASS=34185] 
45.77 0.014308 3 TKT Transketolase [Cricetulus griseus] [MASS=67716] 
57.48 0.0145 1.6 LMNB2 Lamin-B2 [Cricetulus griseus] [MASS=67733] 
62.86 0.014539 1.5 ADSL adenylosuccinate lyase [Cricetulus griseus] [MASS=54955] 
89.69 0.014654 1.6 CCT8 T-complex protein 1 subunit theta [Cricetulus griseus] [MASS=22223] 
75.9 0.014659 1.6 LBR Lamin-B receptor [Cricetulus griseus] [MASS=70428] 
40.42 0.014831 1.3 MCM4 DNA replication licensing factor MCM4 [Cricetulus griseus] [MASS=96542] 
100.56 0.015125 1.4 AKR1A1 Alcohol dehydrogenase [NADP+] [Cricetulus griseus] [MASS=36510] 
41.99 0.01528 1.4 BOLA2 BolA-like protein 1 [Cricetulus griseus] [MASS=13002] 
200.78 0.015326 1.8 SPTBN1 Spectrin beta chain, brain 1 [Cricetulus griseus] [MASS=166268] 
40.24 0.015595 2.2 PA2G4 Proliferation-associated protein 2G4 [Cricetulus griseus] [MASS=43715] 
43.83 0.015626 1.8 NPC2 Epididymal secretory protein E1 [Cricetulus griseus] [MASS=16471] 
54.24 0.015636 1.3 RPL30 60S ribosomal protein L30 [Cricetulus griseus] [MASS=14716] 
100.35 0.015764 1.3 STOML2 Stomatin-like protein 2 [Cricetulus griseus] [MASS=38199] 
669.08 0.015962 1.4 FLNA Filamin-A [Cricetulus griseus] [MASS=263654] 
65.53 0.016153 1.4 SNAP29 Synaptosomal-associated protein 29 [Cricetulus griseus] [MASS=21734] 
171.7 0.016198 1.4 YBX3 DNA-binding protein A [Cricetulus griseus] [MASS=11426] 
61.81 0.016287 1.4 UCHL5 Ubiquitin carboxyl-terminal hydrolase isozyme L5 [Cricetulus griseus] [MASS=37660] 
65.39 0.016512 1.2 ACTR2 Actin-related protein 2 [Cricetulus griseus] [MASS=20222] 
65.72 0.016568 1.4 GPC1 Glypican-1 [Cricetulus griseus] [MASS=86871] 
242.47 0.016589 1.4 HNRNPA3 Heterogeneous nuclear ribonucleoprotein A3 [Cricetulus griseus] [MASS=26953] 
58.36 0.016636 1.3 EIF3C Eukaryotic translation initiation factor 3 subunit C [Cricetulus griseus] [MASS=23144] 
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45.22 0.016895 1.4 PSMD11 26S proteasome non-ATPase regulatory subunit 11 [Cricetulus griseus] [MASS=29618] 
44.45 0.01736 1.2 RPA2 Replication protein A 32 kDa subunit [Cricetulus griseus] [MASS=27524] 
63.14 0.017467 3.2 TARDBP TAR DNA-binding protein 43 [Cricetulus griseus] [MASS=22576] 
76.47 0.017845 1.4 FXR1 RecName: Full=Fragile X mental retardation syndrome-related protein 1 
65.37 0.017889 1.3 BAIAP2 Brain-specific angiogenesis inhibitor 1-associated protein 2  
58.73 0.018158 1.5 TBL2 Transducin beta-like protein 2 [Cricetulus griseus] [MASS=39587] 
455.92 0.018196 1.2 HNRNPA2B1 Heterogeneous nuclear ribonucleoproteins A2/B1 [Cricetulus griseus] [MASS=29047] 
53.28 0.018361 1.1 LMAN2 Vesicular integral-membrane protein VIP36 [Cricetulus griseus] [MASS=40227] 
178.72 0.018574 1.9 GSTM5 Glutathione S-transferase Mu 5 [Cricetulus griseus] [MASS=26967] 
355.42 0.018585 1.4 HIST1H2AG Histone H2A type 1 [Cricetulus griseus] [MASS=28463] 
69.98 0.018808 1.5 PDLIM1 PDZ and LIM domain protein 1 [Cricetulus griseus] [MASS=35971] 
40.29 0.018817 1.3 OPA1 Dynamin-like 120 kDa protein, mitochondrial [Cricetulus griseus] [MASS=117444] 
59.2 0.019116 1.5 RRAS2 Ras-related protein R-Ras2 [Cricetulus griseus] [MASS=18078] 
42.24 0.019157 1.9 UBA52 PREDICTED: ubiquitin B-like [Rattus norvegicus] 
85.81 0.019179 1.2 RPL23A 60S ribosomal protein L23a [Cricetulus griseus] [MASS=17655] 
114.63 0.019394 1.5 TUBA1C tubulin alpha-1C chain [Mus musculus] 
426.28 0.019401 1.2 PLEC Plectin 
110.18 0.019683 1.3 PEX19 Peroxisomal biogenesis factor 19  
115.43 0.019901 3.4 HNRNPD Heterogeneous nuclear ribonucleoprotein D0 [Cricetulus griseus] [MASS=29283] 
57.01 0.019938 2.4 S100A13 Protein S100-A13 [Cricetulus griseus] [MASS=11241] 
46.34 0.020284 1.6 SUCLG1 Succinyl-CoA ligase [GDP-forming] subunit alpha, mitochondrial [Cricetulus griseus] [MASS=34895] 
45.85 0.020412 1.2 ERG11 Lanosterol 14-alpha demethylase [Cricetulus griseus] [MASS=56767] 
64.37 0.020911 1.2 GPS1 COP9 signalosome complex subunit 1 [Cricetulus griseus] [MASS=53947] 
74.72 0.021424 1.4 RNH1 Ribonuclease inhibitor [Cricetulus griseus] [MASS=50022] 
77.01 0.021542 1.2 SES1 Seryl-tRNA synthetase, cytoplasmic 
60.49 0.021554 1.7 RPL27A 60S ribosomal protein L27a [Bos taurus] 
132.1 0.021709 1.4 RPS3A 40S ribosomal protein S3a [Rattus norvegicus] 
86.93 0.021721 1.3 SF3B4 splicing factor 3B subunit 4 [Mus musculus] 
92.41 0.021732 1.6 SLC25A5 ADP/ATP translocase 2 [Cricetulus griseus] [MASS=29247] 
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50.91 0.022257 1.4 RBM28 RNA-binding protein 28 [Cricetulus griseus] [MASS=87436] 
73.45 0.022335 1.2 TPI Triosephosphate isomerase [Cricetulus griseus] [MASS=16434] 
74.38 0.022832 1.3 CSPG4 Chondroitin sulfate proteoglycan 4 [Cricetulus griseus] [MASS=252010] 
135.26 0.022923 1.7 RPL4 60S ribosomal protein L4 [Cricetulus griseus] [MASS=32179] 
74.08 0.022936 1.7 NAT10 N-acetyltransferase 10 [Cricetulus griseus] [MASS=115604] 
44.37 0.023737 1.4 FKBP10 FK506-binding protein 10 [Cricetulus griseus] [MASS=64718] 
58.11 0.023846 1.2 SEPT7 Septin-7 [Cricetulus griseus] [MASS=41218] 
56.84 0.024636 1.5 ATP2B3 Plasma membrane calcium-transporting ATPase 3 [Cricetulus griseus] [MASS=130571] 
41.35 0.024777 1.7 S100A6 protein S100-A6 [Mus musculus] 
99.45 0.024964 1.6 KHSRP Far upstream element-binding protein 2 [Cricetulus griseus] [MASS=62198] 
154.83 0.025369 1.2 YWHAQ 14-3-3 protein theta [Cricetulus griseus] [MASS=27749] 
45.84 0.026109 1.6 RCN2 Reticulocalbin-2 [Cricetulus griseus] [MASS=37132] 
42.38 0.026185 1.3 SAFB Scaffold attachment factor B1 [Cricetulus griseus] [MASS=102833] 
45.15 0.026507 1.9 HNRNPG Heterogeneous nuclear ribonucleoprotein G [Cricetulus griseus] [MASS=42131] 
99.65 0.026755 1.7 NOMO1 Nodal modulator 1 [Cricetulus griseus] [MASS=32948] 
114.55 0.027062 1.5 CSE1L Exportin-2 [Cricetulus griseus] [MASS=110375] 
49.38 0.027317 1.6 RANBP2 E3 SUMO-protein ligase RanBP2 [Cricetulus griseus] [MASS=342142] 
40.15 0.027348 1.5 RBBP4 Histone-binding protein RBBP4 [Cricetulus griseus] [MASS=25330] 
49.76 0.027401 2.2 HYPK huntingtin interacting protein K [Oryctolagus cuniculus] 
65.08 0.027661 2.7 TMEM43 Transmembrane protein 43 [Cricetulus griseus] [MASS=44797] 
56.29 0.027801 1.5 RRP12 RRP12-like protein [Cricetulus griseus] [MASS=153244] 
48.66 0.027862 1.2 IMMT Mitochondrial inner membrane protein [Cricetulus griseus] [MASS=79258] 
57.44 0.027871 1.3 EIF4B Eukaryotic translation initiation factor 4B [Cricetulus griseus] [MASS=69570] 
104.08 0.02788 1.2 DSC1 rCG40478, isoform CRA_b [Rattus norvegicus] 
43.46 0.028009 1.4 CTB5R3 NADH-cytochrome b5 reductase 3 [Cricetulus griseus] [MASS=34236] 
47.77 0.028144 1.5 EZR Ezrin [Cricetulus griseus] [MASS=69372] 
112.09 0.028961 1.2 TAGLN2 Transgelin-2 [Cricetulus griseus] [MASS=22455] 
44.03 0.029486 1.4 RFC4 Replication factor C subunit 4 [Cricetulus griseus] [MASS=39938] 
104.77 0.029896 1.2 EEF1G Elongation factor 1-gamma [Cricetulus griseus] [MASS=27155] 
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52.16 0.029947 1.2 VAPA Vesicle-associated membrane protein-associated protein A [Cricetulus griseus] [MASS=26075] 
69.04 0.030475 1.3 PLOD2 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 [Cricetulus griseus] [MASS=67164] 
85.07 0.030576 1.5 FKBP9 FK506-binding protein 9 [Cricetulus griseus] [MASS=63008] 
76.66 0.030819 1.5 RPL17 60S ribosomal protein L17 [Rattus norvegicus] 
105.29 0.032149 1.3 GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 [Cricetulus griseus] [MASS=30483] 
44.29 0.032227 1.4 PSMD3 26S proteasome non-ATPase regulatory subunit 3 [Cricetulus griseus] [MASS=16842] 
57.62 0.032502 1.4 XRCC1 RecName: Full=DNA repair protein XRCC1; AltName: Full=X-ray repair cross-complementing protein 1 
42.68 0.032765 1.8 RPLP1 60S acidic ribosomal protein P1 [Cricetulus griseus] [MASS=12230] 
132.35 0.033095 1.3 RSL1D11 Ribosomal L1 domain-containing protein 1 [Cricetulus griseus] [MASS=49958] 
43.44 0.033786 1.2 VDAC1 Voltage-dependent anion-selective channel protein 1 [Cricetulus griseus] [MASS=53379] 
56.84 0.033892 1.2 LAP3 Cytosol aminopeptidase [Cricetulus griseus] [MASS=50275] 
56.04 0.034082 1.4 MRPP1 Mitochondrial ribonuclease P protein 1 [Cricetulus griseus] [MASS=59932] 
79.82 0.034525 1.4 VAT1 Synaptic vesicle membrane protein VAT-1-like [Cricetulus griseus] [MASS=28523] 
108.57 0.034692 1.2 GTF2F1 General transcription factor IIF subunit 1 [Cricetulus griseus] [MASS=57283] 
48.77 0.034812 1.7 NDUFA4 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4 [Cricetulus griseus] [MASS=14153] 
61.52 0.034882 1.2 VDAC2 Voltage-dependent anion-selective channel protein 2 [Cricetulus griseus] [MASS=31739] 
57.99 0.035256 1.3 GATAD2A Transcriptional repressor p66 alpha [Cricetulus griseus] [MASS=51734] 
53.22 0.035477 1.2 HMGB1 RecName: Full=High mobility group protein B1; AltName: Full=High mobility group protein 1; Short=HMG-1 
59.07 0.035771 1.4 DNAJC10 DnaJ-like subfamily C member 10 [Cricetulus griseus] [MASS=90672] 
82.09 0.036085 1.2 IRF2BP2 Interferon regulatory factor 2-binding protein 2 [Cricetulus griseus] [MASS=36160] 
46.09 0.036431 1.5 PRPF40A Pre-mRNA-processing factor 40-like A [Cricetulus griseus] [MASS=81478] 
325.97 0.03688 1.9 PKM Pyruvate kinase isozymes M1/M2 [Cricetulus griseus] [MASS=51559] 
62.3 0.036983 1.5 FUBP1 Far upstream element-binding protein 1 [Cricetulus griseus] [MASS=47731] 
63.63 0.037078 1.2 SRSF5 serine/arginine-rich splicing factor 5 [Mus musculus] 
56.67 0.037201 1.3 RCC1 Regulator of chromosome condensation [Cricetulus griseus] [MASS=48887] 
48.38 0.037852 1.5 RPL31 60S ribosomal protein L31 isoform 1 [Homo sapiens] 
107.52 0.037926 9.4 NCAM1 Neural cell adhesion molecule 1 [Cricetulus griseus] [MASS=114316] 
42.67 0.03809 1.3 SDHB Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial [Cricetulus griseus] [MASS=25570] 
45.23 0.038162 1.4 CBR1 carbonyl reductase 1 [Cricetulus griseus] [MASS=30547] 
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42.76 0.038599 1.2 TMOD3 Tropomodulin-3 [Cricetulus griseus] [MASS=39388] 
127.38 0.039203 1.2 CKAP4 Cytoskeleton-associated protein 4 [Cricetulus griseus] [MASS=36359] 
140.2 0.039272 1.3 PARK7 Protein DJ-1 [Cricetulus griseus] [MASS=19929] 
45.17 0.039516 1.2 HADHB Trifunctional enzyme subunit beta, mitochondrial [Cricetulus griseus] [MASS=39535] 
78.61 0.039527 1.4 RINL Ras and Rab interactor-like protein [Cricetulus griseus] [MASS=71795] 
59.78 0.039542 1.5 HIST1H2BC histone H2B type 1-C/E/F/G/I [Homo sapiens] 
102.85 0.039719 1.2 DBN1 Drebrin [Cricetulus griseus] [MASS=65309] 
43.65 0.040374 1.5 RPS23 40S ribosomal protein S23 [Homo sapiens] 
172.46 0.040499 1.3 EEF1A1 elongation factor 1-alpha 1 [Rattus norvegicus] 
56.47 0.041029 1.3 CLU Clusterin [Cricetulus griseus] [MASS=51757] 
93.02 0.041185 2 ATIC Bifunctional purine biosynthesis protein PURH [Cricetulus griseus] [MASS=64651] 
50.73 0.041398 1.9 KRT10 Keratin, type I cytoskeletal 10 [Cricetulus griseus] [MASS=27853] 
83.8 0.04164 1.2 RAB5C Ras-related protein Rab-5C [Cricetulus griseus] [MASS=23483] 
62.92 0.042015 2.8 RPL28 60S ribosomal protein L28 [Cricetulus griseus] [MASS=13065] 
151.51 0.042153 1.2 ENO2 Gamma-enolase [Cricetulus griseus] [MASS=47227] 
175.51 0.042683 1.3 CFL1 cofilin-1 [Rattus norvegicus] 
88.46 0.042854 1.1 SUMO2 small ubiquitin-related modifier 2 precursor [Mus musculus] 
46.05 0.043429 2.7 PRMT1 Protein arginine N-methyltransferase 1 [Cricetulus griseus] [MASS=40522] 
42.13 0.043447 1.3 FDPS Farnesyl pyrophosphate synthetase [Cricetulus griseus] [MASS=43211] 
269.53 0.043714 1.2 EEF1D Elongation factor 1-delta [Cricetulus griseus] [MASS=36598] 
41.69 0.044283 2.1 CAV1 Caveolin-1 [Cricetulus griseus] [MASS=17160] 
57.47 0.044736 1.2 RTCB UPF0027 protein C22orf28-like [Cricetulus griseus] [MASS=47794] 
53.2 0.045027 1.3 CCT8 T-complex protein 1 subunit theta [Cricetulus griseus] [MASS=24801] 
59.64 0.045432 1.9 AHSA1 Activator of 90 kDa heat shock protein ATPase-like 1 [Cricetulus griseus] [MASS=38129] 
40.85 0.045875 1.3 IQCE IQ domain-containing protein E [Cricetulus griseus] [MASS=83194] 
45.11 0.045972 1.3 FOSL1 Fos-related antigen 1 [Cricetulus griseus] [MASS=30263] 
52.47 0.046094 1.3 PPM1G Protein phosphatase 1G [Cricetulus griseus] [MASS=54003] 
40.31 0.046158 1.6 RARS RecName: Full=Arginyl-tRNA synthetase, cytoplasmic; AltName: Full=Arginine--tRNA ligase; Short=ArgRS 
74.38 0.046454 1.2 CSPR2 Cysteine-rich protein 2 [Cricetulus griseus] [MASS=22944] 
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58.3 0.047006 1.3 PRPF31 U4/U6 small nuclear ribonucleoprotein Prp31 [Cricetulus griseus] [MASS=49130] 
89.3 0.047083 1.5 ALLC putative allantoicase [Cricetulus griseus] [MASS=80219] 
100.86 0.047171 3.5 TUFM Elongation factor Tu, mitochondrial [Cricetulus griseus] [MASS=49557] 
53.53 0.04847 1.2 HM13 Minor histocompatibility antigen H13 [Cricetulus griseus] [MASS=37769] 
49.72 0.048702 16.6 MAPRE1 Microtubule-associated protein RP/EB family member 1 [Cricetulus griseus] [MASS=30034] 
41.87 0.048822 1.4 ACTR3 actin-related protein 3 [Mus musculus] 
82.45 0.049156 1.1 ALDH2 Aldehyde dehydrogenase, mitochondrial [Cricetulus griseus] [MASS=45925] 
80.22 0.049456 1.1 GIGYF2 PERQ amino acid-rich with GYF domain-containing protein 2 [Cricetulus griseus] [MASS=150168] 
51.01 0.049711 1.2 RPS28 40S ribosomal protein S28 [Homo sapiens] 
76.21 0.04984 1.3 PRDX2 RecName: Full=Peroxiredoxin-2 
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Figure A10: CT expression patterns for miR-23b/23b* in all CHO clones 
 
 
Figure A10: The dogmatic miRNA expression profile of miR-23b (Red) and miR-23b* (Blue) for all 
clones in the Slow growing panel compared to the Fast growing panel that exhibit an apparent 
increase in miR-23b* expression with no change in miR-23b expression.  
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Figure A11: Raw CT values for miR-532-5p expression in all Fast and Slow CHO 
clones evaluated using TLDA miRNA microarrays 
 
Figure A11: Raw Ct values for the expression of miR-532-5p in all clones within “fast” and “slow” 
growing groups (highlighted in yellow) including the average expression across each group. 
 
 
 
 
 
 
 
 
 
 
 
Clone ID F/S Detector ID Ct Ave Ct
X5.13F.1.41 F hsa-miR-532-5p-4380928 40
X5.13F.2.28 F hsa-miR-532-5p-4380928 33.34163
X5.13F.3.31 F hsa-miR-532-5p-4380928 36.091293
X5.16F.1.40 F hsa-miR-532-5p-4380928 35.938572
X5.16F.2.28 F hsa-miR-532-5p-4380928 35.28528
X5.16F.3.33 F hsa-miR-532-5p-4380928 40
X5.18F.1.39 F hsa-miR-532-5p-4380928 32.416298
X5.18F.2.31 F hsa-miR-532-5p-4380928 40
X5.18F.3.35 F hsa-miR-532-5p-4380928 40 37.96367
X5.22F.1.44 F hsa-miR-532-5p-4380928 40
X5.22F.2.33 F hsa-miR-532-5p-4380928 40
X5.22F.3.27 F hsa-miR-532-5p-4380928 40
X5.2F.1.42 F hsa-miR-532-5p-4380928 40
X5.2F.2.31 F hsa-miR-532-5p-4380928 36.381985
X5.2F.3.25 F hsa-miR-532-5p-4380928 40
X10.2S.1.23 S hsa-miR-532-5p-4380928 22.911198
X10.2S.2.16 S hsa-miR-532-5p-4380928 24.435015
X10.2S.3.15 S hsa-miR-532-5p-4380928 23.092752
X11.1S.1.13 S hsa-miR-532-5p-4380928 32.94388
X11.1S.2.16 S hsa-miR-532-5p-4380928 40
X11.1S.3.14 S hsa-miR-532-5p-4380928 35.9087
X5.11S.1.23 S hsa-miR-532-5p-4380928 31.040468
X5.11S.2.14 S hsa-miR-532-5p-4380928 35.003376 30.99841
X5.11S.3.16 S hsa-miR-532-5p-4380928 32.213932
X5.1S.1.11 S hsa-miR-532-5p-4380928 24.3722
X5.1S.2.16 S hsa-miR-532-5p-4380928 26.736874
X5.1S.3.19 S hsa-miR-532-5p-4380928 24.942024
X7.7S.1.17 S hsa-miR-532-5p-4380928 40
X7.7S.2.20 S hsa-miR-532-5p-4380928 36.03121
X7.7S.3.15 S hsa-miR-532-5p-4380928 35.344524
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 Figure A12: miR-18a expression in a stable miR-17~92 cluster over-expressing 
CHO-K1 parental cell line 
 
Figure A12: The expression of miR-18a was evaluated in a parental CHO-K1 parental cell line stably 
expressing the miR-17~92 cluster.  
 
Figure A13: endogenous miR-23b* levels in miR-23b* sponge CHO-SEAP cells 
 
Figure A13: qPCR assessment of the expression of endogenous miR-23b* in CHO-K1-SEAP clones 
engineered to stably deplete miR-23b*. 
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Figure A14: CHO-SEAP miR-23 clones 4 and 6 transfected with pre-miR-23  
 
Figure A14: CHO-SEAP clones 4 and 6 stably depleted of miR-23 transfected with pre-miR-23 mimic 
demonstrating A) the GFP readings from the real-life Guava ExpressPlus programme and B) the 
average GFP expression within each population. 
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